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Abstract 
Characterisation of transmembrane protein 114 (TMEM114), a protein 
associated with juvenile onset cataract. 
 
Geoffrey Joseph Maher, The University of Manchester, PhD in Genetic 
Medicine, final version submitted January 2011.  
  
Transmembrane protein 114 (TMEM114) is an uncharacterised predicted 
transmembrane protein expressed in the lens epithelium. A balanced 
translocation that transects the putative promoter of TMEM114 is associated 
with autosomal dominant congenital cataract (ADCC), however, coding 
sequence variants in TMEM114 were not identified in a panel of ADCC 
patients. Subsequent to the identification of TMEM114 a similar novel 
transmembrane protein named TMEM114-like protein 1 (TMLP1) was 
identified. This study aimed to functionally characterise the two novel proteins 
TMEM114 and TMLP1.  
 
TMEM114 and TMLP1 showed homology to voltage dependent calcium 
channel gamma (γ) subunits, but TMEM114 and TMLP1 lacked some of the 
key domains present in these proteins. Expression of TMEM114 and TMLP1 
in the developing human eye was identified. TMLP1 was also expressed in 
developing neural tissue. To aid functional characterisation, the murine 
orthologues of Tmem114 and Tmlp1 were cloned and polyclonal antibodies 
were generated. Bioinformatic tools predicted co-and post-translational 
modifications. The predicted plasma membrane localisation of Tmem114 was 
confirmed in vitro in polarised MDCK II cells and the membrane localisation 
was shown to be dependent on the presence of N-linked oligosaccharides. 
Murine Tmlp1 was localised in the endoplasmic reticulum (ER) in MDCK II 
cells, possibly due to the fact that murine Tmlp1 lacks an N-glycosylation site 
present in other species.  
 
The knockdown of Tmem114 in Xenopus tropicalis using antisense 
morpholinos results in microphthalmia (small eye) confirming the protein‟s role 
in eye development and growth. Sequencing of patients with microphthalmia 
and anophthalmia identified a novel heterozygous missense mutation (p.R2Q) 
not present in controls. The p.R2Q variant was not found to affect the 
expression or localisation of the protein.  The p.A147V variant, previously 
reported as a SNP, mis-localises to the endoplasmic reticulum. 
 
In conclusion, this study identifies that TMEM114 is a transmembrane 
glycoprotein with an important role in ocular development in vertebrates, 
although its precise functional role remains to be elucidated. Knockdown of 
Tmem114 in X. tropicalis results in microphthalmia, suggesting that loss of 
function mutations in TMEM114 may be associated with human ocular 
disease. Further characterisation of TMLP1 is required to identify its role in 
human biology. 
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1.1 Epidemiology of Cataract 
In 2002, 37 million people worldwide were affected by blindness, with another 125 million 
visually impaired (Pascolini et al. 2004). In developed countries age-related macular 
degeneration is the most frequent cause of blindness but worldwide cataract is the leading 
cause, responsible for almost half of all cases (Pascolini et al. 2004).  Cataract is an 
opacification of the lens resulting in visual impairment. The formation of cataracts is generally 
age-related but congenital and juvenile onset forms also occur, albeit less frequently. In 
developed countries it is estimated that 3-13.6 children per 10,000 live births are diagnosed 
with cataract by the age of 15, the majority of which are diagnosed in early childhood (Rahi 
and Dezateux 2001; SanGiovanni et al. 2002; Holmes et al. 2003; Graw 2004). 
 
In developing countries incidence rates of juvenile cataract are higher due to environmental 
causes such as rubella infections during pregnancy and due to recessive traits exposed by 
consanguinity. Inherited forms of congenital cataract are estimated to account for 50 % of 
cases (Francis and Moore 2004). Congenital cataracts may develop as part of a syndrome 
such as Lowe (OMIM 309000), Martsolf (OMIM 212720) and Nance-Horan (OMIM 302350) 
(see section 1.6.3), and are also often seen in association with other anterior ocular diseases 
such as microphthalmia and microcornea (Abouzeid et al. 2009). Cataract is more frequently 
inherited independently, most commonly as an autosomal dominant trait and occasionally in 
an autosomal recessive or X-linked manner  (see section 1.6) (Francis et al. 1999). 
 
1.2 Role and structure of the lens  
1.2.1 Role of the lens 
The lens is a highly specialised ovoid tissue in the anterior segment of the eye, suspended 
behind the pupil by zonular fibres from the ciliary body (Figure 1.1A). In conjunction with the 
cornea, the lens functions to transmit and focus light onto the retina, which transmits nerve 
impulses to the brain, being interpreted as vision.  Thus, transparency and refraction of the 
lens are crucial to visual acuity. These optical properties are achieved by the highly organised 
structure and protein content of the lens. Disruption of the refractive properties of the lens by 
altering the protein or cellular organisation results in cataract. 
 
1.2.2 Structure of the mammalian lens 
The human lens is biconvex with the posterior surface more curved than the anterior surface. 
The lens is surrounded by the lens capsule, a thick layer of basement membrane (secreted by 
the lens epithelial cells), which is bathed by the aqueous humour on the anterior side and the 
vitreous humour on the posterior side (Wederell and de Iongh 2006). The majority of the 
avascular lens is composed of differentiated lens fibre cells which are surrounded by a layer 
of cuboidal epithelial cells on the anterior side (Figure 1.1B). The centre of the lens, the lens 
nucleus, is formed during lens development from differentiated posterior epithelial cells 
(Section 1.3.1). The surrounding cortical fibres are formed from anterior epithelial cells which 
divide and differentiate to form fibre cells, a process which continues throughout life in 
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vertebrates (Section 1.4) (Gordon and Donzis 1985). As there is no cell turnover in the lens, 
the lens is ever-growing with newly differentiating cells surrounding the older cells at the 
centre (Gordon and Donzis 1985). 
 
 
 
Figure 1.1. Anatomy of the mature human eye and lens. A) Cross-section of an adult human 
eye. The lens is located in the anterior segment, attached to the ciliary body by zonular fibres. B) Cross-
section of an adult lens. The lens is comprised of two main cell types: epithelia and fibre cells. Central 
epithelial cells at the anterior of the lens are mitotically quiescent, have a flat morphology and become 
more cuboidal towards the germinative zone. In the germinative zone the cells divide, and in the 
transitional zone the post-mitotic cells begin to elongate. The apical ends of the differentiating cells then 
turn and point towards the anterior. The elongating differentiating cells lose their cellular organelles and 
become internalised as more cells differentiate. Elongation continues until opposing elongating cells 
meet and form sutures. Differentiating cells are continually concentrically added throughout life to the 
inner nuclear fibres which are laid down early in development. 
A 
B 
Chapter 1 
 
  
20 
1.2.3 Refractive properties of the lens 
Most living tissues appear non-transparent as the difference in refractive index between and 
within cells (i.e. between cytoplasm and membrane-bound organelles) results in light scatter. 
In order to remain transparent, the lens has a number of adaptations to minimise the 
absorption and scatter of light. Cells in the equatorial region of the lens display little adaptation 
as these cells are located behind the iris so are not on the visual axis. The lens epithelium is 
composed of a thin single layer of cells at the anterior and as this layer of cells is so thin, the 
light scattering caused by it is minimal (Bassnett 2009).   
 
Differentiating and mature fibre cells use different mechanisms to prevent light scatter. 
Differentiating fibre cells at the periphery are uniform in size and hexagonal in cross-section 
(Bassnett and Winzenburger 2003). The hexagonal structure allows close packing of the fibre 
cells to such an extent that the space between the cells is smaller than the wavelength of 
light, minimising light scatter (Michael et al. 2003). The differentiating cells also elongate 
drastically (Section 1.4.4) and elongation increases the cytoplasm to nucleus ratio, reducing 
the contribution of nuclei to light scatter (Coulombre and Coulombre 1963). As fibre cells 
further differentiate they lose their organelles (Section 1.4.6), reducing light scatter associated 
with membrane-bound organelles (Bassnett 1997).  
  
The central fibre cells are much more irregular in morphology and in order than the peripheral 
fibre cells (Bassnett and Winzenburger 2003). These cells are connected by numerous tongue 
and groove inter-digitations (Okinami 1978). This irregular order should increase the refractive 
index but light scatter from the irregular-shaped cells is prevented by equilibrating the 
refractive indexes of the cytoplasm and the cell membrane (Michael et al. 2003). The lens 
nucleus contains a high crystallin concentration (90 % of all water soluble protein) which 
increases the refractive index of the cytoplasm (Keenan et al. 2008). The refractive index of 
the fibre membranes is reduced to match that of the cytoplasm by an increase in 
sphingomyelin content and cholesterol to phospholipids ratio of the membrane (Li et al. 1985; 
Greiner et al. 1994; Tholozan and Quinlan 2007).   
 
The centre of the lens has a uniform refractive index (~1.41) which is higher than that of the 
periphery (~1.37) (Jones et al. 2007; Kasthurirangan et al. 2008), and a gradient of refractive 
indexes occurs from the outside of the nucleus to the lens periphery (Jones and Pope 2004; 
Augusteyn et al. 2008)). This gradient reflects the protein concentration in the lens 
(Fagerholm et al. 1981) and is necessary to correct the longitudinal spherical aberration of the 
lens (Fernald and Wright 1983). Syncytia form between the lateral membranes of 
differentiating cells of the same age and remain in the mature fibres (i.e. from the same 
stratum) (Shestopalov and Bassnett 2003; Shi et al. 2009). Absence of syncytia is associated 
with altered refractive properties of the lens and it has been proposed that the presence of 
syncytia make a more even distribution of protein between cells helping to create a more 
uniform refractive index in cells of the same stratum (Shi et al. 2009).   
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The lens can alter its refractive properties by the process of accommodation. In order to focus 
light from near objects on to the retina, the lens increases refractive power by changing its 
shape to become more globular (Jones et al. 2007) and by reducing the distance between it 
and the cornea (Koretz, Cook, & Kaufman, 2002). This movement is controlled by the ciliary 
body and the zonular fibres that attach to the lens.  
 
 
1.3 Mammalian eye and lens development   
Development of the eye is a complex process involving the interaction of neuroectoderm, 
surface ectoderm, and mesoderm of the developing embryo. Late in gastrulation (mouse 
embryonic day 7 (E7); day 17 human gestation) precursors of the eyes, the eye fields, 
develop in the anterior neural plate. Growth of the diencephalon causes the eye fields to move 
forward (E8/day 21) where they evaginate forming optic pits. The optic pit evaginates further 
forming the optic vesicle which is joined to the neural tube by the optic stalk. 
 
The optic vesicle extends, displacing the mesenchyme between it and the overlying surface 
ectoderm. The resulting interaction between the neural ectoderm of the optic vesicle and the 
surface ectoderm causes the surface ectoderm to thicken, forming the lens placode (E9, day 
27) (Figure 1.2A) (Pei and Rhodin 1970). This is the first step in lens formation and is a key 
stage in eye development. The hyaloid artery, which later in development regresses, supplies 
the developing optic vesicle with nutrients (Beebe 2008). This artery causes differential growth 
in the lens placode, with the cells near the nutrient supply multiplying much quicker, causing 
the lens placode to invaginate forming the lens cup (E10.5, day 29) (Figure 1.2B,C) (Graw 
2003). Filopodia connect the lens placode to the presumptive retina and so invagination of 
both tissues is co-ordinated (Chauhan et al. 2009). 
 
The almost spherical lens vesicle is formed when the lens cup closes, creating a large central 
lumen (E11.5; day 31-35) (Graw 2003). The lens vesicle transiently remains attached to the 
surface ectoderm via the lens stalk. This surface ectoderm, with neural crest-derived 
mesenchyme, will later develop into the cornea (Hay 1979). Mice lacking lenses undergo skin 
differentiation in presumptive corneal epithelial tissue suggesting that signalling from the lens 
is required for corneal development (Zhang et al. 2008). During the formation of the vesicle, 
the neuroectoderm surrounding the invaginating lens epithelium folds over forming two layers 
(Figure 1.2C). The inner part, surrounding the lens vesicle, will later develop into the neural 
retina, whilst the outer layer will give rise to the retinal pigment epithelium (RPE). Contrasting 
with results in chicken which suggested that the presence of the lens is necessary for correct 
retinal development (reviewed in (Chow and Lang 2001), differentiation of the major retinal 
cell types was not affected in mice in which the lens placode was ablated, although ectopic 
RPE formation occured (Zhang et al. 2008). 
.  
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Figure 1.2. Development of the mouse lens. A) The lens placode is induced by the interaction of 
the surface ectoderm and the neural ectoderm of the optic vesicle (E9). B) - E) enlargement of area 
contained in green box in A). B) The surface ectoderm thickens forming the lens placode. C) The lens 
placode invaginates forming the lens cup and the neuroectoderm surrounding the invaginating lens 
epithelium folds over forming two layers the inner nuclear layer and the outer nuclear layer. D) The lens 
cup closes to form the lens vesicle. The retina begins to differentiate and the future cornea (grey) begins 
to appear. E) The cavity of the vesicle is filled by the elongating posterior lens fibre cells.  
 
 
The lumen of the lens vesicle is then filled by elongating primary lens fibre cells, which 
develop from the posterior wall of the vesicle as soon as it is formed (E12.5-14) (Figure 
1.2D,E) (Zhou et al. 2002). However, the epithelial cells at the anterior wall remain as a 
cuboidal epithelial monolayer, establishing polarity in the lens. Once the vesicle is filled, 
mitotic cells from the central epithelial region divide and move to the equatorial region. Here at 
the lens bow, the cells elongate and differentiate into secondary fibres. The growing 
secondary cells surround the central primary cells, forming concentric layers (E15.5). The 
elongated mature fibre cells span the length of the lens, and sutures form where the apical 
ends of two cells are in contact in the anterior of the lens and where the basal ends of two 
cells are in contact in the posterior of the lens (Figure 1.1B). 
 
Rapid growth of the lens occurs during embryogenesis and the first two years of life with 
continual addition of secondary fibre cells (~90 % of adult size) (Gordon and Donzis 1985). 
Throughout the rest of life, secondary fibres are continually added, albeit at a much slower 
Optic vesicle 
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rate, resulting in an ever-growing lens (Gordon and Donzis 1985).  
 
 
1.4 Secondary lens fibre differentiation 
All lens fibre cells originate from lens epithelial cells which have undergone differentiation. 
This co-ordinated process involves proliferation of the epithelial cells, withdrawal from the cell 
cycle, elongation of the cells, expression of fibre-specific genes and degradation of 
organelles. Growth factors from the aqueous, the vitreous and the ciliary body all contribute to 
lens fibre differentiation. 
 
1.4.1 The central lens epithelium remains undifferentiated 
The cells in the central lens epithelium remain in an undifferentiated state. These cells are 
relatively quiescent with a small number of proliferating cells (Zhou et al. 2006). The central 
epithelium cells divide very infrequently leading to the hypothesis that these cells represent a 
stem cell population (Zhou et al. 2006). To inhibit differentiation, the central lens epithelial 
cells express a number of transcription factors. Pitx3, expressed in the central lens epithelium 
and at the lens equator, limits the expression of the cyclin dependent kinase (CDK) inhibitors 
p27
Kip1
 and p57
Kip2 
which are required for cell cycle withdrawal (Zhang et al. 1998; Ho et al. 
2009). AP-2α regulates expression of the cell-adhesion molecule E-cadherin in the epithelium 
and inhibits expression of the fibre specific aquaporin0 (Ohtaka-Maruyama et al. 1998; West-
Mays et al. 2002). Pax6, necessary for lens placode formation, inhibits expression of the lens 
fibre specific βB1-crystallin and the pro-fibre transcription factor c-Maf in the lens epithelium 
(Duncan et al. 2004). The transcription factor lens epithelium-derived growth factor (LEDGF) 
enhances growth and survival of the all lens epithelial cells (Singh et al. 2000; Kubo et al. 
2003). 
  
1.4.2 Cell proliferation  
At the peripheral region of the lens epithelium, the germinative zone, the epithelial cells 
proliferate and move to the transition zone (Zhou et al. 2006). Low concentrations of FGF, 
found in the aqueous humor that baths the central epithelium, are associated with proliferation 
of lens epithelial cells (Chamberlain and McAvoy 1989). The lens expresses four tyrosine 
kinase receptors (FGFR1 to 4) (Robinson 2006) and FGFR-1 and -2 are highly expressed in 
the equatorial region (Garcia et al. 2005). Mice in which FGFR-1, -2 and -3 have been 
knocked out in combination have abnormal proliferation in prospective lens fibre cells as well 
as other anomalies (Zhao et al. 2008). In vitro FGF-1 and -2, insulin-like growth factor (IGF), 
epidermal growth factor (EGF), platelet-derived growth factor (PDGF) and aqueous humour 
are all associated with lens cell proliferation (Iyengar et al. 2006). The Wnt/β-catenin pathway 
is associated with proliferation as loss of β-catenin results in decreased cell proliferation (Cain 
et al. 2008)
 
and overactivating the Wnt pathway increases epithelial cell proliferation (Martinez 
et al. 2009).  
 
At the molecular level, proliferation is promoted by the transcription factors Pitx3 and FoxE3 
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(Medina-Martinez et al. 2005; Ho et al. 2009).  Loss of the gap junction protein connexin 50 
(Cx50) is associated with reduced proliferation of the equatorial and central epithelium (White 
et al. 2007). Activity of Src family tyrosine kinases (SFKs) is associated with inhibiting 
assembly of N-cadherin junctions which is thought to be necessary to maintain cell 
proliferation (Griep 2006).   
 
1.4.3 Withdrawal from the cell-cycle  
In the transition zone cells undergo the first step in differentiation: withdrawal from the cell 
cycle. The cell cycle inhibitor p57
Kip2 
is highly expressed in cells at the transition zone (Lovicu 
and McAvoy 1999) and combined loss of p57
Kip2
 and p27
kip1
 results in hyperproliferation and 
apoptosis of fibre cells (Zhang et al. 1998). Upregulation of p57
Kip2 
and
 
p27
kip1 
is
 
dependent on 
expression of the homeobox transcription factor Prox1 (Wigle et al. 1999), the presence of 
FGF and the inhibition of SFK activity (Walker et al. 2002). 
 
As the cells move more posteriorly during differentiation they are exposed to higher 
concentrations of FGF from the vitreous humour (Lovicu and McAvoy 2005). This high 
concentration of FGF increases Erk1/2 activation leading to cell cycle withdrawal and 
differentiation (Lovicu and McAvoy 2001; Iyengar et al. 2006; Iyengar et al. 2007; Zhao et al. 
2008). Of the four FGF receptors expressed in the lens FGFR-2 has been shown to be 
directly involved in cell cycle withdrawal (Garcia et al. 2005). 
 
 
The retinoblastoma protein (pRb) is reported to be abundant at the lens equator (Griep 2006) 
and epithelial cells lacking pRb expression fail to withdraw from the cell cycle (Fromm et al. 
1994; Morgenbesser et al. 1994). Active pRb binds to and represses E2F transcription factors, 
leading to down-regulation of the E2F targets involved in cell cycle progression (Dyson 1998). 
The transcription factor Pax6 also controls cell cycle withdrawal, as Pax6-deficient cells at the 
lens equator fail to exit the cell cycle (Shaham et al. 2009). 
 
1.4.4 Cell migration and elongation 
Past the transition zone, the apical ends on the differentiating cells turn through 90° and point 
towards the anterior (Figure 1.3) (Grove et al. 2004). The apical ends of the migrating 
differentiating cells contact the apical membranes of the lens epithelium at the epithelial cell-
fibre interface (Grove et al. 2004). The basal membrane remains in contact with the lens 
capsule. As the cell migrates to the interior of the lens it elongates several hundred fold as the 
depth of the lens increases (Coulombre and Coulombre 1963). This movement is dependent 
on the reorganisation of cell-cell contacts between the apical membrane of the epithelium and 
the anterior end of the fibre cells, and between the posterior end of fibre cells and the 
posterior lens capsule. The cells finally detach from the lens epithelium and lens capsule and 
interlock with the opposing cell forming a suture, with posterior sutures forming before anterior 
(Bassnett and Winzenburger 2003; Kuszak et al. 2004). Although sutures are present in 
vertebrate lenses, the arrangement of sutures is not conserved, with four distinct types 
(Kuszak et al. 2004). 
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Figure 1.3. Cell-cell contacts at the lens equator. The epithelial cells in the germinative zone 
divide and at the transition zone the cells elongate. Past the transition zone, the differentiating cells turn 
towards the anterior. The apical ends of the elongating cells form a suture known as the modiolus or 
lens fulcrum. The basal membranes of the newly differentiated fibre cells remain in contact with the lens 
capsule and the apical membranes of the cells are in contact with the apical membranes of the lens 
epithelial cells at the epithelial-fibre interface. 
 
 
Signalling factors from the ciliary body and vitreous humour promote migration of the 
differentiating cells (Zelenka 2004). As cells migrate and elongate the adhesive and junctional 
properties of the cells change. The transcription factor AP2-α is expressed in lens epithelia 
and expression is lost at the lens equator (West-Mays et al. 1999). AP2-α down-regulates 
expression of the adherens junction protein E-cadherin, which, in many tissues, is associated 
with the onset of cell migration (West-Mays et al. 2002). The adaptor protein Abi-2 is 
expressed at the ends of migrating fibre cells in the transition zone and is present at the 
epithelial-fibre interface. Loss of Abi-2 expression results in defects in orientation, migration 
and elongation of differentiating cells (Grove et al. 2004). Phosphorylated regulatory myosin 
light chain-2 (phospho-MLC), which colocalises with actin filament in elongating and 
differentiating primary and secondary lens fibres, is also thought to have a role (Maddala et al. 
2007). 
 
When lens differentiation is initiated, actin, present in the form of stress fibres in the 
epithelium, dissociates and is reorganised into membrane-attached cortical bundles (Lo et al. 
1997; Weber and Menko 2006). This is in part dependent on actin-binding proteins (Zelenka 
2004) and on the formation of N-cadherin cell-cell junctions (Ferreira-Cornwell et al. 2000; 
Weber and Menko 2006). Thus, a switch from E-cadherin junctions in the epithelia to N-
cadherin junctions in the differentiating fibres occurs (Pontoriero et al. 2009). 
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In both lens epithelial and fibre cells, N-cadherin forms a complex with β-catenin (Leonard et 
al. 2008).  Localisation of N-cadherin in the lens fibre cell membrane, where it is mainly in the 
short sides of the hexagons and colocalises with β-catenin (Straub et al. 2003) and F-actin 
(Leonard et al. 2008), is dependent upon the activation of ephrin-A2 (Cooper et al. 2008). 
Activation of ephrin-A2 is dependent on expression of the axon guidance molecule ephrin-A5. 
In ephrin-A5 knockout lenses, which develop cataract, N-cadherin fails to bind β-catenin and 
remains in the cytoplasm (Cooper et al. 2008). In the differentiating and mature fibres there is 
an increase in N-cadherin binding to γ-catenin and they colocalise at the cell vertices 
(Leonard et al. 2008). 
 
Movement along the posterior capsule is mediated by the basal membrane of the fibre cell, 
which is rich in β1 and α6 integrins and associated cytoskeletal elements, interacting with the 
extracellular matrix (Bassnett et al. 1999; Walker and Menko 1999). The serine/threonine 
kinase Cdk5 localises to the tips of elongating fibre cells, where it is present in high 
concentrations (Gao et al. 1997; Negash et al. 2002). Substrates of Cdk5 have roles in cell 
migration, and in vitro overexpression of Cdk5 enhances adhesion of lens epithelial cells to 
extracellular matrix (Negash et al. 2002). 
 
1.4.5 Expression of fibre-specific proteins 
Differentiation is associated with large changes in gene expression, with downregulation of 
epithelium-specific genes and up regulation of a number of fibre-specific genes including β-
crystallin, aquaporin0, MP20, Cx46 and beaded filament proteins. The effects of FGF on 
expression of lens fibre specific proteins are dependent on the activity of members of the 
bone morphogenetic protein (BMP) family of proteins (Boswell et al. 2008). In vitro, EGF and 
PDGF-A, present in the vitreous as well as the more potent IGF-1 upregulate the expression 
of fibre-specific genes such as β-crystallin (Wang et al. 2010a). Post cell-cycle withdrawal 
FGF is also involved in the accumulation of the transcription factor c-Maf, induction of 
crystallin expression and gap junction formation (Le and Musil 2001a; Lovicu and McAvoy 
2001; Zhao et al. 2008). 
 
1.4.5.1 Expression of β- and γ-crystallins 
High concentrations of the structural crystallin proteins exist in the lens contributing to 
refractive power. Expression of β-crystallins serve as a marker of lens fibre cells, and 
expression coincides with the loss of Pitx3 (Ho et al. 2009). c-Maf is upregulated
 
during fibre 
cell differentiation (Duncan et al. 2004) and enhances expression of multiple crystallins, 
particularly the γ-crystallins (Kim et al. 1999). Similarly, the transcription factors Sox1 and 
Prox1 up-regulate expression of multiple γ-crystallins (Nishiguchi et al. 1998; Wigle et al. 
1999). Loss of the epithelial transcription factor Pitx3 also associates with increased γ-
crystallin expression (Ho et al. 2009). 
 
1.4.5.2 Change in aquaporin expression 
Aquaporins are integral membrane proteins that facilitate the passive movement of water 
between cells (Agre et al. 2002). Aquaporin1 (AQP1), expressed in the lens epithelium is 40 
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times more efficient at facilitating water movement than AQP0, which is expressed only in 
terminally differentiated fibre cells (Varadaraj et al. 2007). AQP0 is the most abundant 
membrane protein in lens fibre cells (Bassnett et al. 2009) and, in addition to its water 
function, it is postulated to have a role in cell-cell adhesion (Kumari and Varadaraj 2009).  
 
1.4.5.3 Change in connexin expression  
The lens expresses three connexins (Cx), the subunits of gap junctions. Gap junctions 
between cells allow the passage of small molecules and ions, and are important in 
maintaining physiology in lens fibre cells (Patterson and Delamere 1992). Cx43 is restricted to 
epithelial cells where it is expressed at low levels and is required for maintaining lens 
transparency (Beyer et al. 1989; Gong et al. 1997). Upon differentiation Cx46 expression is 
initiated and high levels are found in lens fibres (Paul et al. 1991). In the differentiating fibres 
Cx46 forms gap junctions with Cx50 (Konig and Zampighi 1995), a connexin that is expressed 
in both epithelial and fibre cells (White et al. 1992; White et al. 2007). The gap junction 
coupling conductance in in vitro differentiating fibres is increased by FGF at concentrations 
expected in the lens equator (Le and Musil 2001b). Mice lacking Cx46 display normal lens 
growth and fibre differentiation and develop cataract postnatally (Gong et al. 1997). Whilst 
Cx50 is necessary for lens growth and development, Cx46 is necessary for the maintenance 
of lens transparency (Gong et al. 1997; Rong et al. 2002).  
 
1.4.5.4 Expression of beaded filament proteins 
The expression of beaded filament proteins occurs after elongation of fibre cells, and have a 
role in stabilisation after differentiation (Blankenship et al. 2001). These lens specific 
intermediate filament proteins, filensin and phakinin/CP49 (BFSP1 and BFSP2, respectively), 
are highly expressed and localise at the cell membrane of peripheral cortical fibres and the 
cytoplasm in deeper cortical fibres (Oka et al. 2008). The beaded filament proteins act to 
minimise light scatter by their involvement in ensuring that cortical fibre cells adopt the correct 
spatial organisation (Sandilands et al. 2003; Song et al. 2009). 
 
1.4.6 Degradation of organelles 
To maintain transparency, mature lens fibres lack organelles (Bassnett and Beebe 1992). All 
cytoplasmic organelles are degraded in a coordinated manner in primary lens fibre cells and 
in the final stage of secondary lens fibre differentiation (Bassnett 2002). In mice the loss of 
organelles begins at E17/18 and is complete when the eyelids are first opened, 14 days after 
birth (Vrensen et al. 1991).  In the chicken lens, organelles in the lens core are degraded at 
E12 forming an organelle free zone (OFZ) (Bassnett and Beebe 1992). At first the OFZ only 
includes the primary cells but this region expands at a rate of 20 cell widths per day to include 
the secondary fibres. The mitochondria in cells bordering the OFZ swell and suddenly 
fragment. This process is rapid with the loss of numerous mitochondrial markers within 2-4 
hours (Bassnett and Beebe 1992; Dahm et al. 1998; Zandy and Bassnett 2007). Degradation 
of the endoplasmic reticulum also occurs within a short time period (Bassnett 1995).  
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The Golgi apparatus fragment into small structures apical to the cell nuclei which later 
disintegrate (Bassnett 1995). Degradation of the nucleus is less rapid and the process varies 
among species. In primates, the nucleus disintegrates and residual nuclear particles persist 
indefinitely in the cytoplasm (Bassnett 1997). The nucleus initially becomes more spherical 
and the chromatin condenses and fragments.  DNase II-like acid DNase (DLAD) is expressed 
only in the lens and is believed to digest the chromosomal DNA (Nakahara et al. 2007). This 
degradation of nuclear material results in mature fibre cells losing the capacity for de novo 
protein synthesis. Thus, proteins in the core of the lens nucleus have been present since pre-
natal and early post-natal development. 
 
The mechanism behind organelle degradation remains to be resolved. Mice lacking the 
effector caspases known to be expressed in the lens undergo normal organelle breakdown, 
suggesting that apoptosis is not the mechanism (Zandy et al. 2005). Mice lacking the 
autophagy gene Atg5 are also unaffected (Matsui et al. 2006). Recent evidence suggests that 
organelle degradation may be dependent upon the ubiquitin proteasome pathway (UPP) 
(Zandy and Bassnett 2007). Upon differentiation, members of the UPP degradation system 
redistribute from the cytoplasm to the nucleus (Girao et al. 2005). Inhibition of the UPP results 
in the elimination of the mitochondrial marker succinate-ubiquinone oxidoreductase from the 
differentiating central fibre cells (Zandy and Bassnett 2007). 
 
In summary, the adult lens is continually growing, forming from the proliferation and 
differentiation of epithelial cells at the lens periphery. Differentiating cells increase in length 
several hundred fold as they migrate, and lose the capacity for gene expression as the 
nucleus and other cytoplasmic organelles are degraded. These changes and the expression 
of crystallins, AQP0, connexins and beaded filaments all contribute to the transparency of the 
lens. 
 
 
1.5 Diagnosis, classification, and treatment of congenital cataract 
1.5.1 Diagnosis and classifications of congenital cataract  
Cataract is readily identifiable as light scattering regions by slit lamp examination (oblique 
illumination) or retroillumination. Congenital cataract is genetically and phenotypically 
heterogeneous and types are classified according to position and type of opacity (Table 1.1)  
(Reddy et al. 2004). Lens opacities are commonly found in the nuclear and cortical fibres and 
may also be found in both (“total cataract”) (Amaya et al. 2003). Nuclear cataracts are 
restricted to the embryonic nuclear fibres (Figure 1.4A). Opacities in the central nuclear fibres 
may be solid or dust-like (pulverulent) (Reddy et al. 2004). Visual acuity is greatly affected by 
the presence of solid and dust like opacities, but cerulean cataracts have little effect on visual 
acuity. Isolated cortical opacities are rare and as they typically lie outside of the visual axis 
they therefore have little effect on visual acuity (Ionides et al. 1999). Cerulean cataracts, 
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which typically have a juvenile rather congenital onset, appear as blue and white dots 
throughout the lens and don‟t require surgery until adulthood (Bodker et al. 1990). 
 
Sutural cataracts uniquely display a Y-shaped opacity and can be present at the anterior or 
posterior (Figure 1.4B) (Zhang et al. 2006). Sutural cataracts are distinct form anterior polar 
and posterior polar cataracts which are more common (Ionides et al. 1999). In lamellar 
cataracts, the opacities are restricted to a layer, or layers, of cells which represent a specific 
generation of secondary lens fibres. A defect in the development of this specific generation of 
cells when they were at their most metabolically active results in restricted opacification 
(Brown and Bron 1996). Although a clear separation from the cortex is usually seen, the 
nuclear fibre may also show some opacification (Figure 1.4C) (Amaya et al. 2003). Acueliform 
cataracts are rare and present as unique fibreglass–like
 
projections (Figure 1.4D) (Zenteno et 
al. 2005).   
1.5.2 Why study a treatable disease? 
Cataract is a treatable disease but the only effective medical treatment is surgery to remove 
the cataractous lens. Treatment of congenital or juvenile cataract is expensive with surgery 
and post-operative care recently estimated to cost an average of almost $20,000 per patient 
(Stager et al. 2009). The loss of the lens may be corrected by the insertion of an artificial 
intraocular lens (IOL) that is positioned in the place of the original lens, although this may be 
preceded by a period when the refractive error caused by loss of the lens is corrected using 
contact lenses. There are a number of risks associated with cataract surgery in the young. 
Aphakic glaucoma, strabismus and amblyopia are common risks of lens removal procedures, 
with aphakic glaucoma particularly prevalent in the very young (Allen et al. 2009; Khan and Al-
Dahmesh 2009; Yu and Dahan 2009). Other rare complications include retinal detachment 
and endophthalmitis (inflammation of the intraocular cavities) (Stager et al. 2009).  
 
Early vision loss due to congenital cataracts affects visual development at the time of vision 
loss and has also been shown to affect aspects of vision that are acquired later on in visual 
development (Lewis and Maurer 2009). Therefore, early diagnosis and treatment of congenital 
and early onset forms of cataract is necessary to maximise the visual capabilities of patients 
later on in life. Understanding the genetic causes of cataract may benefit future treatment by 
identifying the molecular mechanisms behind cataract formation. Cataract is the most 
common cause of blindness in adults worldwide (Pascolini et al. 2004), and identifying genes 
involved in juvenile onset cataract will aid understanding of the causes of age-related cataract. 
Identifying mutations which cause congenital cataract can also help in genetic counselling. 
Parents at risk of having a child with congenital cataract can be counselled and made aware 
of the potential for cataract formation in their future offspring. This can help with early 
diagnosis and treatment which may aid their prospects of achieving maximum visual acuity. 
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Figure 1.4. Examples of congenital cataract. Lenses of cataract patients visualised using direct 
photogrpahy (A,B) or retroillumination (C,D). Cataracts are visualised as silhouettes when light is 
reflected from the retina using retroillimuniation. To the right hand side are schematics representing the 
images on the left. (A) Nuclear cataract. B) Sutural cataract has a typical Y shaped appearance. C) 
Lamellar cataract visualised by retroillumination. D) Acueliform cataract visualised by retroillumination.  
Schematic legend: White shape on black background = cataract. Brown/blue = iris. White = sclera. 
Cataract images were supplied by Professor Graeme Black DPhil FRCOphth, Central Manchester 
University Hospitals NHS Foundation Trust.  
 
1.6 Mutations associated with congenital cataract  
Mutations in more than 25 genes have been associated with non-syndromic congenital or 
early-onset cataract (Table 1.1). Approximately half of cases which present have mutations 
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in genes encoding the crystallins, and about a quarter are associated with connexin mutations 
(Hejtmancik 2008). Mutations in numerous transcription factors result in congenital cataract, 
although these are usually seen with other ocular abnormalities. 
 
Table 1.1. Human genes with mutations associated with non-syndromic congenital or 
juvenile cataract. Accession numbers are from the GenBank database. Chrom: chromosomal 
location. Inh: inheritance pattern. AD: autosomal dominant. AR: autosomal recessive. XL: X-linked. 
OMIM: Online Mendelian Inheritance in Man reference numbers. Where OMIM accessions were 
unavailable, the original paper reporting the mutation is referenced. 
Gene Accession  Chrom 
 
Inh  Morphology OMIM 
Transcription Factors     
FOXE3 NM_012186 1p32 AD No lens pathology details 107250, 601094 
HSF4 NM_001538 16q21-q22.1 AD Lamellar, nuclear, total 602438 
   AR Total (Smaoui et al. 2004) 
MAF NM_001031804 16q23 AD Lamellar pulverulent, cerulean 177074 
PITX3 NM_005029 10q25 AD Posterior polar 602669 
VSX2/CHX10 NM_182894 14q24.3 AR No lens pathology details  142993 
PAX6 NM_000280,  11p13 AD No lens pathology details  607108 
Structural Proteins     
CRYAA NM_000394 21q22.3 AD Nuclear, lamellar, total 123580 
   AR No lens pathology details   
CRYAB NM_001885 11q23.3−24.2 AD Posterior polar, lamellar 123590 
CRYBA3/BA1 NM_005208 17q11-q12 AD Nuclear, sutural 600881 
CRYBA4 NM_001886 22q11.2 AD Lamellar 123631 
CRYBB1 NM_001887 22q11.2 AD Pulverulent 600929 
   AR Nuclear  
CRYBB2 NM_00496 22q11.2 AD Variable 123620 
CRYBB3 NM_004076 22q11.2 AR Nuclear 123630 
CRYGC NM_020989 2q33−q35 AD 
Nuclear lamellar, lamellar, 
zonular perverulent 
123660, 123680, 
601286 
CRYGD NM_006891 2q33−q35 AD Variable 115700, 123690 
CRYGS NM_017541 3q26.3-qter AD Polymorphic cortical  123730 
BFSP1 NM_001195 20p11.23-p12.1 AR Zonular nuclear, pulverulent 603307 
BFSP2 NM_003571 3q21-q25 AD Nuclear, sutural, lamellar 603212 
Vimentin NM_003380 10p13 AD Pulverulant  193060 
Membrane Associated Proteins     
GJA3/CX46 NM_021954 13q11−13 AD Variable 601885 
GJA8/CX50 NM_005267 1q21-q25 AD 
Nuclear, zonular pulverulent, 
total, posterior subcapsular 116200 
   AR No lens pathology details (Ponnam et al. 2007) 
AQP0 NM_012064 12q12−14.1 AD Variable 154050  
LIM2 (MP20) NM_002316 19q AR Total 154045 
NHS NM_198270 Xp22.13 XL  Total 300457 
      
Other      
GCNT2 NM_001491 6p24-p23 AR No lens pathology details  110800 
EYA1 NM_172060 8q13.3 AD Nuclear 601653 
CHMP4B NM_176812 20q11.22 AD Posterior 610897 
EPHA2 NM_004431.2 1p36 AD posterior polar  176946  
   AR Nuclear (Kaul et al. 2010) 
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1.6.1 Transcription factors 
The transcription factor PAX6 is one of the key proteins in the induction of eye formation. 
Pax6 is expressed in the presumptive lens ectoderm, and expression is required for formation 
of the lens placode and subsequently the lens. Mutations in murine Pax6 result in the failure 
of the optic vesicle and overlying ectoderm to interact, compromising one of the key inductive 
events in eye development (Hogan et al. 1986). When Pax6-deficient surface ectoderm is 
transplanted onto a wildtype optic vesicle, lens formation fails to occur (Fujiwara et al. 1994). 
The inductive properties of Pax6 are conserved in vertebrates and non-vertebrates as ectopic 
expression of murine Pax6 induces functional ommatidal eyes in the legs or antennae of 
Drosophila (Halder et al. 1995). Pax6 is a master regulator of other transcription factors 
important for eye development such as Foxe3, Pitx3, Maf, Mitf and Vsx2 (Cvekl et al. 2004) 
and mutations in these genes are associated with congenital cataract (Table 1). Mutations in 
PAX6 are commonly associated with aniridia (absence of the iris) (OMIM 106210) (Tzoulaki et 
al. 2005) but a number of mutations in PAX6 have been associated with congenital cataract 
(Glaser et al. 1994; Azuma et al. 1999; Hanson et al. 1999). 
 
1.6.2 Structural proteins 
Mutations in lens structural proteins are most commonly associated with congenital cataract 
(Hejtmancik 2008). The α-crystallins, large complexes of two subunits, αA- and αB- crystallins, 
represent ~30 % of the soluble protein in the lens (Bloemendal and Groenewoud 1981). 
These proteins have a number of roles in the lens other than their contribution to refractive 
index. Due to the lack of organelles, there is no protein turnover in the mature lens fibres. The 
α-crystallins act as chaperones preventing the aggregation and degradation of the life-long 
expressed proteins in the lens, including other crystallins (Horwitz 1992; Acosta-Sampson and 
King 2010). Both α-crystallins are necessary for microtubule assembly in lens epithelia (Xi et 
al. 2006). Other roles specific to αA-crystallin in the lens include protection against apoptosis 
(Andley et al. 2002; Morozov and Wawrousek 2006; Xi et al. 2008) and assembly of beaded 
filaments (Carter et al. 1995). αB-crystallin is predominantly expressed in the epithelium and 
may have a role in genomic stability (Andley et al. 2001). 
 
Mutations in αA-crystallin have been associated with autosomal dominant and recessive 
forms of congenital cataract. Heterozygous mutations in the conserved core α-crystallin 
domain cause dominant cataract by altering protein interactions (Fu and Liang 2003). The 
dominat cataract associated heterozygous mutation R49C, which lies outside the core α-
crystallin domain, loses the ability to protect against apoptosis (Mackay et al. 2003), and 
activates the unfolded protein response (Watson and Andley 2010). Cell expressing the 
R12C, present in the heterozygous state in cases of autosomal dominant cataract, exhibit an 
altered heat shock response (Zhang et al. 2009). A homozygous nonsense mutation in the N-
terminus of CRYAA results in recessive congenital cataract (Pras et al. 2000), suggesting that 
lack of CRYAA function is associated with recessive cataract, but gain of function mutations 
are associated with dominant cases.   
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The β- and γ-crystallins are genetically and functionally distinct from the α-crystallins (Graw 
2009). These crystallins are expressed in the lens fibres and contribute to the refractive power 
of the lens. Mutations in many of these genes, as well as genes that regulate β- and γ-
crystallin expression (e.g. MAF and HSF4) are associated with congenital cataract. The lens 
fibres express two lens-specific intermediate filament proteins filensin and phakinin/CP49 
(BFSP1 and BFSP2, respectively) which form the beaded filament in differentiated lens fibre 
cells (Maisel and Perry 1972). Mutations in both proteins are associated with juvenile-onset 
cataract (Conley et al. 2000; Ramachandran et al. 2007) and a role in myopia has also been 
hypothesised for  BSFP2 (Zhang et al. 2004). Recently, a dominant missense mutation in the 
widely expressed intermediate filament protein vimentin was associated with pulverant 
congenital cataract (Sandilands et al. 1995; Muller et al. 2009). Although vimentin knockout 
mice do not display a lens phenotype (Colucci-Guyon et al. 1994), missense mutations in 
(Bornheim et al. 2008), and overexpression of (Capetanaki et al. 1989) vimentin in mice 
results in cataract.  
 
 
1.6.3 Membrane associated proteins 
The lens expresses a number of unique membrane proteins such as the gap junction proteins 
CX46 and CX50, and the highly prevalent AQP0 and MP20. Mutations in each of these 
proteins have been associated with congenital cataract, underlying their importance in lens 
homeostasis. As the lens is avascular, gap junctions and water channels are necessary for 
the delivery of nutrients to and the removal of waste from the central fibre cells (Gong et al. 
2007). As stated previously in section 1.4.5.3, connexins play an important role in fibre cell 
physiology and mutations in both of the fibre cell-expressed connexin genes (CX46 and 
CX50) result in congenital cataract (Addison et al. 2006; Vanita et al. 2006; Gao et al. 2010).   
 
AQP0 is the most abundant membrane protein in lens fibre cells (Bassnett et al. 2009) and 
Aqp0 knockout mice display congenital cataract (Shiels et al. 2001; Al-Ghoul et al. 2003). 
AQP0 is a member of the aquaporin family of proteins which facilitate the passive movement 
of water between cells (Agre et al. 2002). However, AQP0 is much less efficient at facilitating 
water movement across the membrane than AQP1 (Chandy et al. 1997), which is expressed 
in the lens epithelium (Varadaraj et al. 2007). An in vitro role in cell-cell adhesion has been 
demonstrated for AQP0, but not AQP1, suggesting that AQP0 has functional roles beyond 
water transport (Kumari and Varadaraj 2009; Varadaraj et al. 2010). Deletions and missense 
mutations affecting both the transmembrane and extracellular loops have been associated 
with congenital lamellar cataract (Francis et al. 2000; Geyer et al. 2006; Gu et al. 2007; Wang 
et al. 2010c).  
 
A single missense mutation in the fourth transmembrane domain  of  lens intrinsic membrane 
protein 2 (LIM2) has been associated with recessive congenital cataract (Ponnam et al. 2008).  
A phenotypically milder form of recessive cataract with a later, but pre-senile, onset is 
associated with a missense mutation in the third transmembrane domain (Pras et al. 2002). 
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This protein, the second most abundant membrane protein in lens fibres, will be discussed in 
more detail below (Section 1.7.4). 
 
Null mutations in the Nance-Horan Syndrome protein (NHS) cause Nance-Horan Syndrome, 
an X-linked disorder typified by anterior ocular anomalies, dental anomalies, dysmorphic facial 
features and mental retardation  (Ding et al. 2009). Copy number variants of the NHS gene 
are associated with congenital cataract with a possible link with heart defects (Coccia et al. 
2009). NHS is expressed in at least 5 isoforms (Brooks et al. 2010). According to the 
nomenclature used by Brooks et al., isoforms NHS-A and NHS-1A contain exon 1 and are 
expressed in epithelia (Sharma et al. 2006; Sharma et al. 2009). The Xcat mouse which 
displays bilateral total cataract as well as other NHS phenotypes has reduced expression of 
exon 1 isoforms (Huang 2006). NHS-1A interacts with the tight junction protein ZO-1 and 
colocalises with ZO-1 in developing epithelial tissues (Sharma et al. 2009) and in vitro 
(Sharma et al. 2006).   
 
Exon 1 of NHS encodes a WAVE homology domain (WHD) and NHS isoforms with this 
domain have roles in maintenance of cell morphology and size (Brooks et al. 2010). These 
WHD containing isoforms interact with the Abl-interactor (Abi) adaptor proteins associated 
with actin polymerisation (Stradal et al. 2001) and the NHS isoforms maintain the contractile 
actin ring at the cell circumference (Brooks et al. 2010). This actin ring acts to provide cell 
shape and strength for cell adhesion. Abi2 is expressed at the tips of migrating secondary 
fibre cells at the epithelial fibre interface and knockout mice display defects in migration and 
orientation of secondary fibres and fail to form sutures (Grove et al. 2004).  
 
 
1.7 TMEM114  
1.7.1 Discovery of TMEM114 
Transmembrane protein 114 (TMEM114) is associated with dominant bilateral congenital or 
juvenile cataract through its proximity to the breakpoint in a balanced translocation between 
16p13.3 and 22q11.2 (Jamieson et al. 2007). A four generation family presented with 
congenital or juvenile cataract inherited in a dominant pattern (Figure 1.5A). Some of the 
affected also presented with developmental kidney abnormalities (Figure 1.5B). A balanced 
translocation t(16;22)(p13.3;q11.2) segregated with those affected. Limited clinical details and 
no photographs were available for the affected members of the family.  
 
The chromosomal region 16p.13.3 had previously been identified as a locus associated with 
congenital cataract and microphthalmia (OMIM 156850) (Yokoyama et al. 1992). Analysis of 
the breakpoint regions using somatic cell hybrids revealed the translocation transected a 
region of 16p13.3 not sequenced by the human genome project. The BAC AC074052, located 
telomeric to the breakpoint, contained an EST (BF727259) from a human lens library. A 
homologous sequence encoded by four exons was identified in mouse, FANTOM clone 
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4930511J11 (Kawai et al. 2001). The predicted third and fourth exons of the human EST 
(BF727259) are present in BAC AC074052 with the predicted fourth exon furthest away from 
the breakpoint. Blast analysis against the human genome with the predicted human and 
murine exons 1 and 2 failed to identify any sequence similarity. This suggested that exons 1 
and 2 were located in a gap in the sequence of the genome. Exons 1 and 2 were later 
identified in a short fragment of sequence by Celera. 
 
The breakpoint lay in the putative promoter region of TMEM114, 673 nucleotides upstream of 
the predicted start codon and 151 nucleotides from the predicted transcription start site. The 
translocation was predicted to result in the separation of the coding sequence from the 
upstream regulatory regions of TMEM114, suggesting dysregulation as the likely disease 
mechanism (Jamieson et al. 2007).   
 
 
 
Figure 1.5. Pedigree and phenotypes of the family with the balanced translocation 
t(16;22)(p13.3;q11.2). A). Pedigree of the family displaying juvenile onset cataract. Affected 
individuals are highlighted in black, unaffected in white. Individuals tested and found to have the 
balanced translocation 46,XX,t(16;22)(p13.3;q11.2) or 46,XY,t(16;22)(p13.3;q11.2) are indicated by a T. 
Individuals tested and found to have a normal karyotype are indicated by a N. Individuals not tested but 
inferred to have a normal karyotype are indicated by a (N). An asterisk denotes those tested and found 
to have a renal abnormality. B) Clinical details of the available patients. 
 
 
Patient Lens opacities Age at operation Other phenotypes 
I.1 Juvenile onset Childhood to early adulthood Not known 
II.2-5, II.8 Juvenile onset Childhood to early adulthood Not known 
III.7 Juvenile onset Childhood to early adulthood 
Partial right duplex 
collecting system 
III.4 Juvenile onset 
Right eye: 7 years.  
Left eye: 23 years 
Partial right duplex 
collecting system 
III.3 Juvenile onset Childhood to early adulthood Not known 
IV.4 
Congenital: lamellar, central 
core, posterior sutural  
Later: anterior polar 
Left eye: 6 years 
Right eye: 7 years 
Absent Left kidney 
B 
A 
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1.7.2 TMEM114 bioinformatics 
The predicted TMEM114 gene encodes a 223 amino acid protein from four exons. 
Orthologues are found in mammals, chicken, frog and zebrafish (Jamieson et al. 2007). 
TMEM114 belongs to the PMP-22/EMP/MP20/Claudin family of transmembrane proteins 
(Pfam PF00822) (Jamieson et al. 2007). Proteins in this family are small (~18-25 kDa) and 
have four transmembrane domains with two extracellular loops. Members of this family 
include the epithelial tight junction proteins claudins and the more distantly related voltage 
dependent calcium channel gamma (γ) subunits. 
 
Murine Tmem114 was first identified as a possible voltage dependent calcium channel γ 
subunit in the RIKEN collection of brain cDNA clones (4930511J11) (Kawai et al. 2001; 
Gustincich et al. 2003). Cataract has been associated with increased intracellular Ca
2+
 levels 
in lens epithelial cells resulting from the loss of Ca
2+
 regulation (Gupta et al. 2004a). 
Reduction of intracellular calcium levels has been shown to inhibit proliferation of epithelial 
cells in a human lens epithelial cell line (Meissner and Noack 2008). To date, mutations in 
voltage dependent calcium channel γ subunits have not been associated with congenital 
cataract. 
 
 
1.7.3 Claudins and tight junctions 
Claudins are transmembrane proteins that form the major component of epithelial tight 
junctions (Simon et al. 1999; Van Itallie et al. 2001). Head-to-head binding of claudins at the 
apical end of the lateral border between adjacent epithelial cells forms close connections, 
producing a selective barrier to diffusion which regulates the flow of ions, solutes and water 
across epithelia (paracellular transport). This barrier is measured as transepithelial resistance 
(TER) and the properties of barriers are determined by the claudins present which can vary 
from cell to cell (Gow et al. 1999; Simon et al. 1999), or in a developmental stage-specific 
manner (Simon et al. 1999; Troy et al. 2007). There are 23 claudins in the human genome, 
but the properties and function of a number of claudins (13, 17, 20, 21-24) have yet to be 
elucidated. A number of claudins are expressed in the kidney, and claudin expression varies 
in distinct regions of the kidney (reviewed in (Angelow et al. 2008). Mutations in two claudins 
have been associated with human diseases, both genes associated with a renal tube disorder 
familial hypercalciuric hypomagnesemia with nephrocalcinosis (FHHNC) (Konrad et al. 2006; 
Hampson et al. 2008). 
 
Tight junctions divide polarised epithelial cells into distinct apical and basolateral membrane 
domains, although they are not involved in sorting proteins to specific domains (Umeda et al. 
2006). Localisation of claudins at the tight junction is dependent on the scaffold proteins 
zonula occludens-1 (ZO-1) and ZO-2 (Umeda et al. 2006). An isoform of the Nance-Horan 
syndrome protein, a protein associated with cataract and Nance-Horan syndrome, localises to 
the tight junction, although its role there remains to be elucidated (Sharma et al. 2009). 
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Tight junctions have been observed by electron microscopy in human (Lo and Harding 1983) 
and rat lenses (Zampighi et al. 2000), but not in the mouse lens (Goodenough et al. 1980). 
The presence of tight junctions in the lenses of frog (Lo and Harding 1983) and chicken 
(Goodenough et al. 1980), however, suggests that tight junctions are conserved and are likely 
to be present in mouse lens epithelia. Further indirect support for tight junctions in mouse lens 
epithelia is the presence of relatively high levels of ZO-1 compared to those found in the lens 
fibres (Nielsen et al. 2003). Tight junctions in bovine lens epithelia have low transepithelial 
resistance (TER) but are functional (Zhang and Jacob 1994). In bovine lens epithelia some 
colocalisation of the adherens junction protein E-cadherin and ZO-1 is observed (Sugiyama et 
al. 2008). In the rat lens, tight junctions, which have the appearance of having low TER, are 
present in the central epithelia where they colocalise with gap junctions (Zampighi et al. 
2000). The epithelial cells close to, and at, the equator lack tight junctions, but gap junctions 
are increased and are found connecting the neighbouring fibre cells (Zampighi et al. 2000).  
 
1.7.4 Members of the Pfam00822 family in the lens 
In the lens claudin-1, a ubiquitously expressed claudin (Furuse et al. 2002), localises to the 
tight junctions of the epithelium (Sugiyama et al. 2008). The presence of other claudins in the 
lens has not yet been reported. Peripheral myelin protein 22 (Pmp22), highly expressed in 
Schwann cells, has recently been detected in lens fibre cells (Ivanov et al. 2005; Bassnett et 
al. 2009). Mutations and copy number variants of PMP22 are associated with multiple 
neuropathies including Charcot-Marie-Tooth type 1A disease (Nelis et al. 1996; Jen et al. 
2005). 
 
Lens intrinsic membrane protein, LIM2 (MP20), is the second most prevalent membrane 
protein in lens fibre cells and is highly conserved in vertebrates (Rao et al. 1989; Steele et al. 
2000). In peripheral fibre cells Mp20 is located in the cytoplasm but in deeper fibre cells Mp20 
relocates to the plasma membrane (Tenbroek et al. 1992; Grey et al. 2003). This relocation 
coincides with the formation of a diffusion barrier between the fibre cells and suggests Mp20 
has a role in cell adhesion (Grey et al. 2003). Further support for Mp20‟s role in adhesion lies 
with its apparent interaction with galectin-3, a galactosidase-binding lectin which modulates 
cell-to-cell adhesion (Gonen et al. 2001). Mp20 also has a role in the fusion of cells in the 
formation of the lens syncytium (Shi et al. 2009). 
 
Homozygous missense mutations in human LIM2 are associated with recessive congenital 
(Ponnam et al. 2008) and presenile (Pras et al. 2002) cataracts. The To3 (total opacity of lens 
#3) mouse displays autosomal semi-dominant congenital cataracts caused by a missense 
mutation (p.G15V) in Lim2 (Kerscher et al. 1996; Steele et al. 2000). In homozygous mutants 
the primary fibres are disorganised, as are the secondary fibres, some of which still retain 
their nuclei (Steele et al. 1997). This results in abnormal refractive properties in the peripheral 
cortex (Shiels et al. 2007). The mutated Mp20 is restricted to a compartment of the Golgi 
apparatus and fails to insert in the plasma membrane (Zhou et al. 2002). Lim2 knockout mice 
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fail to develop syncytia and present with pulverulent nuclear opacities and have altered 
refractive properties in the peripheral fibres (Shiels et al. 2007; Shi et al. 2009). 
 
Peptide sequences from two other distantly related members of the PF00822 family, TMEM47 
and PERP were also identified in a mass spectrometry analysis of lens fibres (Bassnett et al. 
2009). TMEM47, also known as Brain Cell Membrane Protein 1 (BCMP1) or transmembrane 
4 superfamily member 10 (TM4SF10),  is widely expressed, with high levels in the brain 
(Christophe-Hobertus et al. 2001). TMEM47 is the vertebrate homologue of the C. elegans 
adherens junction protein VAB-9 (Christophe-Hobertus et al. 2001; Simske et al. 2003). A 
study focusing on TMEM47 expression in the kidney identified that Tmem47 was temporarily 
expressed in the membrane of developing podocytes and renal tubules (in the basal part of 
the lateral membranes in renal tubules) (Bruggeman et al. 2007). PERP (p53 effector related 
to PMP22) is ubiquitously expressed, with highest expression in stratified epithelia where it 
localises to desmosomes (Hildebrandt et al. 2000; Ihrie et al. 2005). Downregulation of PERP 
is associated with numerous aspects of cancer such as cell cycle control (Attardi et al. 2000), 
loss of cell-cell adhesion (Ihrie et al. 2005), upregulation of inflammation-related genes 
(Beaudry et al. 2010b) and has been associated with squamous cell carcinoma in human skin 
(Beaudry et al. 2010b) and uveal melanoma (Davies et al. 2009). PERP is also involved in 
wound healing, promoting cell-adhesion in wound closure (Beaudry et al. 2010a). The function 
of either protein in the lens has not been identified, although PERP is upregulated in p53 
knockout lenses (Wang et al. 2010d).  
 
1.7.5 Expression of TMEM114 
In the adult mouse, Tmem114 is expressed in the eye, cerebellum and testis (Figure 1.6A) 
(Jamieson et al. 2007). In the developing eye Tmem114 is expressed as early as E13.5 and is 
upregulated post-natally (Figure 1.6B). Expression is significantly higher in the epithelial cells 
than the fibre cells of the lens. Tmem114 expression was detected in the central lens 
epithelium by in situ hybridisation (Figure 1.7A). The strongest signal was obtained in the 
cuboidal cells close to the periphery above the lens equator (Figure 1.7B). Expression was 
also detected in the transitional zone where epithelial cells differentiate into elongated fibre 
cells, but expression is down-regulated upon differentiation of lens epithelial cells into lens 
fibre cells (Figure 1.7B) (Jamieson et al. 2007).  
 
 
1.7.6 Sequence variants in TMEM114 
The breakpoint in the translocation that led to the identification of TMEM114 lies in the 
predicted promoter region, 151 nucleotides upstream of the predicted transcription start site 
(Jamieson et al. 2007). Promoter sequence analysis suggests that it contains binding sites for 
differentiation- and lens-specific transcription factors including Pax6 and AP2. This suggests 
that the translocation results in dysregulation of expression of the gene (Jamieson et al. 
2007).  
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After identifying TMEM114‟s association with autosomal dominant juvenile cataracts, a panel 
of 130 autosomal dominant congenital cataract (ADCC) patients was screened for mutations 
in TMEM114. Three heterozygous sequence variants which result in amino acid substitutions 
were identified (Jamieson et al. 2007). The sequence variants c.104T>C (p.I35T) and 
c.318T>G (p.F106L) were each found in one patient, and were not detected in 200 normal 
control chromosomes. Apparently unaffected family members of these patients had the same 
heterozygous changes. The missense mutation c.440C>T (p.A147V) was identified three 
times in the cohort, but when family members of one of the affected were screened, it was 
found that one affected family member did not harbour this sequence variant. Therefore, this 
variant was deemed a polymorphism (Jamieson et al. 2007). 
 
 
 
Figure 1.6. Expression of Tmem114 in embryonic and adult mouse. A) RT-PCR from a 
panel of adult mouse tissues reveals expression of Tmem114 in the eye, cerebellum and testis. B) RT-
PCR in the developing eye reveals weak expression from E13.5. Expression is upregulated postnatally. 
In the lens, expression is mainly restricted to the lens epithelium (E), with little expression in the lens 
fibres (F). Figure adapted from (Jamieson et al. 2007). 
 
 
 
A B 
Figure 1.7. Tmem114 in situ hybridisation in 
P21 mouse lens. Staining was observed in the 
central epithelium (epi) (A) and in the epithelial cells 
at the lens equator including the at the transition 
zone (tz) (B). Expression was highest above the lens 
equator (arrowhead). Staining was not detected in 
the lens fibres (f). Figure adapted from (Jamieson et 
al. 2007). 
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Chapter 2: Materials and Methods 
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2.1 Suppliers 
All chemicals used were purchased from Sigma-Aldrich Company Ltd or Fisher Scientific and 
were of molecular biology grade, unless otherwise indicated in the text. Nuclease-free water 
(Applied Biosystems) was used for all RNA work and PCR-based techniques. Millipore 
filtered water (Milli-Q® Integral) was used for all other techniques. All DNA primers used were 
synthesised by Eurofins MWG.  
 
2.2 Buffers and Solutions 
Alkaline phosphatase buffer  
100 mM Tris pH 9.5, 50 mM MgCl2, 100 mM NaCl, 0.1 % (v/v) Tween-20  
 
Bleaching solution 
MetOH/H202/formamide (14:6:1) 
 
Blocking solution for western blots   
5 % (w/v) skimmed milk powder (Marvel) in TBST (1 x).  
 
Blotting buffer for western blots  
25 mM Tris-HCl, 150 mM glycine, 20 % (v/v) methanol, 1 % (w/v) SDS.  
 
Bouin’s fixative 
10 % formaldehyde, 5 % (v/v) acetic acid 
 
Glycosylation lysis buffer  
0.1 % SDS, 0.1 % β-mercaptoethanol, 0.5 % IGEPAL in PBS 
 
Hybridisation buffer  
50 %  (v/v) formamide, 5 x SSC buffer (Sigma), 0.1 % (w/v) Torula RNA, 0.01 % (w/v) 
heparin, 1 x Denhart‟s solution (Sigma), 0.1 % (v/v) Tween-20, 0.1 % (w/v) CHAPS, 10 mM 
EDTA.  
 
In situ hybridisation blocking reagent (5 x) 
10 % (w/v) DIG blocking reagent (Roche) in MAB. Autoclaved and stored at 2-8°C.  
 
Maleic Acid Buffer (MAB) 
100 mM Maleic acid, 150 mM NaCl. Adjusted to pH 7.5 
 
MEMFA Salts (10 X) 
1 M MOPS (pH 7.4), 20 mM EGTA, 10 mM MgSO4. Autoclaved 
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MEMFA Fixative 
1 X MEMFA salts, 3.7 % formaldehyde (Baker) 
 
Marc’s Modified Ringers (MMR) (10 x) 
1 M NaCl, 20 mM KCl, 10 mM MgSO4, 20 mM CaCl2, 50 mM HEPES (pH 7.8). Sterilised by 
autoclaving. 
 
PBS-Tw 
0.1 % Tween-20 in sterile PBS (PAA)  
 
RIPA Buffer  
50 mM Tris-HCl (pH 7.4), 1 % (v/v) NP-40, 0.25 % (w/v) sodium-deoxychloate, 1 mM NaCl, 
complete EDTA-free protease inhibitor cocktail (Roche). 
 
SDS-PAGE running buffer  
25 mM Tris-HCl, 20 mM glycine, 5 % (w/v) SDS  
 
SDS-PAGE loading buffer (5 x)           
60 mM Tris-HCl (pH6.8), 25 % (v/v) glycerol, 2 % (w/v) SDS, 5 % (w/v) β-mercaptoethanol, 
0.025 % (w/v) bromophenol blue. 
 
SSC buffer (20 X) 
0.3 M sodium citrate, pH approx. 7.0, containing 3 M NaCl 
 
Sorenson’s phosphate buffer 
0.2 M NaH2PO4 was added to 0.2 M Na2HPO4 until the pH reached 7.3 
 
TAE (10 x)                        
400 mM Tris-acetate, 10 mM EDTA, pH 8 
 
TBST      
10 mM Tris-HCl (pH7.5), 15 mM NaCL, 0.1 % (v/v) Tween 20 
 
TE Buffer  
10 mM Tris-HCl, 1 mM EDTA  
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2.3 Bacteriological procedures 
2.3.1 Genotypes of bacterial strains used in this study.  
 
Table 2.1. Genotypes of bacteria used in this study.  
Bacterial Strain  Genotype  
XL-1 blue competent 
cells 
recA1 endA1 gyrA96 thi-1 hsdR17 supE44 relA1 lac [F´ proAB 
lacIqZΔM15 Tn10 (Tetr)]. 
XL10-Gold® 
ultracompetent cells 
TetrΔ (mcrA)183 Δ(mcrCB-hsdSMR-mrr)173 endA1 supE44 thi-
1 recA1 gyrA96 relA1 lac The [F‟ proAB lacIqZΔM15 Tn10 (Tetr) 
Amy Camr] 
 
 
2.3.2 Preparation of Luria-Bertani (LB) broth or LB agar 
LB broth and LB agar was prepared according to the manufacturer‟s instructions. Antibiotics 
were used in the following concentrations; ampicillin 0.1 mg/ml, kanamycin 0.025 mg/ml. All 
LB broth and agar preparations were autoclaved and cooled before antibiotics were added.  
 
2.3.3 Bacterial Transformation using XL-1 blue competent cells  
1.7 µl of β-mercaptoethanol was added to 100 µl of chemically competent XL-1 blue cells and 
incubated for 10 min on ice. Approximately 200 ng of DNA was then added and incubated on 
ice for 30 mins. The cells were heat shocked at 42 ºC for 45 s and cooled on ice for a further 2 
min. 900 µl of LB broth was added to cells prior to incubation period of 1 hr at 37 ºC and 225 
rpm. 200 μl of the transformation reaction were plated onto LB agar containing antibiotic and 
incubated at 37 ºC for a minimum of 16 hr. 
 
2.3.4 Blue/white selection of bacteria 
To determine if DNA had inserted into the TA vector pGEM T easy, bacteria were screened 
for the production of β-galactosidase. Screening of bacteria was performed by plating cells 
onto LB ampicillin plates containing 0.1 nM IPTG and 40 μg/ml X-gal. Blue colonies indicated 
lack of insert in the plasmid and were disregarded; the white colonies were selected for further 
culture. 
 
2.3.5 Bacterial Transformation using XL-10 ultracompetent cells  
4 µl of β-mercaptoethanol mix was added to 100 µl of chemically competent XL-10 cells and 
incubated for 10 min on ice. Approximately 200 ng of DNA was then added and incubated on 
ice for 30 mins. The cells were heat shocked at 42 ºC for 30 s and cooled on ice for a further 2 
min. 900 µl of LB medium was added to cells prior to incubation period of 1 hr at 37 ºC and 
225 rpm.  200 μl of the transformation reaction were plated onto LB plates containing 
antibiotic and incubated at 37 ºC for a minimum of 16 hr. 
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2.3.6 Bacterial Culture Growth  
Single colonies were isolated from an LB plates containing antibiotic and resuspended in 2-5 
ml (small scale) or 100 ml (medium scale) of LB broth containing antibiotic. The cultures were 
incubated for 16 hrs at 37 ºC and with shaking at 225 rpm. 
 
2.4 Cell Culture procedures 
2.4.1 Cell Culture conditions 
All cells were incubated in their recommended media (stated below) in 75 cm
2
 sterile, non-
pyrogenic, polystyrene flasks at 37 ºC and 5 % CO2. When the cells approached confluency 
they were removed from the flask using trypsin-EDTA (1 x) (PAA) and split at an appropriate 
level into fresh 75 cm
2
 flasks.  
 
2.4.2 Cell Culture Media 
MDCK II cells were incubated in Dulbecco's Modified Eagle Medium (DMEM) (Invitrogen), 
supplemented with 10 % (v/v) FBS (PAA), 100 units/ml penicillin/streptomycin (PAA) and 1 % 
non-essential amino acids (PAA).  
 
HEK293 cells were incubated in Minimum Essential Eagle Medium with L-glutamine (Sigma), 
supplemented with 10 % (v/v) FBS (PAA), 1 % non-essential amino acids (PAA), 0.25 mg/ml 
gentamycin (Sigma) and 100 units/ml penicillin/streptomycin (PAA). 
 
FHL124 cells were incubated in DMEM (Invitrogen), supplemented with 5 % (v/v) FBS (PAA) 
and 100 units/ml penicillin/streptomycin (PAA). 
 
2.4.3 Transient transfections 
MDCK II cells were split 24 hrs prior to transfection and were seeded at a density of 1 x 10
6
 
cells per well of a 6 well plate and transfected with 4 μg of plasmid DNA, or seeded at a 
density of 5 x 10
5 
cells per Transwell® polyester membrane insert (pore size 0.4; Corning) and 
transfected with 1 μg of plasmid. DNA was transfected with Lipofectamine™2000 or 
Lipofectamine™LTX (Invitrogen) in accordance with the manufacturer‟s protocol. Medium was 
changed after 6 hrs.  
 
HEK293 cells were split 24 hrs prior to transfection and 2.5 x 10
5 
cells were seeded per well in 
a 6 well plate. Cells were transfected with 0.4 μg of plasmid DNA using Effectene® 
transfection reagent (Qiagen) in accordance with the manufacturer‟s protocol.  
 
FHL124 cells were split 24 hrs prior to transfection and were seeded at a density of 2.5 X 10
5
 
cells per Transwell® polyester membrane insert (pore size 0.4; Corning) and transfected with 
0.4 μg of plasmid. DNA was transfected with Effectene® transfection reagent (Qiagen) in 
accordance with the manufacturer‟s protocol. 
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2.4.4 Stable cell generation 
The expression vector pcDNA3.1(-) contains a Neomycin resistance gene (Figure 9.1). Stable 
cell lines expressing pcDNA3.1(-) were created by selecting for resistance to G418/Geneticin 
(PAA). Cloned pcDNA3.1(-) constructs were linearised with the restriction enzyme Bgl II, run 
on an agarose gel and purified by gel extraction (Section 2.5.1.13). MDCK II cells were 
transfected with the linearised plasmid DNA (Section 2.4.3). 48 hrs post-transfection, cells 
were split 1:60 in normal maintenance medium supplemented with 1.5 mg/ml G418. Media 
containing 1.5 mg/ml G418 was changed every 24 hrs for 5 days. Resistant colonies were 
then isolated and cultured further in 24 well plates. Stable transfected cells were identified by 
western blot.  
 
2.5 Nucleic acid procedures 
2.5.1 DNA methods 
2.5.1.1 Polymerase chain reaction (PCR) 
Routinely, PCRs were performed using Reddymix™ Custom PCR master mix (Abgene) with 
extension at 72 °C. When sequence fidelity was essential or for the amplification of long 
templates, Reddymix™ HiFidelity PCR master mix (Abgene) was used with extension at 68 
°C. Reactions were composed of 1 x Reddymix™ master mix, 0.5 µM forward and reverse 
primers and 20 ng of DNA. 10 % DMSO (v/v) was additionally added for the amplification of 
GC rich templates. PCR reactions were prepared in 0.2 ml thin-walled PCR tubes or plates 
(Thermo Scientific) and cycled on an MJ Research Peltier Thermal Cycler PTC-225 or a G-
Storm GS482 Thermal cycler. Unless otherwise indicated, standard PCR cycling parameters 
used for all reactions, stated in Table 2.2.  
 
Table 2.2. Cycling parameters for PCR 
Cycling stage Temperature (°C) Time  Cycles  
Initial denaturation 94 °C 5 min X 1  
Denaturation 94 °C   30 s  
 X 30 Annealing Y °C  30 s 
Extension 72 / 68 °C  1 min kb
-1
 
Final Extension 72 / 68 °C  10 min X 1  
Hold 4 °C Hold X 1 
Y = optimal annealing temperature for each primer pair. Optimal annealing temperatures were 
identified by running gradient temperatures. Primer sequences and annealing temperatures 
are available in section 9.3. 
 
For RT-PCR reactions, the expression of a housekeeping gene was used as a control for 
equal cDNA. The endpoint of all RT-PCRs was determined to be within the exponential phase 
by performing linearity reactions. Controls for the reverse transcriptase reaction (no reverse 
transcriptase added to the cDNA reaction – Section 2.5.13) and controls for the PCR reaction 
(no template control) were also performed. All primers were designed to amplify across at 
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least one intron and all RT-PCR products were sequenced to confirm indentity (Section 
2.5.1.8).   
 
2.5.1.2 Agarose gel electrophoresis 
DNA was analysed by gel electrophoresis typically with 2 % (w/v) (for fragments up to 1 kb) 
and 1 % (w/v) (for fragments over 1 kb) agarose-TAE gels. DNA was mixed with 1 X DNA 
loading dye (Bioline) and loaded into wells next to a standard size marker (Bioline) and run at 
typically 90 V in 1 X TAE buffer until the desired separation was achieved. Loading dye was 
not added to Reddymix samples. Prior to casting 0.01 % (v/v) µl of SafeView Nucleic Acid 
Stain (NBS Biologicals) was added to all gels to enable the DNA to be visualised on a 
transilluminator (UV light of wavelength 205 nm).  
 
2.5.1.3 Measurement of DNA concentration  
DNA concentration was measured by resolving a known volume on an agarose gel and 
comparing band intensity with standardised DNA molecular weight ladders (Hyperladder I and 
IV; Bioline).  DNA concentration was also measured with a photometer at 260 nm 
(BioPhotometer plus, Eppendorf). 
 
2.5.1.4 Column purification of PCR products 
PCR products were purified using either Montage Millipore PCR clean up kit or Geneclean 
Turbo kit in accordance with the manufacturers‟ instructions and eluted in dH20.  
 
2.5.1.5 Enzymatic purification of PCR products 
When large numbers of PCR products were required to be purified the enzyme ExoSAP-IT
® 
(USB) was used accordance with the manufacturer‟s instructions.  
 
2.5.1.6 Ethanol precipitation of DNA 
To each DNA sample 2.5 X the sample volume of 95 % (v/v) ethanol and 0.1 X the sample 
volume of 3 M sodium acetate (pH 5.3) was added. When purifying sequencing reactions 
EDTA was added to a final concentration of 10 mM.  Samples were then incubated at room 
temperature for 15 min. The DNA was pelleted at 16000 RCF for 15 mins and washed in 70 % 
(v/v) ethanol. The pellet was air-dryed and resuspended in nuclease-free H20.   
 
2.5.1.7 Phenol/chloroform extraction of DNA 
DNA was purified using a phenol/chloroform extraction method when the resultant DNA was 
required to be of particularly high quality. Samples were made up to 200 μl with TE buffer and 
an equal volume of phenol:chloroform (1:1) was added. The samples were vortexed for 15 s, 
and centrifuged at 16,000 RCF for 45 s. The upper phase was removed and transferred to a 
new 1.5 ml tube. The phenol phase was re-extracted by adding 100 μl of TE buffer, vortexing 
for 15 s, and centrifuging at 16,000 RCF for 45 s. The upper phase was added to the 
supernatant from the previous extraction. Next 30μl of 3 M Sodium Acetate pH 5.2, 3 μl of 1 M 
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MgCl2 and 800 μl 100 % EtOH were added and the sample was vortexed and incubated on 
dry ice for 1 hr. The sample was pelleted at 14,000 rpm at 4 °C for 15 mins. The supernatant 
was discarded and the pellet was washed with 70 % EtOH, pelleted for 5 mins and the 70 % 
EtOH was removed. The pellet was left to air dry and resuspended in nuclease-free dH20 
 
2.5.1.8 BigDye™ Terminator Cycle Sequencing  
Sequencing analysis of plasmid DNA and PCR products was performed using BigDye™ 
Terminator version 3.1 (Applied Biosystems). The 10 μl sequencing reactions consisted of the 
following components: 10-250 ng of plasmid DNA or purified PCR product, 0.5 µM 
sequencing primer, 0.875 x BigDye Sequencing buffer and 1 µl of BigDye™ Terminator v3.1 
and dH20 up to 10. Sequencing reactions were prepared in 0.2 ml thin-walled PCR tubes and 
cycled on an MJ Research Peltier Thermal Cycler PTC-225. The following cycling parameters 
were used: 94 °C for 4 mins followed by 25 cycles of 94 °C for 20 s, 55 °C for 20 s and 60 °C 
for 4 mins.  
 
2.5.1.9 Purification of sequencing products  
Ordinarily, DNA was then precipitated in ethanol (Section 2.5.1.6) and the resultant pellet was 
sequenced by the core facility using (Faculty of Life Sciences, The University of Manchester) 
an ABI Prism 3100 Genetic Analyser (Applied Biosystems).  
 
For large-scale sequencing in 96 well plates, DNA was purified using Sephadex plates. 
Sephadex plates were prepared by filling wells of Millipore multiscreen 96 well filter plates 
with Sephadex and adding 300 μl of dH2O. Catch plates were placed under the Sephadex 
plates and the plates were centrifuged at 910 RCF for 5 mins. The catch plates were then 
emptied, 150 μl of dH2O was added to each Sephadex plate and the plates were centrifuged 
at 910 RCF for 5 mins with catch plates underneath. The catch plates were then emptied. A 
10 ul volume of Hidi Formamide (Applied Biosystems) was placed into each well of a non-
skirted 96 well plate. The sequencing reaction product was placed into the wells of the 
Sephadex plate, and then centrifuged at 910 RCF for 5 mins into the plate containing Hidi 
Formamide. Sequencing was then performed on an ABI Prism 3100 (Applied Biosystems) at 
the core facility (Faculty of Life Sciences, The University of Manchester). 
 
2.5.1.10 Sequence trace analysis 
Patient sequences were compared to a wildtype reference sequence using the Staden 
package Pregap4 1.4b1. All other sequencing reactions were analysed using BioEdit version 
7.0.  
 
2.5.1.11 Plasmid DNA Preparation  
Plasmid DNA was extracted from overnight bacterial cultures (LB containing the appropriate 
antibiotic) using QIAprep mini kit® (2-5 ml) and the QIAprep midi kit® (100 ml) (Qiagen) 
plasmid preparation kits according to manufacture‟s protocol. DNA samples extracted using 
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QIAprep mini kit® and the QIAprep midi kit® were eluted with 50 µl and 500 µl of dH20, 
respectively.  
 
2.5.1.12 Restriction enzyme digests 
Restriction enzyme digests were performed using restriction enzymes (NEB or Roche) and 
their corresponding buffers according to the manufacturers‟ protocols.  
 
2.5.1.13 Gel extraction of DNA 
PCR fragments or digested DNA fragments were run on agarose gels (Section 2.5.1.2). DNA 
was visualised on a transilluminator (UV light of wavelength 205 nm) and the desired bands 
were excised from the gel using a clean scalpel blade. DNA was extracted from the gel 
fragments using QIAquick Gel® extraction kit (Qiagen) in accordance with manufacturer‟s 
protocol. DNA was eluted in nuclease-free H20.  
 
2.5.1.14 Dephosphorylation of DNA  
Alkaline phosphatase was used to prevent the re-ligation of linearised vector DNA with 
compatible ends. Dephosphorylation of DNA was achieved by adding 2 U of alkaline 
phosphatase (Roche) to approximately 1 µg of DNA and alkaline phosphatase buffer (1 x) 
(Roche). Reactions were incubated at 37 ºC for 1 hr. The reaction was terminated by adding 
one tenth of the volume of 0.2 M EGTA and heating 65 ºC for 10 mins.  
 
2.5.1.15 Ligation of DNA 
Following restriction enzyme digests ligation reactions were performed with 50-100 ng vector 
DNA, 1 U T4 DNA ligase and 1 x buffer (Promega). Vector and insert ratios were determined 
using the following equation:  
 
vector (ng) x insert (kb) x ratio of insert: vector = insert (ng) 
vector (kb)   
 
Generally, ratios of 1:1 and 3:1 insert:vector were used for ligation reactions. Reactions were 
incubated at room temperature for 4 hrs or 4 ºC overnight. A vector only ligation was used as 
a negative control.  
 
2.5.1.16 TA cloning 
PCR products were cloned using pGEM-T Easy kit (Promega) (Figure 9.2) in accordance with 
the manufacturer‟s protocol.  
 
2.5.1.17 Site-directed mutagenesis 
Site-directed mutagenesis was performed using the Quikchange Lightning kit (Stratagene) in 
accordance with the manufacturer‟s instructions. Dpn I digestion was extended to 1 hr. 
2.5.2 RNA methods 
2.5.2.1 RNA extraction from cells and tissues 
Chapter 2 
 
  
49 
RNA was extracted and purified from mammalian cells using the QIAshredder® kit (Qiagen) 
and the RNeasy® mini kit (Qiagen) according to the manufacturer‟s instructions. Tissue was 
snap-frozen, crushed by RNase-free pestle and mortar and RNA from 30 mg of tissue was 
purified using the QIAshredder® kit (Qiagen) and the RNeasy® mini kit (Qiagen) according to 
the manufacturer‟s instructions. RNA was eluted in 30 µl RNase-free dH20. The integrity of 
each RNA extraction was confirmed by loading 5 µl of each sample into 2 % agarose 
gel and confirming the presence of the 28S and 18S rRNA bands. RNA extracted from human 
eyes at Carnegie stage 21 and Foetal stage 2 was obtained from the MRC-Wellcome Trust 
Human Developmental Biology Resource at Newcastle University, UK. 
 
2.5.2.2 DNase treatment of RNA 
30 µl RNA sample was DNase treated with 2U RNase-free DNase I (Ambion) and 3.5 µl 
DNase I Buffer at 37 °C for 1 hr. The sample was heated to 70 °C for 10 min to denature the 
enzyme. 
 
2.5.2.3 Reverse transcription 
Approximately 1 µg of RNA, 0.2 µg of random hexamers (Roche) and RNase-free H20 up to 
total volume of 12 µl was mixed and heated at 70 ºC for 10 mins and incubated on ice for 5 
mins. Next, 10 U of RNase inhibitor (Roche), 1 mM dNTPs, 1 x Bioscript reaction buffer and 
50 units of Bioscript reverse transciptase (Bioline) were then added to the reaction and 
incubated at 37 ºC for 1 h. Reactions were terminated by incubating at 70 ºC for 10 min to 
denature the reverse transcription enzyme. Control reactions replacing the enzyme with 
RNase-free H20 were performed for each sample. All resultant cDNA was stored at 4 ºC and 
used within 1 week of synthesis. 
 
2.5.2.4 In vitro transcription of DIG-labelled probes 
Linearised DNA fragments used for in situ hybridisation probe transcription were purified by 
Phenol/Chloroform extraction followed by ethanol precipitation (Section 2.5.1.7). 2.5 μg 
linearised template DNA was incubated in 1 X transcription buffer (Roche), 2.5 μl DIG RNA 
labelling mix,  90 U RNA polymerase (T7 or SP6), 20 U RNase inhibitor (Roche) and made up 
to a volume of 50 μl with nuclease-free H20 at 37°C for 2 hrs. 1 μg RNAse-free DNase was 
added and incubated for 10 mins at 37°C. RNA was then purified on a Micro bio-spin P6 
column (Biorad) in accordance with the manufacturer‟s instructions, ethanol precipitated 
(Section 2.5.1.6) on dry ice and resuspended in nuclease-free H20. The integrity and 
concentration of the RNA was identified by heating a sample to 65 °C for 5 mins and running 
on an agarose gel against a marker of known size and concentration. The probe was then 
diluted in hybridisation buffer at a concentration of 1 μg/mL and stored at -20 °C.  
 
2.5.2.5 In situ hybridisation 
The following steps were performed at room temperature unless otherwise stated. 
Dehydrated Xenopus tropicalis embryos (Section 2.7.5) were placed in glass vials and 
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washed in 75 % MetOH in H2O, 50 % MetOH in H2O, 25 % MetOH in PBS-Tw for 5 mins 
each, followed by two washes in PBS-Tw. The embryos were then incubated in 5 µg/ml 
Proteinase K for 10 mins, followed by two 5 min washes in 0.1 M triethanolamine (pH 7.5). 
2.5 µL of acetic anhydride was added to the 0.1 M triethanolamine sample and incubated for 
5 mins. A further 2.5 µL of acetic anhydride was then added and incubated for 5 mins, 
followed by two washes in PBS-Tw. Embryos were then fixed in 4 % formaldehyde in PBS-
Tw, followed by two 5 min washes PBS-Tw. Samples were then incubated in hybridisation 
buffer for 3 hrs at 60 ºC followed by an over-night incubation at 60 ºC in hybridisation buffer 
containing a DIG-labelled RNA probe (1 μg/mL).  
 
The probe was removed and stored at –20 ºC for future use. Probes were re-used no more 
than three times. Embryos were washed in hybridisation buffer for 5 mins followed by four 20 
min washes in 2 X SSC buffer. Embryos were RNase-treated with 10 µL RNase cocktail 
(Roche) per ml of 2 X SSC for 30 mins at 37ºC, and the RNase was removed by washing with 
2 X SSC at room temperature for 10 mins. Samples were subsequently washed twice with 0.2 
X SSC at 60ºC for 20 mins each. SCC buffer was removed by washing the samples twice for 
5 mins in MAB. Samples were blocked for 1 hr in 1 x in situ blocking solution in MAB, and 
incubated with anti-DIG alkaline phosphatase Fab fragments in blocking solution containing 
20 % (v/v) heat-treated Lamb serum (HTLS) for 5 hrs. Excess antibody was removed by 
washing three times in MAB for 5 mins followed by an overnight wash in MAB at 4ºC. 
Samples were then washed two times in alkaline phosphatase buffer and incubated in the 
dark in alkaline phosphatase buffer containing 4.5 µL/mL NBT (Roche) and 3.5 µL/mL BCIP 
(Roche). When a satisfactory signal was obtained, samples were washed two times in MAB 
for 5 mins and fixed in Bouin‟s fixative for 1 hr. Embryos were then rinsed in 70 % EtOH and 
washed for 5 mins in MetOH and bleached on a light box in bleaching solution. Bleaching 
solution was gradually replaced with PBS and samples were stored in PBS at 4ºC.  
 
2.5.2.6 In vitro transcription of capped mRNA for injection 
Template DNA was linearised downstream of the termination codon and purified by 
phenol/chloroform extraction. Capped mRNA was transcribed using the mMESSAGE 
mMACHINE® Kit (Ambion). The following reaction was assembled at room temperature: 10 µl 
NTP/CAP, 2 µl 10 x transcription buffer, 2 µl T7 polymerase, 1 µg template DNA and H20 up 
to 20 µl. The reaction was performed at 37 °C for 2 hrs. Template DNA was digested by the 
addition of 1 U RNase-free DNase I for 10 mins at 37 °C. RNA was purified on a Micro bio-
spin column (Section 2.5.2.4) and ethanol precipitated (Section 2.5.1.6) on dry ice and 
resuspended in nuclease-free H20.  The integrity and concentration of the RNA was identified 
by heating a sample to 65°C for 5 mins and running on an agarose gel against a marker of 
known size and concentration. 
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2.6 Protein Procedures 
2.6.1 Generation of custom polyclonal antibodies 
2.6.1.1 Sigma-Genosys custom polyclonal antibodies 
Synthetic peptides and antibody production was performed by Sigma-Genosys. KLH-
conjugated peptides were synthesised and purified on a Discovery HS C18 HPLC Column (3 
µm) by Sigma-Genosys. New Zealand White Rabbits were selected as the host animal. Single 
peptides were used to immunise two rabbits. Peptides and their final purity are as follows: 
 
Protein Rabbit Numbers Peptide Purity 
Tmem114 4671 & 4672 KLH-[C]-ARALSLSQRQDQAI 59 % 
Tmlp1 4673 & 4674 KLH-[C]-SLSQRPGVPHSVIL 66 % 
Purified antibodies were supplied as solutions. 1 mg of dehydrated peptide was resuspended 
in 50 µl acetic acid and made up to 1 ml with sterile PBS as according to manufacturer‟s 
instructions.  
 
Table 2.3. Sigma-Genosys antibody production schedule. *estimated. Complete Freund's 
Adjuvant (CFA); Incomplete Freund's Adjuvant (IFA). 
Time Procedure Additional information 
Day 0 Pre-immune bleed 
Immunisation #1 200 μg peptide in CFA 
Day 14 Immunisation #2 100 μg peptide in IFA 
Day 28 Immunisation #3 100 μg peptide in IFA 
Day 42 Immunisation #4 100 μg peptide in IFA 
Day 49 Test bleed #1 5 ml 
Day 56 Immunisation #5 100 μg peptide in IFA 
Day 63 Test bleed #2 
ELISA 
5 ml 
Day 70 Immunisation #6 100 μg peptide in IFA 
Day 77 Test bleed #3 5 ml 
Day 155 Immunisation #7 100 μg peptide in IFA 
Day 162 Test bleed #4 5 ml 
Day 179 Immunisation #8 100 μg peptide in IFA 
Day 186 Final Bleed Tmem114: 56 ml, 52 ml  
Tmlp1: 61 ml 68 ml 
Day 214* Purification 
ELISA  
 
2.6.1.2 New England Peptide custom polyclonal antibodies 
Synthetic peptides and antibody production was performed by New England Peptide. 
Peptides and their final purity are as follows: 
Protein Rabbit Numbers Peptide Purity 
Tmem114 F4140 & F4141 KLH-[C]-ARALSLSQRQDQAI >85 % 
Tmlp1 F4142 & F4144 KLH-[C]-SLSQRPGVPHSVIL >85 % 
1 mg of dehydrated purified antibody was resuspended in 1 ml distilled H20 as according to 
manufacturer‟s instructions. Resuspended purified antibodies were aliquoted and stored at -
80°C.  
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Table 2.4. New England Peptide antibody production schedule 
Time Procedure Additional information 
Day 0 Pre-immune bleed 
Immunisation #1 
5 mL per rabbit 
peptide in CFA 
Day 14 Immunisation #2 peptide in IFA 
Day 28 Immunisation #3 peptide in IFA 
Day 42 Immunisation #4 No details available 
Day 49 Production bleed #1 
ELISA 
40-50 mL 
Day 56 Immunisation #5 No details available 
Day 63 Production bleed #2 
ELISA 
40-50 mL 
Day 70 Immunisation #6 No details available 
Day 77 Production bleed #3 40-50 mL 
Day 84 Final bleed 
Purification 40-50 mL antiserum per column 
 
2.6.2 Antibodies used in this study 
Table 2.5. Primary antibodies used in this study. Abbreviations: Western blot (WB), 
immunofluorescence (IF), immunohistochemistry (IHC), overnight (O/N). 
Primary Antibody Technique Supplier Temp Time Working 
dilution  
Custom polyclonal anti-
mTmem114 final bleed 
WB, IHC 
IF 
Sigma 4 °C 
RT 
O/N 
1 hr 
1:1000 
Custom polyclonal anti-
mTmem114 purified 
WB, IHC 
IF 
Sigma 4 °C 
RT 
O/N 
1 hr 
1:20 
Custom polyclonal anti-
mTmlp1 final bleed 
WB 
IF 
Sigma 4 °C 
RT 
O/N 
1 hr 
1:1000 
Custom polyclonal anti-
mTmlp1 final bleed 
WB 
IF 
NEP 4 °C 
RT 
O/N 
1 hr 
1:1000 
Custom polyclonal anti-
mTmlp1 purified  
WB 
IF 
NEP 4 °C 
 
O/N 
1 hr 
1:200 
Mouse monoclonal anti-
V5 tag IgG2a   
WB, IF 
 
AbD Serotec  RT 1 hr 1/2,000 
 
Rabbit polyclonal anti-
ZO-1 (61-7300) 
IF Invitrogen  RT 1 hr 1/1,000 
Rat monoclonal  anti-ZO-
1 (R26.4C) 
IF Developmental Studies 
Hybridoma Bank 
RT 1 hr 1:200 
FITC conjugated mouse  
monoclonal anti-E-
Cadherin IgG2a  (612130) 
IF  BD Biosciences  RT 45 
mins 
1/1,000 
Mouse monoclonal anti–
GM130 IgG1  
IF BD Biosciences RT 1 hr 1/1,000 
Goat polyclonal anti-
GRP94 
IF Santa Cruz Biotechnology RT 1 hr 1/200-
1/500 
Mouse monoclonal anti–
GAPDH 1gG1 
WB Santa Cruz Biotechnology RT 1 hr 1/20,000 
Goat polyclonal anti-β-
actin 
WB Santa Cruz Biotechnology RT 1 hr 1/20,000 
Rabbit primary antibody 
isotype control (08-6199) 
IHC Invitrogen 4 °C O/N Neat 
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Table 2.6. Secondary antibodies used in this study. Abbreviations: Western blot (WB), 
immunofluorescence (IF), immunohistochemistry (IHC). 
Secondary Antibody Tech
nique 
Supplier Incubation 
temperature 
Incubation  
Time 
Working 
dilution  
Goat anti-mouse HRP WB Pierce RT 45 mins  1/2,000 
Goat anti-rabbit HRP WB Pierce RT 45 mins  1/2,000 
Rabbit anti-goat HRP WB Pierce RT 45 mins  1/2,000 
AlexaFluor 488 chicken 
anti-mouse IgG (H+L) 
IF  Invitrogen RT 45 mins  1/2,000 
AlexaFluor® 488 goat anti- 
mouse IgG (H+L) 
IF Invitrogen RT 45 mins  1/2,000 
AlexaFluor® 594 goat anti- 
mouse IgG (H+L) 
IF Invitrogen RT 45 mins  1/2,000 
AlexaFluor® 488 goat anti- 
rabbit IgG (H+L) 
IF Invitrogen RT 45 mins  1/2,000 
AlexaFluor® 594 goat anti- 
rabbit IgG (H+L) 
IF Invitrogen RT 45 mins  1/2,000 
AlexaFluor® 488 goat anti- 
rat IgG (H+L)  
IF Invitrogen RT 45 mins  1/2,000 
 
Table 2.7 Labelled stains used for immunofluorescence and immunohistochemistry 
Name Target Supplier Incubation 
temperature 
Incubation  
Time 
Working 
Conc. 
Phalloidin-
Tetramethylrhodamine B 
isothiocyanate (P1951) 
Filamento
us actin 
Sigma-
Aldrich 
RT 45 mins  2.5μg/m
L 
VECTASHIELD® Hard Set 
Mounting Medium with DAPI 
(H-1500) 
DNA Vector  RT -  1.5μg/m
L 
 
 
2.6.3 Sample lysis and preparation 
Cells or tissues homogenised by pestle and mortar were lysed in ice cold RIPA buffer 
containing complete protease inhibitor cocktail (Roche), rotated for 30 mins at 4 °C, 
centrifuged at 4 °C for 15 mins. The supernatant was taken to a new tube to which 5 X SDS 
loading buffer was added.  
 
2.6.4 In vitro transcription and translation  
Proteins were in vitro transcribed and in vitro translated from plasmid DNA using the Human 
In Vitro Glycoprotein Expression Kit for DNA Templates (Pierce) in accordance with the 
manufacturer‟s instructions.  
 
2.6.5 De-glycosylation assays 
2.6.5.1 N-glycosidase F (PNGase F) de-glycosylation assay 
For N-glycosylation assays, cells were lysed in glycosylation lysis buffer and EDTA was 
added to a final concentration of 50 mM. 1 U PNGase F was then added to 25 µl samples 
and incubated at 37 °C overnight. 5 µl of 5 X SDS loading buffer was added to each sample 
to stop the reaction. 
Chapter 2 
 
  
54 
2.6.5.2 Endo H de-glycosylation assay  
2 µl of 10 X denaturation buffer was added to 18 µl of RIPA lysates and the samples were 
incubated at room temperature for 10 mins. 2.5 µl of G5 reaction buffer and 2 µl of Endo H 
(Roche) were added and incubated at 37 °C for 2 hrs. The reaction was stopped by the 
addition of 6 µl of 5 X SDS loading buffer.   
 
2.6.6 SDS Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
SDS-PAGE was used for the detection and analysis of protein. Prior to SDS-PAGE, samples 
denatured at 37 °C for 20 mins. The denatured proteins were then run on an SDS denaturing 
gel at 120-150 volts in 1 X running buffer next to an appropriately sized molecular weight 
marker (Bio-rad). Components of the gels were as follows:  
 
Stacking Gel  
625 mM Tris HCl pH 6.8, 0.1 % (w/v) SDS, 4 % (v/v) acrylamide/bis, 0.075 % (w/v) 
ammonium persulphate, 0.2 % (v/v) Tetramethylethylenediamine (TEMED). 
 
Resolving Gel           
375 mM Tris HCl pH 8.8, 0.1 % (w/v) SDS, 12-15 % (v/v) acrylamide/bis, 0.125 % (w/v) 
ammonium persulphate, 0.1 % (v/v) TEMED 
 
2.6.7 Coomassie stain  
SDS-PAGE gels washed three times in dH20 for 5 mins, then incubated in EZBlue
TM
 gel 
staining reagent (Sigma) for 1 hr at room temperature and then washed in dH20 until bands 
appeared visible and background stain was removed.  The whole protocol was performed on 
a rocking platform. Gels were stored in dH20 at 4 °C. 
 
2.6.8 Western Blot Analysis 
Following SDS-PAGE gels were washed in transfer buffer and layered between a pre-soaked 
nitrocellulose membrane and three layers of filter paper in a semi-dry blotter (Bio-Rad). 
Protein was transferred onto the membrane at 15 volts for 1 hr. The membrane was then 
incubated with the following solutions on a rocking or rotating platform. Membranes were 
blocked in 5 % (w/v) skimmed milk powder (Marvel) in TBST for 2 hrs at room temperature. 
Membranes were then incubated in primary antibody diluted in 5 % skimmed milk 
powder/TBST as according to Table 2.5. The membranes were then washed 3 times for 10 
mins in TBST. Next membranes were incubated in secondary antibody in skimmed milk 
powder in TBST for 45 mins at room temperature (Table 2.6). The membranes were then 
washed 3 times for 10 mins in TBST. Finally, the membranes were incubated with enhanced 
chemiluminescence Western Blotting Detection Reagents (Amersham Bioscience) for 1 min, 
and then exposed onto Hyperfilm enhanced chemiluminescence (Amersham Bioscience) until 
bands were visible. Films were developed in GBX Developer (Kodak), fixed in GBX fixer 
(Kodak) and washed in dH20.  
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2.6.9 Western blot stripping 
When re-probing of a membrane was required, the nitrocellulose membrane was stripped by 
incubating in Restore Western Blot stripping buffer (Pierce) for 30 mins at 37 °C. The 
membrane was then washed three times in TBST for 10 mins and then blocked and probed 
with antibodies as described in Table 2.5 and Table 2.6.  
 
2.6.10 Peptide competition assay  
Antibodies were incubated with an equal volume of peptides at a concentration of 1 mg/ml at 
room temperature for 2 hrs. The antibody was then diluted to the optimised working dilution 
(Table 2.5). 
 
2.6.11 Mass spectrometry  
MALDI (Matrix Assisted Laser Desorption/Ionisation) TOF-TOF (Time Of Flight) mass 
spectrometry was performed by the Bimolecular analysis core facility (Faculty of Life 
Sciences, The University of Manchester) using an Ultraflex II (Bruker). Bands of interest were 
excised from EZBlue-stained SDS-polyacrylamide gels using sterile razor blades. Gel pieces 
were incubated in acetonitrile for 5 mins and then dried by vacuum centrifugation. The protein 
within each sample was then reduced by incubating in 10 mM dithiothreitol in 25 mM 
ammonium hydrogen carbonate at 56 C for 1 hr. The samples were incubated in alkylating 
agent, 55 mM Iodoacetamide, in 25 mM ammonium hydrogen carbonate at 22 C for 45 mins 
in a dark room. The samples were washed with 25 mM ammonium hydrogen carbonate, 
acetonitrile, 25 mM ammonium hydrogen carbonate and acetonitrile for 5 mins each 
respectively. The gel pieces were dried by vacuum centrifugation. Samples were incubated in 
10 % (v/v) trypsin solution (12.5 ng/µl) in 25 mM ammonium hydrogen carbonate at 4 C for 
45 mins and then at 37 C for 16 hrs. Peptides were extracted from the samples with 20 mM 
ammonium hydrogen carbonate for 20 mins followed by two further extractions with 5 % 
formic acid in 50 % acetonitrile. Supernatant samples were pooled and concentrated. Peptide 
samples were stored at -20 C until mass spectrometry analysis was performed.  
 
Nano-scale liquid chromatographic tandem mass spectrometry (nLC-MS/MS) was performed 
by the Fingerprints Proteomics Facility at the University of Dundee. Bands of interest were 
excised from EZBlue-stained SDS-polyacrylamide gels using sterile razor blades, and shipped 
to the Fingerprints Proteomics Facility at ambient temperature in 1.5 ml sterile tubes. Gel 
bands were further sectioned and the proteins in the gel were digested by and in-gel digestion 
procedure in a laminar flow cabinet. The digests were then fractioned by Strong Cation 
eXchange into 10 or more fractions prior to 1D nLC-MS-MS. Obitrap protein identification 
analysis was performed on a 4000 QTRAP (Applied Biosystems) MS-MS system by 
personnel at the Fingerprints Proteomics Facility. Identified protein fragments were compared 
to the International Protein Index (IPI) and Genbank databases. 
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2.6.12 Immunofluorecent staining of cell lines 
Non-polarised cells were grown on chamber slides (Scientific Lab Supplies Ltd). In order to 
polarise MDCK II cells the cells were grown on Transwell® polyester membrane inserts (pore 
size 0.4; Corning) for 48 hrs. Cells were fixed 48 hrs post-transfection. Cells were then rinsed 
3 times with PBS on ice and cells were fixed in a methanol:acetone mix (1:1) for 10 mins and 
rehydrated with PBS for 10 mins. Alternatively, cells were rinsed 3 times with PBS on ice and 
cells were fixed with 4 % paraformaldehyde in PBS for 20 min. Cells were then washed for 2 x 
5 min with PBS. Autofluorescence of the sample was quenched by 3 x 5 min washes with 
0.25 % NH4Cl. Cells were subsequently permeabilised with 0.1 % Triton X-100 for 10 min and 
washed for 2 x 5 min with PBS. 
 
Cells were blocked in 5 % FBS in PBS for 30 min at room temperature and incubated in 
primary antibody in block solution at room temperature for 1 h. Cells were then washed with 3 
x 5 min PBS plus 0.1 % Tween-20 (PBS-Tw) and incubated for a further 20 mins in block 
solution. Cells were then incubated with secondary antibody(s) in block solution at room 
temperature for 1 h and subsequently washed for 3 x 5 min with PBS-Tw. Transwell filters 
were then cut from the inserts and mounted onto microscope slides. The chambers on 
chamber slides were removed. Cover slips were finally mounted onto a microscope slide with 
VECTASHIELD® Hard Set Mounting Medium with DAPI (H-1500) (Vector Laboratories) and 
sealed with nail varnish. Stained cells were visualised on a Leica DM 5000 microscope and 
for the majority of experiments, images were taken on a Nikon upright confocal microscope 
(Section 2.6.14).  
 
2.6.13 Immunohistochemistry 
For staining, OCT embedded sections were washed four times for 5 mins in PBS, and 
blocked for 1 hr at room temperature in 5 % goat serum (Abcam). Slides were then incubated 
in primary antibody in blocking solution or a rabbit isotype control at 4 °C overnight in a humid 
container. Slides were washed two times for 10 mins in PBS followed by 10 mins in blocking 
solution. Blocked slides were incubated with fluorescent secondary antibodies at appropriate 
concentrations in a dark chamber for 45 mins at room temperature and then washed three 
times in PBS for 10 mins. Cover slips were finally mounted with VECTASHIELD® Hard Set 
Mounting Medium with DAPI (H-1500) (Vector Laboratories) and sealed with nail varnish. 
Stained cells were visualised on a Leica DM 5000 microscope and in some cases images 
were taken on a Nikon upright confocal microscope (Section 2.6.14). 
 
2.6.14 Confocal microscopy  
Images were collected using a Nikon C1 confocal on an upright 90i microscope with a 60 x 
1.40 Plan Apo objective and 3 x confocal zoom. The confocal settings were as follows; 
pinhole 30 μm, scan speed 400 Hz unidirectional, format 1024 x 1024. Images for DAPI, 
Alexa Fluor 488 and Alexa Fluor 594 were excited with the 405 nm, 488 nm and 594 nm laser 
lines respectively.  
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2.6.15 Transmission electron microscopy 
Stable MDCK II cells expressing mTmem114 were cultured on Transwell® polyester 
membrane inserts (pore size 0.4; Corning) for 5 days. Samples were fixed with 4 % PFA in 
0.1 M phosphate buffer overnight. The fixed cells were then prepared for imaging by Dr. 
Aleksandr Mironov, an experimental officer in the Electron Microscopy Facility, Faculty of Life 
Sciences University of Manchester. The samples were dehydrated through the series of 
ethanol and embedded in LR White resin that was polymerized over 48 hrs at 4 °C. Sections 
of 70 nm thickness were labelled with primary and subsequently secondary antibodies 
conjugated with 10 nm colloidal gold. After labelling sections were contrasted with 1 % uranyl 
acetate in water for 10 min. Images were acquired with FEI Tecnai 12 Biotwin microscope at 
80 kV accelaration voltage by Dr. Aleksandr Mironov. 
 
2.7 Xenopus tropicalis procedures 
2.7.1 Induction of ovulation and obtaining embryos 
To prime adult females for ovulation, 15 U of pregnant mare serum gonadotropin (PMSG) was 
injected into the dorsal lymph sac 72 hrs before full induction. To induce ovulation, females 
were injected with 150 U of human chorionic gonadotropin (hCG). The male was also injected 
with 150 U of hCG. The oocytes were collected 3-4 hrs post-induction. Oocytes were collected 
manually by squeezing the abdomen of the females and then placed in a Petri dish coated 
with L-15 media supplemented with 10 % FBS.  
 
2.7.2 Fertilisation of oocytes 
Adult males were anaesthetised in 0.1 % MS222 for 25 mins. A reflex test was performed to 
confirm anaesthetisation and the male was sacrificed via pithing methods. Testes were 
removed and homogenised in L-15 containing 10 % FBS using mini-homogeniser/1.5 ml tube 
immediately before use. Homogenised testes in L-15 containing 10 % FBS were pipetted on 
to unfertilised oocytes and incubated for 2 mins. The fertilising oocytes were then covered 
with 0.1 x MMR for 20 mins, removed, and replaced with 2 % free-base cysteine in 0.1 x MMR 
at pH 7.8-8.0 for 20 mins to remove the jelly from the embryos. Cysteine was removed by 
washing three times in 0.1 x MMR, with a final wash into 0.1 x MMR + 3 % Ficoll. 
 
2.7.3 Injection of embryos 
Embryos in 3 % Ficoll in 0.1 x MMR were placed on 800 μm meshes in petri dishes. The 
solution was removed until the surface tension holds the embryos in place. Typically, 1 nl of 
diluted morpholino, DNA or capped mRNA was injected at the 1-2 cell stage for bilateral 
injections, or injected into one cell at the 4 cell stage for unilateral injections using a 
Picospritzer microinjector (Nanotech). Injected and uninjected embryos were then placed in 3 
% Ficoll in 0.1 x MMR on agarose (1 % (w/v) in 0.01 x MMR). Dividing embryos were counted 
and sorted into 6-well dishes coated with 2.5 % agarose in 0.1 x MMR and incubated in 0.1 x 
MMR with 1 x gentamycin at 22-25 °C. Embryos were removed to normal culture at stage 4. 
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2.7.4 Culture and phenotyping of embryos 
Embryos were routinely cultured to stage 45 in 6-well plates (approximately 50 embryos per 
well) in 0.1 x MMR containing 1 x gentamycin. Developmental stages were assessed in 
accordance with Nieuwkoop and Faber (1967). Phenotyping of morpholino-injected embryos 
was performed at stages 41-43. Phenotyping of EGFP-injected embryos was performed at 
stages 33-35. Phenotyping of capped mRNA-injected embryos was performed 16 hrs post-
injection.  
 
2.7.5 Fixing embryos for in situ hybridisation  
Membranes were removed from embryos manually using forceps. The embryos were 
incubated in MEMFA for 2 hrs, washed in 30 % MetOH: 70 % MEMFA, 50 % MetOH/:50 % 
MEMFA, 70 % MetOH: 30 % MEMFA, for 10 mins each, washed in 100 % MetOH and stored 
in fresh 100 % MetOH at -20 ºC. 
 
2.8 Histology 
2.8.1 OCT embedding and sectioning 
Lenses from sacrificed adult mice were washed in PBS on ice, fixed in 4 % paraformaldehyde 
at room temperature for 10 mins, and washed three times for 10 mins in PBS. Lenses were 
mounted, and sectioned by the University of Manchester core histology facility. Fixed lenses 
were mounted in OCT compound on pre-chilled chucks. 10 mm thick sections (equatorial 
plane) were cryosectioned at -18 °C on a cryostat (Shandon AS260) and placed on poly-L-
lysine-coated slides. Slides were stored at – 80 °C until use.  
 
2.8.2 Parrafin embedding and sectioning 
Whole sacrificed Xenopus tropicalis embryos were washed in sterile PBS on ice, and fixed in 
MEMFA overnight at 4°C. Samples were then dehydrated in 30 %, 50 % and 70 % EtOH-
sterile PBS for 1 hr each. Samples were then processed for paraffin was embedding on a 
Shandon Citadel 2000 tissue processor using the following protocol. Samples were immersed 
in 70 % IMS three times for 30 mins, followed by three immersions in 90 % IMS for 30 mins 
each. Samples were finally dehydrated in 100 % IMS three times for 30 mins. Dehydrated 
tissues were then immersed in xylene three times for 30 mins each at room temperature. 
Finally samples were immersed in paraffin at 58 °C two times for 1 hr each. Samples were 
then manually orientated and embedded in paraffin at 58 °C. Once set, the paraffin block was 
sectioned at 5 µm using a rotary microtome. Sections were placed on poly-lysine-coated 
slides and dried overnight at 37 °C.  
 
2.8.3 Haematoxylin and eosin staining of sections 
Sections were stained with hematoxylin and eosin by immersing in the following reagents 
consecutively at room temperature (Table 2.8). Slides were then mounted in Histomount 
mouting medium (National diagnostics) and covered with a glass cover slip. 
 
Chapter 2 
 
  
59 
Table 2.8 Haematoxylin and eosin staining solutions 
Wash Reagent Time 
(mins:ss) 
Wash Reagent Time 
(mins:ss) 
1 Xylene 5:00 13 Tap H20 2:00 
2 Xylene 3:00 14 Tap H20 5:00 
3 Xylene 3:00 15 Eosin 0:30 
4 100 % IMS 3:00 16 Distilled H20 1:00 
5 100 % IMS 2:00 17 70 % IMS 1:00 
6 100 % IMS 2:00 18 95 % IMS 1:00 
7 95 % IMS 2:00 19 100 % IMS 
IMS 
2:00 
8 70 % IMS 2:00 20 100 % IMS 2:00 
9 Tap H20 2:00 21 100 % IMS 2:00 
10 Haematoxylin 4:00 22 Xylene 2:00 
11 Tap H20 3:00 23 Xylene 3:00 
12 Acid alcohol 0:04 24 Xylene 5:00 
 
 
2.9 Bioinformatics 
The URLs for software used are available in Section 9.1. Accession numbers for sequences 
used are available in Section 9.2.  
 
2.9.1 Topology prediction 
Topologies were predicted using default settings of the prediction tools HMMTOP, TMMOD, 
TMPRED, TOPPRED, TMHMM and Philius. 
 
2.9.2 Signal peptide prediction 
Signal peptides were predicted using both neural network (NN) and Hidden Markov Model 
methods in the SignalP3.0 software. Signal peptides were also predicted using default 
settings of Philius. 
 
2.9.3 Glycosylation prediction 
N- and O-glycosylation sites were predicted using default settings of the NetNGlyc1.0 Server 
and NetOGlyc3.1 Server, respectively. 
 
2.9.4 Phosphorylation prediction 
Phosphorylation sites were predicted at tyrosine, threonine and serine residues using the 
NetPhos2.0 software and the kinases predicted to act at the identified sites were predicted 
using NetPhosK1.0 software. 
 
2.9.5 Palmitoylation prediction 
Palmitoylation sites were predicted using the CSS-Palm2.0 software with the high threshold 
setting. 
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2.9.6 Sulphation prediction 
Sulphation sites were predicted using the Sulfinator prediction tool.  
 
2.9.7 Molecular mass prediction 
The molecular mass of proteins was predicted using the average setting on the Compute 
pI/MW tool. 
 
2.9.8 Multiple alignments 
Typically multiple alignments were created using ClustalW with default settings at the EBI 
server or using default settings of ClustalW embedding in the BioEdit software. On some 
occasions manual readjustments to the alignment were made. For phylogenetic tree 
construction sequences were aligned using default settings of the ClustalW embedded in the 
Seaview software. 
 
2.9.9 Pairwise alignment 
Percentage pairwise identities were determined using default settings of the ALIGN software. 
 
2.9.10 Phylogenetic tree construction 
Phylogenetic trees were constructed using Seaview software. Trees were constructed from 
aligned sequences (Section 2.9.8) using the neighbour-joining method based on observed 
distances with gap sites ignored. Bootstrap proportions (Felsenstein 1985) were used to 
assess the robustness of tree with 10,000 bootstrap replications. Bootstrap values of less than 
50 were not considered significant.  The protein Clarin-1 was used as an outgroup as 
recommended by (Adato et al. 2002; Price et al. 2005). 
 
2.9.11 Gene structure identification 
Where available the gene structure was retrieved from the Ensembl database. The gene 
structure of TMEM114 was previously reported (Jamieson et al. 2007). The gene structure of 
TMLP1 was determined by comparing the cDNA sequences to genomic DNA sequences.
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Chapter 3: In  silico analysis of TMEM114 and  TMLP1
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3.1 Introduction 
As is evident from Chapter 1, there is little reported information about TMEM114 and the 
protein it encodes. Jamieson et al., who first identified TMEM114, determined its exomic 
structure and the 223 amino acid encoded protein. The protein was found to have a predicted 
transmembrane topology that was similar to that of the PMP-22/EMP/MP20 family of proteins. 
However, the relationship of TMEM114 to these other proteins was not investigated. Some 
TMEM114 orthologues were identified such as in mouse, chicken and zebrafish, but 
information regarding some intermediate species and lower species was lacking. Also, the 
presence or absence of functional motifs and post-translational modifications was not 
reported. Therefore, in this chapter, the aim was to expand upon the available information 
about TMEM114 using in silico techniques. This information would then a) lead to greater 
understanding of TMEM114‟s relationships and functionality and b) be used to devise 
appropriate experiments to investigate its functional role. Prior to the undertaking of this 
project, as part of a Blastp (http://blast.ncbi.nlm.nih.gov/) database search using the 
TMEM114 protein sequence to identify putative orthologues, a novel putative human protein 
was identified. This chapter thus encompasses the analysis of TMEM114 and this novel 
putative protein of which no analysis had previously been performed. 
 
3.2 Identification of TMLP1 
As stated in the introduction, a novel putative protein (XP_946151.1) was identified which is 
encoded by a gene with five exons located at 17q25.3 (LOC283999) (Urquhart, unpublished) 
(see Section 3.8 for exon structure). The encoded protein is 223 amino acids in length, the 
same length as TMEM114. When both proteins are compared by pairwise alignment, they 
share 43 % amino acid identity and 61 % similarity (Figure 3.1). Due to its similarity to 
TMEM114, this protein has been named TMEM114-like protein 1 (TMLP1).  
 
 
Figure 3.1. Amino acid sequence of TMLP1 aligned with TMEM114. Alignment of human 
TMEM114 with its paralog TMLP1 showing their similarity. Black highlight = identical amino acid.  Grey 
highlight = similar amino acids. Sequences were aligned with ClustalW. 
 
3.3 Predicted topologies of TMEM114 and TMLP1 
3.3.1 Topology prediction 
The transmembrane topology of TMEM114, predicted using the transmembrane topology 
prediction tool TMHMM (Sonnhammer et al. 1998), has previously been reported (Jamieson 
et al. 2007). TMEM114 has four predicted transmembrane domains (TMDs) with two 
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extracellular loops (ECLs) and short intracellular amino- (N-) and carobxy- (C-) termini. To 
support this predicted topology, four further transmembrane topology prediction tools were 
used. Although there are slight differences in the positioning of the TMDs the overall topology 
of TMEM114 as having four TMDs with a short intracellular C-terminus is retained (Table 3.1). 
 
Table 3.1. Topology predictions for TMEM114 and TMLP1. Numbers refer to amino acid 
numbering from N- to C-termini. TMD  = transmembrane domain 
 HMMTOP TMMOD TMPRED TOPPRED TMHMM 
Inside 1-5 1-11 1-7 1-7 1-4 
TM1 6-29 12-35 8-33 8-28 5-27 
Outside 30-105 36-105 34-108 29-103 28-106 
TM2 106-129 106-130 109-135 104-124 107-129 
Inside 130-135 131-133 136-136 125-132 130-133 
TM3 136-159 134-158 137-161 133-153 134-156 
Outside 160-185 159-188 162-193 154-182 157-186 
TM4 186-210 189-209 194-213 183-203 187-209 
Inside 211-223 210-223 214-223 204-223 210-223 
 
 HMMTOP TMMOD TMPRED TOPPRED TMHMM 
Inside 1-3 1-3 1-3 1-3 1-4 
TM1 4-27 4-27 4-27 4-24 5-27 
Outside 28-95 28-95 28-95 25-94 28-96 
TM2 96-120 96-106 95-120 95-115 97-119 
Inside 121-124 117-122 121-124 116-121 120-125 
TM3 125-149 123-148 125-147 122-142 126-148 
Outside 150-173 149-171 148-188 143-188 149-209 
TM4 174-198 172-196 189-209 189-209   
Inside 199-203 197-223 210-223 210-223   
 
 
To determine if TMLP1 also has a transmembrane topology, all five transmembrane topology 
prediction tools were used (Table 3.1). All five topology prediction tools predicted TMLP1 to 
be a transmembrane protein, four of which predicted it to have four transmembrane domains 
(i.e a tetraspan topology). The predicted topology consists of a short intracellular N-terminus, 
two extracellular loops, the first (ECL1) of which is larger than the second (ECL2), a short 
intracellular loop between TMD2 and TMD3 and an intracellular C-terminus. Of the four, two 
tools [HMMTOP (Tusnady and Simon 2001) and TMMOD (Kahsay et al. 2005)] predicted an 
ECL2 of <24 amino acids resulting in an internal C-terminus of ~25 amino acids. TMPRED 
(Hofmann and W. 1993) and TOPPRED (von Heijne 1992) predicted ECL2 to be ~40 amino 
acids, shortening the intracellular C-terminus to 13 amino acids. This is a similar topology to 
that predicted for TMEM114. The prediction tool TMHMM, which predicts TMEM114 to have 
TMEM114 
TMLP1 
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four transmembrane domains (Jamieson et al. 2007), predicted TMLP1 to have just the first 
three TMD domains with a long extracellular C-terminus .  
 
3.3.2 Signal peptide prediction 
Eukaryotic membrane proteins contain signal peptides which are necessary for the insertion 
of the proteins into the endoplasmic reticulum (ER) membrane. The prediction tool SignalP 
(Bendtsen et al. 2004) predicts the probability of a protein containing a signal peptide and the 
probability that the predicted peptide is cleaved or uncleaved after transport. Predictions are 
made using one of two methods: neural networks (SignalP-NN) or Hidden Markov Models 
(SignalP-HMM). Signal peptides were predicted in both TMEM114 and TMLP1. For TMEM14 
SignalP-NN predicted a cleavage site of the predicted signal peptide between residues p.A26 
and p.I27 and SignalP-HMM between residues p.G28 and p.T29. This predicted signal 
peptide encompasses the first transmembrane domain (TMD1), which is predicted to end at 
p.I27 (Jamieson et al. 2007). Cleavage sites for signal peptide in TMLP1 were predicted 
between residues p.S28 and p.29D (SignalP-NN) or between p.A27 and p.S28 (SignalP-
HMM) which also encompass TMD1 (Table 3.1).  
 
3.3.3 Combined signal peptide and topology prediction 
The predicted signal peptides for TMEM114 and TMLP1 consist of the intracellular N-terminus 
and TMD1. Cleavage at these sites would result in loss of TMD1, making the N-terminus in 
the mature protein extracellular. However, in the presence of downstream TMDs, predicted 
signal peptides may remain uncleaved (known as signal anchors) acting as the first 
transmembrane domain of the protein (Schatz and Dobberstein 1996). There are some 
examples of proteins with multiple transmembrane proteins with signal peptides, e.g. 
calcitonin receptor (Uniprot P30988). The combined signal peptide and topology prediction 
tool Philius (Reynolds et al. 2008) is designed specifically for transmembrane proteins, was 
used to test prior predictions made (Section 3.3.1 and 3.3.2). TMEM114 is predicted to have a 
cleaved signal peptide with cleavage occurring between amino acids p.I27 and p.G28 (Figure 
3.2). Confidence in the signal peptide prediction was 63 %. The TMD and ECL predictions 
were similar to previously described (Jamieson et al. 2007). Confidence in this prediction was 
63 % for the topology and 66 % for the overall prediction. TMLP1 was predicted to have a 
similar structure, with cleavage occurring between residues p.S28 and p.D29, as predicted by 
SignalP-NN (Figure 3.2). Confidence in the signal peptide prediction was high (97 %).  Philius 
predicted an intercellular C-terminus of 23 amino acids, similar to that predicted by HMMTOP 
and TMMOD (Table 3.1). Confidence in this prediction was 83 % for the topology and 99 % 
for the overall prediction.  
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Figure 3.2. Signal peptide and membrane topology for TMEM114 and TMLP1 as 
predicted by Philius. TMEM114 contains a signal peptide (red) of 27 amino acids and three 
transmembrane domains (yellow). Between the transmembrane domains lie large extracellular domains 
(green) and short intracellular regions (blue). TMLP1 contains a signal peptide (red) of 28 amino acids 
and three transmembrane domains (yellow). A long intracellular C-terminus of 23 amino acids is 
predicted. 
 
3.3.4 Extracellular loop 1 (ECL1) 
3.3.4.1 Prosite motif PDOC01045 
As discussed in section 1.7.2, TMEM114 shows homology to the Pfam00822 family of 
transmembrane proteins. This family of small (~18-25 kDa) integral membrane proteins 
encompasses the claudins, MP20, PMP22 and epithelial membrane proteins-1, -2 and -3 
(EMP-1, -2, -3). These proteins contain four transmembrane domains with two extracellular 
loops, the first of which is larger than the second. The first extracellular loop (ECL1) contains 
a conserved W-GLW-C-C motif (Prosite motif PDOC01045) (Figure 3.3). This transmembrane 
topology and the W-GLW-C-C motif are also features of the voltage dependent calcium 
channel γ subunits, a more distally related group of proteins. ECL1 is functionally important for 
both claudins and the γ subunits (Tomita et al. 2004; Wen et al. 2004). To begin to elucidate 
the function of TMEM114 and TMLP1, both proteins were compared to Pfam00822 family 
members and γ subunits to identify shared properties and domains.  
 
To determine if TMLP1 also contains a W-GLW-C-C motif in ECL1, an alignment of ECL1 
from Pfam00822 family members and the voltage dependent calcium channel γ subunits was 
performed. ECL1 in TMEM114 and TMLP1 are larger than those in claudins but of similar size 
to that of the γ subunits (Figure 3.3). TMEM114 and TMLP1 also contain the PDOC01045 
motif in ECL1. The complete W-GLW-C-C motif is not present in EMP2, EMP3, MP20, 
TMEM47, PERP, claudin-10b and claudin-15 as these proteins lack the conserved glycine (G) 
residue. In the Prosite annotation of the PDOC01045 motif, the final cysteine (C) is 
immediately preceded by either S, T, D, E, N, Q, or H, but alternative residues are found in 
TMEM114 and TMLP1. The spacing between the two cysteines is generally less than nine 
amino acids in the majority of family members, but is greater than twenty amino acids in γ1, 
γ6 and claudin-like protein 24 (CLP24).  The majority of the claudins and the γ subunits 
contain a glycine residue (G) four residues before the final cysteine, but this glycine is not 
present in TMEM114, or the EMPs, CLP24, TMEM47 and PERP. The majority of family 
members also contain an arginine-alanine (RA) sequence 3-4 amino acids from TMD2 which 
TMLP1 
TMEM114 
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is present in TMLP1 but not in TMEM114.  
 
3.3.4.2 Glycosylation 
Glycosylation is one of the most abundant protein modifications in eukaryotes (Turnbull and 
Field 2007). Glycosylation is the addition of oligosaccharides to specific amino acids and is a 
common feature in secreted proteins and membrane proteins with extracellular regions (Cao 
et al. 2009). Addition of oligosaccharides to asparagine residues, known as N-linked 
glycosylation, occurs in a co-translational manner in the ER. N-glycosylation may promote 
protein folding by interacting with chaperones (Tokhtaeva et al. 2010) and may affect sorting 
to specific membrane domains (Vagin et al. 2009). O-linked glycosylation is the post-
translation addition of oligosaccharides to serine or threonine residues and may also have a 
role in protein trafficking (Yeaman et al. 1997). All eight γ subunits contain predicted N-
glycosylation sites in ECL1 as do EMP-1,-2,-3, PMP22 and MP20 (Price et al. 2005). Only two 
claudins contain predicted N-glycosylation sites in ECL1 (CLDN-1 and -12) (Price et al. 2005).  
 
The NetNGlyc 1.0 Server (Gupta et al. 2004b) was used to identify putative N-glycosylation 
sites in the ECLs of TMEM114 and TMLP1. TMEM114 contains 2 predicted sites in ECL1 at 
residues p.N55 and p.N89 (Figure 3.3). These predicted glycosylation sites are conserved 
across species (Figure 3.4A). TMLP1 contains a single predicted site at residue p.N41 (Figure 
3.3). However, both murine and rat Tmlp1 lack the conserved asparagine-linked site (Figure 
3.4B). No O-linked glycosylation sites were predicted for TMEM114 or TMLP1 by NetOGlyc 
3.1 (Julenius et al. 2005). 
 
3.3.5 Extracellular loop 2 (ECL2) 
In TMEM114, TMLP1 and other Pfam00822 family members the second extracellular loop 
(ECL2) is shorter than ECL1. No functional motifs have been identified to date in Pfam00822 
family members or in the calcium channel γ subunits. To identify any common residues or 
motifs, ECL2 of TMEM114, TMLP1, Pfam00822 family members and the voltage dependent 
calcium channel γ subunits were aligned (Figure 3.5). The regions of ECL2 adjoining the 
transmembrane domains in TMEM114 and TMLP1 were similar, beginning with the residues 
YIxY (where x is any amino acid) and ending with the GWS sequence of amino acids. These 
motifs were similar to those of γ2, γ3, γ4, γ5, γ7, γ8 and claudin-16. Almost all members of the 
Pfam00822 family had a tyrosine (Y) or phenylalanine (F) close to the end of ECL2. The 
majority of claudins had a FY or FF motif in the centre of ECL2 and some claudins had 
conserved proline (P), lysine (K) and glutamic acid (E) amino acids. ECL2 of the EMPs, 
PMP22, MP20, CLP24, PERP and TMEM47 were shorter and lacked the conserved motifs 
present in the other family members.  
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Figure 3.3. Alignment of the first extracellular loop (ECL1) of TMEM114, TMLP1 and 
Pfam00822 proteins. Identical residues present in more than 70 % of sequences are highlighted.  
Predicted N-linked glycosylation sites (NetNGlyc) are boxed in red. To facilitate alignment, gaps were 
introduced (-) and some amino acids were removed: (1) = RIPMDDSKTCGPIT. (2) = 
RLWQADVPVDRDTCGPAE. (3) = GGASEKKDPG. (4) = DRTRGGPSPGARAGQ. (5) = EGGGS. ECL1 
sequences were based on TMPRED toplogy predictions. 
 
 
Figure 3.4. Conservation of N-glycosylation sites in TMEM114 and TMLP1. A) Two 
predicted N-glycosylation sites (*) are present in the 1st extracellular loop of TMEM114 at residues 55 
and 89. B) One predicted N-glycosylation site (*) is present in the 1st extracellular loop of TMLP1 at 
residue 41. This site is not present in mouse and rat. Numbers refer to human amino acid sequence. 
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Figure 3.5. Alignment of the second extracellular loops of TMEM114, TMLP1, 
Pfam00822 family members and the voltage dependent calcium channel γ subunits.  
Conserved amino acids are boxed. Amino acids with similar properties are grouped into colour-coded 
groups. Dark green = A/G/I/M/L/V; Red = D/E; Blue = K/R; Light blue = S/T; Black = F/Y; Grey = N/Q; 
Wine = C; Purple = P; Pink = H; Orange = W  
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3.3.6 Carboxy termini 
To determine if the C-termini of TMEM114 or TMLP1 contain conserved motifs the C-termini 
of TMEM114 and TMLP1 orthologues were aligned (Figure 3.6). The C-terminus of TMEM114 
is conserved in mammals, but shows little conservation in chicken (Gallus gallus), African 
clawed frog (Xenopus tropicalis) or zebrafish (Danio rerio) (Figure 3.6A) (Jamieson et al. 
2007). This C-terminus is rich in arginine, serine and leucine residues and terminates with two 
hydrophobic residues (alanine and isoleucine). The C-terminus of TMLP1 in primates is 
distinct from that of non-primates (Figure 3.6B). The final 3 amino acids in primates are 
encoded by a fifth
 
exon not present in non-primates (Section 3.8). In non-primate mammals 
TMLP1 terminates in three hydrophobic residues, but in primates the C-terminus is highly 
polar.  
 
The short intracellular C-terminus of claudins is required for correct localisation and the 
majority of claudins end in tyrosine-valine (YV) PDZ binding motifs which interact with adaptor 
proteins (Figure 3.7) (Itoh et al. 1999; Jeansonne et al. 2003). The C-termini of the γ subunits 
are highly variable in length and four of the subunits (γ2, γ3, γ4, γ8) also contain PDZ binding 
motifs (TTPV) for protein interaction (Milstein and Nicoll 2009). The C-termini of TMEM114 
and primate and non-primate TMLP1 do not contain PDZ-binding motifs and are much shorter 
than the C-termini of claudins and the majority of the γ subunits (Figure 3.7). Although similar 
in size to some of the other family members, the C-termini TMEM114 and TMLP1 show little 
similarity to those proteins in terms of amino acid sequence. 
 
 
Figure 3.6. Alignment of the carboxy termini from TMEM114 and TMLP1 orthologues. 
Carboxy termini and the 4
th
 transmembrane domain (TMD4) as predicted by Philius. Identical residues 
are highlighted in black. Grey = similar residues. Threshold levels for similar residues were 80 % for 
TMEM114 and 66 % for TMLP1. 
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Figure 3.7. Alignment of the carboxy termini of Pfam00822 family members. Depending 
on prediction tools used, TMLP1 has a relatively short (14 residue) or long (24 residue) (brackets) C-
terminus. PDZ binding motifs (blue box) are present in the voltage dependent calcium channel γ2, γ3, γ4 
and γ8 subunits and in the majority of claudins. * = end of protein sequence. To aid alignment the 
following amino acids were deleted from the γ8 subunit: (1) = 
LAGAGGGGGGAVGAFGGAAGGAGGGGGGGGGAGAE,  
(2) = TVTVTGPPAPPAPAPPAPSAPAPGTLAKEAAASNT 
 
 
3.4 Post-translational modifications  
3.4.1 Phosphorylation 
The function of proteins may be regulated by the addition and removal of phosphates. To 
assess whether TMEM114 and TMLP1 are potentially regulated by phosphorylation, 
phosphorylation sites were predicted using NetPhos2.0 (Blom et al. 1999) and the kinases 
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predicted to act at the identified sites were determined using NetPhosK 1.0 (Blom et al. 2004). 
A number of phosphorylation sites were predicted for TMEM114, all of which were in non-
transmembrane regions (Figure 3.8). One serine site was conserved down to Xenopus 
tropicalis, but the confidence level for this prediction was moderate.  A number of serine sites 
and a single threonine site were conserved in human and mouse. Predictions for TMLP1 
phosphorylation sites show little conservation (Figure 3.9).  
 
A 
hTMEM114        MRVHLGGLAGAAALTGALSFVLLAAAIGTDFWYIIDTERLERTGPGAQDLLGSINRSQPE 60 
mTmem114        MRVRLGALAGAAALSGALSFVLLAAAIGTDFWYIIDTERLERSSQRMRDQ-GPANRSQQE 59 
xTmem114        MKLKLSMLSVFVAVVGILSFISLVVAIGTDFWYIIDASRLEKITN------------FSD 48 
                *:::*. *:  .*: * ***: *..***********:.***:                 : 
 
hTMEM114        PLSSHSGLWRTCRVQSPCTPLMNPFRLENVTVSESSRQLLTMHGTFVILLPLSLILMVFG 120 
mTmem114        PLSSHSGLWRTCRVQSSCTPLMNPFWQENVTVSDSSRQLLTMHGTFVILLPLSLIVMVFG 119 
xTmem114        PLSSHSGLWRMCKFKNKCLPLINPFRLGNLNFTDSQKQLLSMHGTLVILLPLSLILMIFG 108 
                ********** *:.:. * **:***   *:..::*.:***:****:*********:*:** 
 
hTMEM114        GMTGFLSFLLQAYLLLLLTGILFLFGAMVTLAGISVYIAYSAAAFREALCLLEEKALLDQ 180 
mTmem114        GMTGFLSFLLRAHLLLLLTGILFLFGAMVTLTGISIYIAYSAVAFREAVCLLEERALLDQ 179 
xTmem114        GMTGFVSILARAYLLLLLTGMLFLFGALVTLTGISIYIAYSAAAFKDAVCILGN-KILED 167 
                *****:*:* :*:*******:******:***:***:******.**::*:*:* :  :*:: 
 
hTMEM114        VDISFGWSLALGWISFIAELLTGAAFLAAARELSLRRRQDQAI 223 
mTmem114        VDIRFGWSLALGWISFVSELLTGVVFLAAARALSLSQRQDQAI 222 
xTmem114        IDIQFGWSLALAWISFITEILTGIAFLVAARVTGLKRRRREQV 210 
                :** *******.****::*:*** .**.***  .* :*: : : 
B 
Homo  sapiens Mus musculus Xenopus tropicalis 
AA Con Kinase AA Con Kinase AA Con Kinase 
T37 0.97 CKII   T37 0.97 CKII        
    S44 1.00 DNAPK        
S57 0.93 DNAPK, ATM, cdc2       S56 0.73 DNAPK, cdc2         
    S62 0.85  S51 0.93   
S76 0.98 P38mapk, PKA, cdk5     S75 0.72 PKA      
S95 0.71  S94 0.83  S83 0.85 DNAPK    
S184 0.77           
S214 0.93 PKC    S213 0.64 RSK,  PKC, PKA             
      S215 0.91 DNAPK, ATM, PKC             
 
Figure 3.8. Predicted phosphorylation sites and the associated kinases for TMEM114. 
A) Alignment of TMEM114 from Homo sapiens (h), Mus musculus (m) and Xenopus tropicalis (x) with 
phosphorylation sites predicted by NetPhos 2.0. Blue = Serine site. Yellow = Threonine site. Bold font = 
predicted transmembrane domain. B) Amino acids (AA) predicted to be phosphorylated with the 
confidence (Con) level of the prediction according to NetPhos 2.0. Predicted kinases which act at the 
site, predicted using NetPhosK 1.0 are also included. Abbreviations: CKII = casein kinase II; DNAPK = 
DNA-dependent protein kinase; ATM = Ataxia telangiectasia mutated; cdc2 = cell division control protein 
2 (or Cyclin dependent kinase 1); P38mapk = p38 mitogen-activated protein kinase; PKA = Protein 
kinase A, cdk5 = Cyclin-Dependent Kinase5; PKC = Protein kinase C; RSK = ribosomal s6 kinase 
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A 
hTMLP1          MARLGALLLAAALGALLSFALLAAAVASDYWYILEVADAGNGSAWPGRAELLSSHSGLWR 60 
mTmlp1          MALLATLLLSAALGALLSFALLAAAVASDYWYILEVADAGG-----LGGVQLFSHSGLWR 55 
cTmlp1          MARLGALLLAAALGALLSFALLVAAVASDYWYVLEVAAAGN------RTQRLSSHSGLWR 54 
                ** *.:***:************.*********:**** **.          * ******* 
 
hTMLP1          ICEGQNGCIPLVDPFASESLDVSTSVQHLILLHRAVIVVLPLSLVLLVCGWICGLLSSLA 120 
mTmlp1          TCEGQNSCVPLIDPFASAGLEVSPSVQHLLSLHRTVMVVLPLSLVLIVCGWVCGLLSSLS 115 
cTmlp1          VCEGQNSCIPLIDPFASENLDVPTSVRHLISLHRAIMVVLPLSLVLVVCGWICGLFSSLA 114 
                 *****.*:**:***** .*:*..**:**: ***:::*********:****:***:***: 
 
hTMLP1          QSVSLLLFTGCYFLLGSVLTLAGVSIYISYSHLAFAETVQQYGPQHMQGVRVSFGWSMAL 180 
mTmlp1          QSVPLLLATGCYFLLGGALTLAGLSIYISYSHLAFVEAARTYGVTHVQNVHISFGWSLAL 175 
cTmlp1          QSVLLLLFTGCYFLLGGALTLVGISVYISYSHLAFAETARQFGPRHVQHVRVGFGWSLAL 174 
                *** *** ********..***.*:*:*********.*:.: :*  *:* *::.****:** 
 
hTMLP1          AWGSCALEAFSGTLLLSAAWTLSLSPPICGHLSPQQVGGRGGD 223 
mTmlp1          AWASCASEVLSGALLLAAARLLSLSQRPGV---PHSVIL---- 211 
cTmlp1          AWGSCASEVLSGILLLTAARALRLSRRQGG---PHSVAV---- 210 
                **.*** *.:** ***:**  * **        *:.*       
B 
Homo sapiens Mus musculus Canis familiaris 
AA Con Kinase AA Con Kinase AA Con Kinase 
S53 0.59         S47 0.99   
         S48 0.99 RSK, PKA 
S83 0.72             
         S79 0.82   
    S86 0.80 PKC      
         S143 0.77   
         T152 0.77   
    T156 0.57 PKC      
S173 0.72 PKC, PKA S198 0.59 RSK, PKC, PKA      
      S200 0.98 DNAPK, ATM  S199 1.00 PKC 
 
Figure 3.9. Predicted phosphorylation sites and the associated kinases for TMLP1. A) 
Alignment of Tmlp1 from Homo sapiens (h), Mus musculus (m) and Canis familiaris (c) with 
phosphorylation sites predicted by NetPhos 2.0. Blue = Serine site. Yellow = Threonine site. Bold font = 
predicted transmembrane domain. B) Amino acids (AA) predicted to be phosphorylated with the 
confidence (Con) level of the prediction according to NetPhos 2.0. Predicted kinases which act at the 
site, predicted using NetPhosK 1.0 are also included. Abbreviations: RSK = ribosomal s6 kinase; PKA = 
Protein kinase A; PKC = Protein kinase C; DNAPK = DNA-dependent protein kinase; ATM = Ataxia 
telangiectasia mutated. 
 
3.4.2 Palmitoylation 
Palmitoylation of membrane proteins increases the hydrophobicity of transmembrane regions 
to promote membrane association. Palmitoylation involves the addition of the lipid palmitate to 
cysteine residues. Palmitoylation sites were predicted using CSS-Palm 2.0 (Ren et al. 2008). 
TMLP1 contains three predicted palmitoylation sites which were conserved across species. 
Scores were highest for the two sites present in TMD2, p.C109 and p.C113 (Figure 3.10). A 
weak, but significant score was obtained for p.C131. TMEM114 contains a single predicted 
site at p.C170 in ECL2 but the score was not significant (data not shown).  
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      hTMLP1          MARLGALLLAAALGALLSFALLAAAVASDYWYILEVADAGNGSAWPGRAELLSSHSGLWR 60 
mTmlp1          MALLATLLLSAALGALLSFALLAAAVASDYWYILEVADAGG-----LGGVQLFSHSGLWR 55 
cTmlp1          MARLGALLLAAALGALLSFALLVAAVASDYWYVLEVAAAGN------RTQRLSSHSGLWR 54 
                ** *.:***:************.*********:**** **.          * ******* 
 
hTMLP1          ICEGQNGCIPLVDPFASESLDVSTSVQHLILLHRAVIVVLPLSLVLLVCGWICGLLSSLA 120 
mTmlp1          TCEGQNSCVPLIDPFASAGLEVSPSVQHLLSLHRTVMVVLPLSLVLIVCGWVCGLLSSLS 115 
cTmlp1          VCEGQNSCIPLIDPFASENLDVPTSVRHLISLHRAIMVVLPLSLVLVVCGWICGLFSSLA 114 
                 *****.*:**:***** .*:*..**:**: ***:::*********:****:***:***: 
 
hTMLP1          QSVSLLLFTGCYFLLGSVLTLAGVSIYISYSHLAFAETVQQYGPQHMQGVRVSFGWSMAL 180 
mTmlp1          QSVPLLLATGCYFLLGGALTLAGLSIYISYSHLAFVEAARTYGVTHVQNVHISFGWSLAL 175 
cTmlp1          QSVLLLLFTGCYFLLGGALTLVGISVYISYSHLAFAETARQFGPRHVQHVRVGFGWSLAL 174 
                *** *** ********..***.*:*:*********.*:.: :*  *:* *::.****:** 
 
hTMLP1          AWGSCALEAFSGTLLLSAAWTLSLSPPICGHLSPQQVGGRGGD 223 
mTmlp1          AWASCASEVLSGALLLAAARLLSLSQRPGV---PHSVIL---- 211 
cTmlp1          AWGSCASEVLSGILLLTAARALRLSRRQGG---PHSVAV---- 210 
                **.*** *.:** ***:**  * **        *:.* 
 
Figure 3.10. Predicted palmitoylation sites for TMLP1. TMLP1 contains three predicted 
palmitoylation sites which are conserved in Homo sapiens (h), Mus musculus (m) and Canis familiaris 
(c). Two sites with the highest prediction scores are present in TMD2. Colours refer to prediction scores: 
Yellow = <1, Green = 1-1.49, Pink 1.5-2. Sites were predicted using CSS-Palm 2.0.   
       
 
3.5 Phylogenetic Analysis of TMEM114 and TMLP1 with Pfam00822 
Both TMEM114 and TMLP1 have similar features to members of the Pfam00822 family of 
claudins, EMPs and voltage dependent calcium channel γ subunits as they have a predicted 
tetraspan topology and contain the W-GLW-C-C motif in ECL1. To determine the relationship 
of TMEM114 and TMLP1 to members of this family a phylogenetic tree was constructed by a 
neighbour-joining method based on ClustalW multiple alignments using the software Seaview 
(Gouy et al. 2010). Bootstrap values are an indicator of how robust branches of a tree are 
(scored as percentages with 100 indicating maximum robustness). Only branches with 
bootstrap values of >50 were considered significant. The claudins form distinct branches from 
the γ subunits and the EMP/PMP/MP20 family members (Figure 3.11), as previously 
described (Price et al. 2005). TMEM114 and TMLP1 show the greatest similarity to each other 
and they cluster with the γ subunits on distinct branches from γ1 and γ6 and from the other γ 
subunits (Figure 3.11). Members of the Pfam00822 family of proteins vary greatly in their 
intracellular domains, particularly the C-termini (Figure 3.5). Therefore, a phylogenetic tree 
was also constructed using the most conserved regions of the proteins in this family, i.e. from 
the beginning of TMD1 to the end of TMD 4. A similar tree was constructed with these 
sequences, with TMEM114 and TMLP1 branching with the γ subunits but distinct from γ1 and 
γ6 and the other γ subunits (Figure 3.12). 
 
Performing a pairwise alignment with of TMEM114 and TMLP1 with each other and other 
members of the Pfam00822 family of proteins confirmed that TMEM114 and TMLP1 show the 
greatest similarity to each other (Table 3.2). TMLP1 shows greatest amino acid identity with 
the γ6 subunit when full-length sequences and TMD1-TMD4 sequences are compared. The 
TMD1-TMD4 region of TMEM114 shows greatest similarity to the γ2, γ3, γ4 and γ8 subunits 
(Table 3.2). 
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Figure 3.11. Phylogenetic tree of human TMEM114, TMLP1 and Pfam00822 proteins. A 
phylogram of full-length protein sequences was constructed using ClustalW and the neighbour-joining 
method. The protein Clarin-1 was used an outgroup.  TMEM114 (green box) and TMLP1 (red box) 
cluster with the voltage dependent calcium channel γ subunits (CACNGs) on distinct branches from the 
claudins and EMP/PMP/MP20 family members. The scale bar indicates the branch length that 
corresponds to 0.05 substitutions per position. Numbers indicate bootstrap values as the percentage of 
10,000 replicates for each branch. Bootstrap values of less than 50 were considered non-significant and 
are not displayed. 
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Figure 3.12. Phylogenetic tree of TMD1-TMD4 of human TMEM114, TMLP1 and 
Pfam00822 proteins. A phylogram of an amino acid alignment of the 1st transmembrane domain 
through to the 4
th
 transmembrane domain was constructed using ClustalW and the neighbour-joining 
method. The protein Clarin-1 was used an outgroup. TMEM114 (green box) and TMLP1 (red box) 
cluster with the calcium channel γ subunits (CACNGs) on distinct branches from the claudins and 
EMP/PMP/MP20 family members. The scale bar indicates the branch length that corresponds to 0.05 
substitutions per position. Numbers indicate bootstrap values as the percentage of 10,000 replicates for 
each branch. Bootstrap values of less than 50 were considered non-significant and are not displayed. 
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Table 3.2. Pairwise alignment of TMEM114 and TMLP1 with voltage dependent calcium 
channel γ subunits and EMPs, MP20, PMP22 and CLP24. Percentage pairwise amino acid 
identities were determined using the ALIGN program (Genestream).   
 TMLP1 MP20 EMP-1 EMP-2 EMP-3 PMP22 CLP24 PERP TMEM47  
TMEM114 42.7 19.8 21.1 23.2 22.0 23.2 20.7 20.3 19.7 full-length 
 42.7 20.9 21.2 21.2 21.4 23.2 22.6 19.9 19.4 TM1-TM4 
           
 γ1 γ2 γ3 γ4 γ5 γ6 γ7 γ8   
TMEM114 20.6 18.1 19.3 21.1 18.1 18.9 16.7 17.6 full-length 
 22.3 25.4 25.6 28.9 23.2 19.4 19.5 26.6 TM1-TM4 
           
           
 TMEM114 MP20 EMP-1 EMP-2 EMP-3 PMP22 CLP24 PERP TMEM47  
TMLP1 42.7 22.2 19.3 22.0 23.7 21.4 20.6 21.9 21.3 full-length 
 42.7 22.1 20.4 23.3 24.2 21.3 21.0 21.1 22.9 TM1-TM4 
           
 γ1 γ2 γ3 γ4 γ5 γ6 γ7 γ8   
TMLP1 22.9 19.8 22.0 21.0 23.5 25.0 21.0 17.4 full-length 
 22.2 23.9 25.4 25.7 26.3 28.7 23.3 23.1 TM1-TM4 
 
 
 
3.6 Identifying orthologues of TMLP1 
In order to identify orthologues of TMLP1 a Blastp search was performed using the predicted 
protein sequence of TMLP1.  A number of TMEM114 orthologues were identified, confirming 
the similarity of TMLP1 to TMEM114. Other hypothetical proteins were also identified in 
animals as evolutionary distant as zebrafish. In zebrafish two distinct protein sequences with 
moderate levels of similarity to TMLP1 were identified (XP_001919554; XP_001340845) both 
annotated as TMEM114-like proteins (Figure 3.13). 
 
 
Figure 3.13. Alignment of putative zebrafish Tmlp1 orthologues XP_001919554 and 
XP_001340845 with human and murine Tmlp1. Black highlight = identical residue in three or 
more proteins. 
 
To determine if either of the zebrafish TMLP1-like proteins is an orthologue of TMLP1, the 
genes surrounding TMLP1 were compared to those surrounding both zebrafish genes. In 
humans, TMLP1 is located on chromosome 17q25.3 and is flanked by threonine aldolase 
pseudogene 1 (THA1P), suppressor of cytokine signalling 3 (SOCS3), cytohesin 1, ubiquitin 
specific peptidase 36 (USP36) and tissue inhibitor of metalloproteinase 2 (TIMP2) on the 
telomeric side. To the centromic side TMLP1 is flanked by a baculoviral IAP repeat (BIRC5), 
arylformamidase (AFMID), thymidine kinase (TK1) and synaptogyrin (SYNGR2) (Figure 
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3.15). The zebrafish gene encoding the protein XP_001919554 (XM_001919519 / 
LOC100150722) is located on chromosome 12 immediately next to threonine aldolase 1 and 
Socs3b. On the other flanking side of LOC100150722 is a baculoviral IAP repeat, cytohesin 1-
like, and Timp2. The zebrafish gene encoding the protein XP_001340845 (XM_001340809 / 
LOC100000694), located on chromosome 3 is in proximity to Socs3a, cytohesin 1, Usp36 and 
Timp2b. On the other flanking side is a Timp2b-like gene and galectin-3. 
 
 
Figure 3.14. TMLP1 and its surrounding genes on human chromosome 17q25.3. Human 
TMLP1 (LOC283999) is flanked by baculoviral IAP repeat (BIRC5), arylformamidase (AFMID), thymidine 
kinase (TK1) and synaptogyrin (SYNGR2) on the centromeric side and threonine aldolase pseudogene 
1 (THA1P) and more distantly, suppressor of cytokine signalling 3 (SOCS3), on the telomeric side. 
Arrows represent direction of transcription. Image taken from NCBI Mapviewer human (Homo sapiens) 
Build 37.1.  
 
Both putative Tmlp1 orthologues in zebrafish are in close proximity to Socs3 genes. The 
genomes of zebrafish and other fish contain two copies of Socs3, but a single copy of Socs3 
is present in the genome of animals that evolved after fish (Wang et al. 2010b). Therefore, if 
one can determine if the SOCS3 present in the human genome is descended from either 
Socs3a or Socs3b, then one may infer that human TMLP1 is descended from the putative 
Tmlp1 close to the ancestor of SOCS3. To identify which zebrafish copy of Socs3 mammals 
show most similarity to a multiple alignment was created using protein sequences (Figure 
3.15). Both Socs3a and Socs3b show significant similarity to murine and human Socs3. It is 
therefore not obvious which zebrafish gene the mammalian genes are descended from.  
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Figure 3.15. Alignment of zebrafish suppressor of cytokine signalling 3 genes Socs3a 
and Socs3b with murine and human Socs3. Sequences were aligned with Clustalw. Numbering 
refers to human SOCS3 amino acids. Black highlight = identical residues 
 
 
In the next attempt to elucidate the conservation of Tmlp1, the aim was to identify Tmlp1 in 
species intermediate to mammals and fish; chicken (Gallus gallus) and X. tropicalis. Using 
Blastp, tBlastn and Blastn searches against nucleotide and EST databases, no sequences of 
reasonable similarity to TMLP1 were identified. Performing the same searches with both 
zebrafish sequences also failed to identify similar proteins. The regions syntenic to 17q25.3 in 
humans were then identified in the chicken genome. In chicken, threonine aldolase 
pseudogene 1 and arylformamidase are present at the same locus but Tmlp1 is not present 
between these genes on MapViewer (Figure 3.16). When the sequence between the two 
genes was downloaded it revealed that there was a gap in the sequence in contig 
NW_001471506.1. Similarly, there are also gaps in the sequence in this region in the 
opossum Monodelphis domestica (NW_001581875.1). 
 
Creating a phylogenetic tree with the TMEM114 orthologues, the TMLP1 orthologues and 
putative zebrafish orthologues and human and zebrafish Pfam00822 family members 
revealed that the putative zebrafish orthologues of Tmlp1 are closer in relationship to TMLP1 
than to other zebrafish proteins (Figure 3.17).  
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Figure 3.16. Chicken contig NW_001471506.1 on chromosome 18. No gene is annotated 
between arylformamidase (Ammd) and L-threonine aldolase. Sequence gaps (black bars) in the contig 
(green bar), show that the sequence between the two genes has not been identified. Arrows represent 
direction of transcription. Image from NCBI Mapviewer chicken (Gallus gallus) Build 2.1.  
 
 
NW_001471506.1 
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Figure 3.17. Phylogenetic tree of human and zebrafish orthologues and putative 
orthologues of TMEM114, TMLP1 and Pfam00822 proteins. A phylogram of full-length protein 
sequences aligned using ClustalW was constructed using the neighbour-joining method. Cldn = claudin; 
CACNG = voltage dependent calcium channel gamma subunit; Dr = Danio rerio (Zebrafish); Mm = 
Macaca mulatta; Mus = Mus musculus; Rn = Rattus norvegicus; Bt = Bos Taurus; Cf = Canis familiaris; 
Md = Monodelphis domestica; Gg = Gallus gallus; Xt = Xenopus tropicalis. The scale bar indicates the 
branch length that corresponds to 0.05 substitutions per position. Numbers indicate bootstrap values as 
the percentage of 10,000 replicates for each branch. Bootstrap values of less than 50 were considered 
non-significant and are not displayed. 
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3.7 Expression of TMEM114 and TMLP1 
ESTs encoding the third and fourth exons of TMEM114 belong to the Unigene cluster 
Hs.150849. ESTs are present in the foetus and more prominently in the adult. Expression is 
restricted to three tissues: prostate (5 transcripts per million (TPM)), lens (47 TPM) and lung 
(94 TPM) (NCBI aceview LOC283953). All lung samples are from carcinoids (rare slow-
growing neuroendocrine tumours) (Dahabreh et al. 2009). Single ESTs for the murine 
orthologue were cloned from the retina, brain, testis, oocyte and stomach (Unigene 
Mm.159318). All murine ESTs were from adult tissue. 
 
ESTs from TMLP1 have been detected in adult brain (hippocampus and hypothalamus) (11 
TPM) and in embryonic stem cells (Unigene Hs.632228). Available cDNA clones from brain 
tissue reveal that it is alternatively spliced (Figure 3.18). When exon 2 is spliced out, 28 amino 
acids of ECL1 are omitted. When exons 2 and 3 are spliced out, 73 amino acids of ECL1, 
TMD2 and TMD3 are omitted. This results in a shift of the TMDs producing a three-TMD 
protein with an extracellular C-terminus (Figure 3.18). 
 
To identify the 5‟UTR of TMLP1 the EST BC042066.1 was compared to the genomic 
sequence. The predicted 5‟UTR was 624 nucleotides in length and omitted 90 nucleotides 
from the genomic sequence. This short sequence begins and ends in intron splice donor and 
acceptor sites (GTXXX and XXXAG, respectively) suggesting that transcription occurs from 
another exon upstream (Exon 1a) of what was previously considered to be exon1 (Figure 
3.19). 
 
             _                         ___ 
TMLP1            MARLGALLLAAALGALLSFALLAAAVASDYWYILEVADAGNGSAWPGRAELLSSHSGLWR 60 
BC036810.1       MARLGALLLAAALGALLSFALLAAAVASDYWYILEVADAGNGSAWPGRAELLSSHSGLWR 60 
BC042066         MARLGALLLAAALGALLSFALLAAAVASDYWYILEVADAGNGSAWPGRAELLSSHSGLWR 60 
                 ************************************************************ 
                  -     - 
TMLP1            ICEGQNGCIPLVDPFASESLDVSTSVQHLILLHRAVIVVLPLSLVLLVCGWICGLLSSLA 120 
BC036810.1       ICEV---------------------------LHRAVIVVLPLSLVLLVCGWICGLLSSLA 93 
BC042066         ICEG-------------------------------------------------------- 64 
                 ***                                                          
 
TMLP1            QSVSLLLFTGCYFLLGSVLTLAGVSIYISYSHLAFAETVQQYGPQHMQGVRVSFGWSMAL 180 
BC036810.1       QSVSLLLFTGCYFLLGSVLTLAGVSIYISYSHLAFAETVQQYGPQHMQGVRVSFGWSMAL 153 
BC042066         -----------------VLTLAGVSIYISYSHLAFAETVQQYGPQHMQGVRVSFGWSMAL 107 
                                  ******************************************* 
 
TMLP1            AWGSCALEAFSGTLLLSAAWTLSLSPPICGHLSPQQVGGRGGD 223 
BC036810.1       AWGSCALEAFSGTLLLSAAWTLSLSPPICGHLSPQQVGGRGGD 196 
BC042066         AWGSCALEAFSGTLLLSAAWTLSLSPPICGHLSPQQVGGRGGD 150 
              ******************************************* 
Figure 3.18. Amino acid sequences encoded by alternatively spliced cDNAs from 
TMLP1. The protein encoded by cDNA BC036810, which lacks exon 2, maintains the same topology as 
full-length TMLP1, but the altered splice site results in the incorporation of a valine (V) in place of glycine 
(G) at p.64. cDNA BC042066.1 lacks both exons 2 and 3 and encodes a protein with three predicted 
transmembrane domains and an extracellular C-terminus. Yellow = TMD, Green = extracellular domain, 
Blue = intracellular domain. The W-GLW-C-C motif is marked by the red bar above the sequence. 
Topology predicted by TMPRED. 
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Genomic GTCCTAGAAGGTTCTTTCTGCCTGTTTTCTCCgtgagtgactggacaggcagaggccggccttgctggagggg 
BC042066.1 GTCCTAGAAGGTTCTTTCTGCCTGTTTTCTCC----------------------------------------- 
  
Genomic gcatttgtaattatgagtgaatccaaaacaaggttttttccttccgcagCCCCCCGCCCGGCTGTGGGGCCCA 
BC042066.1 -------------------------------------------------CCCCCCGCCCGGCTGTGGGGCCCA 
  
Genomic GCCACTGCACTTCACCGGATGCCGTCTGGTTGGTCCTCAGGACTGATACAGACCAGGACCCCAGGGCCAGCCC 
BC042066.1 GCCACTGCACTTCACCGGATGCCGTCTGGTTGGTCCTCAGGACTGATACAGACCAGGACCCCAGGGCCAGCCC  
  
Genomic GTGCCAGGCTCCTATGCTTCCAGGAGCACGGGTGGGTGGTCCTGCTGCCTGGCCGGCCATCCTCCTGGGGTCG 
BC042066.1 GTGCCAGGCTCCTATGCTTCCAGGAGCACGGGTGGGTGGTCCTGCTGCCTGGCCGGCCATCCTCCTGGGGTCG 
  
Genomic GTCTCTGGCCGATCCTCCCTCCTCCTCTCAAGCCCTGCACAGCCCGGCCAGGCAGGTGCATCTTGTTTGGCTG 
BC042066.1 GTCTCTGGCCGATCCTCCCTCCTCCTCTCAAGCCCTGCACAGCCCGGCCAGGCAGGTGCATCTTGTTTGGCTG 
  
Genomic CTGAGGAGCCGGGGGTTCAGGGAAATTAAGGAACGTGCCCAGGGACCCGGGGCCAGCCCGTGGGGACGCTGGG 
BC042066.1 CTGAGGAGCCGGGGGTTCAGGGAAATTAAGGAACGTGCCCAGGGACCCGGGGCCAGCCCGTGGGGACGCTGGG 
  
Genomic ATTGGAGCCCAAGCCCCAGGTTCGCCGCGCGGCTCTCGACTTCCTCTCCTTTCCCCCAGGGGCGAGCTCAGCG 
BC042066.1 ATTGGAGCCCAAGCCCCAGGTTCGCCGCGCGGCTCTCGACTTCCTCTCCTTTCCCCCAGGGGCGAGCTCAGCG 
  
Genomic ACCGCAGAGAGGTGGGGTCGATCTCCCTGCGACCCCAGGGGGCCCGCGAGGCCAGTGCGCGGGCAGGAGCGGG 
BC042066.1 ACCGCAGAGAGGTGGGGTCGATCTCCCTGCGACCCCAGGGGGCCCGCGAGGCCAGTGCGCGGGCAGGAGCGGG 
  
Genomic GACGTGCTCAGAAGAGCCGGGCGCCGCCGCGCCCGCCCGCCCCCCGTCCCCCGGCTCCCGGCTCCGCGCGCCC 
BC042066.1 GACGTGCTCAGAAGAGCCGGGCGCCGCCGCGCCCGCCCGCCCCCCGTCCCCCGGCTCCCGGCTCCGCGCGCCC 
  
Genomic CCCGCCGCCCCCGGGGCCCTGCTACCCCCGACCCGTCCCCTCCCGCCGGCCGCCCCCATGGCCCGGCTGGGCG 
BC042066.1 CCCGCCGCCCCCGGGGCCCTGCTACCCCCGACCCGTCCCCTCCCGCCGGCCGCCCCCATGGCCCGGCTGGGCG 
 
Figure 3.19. Identification of the 5’UTR of TMLP1. Comparison of EST BC042066.1 to the 
genomic sequence revealed a gap in the alignment of 90 nucleotides (lower case). This gap begins with 
a GT and ends in AG suggesting it is an intron. The translation start site (ATG) is underlined and the 
coding sequence is in bold. 
 
 
3.8 Gene structure of TMEM114 and TMLP1 
To look further at the conservation of TMEM114 and TMLP1, the structure of both genes was 
compared in a number of species. When the structure of TMEM114 was being investigated a 
Blastn search with the available sequence for the sequence upstream of TMEM114 revealed 
a gap in the sequence assembly in the human genome project (Figure 3.19A). To identify the 
size and sequence of the gap between the two adjoining contigs, primers were designed to 
cross the gap. PCR amplification with the primers resulted in a 3,360 bp amplicon, 
representing a gap of 1,577 bp (Figure 3.19B). The sequence of this 3.4 kb amplicon was 
then determined by primer walking and submitted to the GenBank database (accession 
number GQ267544.1) (Sequence in Section 9.6). 
 
The exon structure of TMEM114 is largely conserved (Figure 3.21). Exons 2, 3 and 4 do not 
differ in length in different species. However, these exons have different levels of conservation 
of encoded amino acids. The amino acids encoded by exon 3 which form TMD2 and half of 
TMD3 are highly conserved. Exon 4 shows much higher conservation in its encoded 
transmembrane domains regions than in ECL2 or the intracellular C-terminus. Exon 1 shows 
relatively low levels of conservation and differs in length in different species. Two regions 
containing the residues W-GLW-C of the W-GLW-C-C motif are conserved. The residues in 
TMD1 are conserved in mammals (human and mouse) but are less so in chicken and 
Xenopus. Exon 2 is also highly similar in humans and mouse, but is less conserved in chicken 
and Xenopus. 
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Figure 3.20. Identification of the gap between contigs NW_001838341 and 
NW_001838342. A) A Blastn search with the available DNA sequence upstream of exon 1 of 
TMEM114 (red bar) aligned to the contig NW_001838341 (green bar). A gap in sequence between 
NW_001838341  and NW_001838342 (green bar) was identified. Image taken from NCBI Mapviewer 
human (Homo sapiens) Build 37.1. B) Amplification across the gap region between the two contigs 
produced a 3.360 bp amplicon, representing a gap of 1,577 bp.  
 
 
Human TMLP1 contains six exons and encodes TMLP1 from the latter 5 exons, in 
comparison to being encoded by four exons in non-primates. The final exon in TMLP1 
encodes just three amino acids (Figure 3.22). Exon 3 is highly conserved and encodes parts 
of TMD2 and TMD3. The regions of exon 4 that encode TMD3 and TMD4 are also conserved. 
Exon 2 shows some degree of conservation. Exon 1 is highly conserved except for a short 
region in ECL1 that is only present in humans.  
 
Comparison of the structure of TMEM114 and TMLP1 revealed that exons 2 and 3 are the 
same size in both genes, but the intron between them is vastly different in size (Table 3.3). 
The intron/exon boundaries surrounding exon 2 appear similar between both genes, but other 
intron/exon boundaries show little similarity. Exon 3 of TMEM114 and TMLP1 is the same size 
as exon 3 in γ1 and γ6 and is similar to that of the other γ subunits (Table 3.4). Exon 2 of 
TMEM114 and TMLP1 is similar in size to the γ subunits, differing by 1-2 codons. The 
structure of claudins varies with some encoded by single exons (e.g. CLDN2) and others by 
four (e.g. CLDN1) or five (e.g. CLDN16) exons. The sizes of the exons of the latter are distinct 
from those of the γ subunits. The EMPs and PMP22, although similar in size in terms of exon 
3, show little similarity with the γ subunits or TMEM114 and TMLP1 in terms of other exons. 
The structures of CLP-24, TMEM47 and PERP do not match those of the γ subunits or 
TMEM114 and TMLP1.  
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Table 3.3. Intron/exon boundaries of TMEM114 and TMLP1. Intronic splice donor (GT) and 
splice acceptor (AG) sites are in bold. Exon size refers to nucleotides encoding amino acids. Stop 
codons are coloured in red.  
Exon  Gene 5' Sequence  Exon sequence 3' sequence Exon size Intron size 
1a TMLP1   GTCCTAGAAG………TGTTTTCTCC gtaaccggcc…… - 90bp 
              
1 TMEM114 ……gggctcggcg ATGCGGGTGC………ACCTGCCGGG gtaagggtgc…… 220bp 325bp 
1 TMLP1 ……ggccgccccc ATGGCCCGGC………ATCTGCGAAG gtaaccggcc…… 190bp 1,681bp 
              
2 TMEM114 ……tcctatccag TGCAGAGCCC………CAACTTCTCA gtgagtccgg…… 81bp 16,973bp 
2 TMLP1 ……tgtttcccag GGCAGAACGG………CACCTCATCT gtgagtcctg…… 81bp 617bp 
              
3 TMEM114 ……ctcttctaag CCATGCATGG………CTCTTTGGAG gtaggtgccc…… 138bp 2,081bp 
3 TMLP1 ……tttcctgcag TGCTGCACCG………CTGCTGGGGA gtgagtctgg…… 138bp 4,293bp 
              
4 TMEM114 ……ctccctgcag CCATGGTGAC………GGCCATATGA   233bp   
4 TMLP1 ……tctcccccag GTGTCCTGAC………TGGGAGGGAG gtaagagggg…… 250bp 506bp 
              
5 TMLP1 ……cattttacag AGGGGGAGACTGA  13bp   
 
 
Table 3.4. Gene structure of TMEM114 and TMLP1 compared to members of 
Pfam00822. *: exon size refers to nucleotides encoding amino acids. - : exon does not encode amino 
acids 
 TMEM114 TMLP1 γ1 γ6 γ5 γ7 γ2 γ3 γ4 γ8  
Exon 1* 220 190 289 331 196 196 211 211 220 181  
Intron 1 325 1,681 9,106 5,030 1,443 1,472 114,815 89,768 53,057 14,720  
Exon 2 81 81 75 75 87 87 84 84 84 84  
Intron 2 16,973 617 1,032 1,320 1,497 778 20,971 80,145 6,587 1,637  
Exon 3 138 138 138 138 141 141 141 141 141 141  
Intron 3 2,081 4,293 804 12,179 3,818 25,964 1,466 6,378 5,465 2,072  
Exon 4* 233 250 227 239 146 146 536 512 539 770  
Intron 4   506   321 420      
Exon 5*   13     258 258          
            
 MP20 EMP1 EMP2 EMP3 PMP22 CLP24 PERP TMEM47 CLDN1 CLDN2 CLDN16 
Exon 1* 301 78 78 78 78 280 214 253 233 - 324 
Intron 1 4,575 1,890 3,879 598 1,456 7,365 10,632 30,694 8,947 7,499 13,892 
Exon 2 150 97 91 103 100 156 141 180 165 693 103 
Intron 2 1,778 105 5,495 1,728 19,482 12,705 4,085 13,380 2,618  2,322 
Exon 3 135 141 147 141 141 245 227 266 85   165 
Intron 3 242 712 4,835 808 8,390    1,729  3,387 
Exon 4* 62 158 188 170 164      163   192 
Intron 4           1,397 
Exon 5*                      134 
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3.9 Clarification of the database entries for TMLP1 
Note: The 223 amino sequence used for TMLP1 was based on the GenBank accession 
XP_946151.1 which was identified through the blast search with the TMEM114 protein 
sequence. However, since this sequence was first identified, the GenBank annotation has 
changed. The accession XP_946151.1 has been replaced by NP_001139001.1 which 
describes a 394 amino acid protein. This 394 amino acid protein does not contain the W-
GLW-C-C motif and is predicted to be a globular protein and not a transmembrane protein 
(Philius). This predicted protein sequence is a translation of the predicted mRNA sequence 
NM_001145529.1 which is based in part on the EST BC042066.1 (Figure 3.18, 3.19). 
Translation of this EST in the +3 frame produces the 394 amino acid protein NP_001139001. 
Translation of this EST is the +1 frame produces the splice variant of TMLP1 encoded by 
exons 1, 4 and 5, based on the exonic structure devised in this chapter (Figure 3.22). 
 
Thus, both proteins are predicted to be encoded from the same transcript. The inclusion of 
exon 3, as found in the EST BC036810 (Figure 3.18), does not disrupt the correct frame of 
either of the predicted proteins. However, inclusion of exon 2 which encodes the latter part of 
ECL1 in TMLP1, would result in a premature stop codon being encoded in NP_001139001. 
NP_001139001 shows no similarity to any protein in the human genome and no functional 
motifs were identified in the predicted protein. Thus it is much more likely that the protein 
encoded by locus 283999 is TMLP1 and not NP_001139001. This will be confirmed if 
transcripts including exon 2 can be detected.  
 
On the Ensembl database, both the predicted proteins have been annotated from Loc283999, 
The 196 amino acid isoform of TMLP1 is annotated ENSP00000364084, and the 394 amino 
acid protein encoded from the same locus is annotated ENSP00000402790. However, this 
conflicts with the annotation on the GenBank database as ENSP00000364084 refers to 
NP_001139001. To clarify, for future reference, the Ensembl annotations will be used (i.e. 
ENSP00000364084 = TMLP1 and ENSP00000402790 = the 394 amino acid protein 
NP_001139001) (Table 3.5).   
 
Table 3.5. Accession numbers for predicted proteins encoded by loc283999. The 
Ensembl accession numbers and names are used in this study. 
 
Name Protein type AA Frame Genbank Accession Ensembl Accession 
TMLP1 Transmembrane 196 +1 - ENSP00000364084 
? Globular 394 +3 NP_001139001/ 
ENSP00000364084 
ENSP00000402790 
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3.10 Discussion 
3.10.1 Identification of a novel gene TMLP1 
Through a Blastp search a novel hypothetical protein similar to TMEM114 was identified. This 
protein, named TMEM114-like protein 1 (TMLP1), shares 43 % amino acid identity with 
TMEM114 (Figure 3.1, Table 3.2). This level of amino acid identity is above the “twilight zone” 
of 20-30 % identity at which level it is difficult to assess homology (Doolittle 1987; Pevsner 
2009). This suggested that the proteins may be related. Both proteins are the same size (223 
amino acids), have the same predicted topology and both contain a conserved motif in ECL1.  
 
In order to learn more about the conservation of TMLP1 and to possibly identify a shared 
ancestor of TMEM114 and TMLP1, orthologues of TMLP1 were searched for. Orthologues 
were identified in placental mammals, but not in marsupials, chicken or X. tropicalis. However, 
the contig which contains the homologous chromosomal region in chicken has gaps in the 
sequence where one may have expected to find Tmlp1 (Figure 3.16).  Two potential 
orthologues were identified in zebrafish. Both genes, although more dissimilar than to be 
expected from true orthologues, were in close proximity to genes that human TMLP1 is linked 
with. Animals that evolved after fish contain only one Socs3 gene, but zebrafish and other fish 
species have Socs3a and Socs3b genes (Wang et al. 2010b). The putative zebrafish Tmlp1 
orthologue XP_00130845 is linked with Socs3a, cytohesin 1, Usp36 and Timp2 on 
chromosome 3, whilst XP_001919554 is linked with threonine aldolase and Socs3b on 
chromosome 12. Although both genes are in the correct loci to be orthologues of TMLP1, and 
show greater similarity to TMLP1 than to other zebrafish genes (Figure 3.18), their encoded 
proteins show one distinct difference from TMLP1. Both proteins lack the two cysteine 
residues in the conserved motif W-GLW-C-C (Figure 3.13). The full motif is present in all 
zebrafish claudins, γ subunits and zebrafish Tmem114. Thus these similar proteins may not 
be true functional orthologues of TMLP1. 
 
If Tmlp1 is not present in zebrafish, the question of when it arose and what its closest 
ancestor is remains unanswered. This information is difficult to ascertain due to gaps in the 
available genomes for intermediate species. In mammals, the transmembrane regions of 
TMLP1 are largely conserved, as is ECL1. The intracellular C-terminus is encoded by two 
exons in primates, but only one in non-primates and shows little conservation between the two 
groups of species. This may represent the adoption of a new functional domain. 
 
3.10.2 TMEM114, TMLP1 and the Pfam00822 family 
3.10.2.1 Topology of TMEM114 and TMLP1 
The predicted topology of TMEM114 and TMLP1 is suggestive of a relationship with the 
Pfam00822 family of proteins. Both proteins have four transmembrane domains, short 
intracellular N- and C-termini, two extracellular loops, the first of which being larger than the 
second and containing a conserved motif, and a very short intracellular loop between TMD2 
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and TMD3. As described in section 1.7.2, the Pfam00822 family of proteins contains claudins, 
the main constituent of tight junctions and the more distally related EMPs, PMP22, MP20 and 
CLP24. Although they show little similarity at the sequence level, this family also contains the 
voltage dependent calcium channel γ subunits as these proteins share the same topology and 
conserved motif.  
 
3.10.2.2 Voltage dependent calcium channel γ subunits 
There are eight voltage dependent calcium channel γ subunits in the human genome, but 
despite their name, the main function of the majority of this group of proteins does not involve 
calcium channel activity. Phylogenetically, and functionally, the γ subunits are divided into 
three clusters: (γ1, γ6), (γ5, γ7) and (γ2, γ3, γ4, γ8) (Burgess et al. 2001; Chu et al. 2001; 
Price et al. 2005). The first subunit described, γ1, is a functional calcium channel subunit 
expressed in skeletal muscle which decreases expression and activity of the pore forming 
alpha subunit (Cav1.1) (Sandoval et al. 2007). This is mediated by a direct interaction between 
the two subunits (Arikkath et al. 2003). The γ6 subunit is expressed in skeletal and cardiac 
muscle, with limited neural expression (Burgess et al. 2001; Chu et al. 2001; Fukaya et al. 
2005). This subunit interacts with and negatively regulates cardiac Cav3.1 (Hansen et al. 
2004; Lin et al. 2008). 
  
The stargazer mouse, which displays absence epilepsy and cerebellar ataxia, was found to 
have a disruption in the gene expressing stargazin (Letts et al. 1998). This gene shared 
exonic and protein structure with the γ1 subunit (Letts et al. 1998). As the phenotype of the 
stargazer mouse also showed similarities to mice with mutations in other voltage dependent 
calcium channel subunits (Khosravani and Zamponi 2006), the gene encoding stargazin was 
annotated the γ2 subunit. Although no change was observed in calcium current in neurons of 
stargazer mice (Chen et al. 2000) there was a notable absence of AMPA receptors (AMPARs) 
at the synapses of cerebellar mossy fibre-granule cells (Hashimoto et al. 1999). Transfection 
of γ2 into the stargazin knockout rescued AMPAR activity by mediating trafficking of AMPARs 
to the cell surface (Chen et al. 2000). The ability of the subsequently identified γ3, γ4 and γ8 
to traffic AMPARs (Glutamate receptors 1-4) to the cell membrane gave rise to these subunits 
being named as TARPs (transmembrane AMPA receptor regulating proteins) (Tomita et al. 
2003). As well as modulating AMPAR activity by trafficking, TARPs also regulate the gating of 
AMPARs (Milstein et al. 2007; Sager et al. 2009). 
 
There is little experimental evidence on the ability of γ5 and γ7 subunits to alter calcium 
current, although γ7 can regulate stability of Cav2.2 mRNA (Ferron et al. 2008). Even though 
both proteins can alter AMPAR functionality, the function of γ5 and γ7 is distinct from the 
TARPs, and they have been recently annotated as Type II TARPS (Kato et al. 2008). 
Trafficking of AMPARs by γ7 is specific to GluR1 and GluR2 (Kato et al. 2007), and although 
it does not regulate AMPAR trafficking, γ5 can regulate GluR2 gating, a by regulating specific 
GluR2 transcripts (Kato et al. 2008). 
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3.10.2.3 Relationship of TMEM114 and TMLP1 to Pfam00822 family members 
A phylogenetic tree was constructed to identify the relationship of TMEM114 and TMLP1 to 
other Pfam00822 family members. The claudins form a distinct clade from the calcium 
channel γ subunits and the EMPs, PMP22, MP20 and CLP24. The claudin family separated 
into the classic highly conserved claudins (1-10, 14, 15, 17, 19) and the non-classic non-
conserved claudins (11-13, 16, 18, 20-23) (Krause et al. 2009). 
 
The γ subunits clustered as expected; γ1 and γ6, γ5 and γ7, and γ2, γ3, γ4 and γ8 (Figure 
3.11). TMEM114 and TMLP1 cluster together, in the same clade as the calcium channel γ 
subunits and the EMPs, PMP22, MP20 and CLP24. The bootstrap values for the division of 
the calcium channel γ subunits and the EMPs, PMP22, MP20 and CLP24 were low which 
prevents certainty in the distinction of the relationship between the γ subunits and the 
EMPs/PMP22/MP20. However, it is clear from the phylogenetic tree that TMEM114 and 
TMLP1 are closer in relationship to the calcium channel γ subunits and the EMPs, PMP22, 
MP20, CLP24, PERP and TMEM47 than to any claudin family members. .  
 
The C-termini of proteins in the Pfam00822 superfamily are variable and are much longer in γ 
subunits than the other proteins (Figure 3.7) (Price et al. 2005). To remove this potential 
confounding factor, a phylogenetic tree based on the amino acids from TMD1-TMD4 was 
constructed as recommended by Price et al., 2005. The tree produced was similar with 
TMEM114 and TMLP1 clustering with the γ subunits. However the bootstrap values were 
slightly higher in the TMD1-TMD4 tree. TMLP1 and γ6 had 25 % amino acid identity over the 
full-length of the proteins, and 29 % from TMD1-TMD4, which was more than with any other 
Pfam00822 family member (Table 3.2). TMEM114 showed greatest amino acid identity with 
γ4 (29 %). This level of amino acid identity was lower than that for TMLP1 and γ6 which 
explains why TMEM114 and TMLP1 branched separately from γ4 and the other TARPs.   
 
Pairwise amino acid identity between γ1 and γ6 is 33 %, between γ5 and γ7 is 47 %, and 
between each of γ2, γ3, γ4 and γ8 are greater than 50 % (Burgess et al. 2001). Thus, the 43 
% identity between TMEM114 and TMLP1 is likely to be suggestive of a relationship between 
the two genes. Pairwise identity between non-TARP and TARP γ subunits was typically <25 
% (Burgess et al. 2001), similar to the level of identity between TMEM114 and the other γ 
subunits suggesting a possible relationship. 
 
3.10.2.4 Gene structure 
The gene structure of TMEM114 and TMLP1 was found to be much closer to the non-claudin 
members of the Pfam00822 family. Claudins vary in their exon structure with some encoded 
by a single exon (e.g., claudin-2), others by four (e.g., claudin-1) or five exons (e.g., claudin-
16). The genes encoding the γ subunits (CACNGs) can be divided into specific subgroups by 
their exon structure (Table 3.4). Structurally, TMEM114 is closest to CACNG1 (encoding 
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γ1) and CACNG6 (encoding γ6). TMLP1 in humans is encoded by 5 exons. The murine 
orthologue is encoded by four exons, with a similar structure to that of TMEM114, CACNG1 
and CACNG6. Exon 3 in TMEM114, TMLP1, CACNG1 and CACNG6 is the same size but the 
encoded amino acids show little identity. Exon 2 is similar in size to the CACNGs, but again 
they show little similarity. In TMEM114, TMLP1 and the CACNGs exon 1 encodes TMD1 and 
ECL1 but in the EMP-1, -2, -3 and PMP22, an intron divides TMD1 and ECL1 (Table 3.4) 
(Jetten and Suter 2000), separating these from the other family members. The structure of 
CLP-24, TMEM47 and PERP revealed that they are distinct from the EMPs, PMP22 and 
MP20, despite clustering with them in the phylogenetic tree.  
 
3.10.2.5 Carboxy-termini 
Calcium channel γ subunits vary in length from 222 amino acids (γ1) to 425 amino acids (γ8), 
but typically TMD4 ends at approximately 200 amino acids. Thus, the variety in length is due 
to the length of the intracellular C-terminus. The topology predictions for TMEM114 and 
TMLP1 also predicted TMD4 to finish at approximately 200 amino acids, with C-termini of 13 
and 23 amino acids, respectively (Figure 3.3).  
 
The C-terminus of claudins can dictate the half life of the protein (Van Itallie et al. 2004) and is 
required for targeting to the tight junction (Ruffer and Gerke 2004). The majority of claudins 
contain PDZ binding domains in the final residues of their C-termini. These residues, which 
generally are hydrophobic, are necessary for the interaction of claudins with ZO proteins (Itoh 
et al. 1999) and other PDZ proteins (Roh et al. 2002; Jeansonne et al. 2003). The TARP 
proteins also terminate in PDZ-binding domains (Milstein and Nicoll 2009). Although the 
majority of claudins have tyrosine-valine (YV) type of PDZ binding motifs, the TARPs end in a 
TTPV motif (Figure 3.7). This motif is required for interaction with PSD-95 involved in targeting 
AMPARs at the cell membrane to the synapse (Chen et al. 2000; Schnell et al. 2002). This 
synaptic targeting is also dependent on a nPIST binding domain in the C-terminus (Cuadra et 
al. 2004). Although γ7 (ending in -TTPC) does not end in a typical PDZ-binding domain it has 
the ability to bind PSD-95 and traffic AMPARs (Kato et al. 2007). γ5, which ends in –STPC 
does not bind PSD-95 and does not traffic AMPARs to the synapse (Kato et al. 2007). 
 
Thus it appears that PDZ-binding motifs facilitate the trafficking of AMPARs to the synapse via 
interaction of TARPs with PSD-95, whilst in epithelial cells claudins with PDZ-binding motifs 
bind the tight junction protein ZO-1. The γ subunits which lack PDZ binding domains (γ1, γ5, 
γ6) also lack the ability to bind AMPARs (Chen et al., 2007).  Consequently it is therefore 
unlikely that TMEM114 and TMLP1 interact with ZO-1 or other PDZ proteins involved in 
trafficking of AMPARs. γ1 and γ6 also have short C-termini (22 and 16 amino acids, 
respectively) which lack known functional motifs. The short C-termini of TMEM114 and 
TMLP1 show no similarity to γ1, γ5, γ6 or to any of the claudins. The C-terminus of TMEM114 
is moderately conserved (Figure 3.6) suggesting it may be functionally less important than the 
C-termini of TARPs or claudins. The C-terminus of TMLP1 shows little conservation (Figure 
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3.6). Primates have a longer C-terminus with the final three amino acids encoded by an 
additional exon (Figure 3.22) which may represent the addition of a functional domain.  
 
3.10.2.6 Extracellular loop 1 (ECL1) 
Claudins form apical tight adhesions between the lateral membranes of neighbouring cells; 
the tight junctions. The first extracellular loop (ECL1) of claudins is believed to bridge the 
intercellular space, with opposing loops interacting across the space (Heiskala et al. 2001). 
This head-head trans-interaction can be homo- or hetero-philic (Coyne et al. 2003; Daugherty 
et al. 2007; Krause et al. 2009) and forms charge- (Colegio et al. 2002) and size- (Van Itallie 
et al. 2008) selective pores. The charge of amino acids in ECL1 determines the specificity of 
claudin permeability (Colegio et al. 2002; Wen et al. 2004).  
 
Non-claudin members of the Pfam00822 family are also associated with intercellular 
adhesion. PMP22, expressed at high levels in myelin-forming Schwann cells, is also 
expressed in epithelial cells of the lens, lung and intestine (Baechner et al. 1995; Taylor et al. 
1995). In vitro and in vivo, Pmp22 colocalises with tight junction markers (Notterpek et al. 
2001). EMP-1 localises to tight junctions in the endothelial cells of the blood brain barrier 
(Bangsow et al. 2008). Indirect evidence from a variety of sources also suggests a role in 
adhesion for the lens fibre specific protein MP20. In differentiating lens fibre cells, MP20 
inserts into the plasma membrane at a point which correlates with the formation of a barrier to 
extracellular diffusion (Grey et al. 2003) and lens fibres of MP20-/- mice are much more easily 
separated from each other than those of wildtype mice (Shiels et al. 2007). MP20 expression 
is necessary for formation of the lens syncytium, a process which begins with cell adhesion 
(Shi et al. 2009). 
 
The adhesive capacities of claudins has been demonstrated by stable expression of the 
protein of interest in mouse fibroblast L-cells (Kubota et al. 1999). These cells have little 
endogenous cell-cell adhesion capabilities (Nagafuchi et al. 1987) but cells transfected with 
claudins aggregate (Kubota et al. 1999). Surprisingly, the voltage dependent calcium channel 
γ2 subunit was also demonstrated to have adhesive properties in L-cells (Price 2005). This 
suggests there are common properties between claudins and the γ subunits. It has been 
postulated that the claudins and the γ subunits diverged from a common ancestor and that 
this common ancestor had an adhesive function (Price et al. 2005). Over time the proteins 
diverged and acquired new functions. Both groups of proteins contain the W-GLW-C-C motif 
in ECL1 (Figure 3.4). Mutating these sites in claudins affects homotypic trans-interactions 
suggesting that these residues are important for cell-cell-adhesion (Cukierman et al. 2009). 
TMEM114 and TMLP1 contain the same W-GLW-C-C motif in the first extracellular loop and 
thus may have adhesive functions.  
 
ECL1 of γ2 mediates binding of AMPAR GluR1 but when ECL1 of γ2 is replaced with the 
ECL1 of γ5 binding to GluR1 does not occur (Tomita et al. 2004). This suggests that 
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although ECL1 is involved in binding of GluR1, the W-GLW-C-C motif is not involved in this 
binding. This suggests that the function of ECL1 is not limited to the W-GLW-C-C motif. 
 
3.10.2.7 Extracellular loop 2 (ECL2) 
In claudins-3 and -4, ECL2 acts as a receptor for Clostridium perfringens enterotoxin (Katahira 
et al. 1997; Fujita et al. 2000). This causes structural changes in the tight junction resulting in 
endocytosis of the claudins in the intestine (Katahira et al. 1997). Like ECL1, ECL2 forms 
trans-interactions with claudins of opposing cells (Piontek et al. 2008) thereby also affecting 
the transepithelial resistance of the tight junctions (Piehl et al. 2010). The trans-interactions 
are thought to be mediated by an interface of aromatic amino acids at p.F147, p.Y148 and 
p.Y158 (Piontek et al. 2008). In TMEM114 and TMLP1 there are phenylalanine residues (F) in 
ECL2 that are not immediately followed by tyrosine (Y) (Figure 3.5). TMEM114, TMLP1 and 
the TARPs all end in an aromatic amino acids followed by GWS. TMLP1 also contains two 
other aromatic amino acids within its ECL2, p.Y162 and p.H166. Most claudins also contain 
proline residues in ECL2 (Krause et al. 2009), as does TMLP1 at p.P164.  TMLP1 shows a 
high degree of similarity to γ6, but their ECL2 show little similarity. Both TMEM114 and 
TMLP1 show conservation of the beginning and end of ECL2 with the TARPs. As the 
functional importance of ECL2 in TARPs has yet to be elucidated the significance of this 
similarity remains to be identified.  
 
3.10.3 Co- and post-translational modifications 
Glycosylation of proteins can serve many purposes including protein folding and maintenance 
of correct conformation, intracellular trafficking and cell surface expression (Helenius 1994; 
Gahmberg and Tolvanen 1996). The calcium channel γ subunits and EMPs/PMP22/MP20 all 
contain predicted or confirmed N-linked glycosylation sites, whereas the majority of claudins 
do not (Figure 3.3) (Pareek et al. 1993; Sharp et al. 2001; Ervin et al. 2005). The N-linked 
glycosylation site in γ2 has been demonstrated to be functionally important as mutants at this 
site fail to localise to the cell membrane (Price et al. 2005).  
 
The γ1 and γ6 subunits contain two predicted N-linked glycosylation sites in ECL1 at either 
side of the GLW of the W-GLW-CC motif. TMEM114 also contains sites at either side of the 
GLW (Figure 3.3). These sites are conserved to zebrafish (Figure 3.4). In γ1 transfected cells 
treated with the antibiotic tunicamycin, which inhibits N-linked glycosylation, γ1 retains its 
ability to interact with CaV1.1 (Arikkath et al. 2003). This suggested that γ1 is not glycosylated 
as it maintains its functional interactions. Treating cells with tunicamycin prevents 
glycosylation of all N-linked glycoproteins and disrupts cellular function. Therefore, as the 
localisation of the unglycosylated γ1 was not determined, it is possible that γ1 and CaV1.1 
were not localised at the plasma membrane and that the interaction between γ1 and CaV1.1 
may have occurred in the ER, as loss of glycosylation sites in some membrane proteins is 
associated with misfolding and retention in the ER (Kelley and Kinsella 2003). 
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TMLP1 has a single predicted N-linked glycosylation site. This site, although present in 
canines and bovines, is absent in rodents. This suggests that the prediction may be a false 
positive or that the N-linked glycosylation at this residue may not be functionally significant. 
Notably although all of the non-claudins proteins mentioned contain predicted sites, in vivo 
glycosylation has not been demonstrated for all. MP20 contains a predicted N-glycosylation 
site and interacts with galectin-3 (Gonen et al. 2001), which binds oligosaccharides (Fradin et 
al. 2000; Hirabayashi et al. 2002). However, glycosylation of the site has not been 
demonstrated (Ervin et al. 2005). N-linked glycosylation predictions are based on the 
presence of the N-X-S/T consensus motif (where X is any amino acid except proline). The 
presence of the N-X-S/T site in a protein does not guarantee the addition of N-linked 
oligosaccharides as the conformation of the protein may prevent access of the glycosylation 
machinery to the site (Apweiler et al. 1999). Thus, the glycosylation of TMEM114 and TMLP1 
must be confirmed in vivo.   
 
The intracellular C-termini of claudins contains phosphorylation sites for protein kinase C 
(PKC), casein kinase II and c-amp dependent kinase (Van Itallie and Anderson 2006). The 
effect of the phosphorylation state of claudins is dependent of the specific kinases and 
phosphatases, as dephosphorylation has been shown to both enhance (Nunbhakdi-Craig et 
al. 2002) and disrupt (Banan et al. 2005) epithelial barrier function. Similarly, phosphorylation 
can enhance (Fujibe et al. 2004) or decrease (Kahle et al. 2004; Yamauchi et al. 2004) barrier 
function. The PDZ-binding domain (TTPV) of TARPs contains multiple phosphorylation sites 
(Chen et al. 2007) and phosphorylation of γ2 by mitogen-activated protein kinase (MAPK) and 
Protein Kinase A (PKA) modulate the synaptic clustering of γ2 (Stein and Chetkovich 2010).  
 
The intracellular C-terminus of TMEM114 contains a single PKC site (Figure 3.8). ECL1 also 
contains DNA-dependent protein kinase (DNAPK) and PKA sites.  Therefore TMEM114 may 
be regulated at the protein level by phosphorylation. The predicted phosphorylation sites for 
TMLP1 show little conservation suggesting that it is less likely to be regulated by 
phosphorylation. Similarly, there are few predicted phosphorylation sites in γ1 and γ6 and 
those that are present are not conserved (Chen et al. 2007).    
 
Only γ5 and γ7 are predicted to be phosphorylated at tyrosine residues (Chen et al. 2007). 
These sites are present in the intracellular C-terminus. Human and murine TMEM114 contain 
a predicted tyrosine phosphorylation site in ECL1. Phosphorylation of tyrosine residues is 
associated with signal transduction (Medvedev et al. 2007; Metere et al. 2009). The TARPs 
and γ7 contain predicted tyrosine sulphation sites in ECL1 (Chen et al. 2007). Sulphation of 
tyrosines occurs in the Golgi apparatus lumen and strengthen protein-protein interactions 
(Moore 2003). No sulphation sites were predicted for TMEM114 or TMLP1. 
 
Palmitoylation is a reversible post-translational modification that involves the attachment of 
the lipid palmitate to cysteine residues of membrane proteins (Wolven et al. 1997). This 
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typically occurs in the border region between the transmembrane domain and the cytoplasmic 
domain. Palmitoylation of membrane proteins has roles in trafficking (Singaraja et al. 2009), 
signalling (Macdonald-Obermann and Pike 2009), protein-protein interactions (Yu et al. 2006), 
internalisation (Ohno et al. 2009) and degradation (Percherancier et al. 2001). Palmitoylation 
of claudin-14 near the cytoplasmic end of TMD2 and TMD4 enhances membrane localisation 
(Van Itallie et al. 2005). The other claudin family members also contain predicted 
palmitoylation signals at this site (Van Itallie et al. 2005). The calcium channel γ subunits also 
contain predicted palmitoylation sites, γ6 at the cytoplasmic end of TMD2, the TARPs at their 
N-termini, and γ5 and γ7 at the N- and C-termini (Chen et al. 2007). 
 
The predicted palmitoylation site for TMEM114 was likely to be a false positive as the 
prediction score was weak and the site is present in the extracellular domain. TMLP1 contains 
two predicted sites at the cytoplasmic end of TMD2, similar to γ6 subunit, although the 
surrounding amino acids show little similarity. Thus, palmitoylation may have a role in TMLP1 
function.  
 
Signal sequences are N-terminal sequences that direct transport of nascent peptides of 
membrane proteins to the ER. Signal sequences are recognised by the signal recognition 
particle (SRP) which bind to SRP receptors in the ER membrane (Janda et al. 2010). 
Typically, signal sequences are cleaved after transport. Cleaved signal sequences are known 
as signal peptides, non-cleaved signal sequences are known as signal anchors. Both 
TMEM114 and TMLP1 contain predict signal peptides, with <2 % probability of being signal 
anchors (SignalP). The predicted signal peptides include the first transmembrane domain. 
However, it is well documented that misclassification of signal peptides in transmembrane 
proteins with transmembrane domains near the N-terminus can occur (Kall et al. 2007; 
Reynolds et al. 2008). The prediction tool Philius is a combined transmembrane topology and 
signal peptide program designed to overcome the confusion in signal peptide prediction 
(Reynolds et al. 2008). Philius confirmed the presence of signal peptides in TMEM114 and 
TMLP1, although the confidence level for TMEM114 was only 63 %. However, the likelihood 
that TMEM114 and TMLP1 contain signal peptides is strengthened by the observation that all 
members of the claudins, γ subunits and EMPs/PMP/MP20 were tested and not predicted to 
contain signal peptides. Cleavage of signal peptides which are predicted as transmembrane 
domains is thought to occur for both the calcitonin receptor (Uniprot P30988) and calcitonin 
receptor-like receptor (CRLR) (Uniprot Q16602) (Walker et al. 2010). Cleavage of these TMD 
peptides results in the N-terminus of the mature protein being extracellular. The alteration of 
the structure of the protein is ultimately likely to affect the function of the protein, but without 
functional evidence for other proteins, it is difficult to predict the functional effect on TMEM114 
or TMLP1. In the uncleaved proteins, the beginning of ECL1 is tethered to the transmembrane 
domain. Cleavage of the signal peptide would release this domain from the plasma membrane 
making it accessible to extracellular molecules, suggesting this region may contain interacting 
domains.  
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3.10.4 Expression of TMEM114 and TMLP1 
Human TMEM114 ESTs were identified in the lens, as was found experimentally in mouse 
(Jamieson et al. 2007). The highest expression levels were found in lung carcinoids, but there 
were no ESTs from wildtype lung tissue. Claudin dysregulation is associated with lung 
cancers (Chao et al. 2009) and multiple other forms of cancer (Jung et al. 2010; Kuo et al. 
2010). The type of claudin being misexpressed and the direction of misexpression can be 
used to differentiate between carcinomas (Moldvay et al. 2007; Paschoud et al. 2007).  
 
Expression of Tmem114 is present in the cerebellum of mouse (Jamieson et al. 2007), but 
ESTs of human TMEM114 were not present in the cerebellum. It is not known if the 
expression in the cerebellum is present in the endothelium like claudins (Nitta et al. 2003; 
Shimizu et al. 2008), or if there is neuronal expression like the γ subunits (Burgess et al. 
2001). Like PMP22, TMEM114 potentially may be expressed in epithelial (Baechner et al. 
1995), endothelial (Roux et al. 2004) and neuronal cells (Parmantier et al. 1995).  
 
ESTs for TMLP1 were only available for the human orthologue where it was found in the 
hippocampus and hypothalamus. Human and murine Cacng2, 3, and 4 are expressed in the 
hippocampus and multiple other regions of the brain (Sharp et al. 2001; Moss et al. 2003). 
The stargazing-encoding Cacng2 is particularly highly expressed in the hippocampus (Sharp 
et al. 2001). TMLP1 shows greatest similarity to γ6. However, γ6 is predominantly expressed 
in skeletal and cardiac muscle, with limited expression in the brain (Burgess et al. 2001; Chu 
et al. 2001; Fukaya et al. 2005). The TMLP1 ESTs were detected in two splice isoforms which 
lack exon 2 or exons 2 and 3. Loss of these exons does not alter the frame of the encoded 
protein. Loss of exon 2 shortens ECL1 and results in the loss of the second cysteine of the W-
GLW-C-C motif. It has been postulated, but never demonstrated that the two cysteines of this 
motif form disulphide bonds (Van Itallie and Anderson 2006). If disulphide bond formation 
does occur, then omission of exon 2 may be functionally significant. Exons 2 and 3 encode 
the latter part of ECL1, TMD2 and half of TMD3, thus omission of this exon alters the topology 
of the protein. The topology prediction tools predict that this isoform has three TMDs with an 
extracellular C-terminus. CACNG6 is also detected in alternate isoforms which lacks exon 3 or 
exons 2 and 3 (Burgess et al. 2001). This is predicted to result in the in-frame loss of TMD2 
and TMD3 (Burgess et al. 2001). The functional significance of this isoform has yet to be 
elucidated.  
 
3.11 Conclusion 
As well as showing more similarity to each other than to any other protein, TMEM114 and 
TMLP1 are distinct from the other Pfam00822 proteins due to the presence of a predicted 
signal peptide (Figure 3.23). TMEM114 and TMLP1 belong to the same clade as the voltage 
dependent calcium channel γ subunits and the EMPs, PMP22 and MP20. The pairwise amino 
acid alignments revealed that TMLP1 shows greatest (25 %) identity with γ6. This level of 
identity was greater than the level of identity between γ6 and all of the subunits other than 
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γ1 (Burgess et al. 2001). The exonic structure of TMLP1 in non-primates also resembled that 
of γ6. Similar to TMLP1, γ6 is short with a short intracellular C-terminus which lacks PDZ 
binding domains. The multiple splice isoforms of TMLP1 also reflected those of γ6. However, 
there were notable differences between TMLP1 and γ6. 
 
TMLP1 is expressed in the brain, but γ6 is mainly expressed in skeletal and cardiac muscle, 
with much lower levels of expression in the brain (Burgess et al. 2001; Chu et al. 2001). γ6 
decreases activity of the cardiac low voltage activated Cav3.1 in vitro  (Hansen et al. 2004). 
This modulation is dependent on a GxxxA motif in TMD1 (Lin et al. 2008). This motif is not 
present in TMLP1 although there are GxxxxA and GxxxxxA motifs in TMD1. γ6 null mice are 
phenotypically normal (http://www.informatics.jax.org/external/ko/lexicon/2332.html) although 
information regarding voltage dependent calcium channel activity is not available for these 
mice. Unlike the TARPs, the ability of γ6 to traffic proteins has not been demonstrated.  
 
The γ subunit family are thought to have evolved from a common ancestor through a 
combination of tandem repeats and chromosomal duplications (Burgess et al. 2001; Chu et al. 
2001). These genes are thought to have evolved through duplication with the ancestor of the 
PKC genes, as three of the CACNG loci are in linkage with PKCA, PKCB and PKCG (Burgess 
et al. 2001). In humans CACNG6, CACNG7 and CACNG8 are located at 19q13.4, CACNG1, 
CACNG4 and CACNG5 are located at 17q24, and CACNG2 and CACNG3 are found 
individually at 22q13.1 and 16p12, respectively. With the limited information regarding TMLP1 
orthologues being currently available it is difficult to ascertain if TMLP1 could have arisen 
through duplication of γ6 or the ancestor of γ6.  
 
TMEM114 was previously reported as being related to the claudins, EMPs, PMP22 and MP20 
(Jamieson et al. 2007). The analysis performed here suggests that in terms of pairwise 
alignment and amino acid identity TMEM114 displays most similarity to the TARPs. However, 
there are clear differences between TMEM114 and the TARPs. The TARPs have long 
intracellular C-termini which contain interact with nPIST for trafficking to the plasma 
membrane where the PDZ-binding motif interacts with PSD-95 to mediate trafficking to the 
synapse (Cuadra et al. 2004). TMEM114 lacks both of these interacting domains. However, 
EMP2, which also lacks nPIST and PDZ binding domains, modulates the trafficking of various 
proteins to the cell surface (Wadehra et al. 2004; Wadehra et al. 2005). The TARPs are 
predominantly expressed in neurons (Letts et al. 1998) but Tmem114 is expressed in the 
epithelium of the lens (Jamieson et al. 2007). The amino acid identity of TMEM114 with 
PMP22, a protein which localises to tight junctions in epithelia (Notterpek et al. 2001), was 
also high (Table 3.2). Like TMEM114, PMP22 does not appear to contain a PDZ-binding 
domain. Thus TMEM114 may localise to tight junctions in epithelia. 
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Figure 3.23. Schematic displaying the predicted topologies and predicted co- or post-
translational modifications of TMEM114, TMLP1, voltage dependent calcium channel 
gamma subunits, claudins and EMPs, PMP22 and MP20. * = G is not present in EMP2, EMP3, 
PMP22. Protein names close to modifications indicate that only these specific proteins contain the 
modification. 
TMEM114 TMLP1 
γ2,3,4,8 γ1,6  γ5,7 
EMP,PMP22,MP20 
γ3,4 γ6 
γ7 
EMP-2,3 EMP-3 
Claudins 
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4.1 Introduction  
The developmental expression of Tmem114 was previously described in mouse (Jamieson et 
al. 2007). In this chapter the aim was to further characterise the developmental expression of 
TMEM114 in humans, and by generating polyclonal antibodies to Tmem114, determine the 
expression of the Tmem114 protein in mouse. As TMEM114 is a predicted transmembrane 
protein the localisation of Tmem114 is investigated in a model epithelial cell system. The 
presence of co- and post-translational modifications is also investigated. 
 
 
4.2 Expression of TMEM114  
4.2.1 Expression of TMEM114 in human embryonic development  
Tmem114 has previously been shown to be expressed in the eye, cerebellum and testes of 
adult mice and expressed as early as E13.5 in embryonic mice (Section 1.7.5) (Jamieson et 
al. 2007). Using a panel of human embryonic cDNA from eyes and neural tissue (forebain, 
midbrain, hindbrain, spinal cord) from three developmental stages (Carnegie stage 16/days 
37-42; Carnegie stage 21/days 53-54; Foetal stage 2/day 70-77) the expression of TMEM114 
in the developing human was determined. Expression was not detected in any of the tested 
tissue at CS16 (data not shown). At stages CS21 and F2 expression was restricted to the 
developing eye where expression increased with development (Figure 4.1). 
 
 
Figure 4.1. Embryonic expression of TMEM114 determined by RT-PCR. Expression of 
TMEM114 was detected by amplifying cDNA with primers amplifying exons 1 and 2. A) 
Expression in a panel of eye and CNS tissue at Carnegie Stage 21 (CS21). At CS21 expression of 
TMEM114 is detected in the developing eye. B) Expression in the developing eye. Expression of 
TMEM114 increases between developmental stages CS21 and Foetal stage 2 (F2). Detection of the 
housekeeping gene GAPDH was used as a control for equal cDNA loading in the RT-PCR reactions. 
The endpoint of all PCRs was determined to be within the exponential phase as demonstrated by the 
linearities for each reaction (triangle). H20 represents a no template control.   
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4.2.2 Expression of human and canine TMEM114 in cell lines 
Expression of TMEM114 was not detected in the human lens epithelial cell line FHL124 or in 
Human Embryonic Kidney (HEK) 293 cells (Figure 4.2A). MDCK II cells are of canine origin. 
As no canine positive control was available, primers were designed to amplify canine 
Tmem114 as well as human TMEM114 to act as a positive control. Canine Tmem114 
expression was not detected in MDCK II cells (Figure 4.2B). 
 
 
Figure 4.2. Expression of human TMEM114 and canine Tmem114 in cell lines. A) 
TMEM114 expression (exon 1 – exon 2) was not detected in the human cell lines FHL124 and HEK293. 
cDNA from a CS21 eye was used as a positive control. B) Tmem114 is not expressed in the canine 
kidney epithelial cell line MDCK II. Primers amplifying exons 3 and 4 of canine Tmem114 were designed 
to also amplify human cDNA. cDNA from a CS21 eye was used as a positive control. Detection of the 
housekeeping gene GAPDH was used as a control for equal cDNA loading in the RT-PCR reactions. 
The endpoint of all PCRs was determined to be within the exponential phase as demonstrated by the 
linearities for each reaction (triangle). „RT-‟ are samples to which no reverse transcriptase was added. 
H20 represents a no template control.   
 
4.3 Generation of a polyclonal antibody to murine Tmem114 
As an image clone for human TMEM114 was not available, our studies were performed using 
the highly similar murine orthologue for which a FANTOM clone was available (RIKEN cDNA 
4930511J11). C-terminal V5-tagged Tmem114 (Tmem114-V5) had previously been cloned 
from this FANTOM clone (Urquhart, unpublished). From this V5-tagged clone, untagged 
Tmem114 was cloned into the pGEM-T easy vector (Figure 9.2) and subsequently into the 
expression vector pcDNA3.1(-) (Figure 9.1). Constructs were bi-directionally sequenced to 
confirm that the mTmem114 sequence was correct and in-frame. 
 
4.3.1 Epitope design 
The final C-terminal 14 residues of mTmem114 are predicted to localise intracellularly (Table 
3.1). This intracellular C-terminus is conserved in Tmem114 and showed no significant 
similarity to any known protein. This region is highly conserved in human and bovine 
Tmem114 which would potentially enable the use of the anti-Tmem114 antibody in multiple 
species (Figure 4.3).    
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Figure 4.3. Epitope used for polyclonal antibody generation. Protein sequences were aligned 
with ClustalW2. The 14 amino acid epitope used for polyclonal antibody production is based on murine 
Tmem114 and is boxed in red. This C-terminal region is conserved in humans and bovines. The 
predicted fourth transmembrane domain of murine Tmem114 is in bold.  
 
4.3.2 Initial test bleeds 
Keyhole limpet haemocyanin (KLH) conjugated mTmem114 peptides were synthesised, 
purified and used to immunise two New Zealand white rabbits (#4671 and #4672) (Section 
2.6.1.1). The initial test bleeds were then compared to the pre-immune serum for their 
reactivity to non-transfected MDCK II cells and MDCK II cells transfected mTmem114 by 
western blot. MDCK II cells expressing V5-tagged mTmem114 were used as a control to 
determine if the bands detected were specific to mTmem114. Four main bands ranging from 
approximately 45 kDa to 23 kDa were detected by the V5 antibody (Figure 4.4). The 23 kDa 
band is close to the predicted molecular mass of 25.7 kDa for mTmem114 with the V5 
epitope. Bleed 3 from rabbit #4671 detected bands which were not present in the non-
transfected cells and were not detected by the pre-immune serum (Figure 4.4A). The lowest 
molecular weight band at 22 kDa is close to the predicted molecular mass of 24.4 kDa for 
mTmem114. Additionally, the bands were comparable to those detected with an anti-V5 
antibody against lysates from mTmem114-V5 transfected cells. These data suggest that the 
detected bands are various forms of mTmem114. Non-specific bands were detected at 
approxiamtely 36 kDa in the transfected and non-transfected samples (Figure 4.4A). The anti-
mTmem114 antisera did not detect these 4 bands in cells transfected with V5-tagged 
mTmem114. As the V5-tag was immediately C-terminal to the epitope, it is possible that the 
V5-tag was blocking access of the antibody to the epitope. Rabbit #4672 failed to detect 
mTmem114 by western blot (Figure 4.1B). 
 
4.3.3 Final test bleeds and purified antibodies 
Rabbits #4671 and #4672 were immunised twice more (Section 2.6.1.1) and the final bleeds 
were tested. The final bleed of rabbit #4672 failed to detect transfected mTmem114 (data not 
shown).  The final bleed of rabbit #4671, although functional at 1:1000 dilution (Figure 4.5), 
had significantly lower titres than the initial bleeds, as shown by the ELISA results (Figure 
4.6). The specificity of the final bleed was confirmed using peptide incubation. When the 
antisera was incubated with the peptide antigen prior to use, the antibody failed to detect 
mTmem114, confirming that the antibody is specific against the mTmem114 antigen (Figure 
4.7). The final bleed of rabbit #4671 was chosen for purification on an affinity column 
containing the purified peptide used as the antigen. The purified Tmem114 antibody identified 
Tmem114 although a 1:100 dilution with a long exposure time was required (Figure 4.5 B). 
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Figure 4.4. Testing of anti-mTmem114 antisera from rabbits #4671 (A) and #4672 (B). 
Sera were tested on non-transfected MDCK II cells (NT) and MDCK II cells transfected with untagged 
Tmem114 (Tmem114) or V5-tagged Tmem114 (Tmem114-V5). V5-tagged mTmem114 detected by 
western blot displays 4 bands ranging from approximately 23-45 kDa (braces). A) Bleed 3 from rabbit 
#4671 recognised these same bands when probed against untagged mTmem114, but not when probed 
against V5-tagged mTmem114. One non-specific band of approximately 36 kDa is present in all 
samples detected by bleed 3 and these bands were also present in the pre-bleed. B) Bleeds from rabbit 
#4672 failed to detect mTmem114. 
 
 
Figure 4.5. Testing of final bleed antisera and purified anti-mTmem114 antibody from 
rabbit #4671. Sera were tested on non-transfected MDCK II cells (NT) and MDCK II cells transfected 
with untagged Tmem114 (Tmem114) or V5-tagged Tmem114 (Tmem114-V5). A) 10 minute exposure. 
B) 1hr exposure. Bands specific (marked by braces) to the MDCK II transfected lysates (Tmem114) that 
were not present in the non-transfected cells (NT) were detected by bleeds 3, 4 and the final bleed. The 
purified antibody failed to detect the bands of interest when exposed for 10 mins but faint expression 
was detected at 1:100 dilution when over-exposed. 
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Figure 4.6. ELISA results for rabbit #4671 bleeds and purified antibody against 
mTmem114. At a dilution of 1:1000, reads for all tested post-immunised sera were greater than the 
pre-immunised serum (blue). The final bleed (orange) and purified antibody (green) were much weaker 
than Bleed 2 (red). 
 
 
 
 
 
Figure 4.7. Peptide incubation. To confirm the 
specificity of the #4671 bleed, the antibody was pre-
incubated with the peptide antigen before probing the 
transfected MDCK II lysates by western blot. Pre-
incubation ablated the detection of the 3 bands 
(braces 1-3), confirming they represent mTmem114. 
Tmem114_SPM represents mTmem114 with its 
signal peptide (amino acids 2-28) deleted. This was 
detected at a lower molecular weight (brace 4) than 
WT Tmem114. Pre-incubation with the peptide 
ablated the detection of this solitary band confirming 
it represents mTmem114. Non-specific bands are 
detected at approxiamtely 36 kDa (asterisk). 
 
Chapter 4 
 
  
104 
4.4 Immunofluorescent staining of mTmem114 
4.4.1 Localisation of V5-tagged mTmem114 in FHL124 cells 
TMEM114 is a predicted transmembrane protein expressed in the lens epithelium (Jamieson 
et al. 2007). To identify the localisation of mTmem114 in an appropriate cell line, mTmem114-
V5 was transfected in the lens epithelial cell line FHL124. In FHL124 cells mTmem114-V5 
localised in the cytoplasm and showed strong perinuclear staining (Figure 4.8).   
 
 
Figure 4.8. Localisation of V5-tagged mTmem114 in FHL124 cells. mTmem114-V5 
(green) was localised in the cytoplasm and showed strong perinuclear staining. No staining 
was observed in the nucleus (labelled blue with DAPI). Scale bar = 10 μm 
 
4.4.2 Localisation of V5-tagged mTmem114 in MDCK II cells 
4.4.2.1 Transient expression in MDCK II cells 
MDCK II cells are routinely used to study the localisation of claudins. When mTmem114-V5 
was transiently expressed in MDCK II cells, Tmem114-V5 localised at the cell membrane 
(Figure 4.9). Transient over-expression also resulted in the detection of cytoplasmic 
mTmem114-V5. The stable, moderate expression of a gene is likely to form a truer 
representation of protein localisation than seen with the high levels of transient expression. 
 
 
Figure 4.9. Membrane localisation of V5-
tagged mTmem114 in transiently 
transfected MDCK II cells. Tmem114-V5 is 
detected at the cell membrane and in the 
cytoplasm. The cells on the right are over-
expressing Tmem114-V5. Cells were fixed with 4 
% PFA, permeabilised with 0.2 % Triton X-100, 
and visualised with Leica DM 5000 fluorescent 
microscope.  Bar = 10 μm 
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4.4.2.2 Stable expression of mTmem114 in MDCK II cells 
To establish MDCK II cell lines which stably express either untagged mTmem114 or V5-
tagged mTmem114, cells were transfected with a linearised expression vector containing a 
neomycin resistance gene. Colonies that continued to grow in G-418 selection media were 
isolated and cultured further. Colonies expressing the protein of interest were then identified 
by western blot (Figure 4.10A). When these cells were visualised by immunofluorescence, it 
was found that the cells were not clonal, as some cells did not express the protein of interest 
(Figure 4.10B). In the cells expressing the V5-tagged (Figure 4.10Bi) or untagged mTmem114 
(Figure 4.10Bii), the majority of the protein localised to the cell membrane, with a small pool of 
protein in the cytoplasm. Cells that failed to express mTmem114 displayed little background 
staining, confirming the specificity of the antibody.  
 
 
Figure 4.10. Establishment of MDCK II cell lines which stably express V5-tagged or 
untagged mTmem114. A) Western blot of cell lysates from G-418 resistant colonies. i) Detection of 
V5-tagged mTmem114 using anti-V5 antibody (1:5000) demonstrating positive expression from colony 
#12. ii) Detection of untagged mTmem114 using anti-mTmem114 antibody (1:1000) demonstrating 
positive expression from colonies # 4 and 5. B) Stable Tmem114-expressing cells visualised by 
immunofluorescence using anti-V5 (1:1000) (i) and anti-mTmem114 (1:1000) (ii) antibodies. Both the 
tagged (i) and untagged (ii) colonies were not clonal as not all cells expressed mTmem114-V5 (i) or  
mTmem114 (ii).  
 
4.4.2.3 Localisation of Tmem114 in polarised MDCK II cells 
To determine if mTmem114 is present at tight junctions, like claudins and other members of 
Pfam00822 family (Section 3.10.2.6), confluent MDCK II cells stably expressing untagged and 
V5-tagged mTmem114 were grown on transwell inserts until polarised. MDCK II cells grown in 
this manner were shown to be polarised by labelling with the basolateral marker E-cadherin 
and the tight junction marker ZO-1 (Figure 4.11). The polarised Tmem114 stable cells were 
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then labelled with an anti-ZO-1 antibody and anti-Tmem114 antibodies and visualised using a 
confocal microscope. Tmem114 localised to the apical surface and at lateral membranes but 
did not colocalise with tight junction marker ZO-1 (Figure 4.12A). The lateral membrane 
localisation of Tmem114 resembled that of the adherens junction protein E-cadherin, so 
further colocalisation studies with adherens junction proteins and other junctional proteins 
were attempted. Tmem114 colocalised with E-cadherin at the lateral membrane (Figure 
4.12B). A similar localisation was detected with V5-tagged Tmem114-V5 (Figure 4.12C).  
 
To identify the precise localisation in polarised MDCK II cells, Tmem114 was labelled with 
immuno-nanogold and viewed under an electron microscope. Tmem114 localised to the 
microvilli of the apical cell membrane and to the apical regions of the cytoplasm (Figure 4.13). 
Low levels of staining were also observed in non-transfected cells (data not shown). 
  
 
 
Figure 4.11. Establishment of a polarised epithelial cell line. MDCK II cells were seeded at 
the same density on chamber slides or Transwell filters and labelled 48 h post-seeding. In the cells 
grown on the chamber slide (top), the adherens junction marker E-cadherin (green) and the tight junction 
marker ZO-1 (red) colocalised. When cells were grown on transwell inserts (bottom), ZO-1 localised to 
the tight junction above E-cadherin. Cells were fixed with 1:1 methanol:acetone, labelled, and viewed by 
confocal microscopy. 
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Figure 4.12. Localisation of stably-expressed mTmem114 and mTmem114-V5 in 
polarised MDCK II cells. Cells were labelled with anti-mTmem114 (red), anti-V5 (red), anti-ZO-1 
(green), or anti-E-cadherin (green) and stained with DAPI (blue) as indicated. Colocalisation of red and 
green labels shows as yellow in the composite image. A) mTmem114 localises to the lateral cell 
membrane (Ai) and apical cell  membrane (Aii) but does not colocalise with the tight junction marker ZO-
1 (Aii). B) mTmem114 is predominantly expressed at the apical cell membrane and colocalises with E-
cadherin at the lateral cell membrane. C) mTmem114-V5 localises to the apical cell membrane and 
colocalises with E-cadherin at the lateral cell membrane. Z-stack images to the right of each panel show 
Y-Z cross-sections through the dashed pink line in the X-Y composite images. The left and right sides 
show the basal and apical membranes, respectively. Bar = 10 μm. Cells were fixed with 1:1 
methanol:acetone and viewed by confocal microscopy. 
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4.5 Glycosylation of TMEM114 
4.5.1 Establishing the glycosylation status of mTmem114 
Murine Tmem114 contains two putative N-glycosylation sites at p.N54 and p.N88 (Figure 3.4) 
and when detected by western blot it has a greater molecular mass than predicted (Section 
4.3.2). This suggested post-translational modification of the protein. N-Glycosidase F 
(PNGase F) is an amidase that removes all N-linked oligosaccharides by cleaving the 
innermost N-acetylglucosamine (GlcNAc) from the asparagine residue. When mTmem114-V5 
is treated with PNGase F it is detected at 23 kDa, which approximately corresponds to the 
predicted mass of mTmem114, confirming that Tmem114 is N-glycosylated (Figure 4.14A). 
The antibiotic tunicamycin prevents N-glycosylation by inhibiting N-acetylglucosamine 
transferases. When mTmem114-V5 transfected cells were treated with varying amounts on 
tunicamycin, mTmem114-V5 was detected at 23 kDa in the treated cells, but at 40-45 kDa 
and 30 kDa in the mock treated (Figure 4.14B). This confirms, by an independent method, 
that mTmem114 is N-glycosylated.   
 
The enzyme Endoglycosidase H (Endo H) cleaves N-linked mannose-rich oligosaccharides, 
some N-linked hybrid oligsaccharides but not N-linked complex oligosaccharides. Treating 
mTmem114-V5 lysates with Endo H resulted in a shift in isoform (Figure 4.14C). The 40-45 
kDa isoform was present in both untreated and Endo H treated samples but there was a shift 
of isoform from 30 kDa in the untreated sample to 23 kDa in the treated sample. This confirms 
that the 40-45 kDa isoform contains complex oligosaccharides, the 30 kDa isoform contains 
mannose-rich oligosaccharides and the 23 kDa isoform is unglycosylated. 
 
A B 
C Figure 4.13. Immunogold labelling of 
Tmem114 in stable polarised MDCK II 
cells. Nanogold labelling (indicated by arrows) 
was detected in the microvilli of the apical cell 
membrane (A,B,C) and in the apical regions of the 
cytoplasm (A,B). Some of the microvilli became 
detached during the embedding or sectioning of 
the samples (B). Bar = 200 nm 
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Figure 4.14. Determining the glycosylation state of mTmem114. MDCK II cells were 
transfected with V5-tagged Tmem114 were treated during culture (B) or post-lysis (A, C) to determine 
the presence of N-linked oligosaccharides. A) Enzymatic removal of all N-linked oligosaccharides using 
PNGase F. In untreated lysates (-) mTmem114-V5 is predominantly detected at 40-45 kDa, but in 
PNGase F treated lysates (+) mTmem114-V5 is detected at 23 kDa. B) Preventing the addition of N-
linked oligosaccharides by treating cells with tunicamycin. In mock treated cells (DMSO) mTmem114-V5 
was detected predominantly at 40-45 kDa, and to a lesser extent at 30 kDa. In cells treated with varying 
concentrations of tunicamycin mTmem114-V5 was detected at 23 kDa. C) Enzymatic removal of N-
linked high mannose oligosaccharides using Endo H. In untreated lysates (-) mTmem114-V5 is 
predominantly detected at 40-45 kDa and at 30 kDa. In Endo H treated lysates, mTmem114-V5 is 
detected at 40-45 kDa and at 23 kDa.  
 
 
4.5.2 Establishing the N-glycosylation sites of Tmem114 
To confirm that the predicted N-glycosylation sites, p.N54 and p.N88, are those glycosylated, 
mutants were created by site-directed mutagenesis (SDM) to change the two asparagine 
residues to lysine residues. Both single mutants and a double mutant were created. When 
detected by western blot, the single mutants ran at a smaller mass than the wildtype: p.N54K 
at ~32 kDa and p.N88K at ~30 kDa (Figure 4.15A). The double mutant was detected at 23 
kDa, the same mass as de-glycosylated Tmem114, confirming that it is unglycosylated. When 
all forms were treated with N-Glycosidase F they were detected at 23 kDa. This confirms that 
the increase in mass of wildtype mTmem114 is due to glycosylation at p.N54 and p.N88. 
 
The single glycosylation mutants were detected in a number of isoforms (Figure 4.15A). To 
determine if the added oligosaccharides were mannose-rich or complex, lystates were 
digested with Endo H (Figure 4.15B). As in Figure 4.14C, the intermediate isoform of wildtype 
Tmem114 is sensitive to Endo H digestion. The intermediate isoforms of both p.N54K and 
p.N88K were sensitive to Endo H digestion, but the highest molecular mass isoforms were 
not. Compared to the wildtype, p.N54K and p.N88K had a greater proportion of Endo H 
sensitive to insensitive protein. A higher molecular mass isoform (40 kDa) was detected in the 
unglycosylated p.N54K N88K sample. 
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 Figure 4.15. Identification of the glycosylated residues of mTmem114. MDCK II cells were 
transfected with wildtype or mutant V5-tagged Tmem114 and detected by western blot. A)  Detection of 
V5-tagged glycosylation mutants by western blot and treatment with PNGase F. Single glycosylation 
mutants (p.N54K and p.N88K) were detected at a lower molecular mass than the wildtype (WT). 
Treating the wildtype and single glycosylation mutants with PNGase F (+) resulted in a shift to the 23 
kDa isoform confirming the presence of N-linked oligosaccharides. Untreated (-) and PNGase F treated 
(+) double mutant (p.N54K N88K) protein were also detected at 23 kDa indicating it is not glycosylated. 
B) Sensitivity of the glycosylation mutants to Endo H. Treatment with Endo H resulted in a shift from the 
intermediate isoforms of wildtype, p.N54K and p.N88K to the unglycosylated isoform at 23 kDa. The 
highest molecular mass isoform was resistant to Endo H digestion. 
 
 
4.5.3 Effect of glycosylation on the cellular localisation of mTmem114 
As N-linked glycosylation may have a role in protein stability and transport the effect of the 
mutated sites on cellular localisation was investigated. V5-tagged WT and mutant constructs 
were expressed transiently for 48 hours in MDCK II cells on transwell inserts. Wildtype 
Tmem114-V5 localised to the lateral and apical cell membranes (Figure 4.16 Ai, Bi). The 
single glycosylation mutants (N54K and N88K) localised to the lateral cell membrane (Figure 
4.16 Aii,iii) but not at the apical cell membrane (Figure 4.16 Bii,iii). Some cytoplasmic 
localisation was also detected (Figure 4.16 Aii,iii,Bii,iii). The double mutant N54K N88K failed 
to localise to the cell membrane and had a perinuclear appearance (Figure 4.16 Aiv,Biv). 
PNGase F 
Endo H 
A 
B 
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The perinuclear localisation of the double mutant was suggestive of ER localisation. A number 
of attempts were made to immuno-label the ER but none of the commercially available 
antibodies tested labelled the ER in MDCK II cells, which are of canine origin. 
 
 
Figure 4.16. Localisation of V5-tagged wildtype and glycosylation mutants of 
mTmem114 in MDCK II cells. A) Planar view of labelled cells. B) Z-stack images displaying cross-
section of labelled cells.  WT Tmem114 localised at the lateral (Ai) and apical (Bi) cell membrane. The 
single mutants N54K (Aii, Bii) and N88K (Aiii, Biii) were detected at the lateral cell surface (A ii, iii) but 
not at the apical cell membrane (B ii, iii). The unglycosylated double mutant N54K N88K localised to the 
cytosol (Aiv, Biv). Bar = 10 μm. Cells were fixed with MetOH:Acetone, labelled and imaged by confocal 
microscopy.   
 
4.6 Signal peptide 
The mTmem114 protein contains a predicted signal peptide of 28 amino acids (Section 3.3.3). 
Signal peptides are typically cleaved after transport of the protein. To identify if the predicted 
signal peptide of mTmem114 is cleaved, a construct of mTmem114 was made in which the 
codons encoding the predicted signal peptide (amino acids 2-28) were deleted. This signal 
peptide mutant (SPM) was detected at a lower molecular mass than wildtype mTmem114 
(Figure 4.17).  
 
Figure 4.17. Detection of untagged wildtype 
and signal peptide deleted Tmem114 in MDCK 
II cells. Wildtype mTmem114 (WT) is detected as 3 
bands that vary from 45 kDa to 23 kDa (braces at left 
hand side). Mutant mTmem114 lacking its signal 
peptide (SPM) is detected at a lower molecular mass 
than the WT (brace on right hand side). A non-specific 
band is detected at 36 kDa (asterisk). 
Chapter 4 
 
  
112 
4.7 Tissue expression of mTmem114  
4.7.1 Mouse lens  
After confirming that the antibody was specific to mTmem114 (Section 4.3.3), the presence of 
endogenous mTmem114 in adult mouse tissue was investigated. When the antibody was 
used to probe an adult mouse lens lysate, a single band of ~30 kDa was detected (Figure 
4.18A). This band was not present in the blot incubated with the pre-immune bleed. The band 
ran at a different mass from exogenously expressed mTmem114, but was similar in size to 
the mannose-rich isoform of Tmem114.  
 
To determine if the lens band represented a N-glycosylated form of mTmem114 that was 
modified with different oligosaccharides to those when the protein is processed by MDCK II 
cells, the adult lens fibre lysate was treated with PNGase F and probed with the anti-
mTmem114 antibody by western blot. Although the exogenously expressed mTmem114 in 
MDCK II cells showed a reduction in molecular mass when treated, the molecular mass of the 
lens sample remained constant (Figure 4.18B), confirming that this band was not a 
glycosylated form of mTmem114. 
 
 
Figure 4.18. Expression of mTmem114 in mouse lens. A) MDCK II cells transfected with 
mTmem114 and whole mouse lens lysate were probed with the final bleed and pre-immune bleeds. A 
single band of approx 32 kDa was identified in the lens sample which was not present in the pre-
immune. The band in the central lane is the 37 kDa band from the molecular marker. B) De-glycosylation 
assay. Lysates from transfected samples and mouse lens fibres were incubated with (+) and without (-) 
PNGase F. ++ represents the addition of double the recommended volume of PNGase F. Untreated 
transfected Tmem114 is detected in three isoforms (braces) at 40-45 kDa, 30 kDa and 23 kDa. PNGAse 
F treatment results in a shift to the 23 kDa isoform. No shift is detected for the band from the lens fibre 
lysate. 
 
To determine if the lens fibre band was specific, the mTmem114 antisera was pre-incubated 
with the peptide antigen prior to using it to probe a western blot. Blocking the mTmem114 
antibody only caused the bands from the transfected samples to disappear; the band in the 
lens sample remained at approximately the same intensity (Figure 4.19A). To determine if the 
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continued detection of a band in the lens sample was due to the high abundance of 
mTmem114 in this tissue, or too a high concentration of the antibody, a higher dilution of 
antibody and a greater amount of peptide was used (Figure 4.19B). Increasing the amount of 
the peptide ten-fold reduced, but did not ablate the signal from the 1:1000 antibody dilution. 
When the antibody was used at a dilution of 1:10,000, the band was still detected but when 
the peptide was added, the band was no longer detected. This suggested that the lens fibre 
band is specific for mTmem114.  
 
Figure 4.19. Pre-incubation of mTmem114 antibody against its antigen prior to western 
blot of mouse lens lysate. A) Pre-incubation of the mTmem114 antibody with its peptide antigen 
prevented the detection of mTmem114-specific bands (braces) in the MDCK II transfected sample, but 
the band in the lens sample remained. B) Increasing the peptide concentration to 10 x the suggested 
blocking concentration reduced the band intensity. Reducing the working antibody concentration to 
1:10,000 resulted in the band still being detected. When the antibody at this dilution was pre-incubated 
with the peptide the band was not detected. 
 
 
4.7.2 Mass spectrometry 
In order to confirm the band detected in the lens sample was mTmem114 mass spectrometry 
analysis was performed. Two lens epithelium lysates were run on SDS-PAGE gels and the gel 
was divided in two: one half was stained with EZBlue (Coomassie Brilliant Blue G-250) and 
the other was western blotted with the anti-mTmem114 antibody (Figure 4.20A). The band of 
interest was identified in the EZBlue gel by aligning with the western blot, excised, and 
analysed by MALDI-TOF by the University of Manchester‟s core facility. mTmem114 was not 
detected in the MALDI-TOF analysis (Figure 4.20B).  
 
To reduce the risk of contamination from the highly soluble crystalline proteins, purified 
membrane samples from bovine lens fibres (a gift from Professor Roy Quinlan, University of 
Durham) were used to perform the next mass spectrometry analysis. The anti-mTmem114 
antibody detected a band of similar molecular mass to the mouse sample in three bovine lens 
purified samples; lens fibre cytoskeletal fraction, purified membranes from the lens cortex and 
purified membranes from the lens nucleus. The putative mTmem114 band was not detected 
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by the pre-immune serum. A band of greater molecular mass was also identified in the cortex 
membrane and cystoskeleton samples but as this band was also detected by the pre-immune 
serum it suggests it is non-specific. (Figure 4.21A). The two bands of approximately 33 kDa 
and 34 kDa detected in the cortex fibre sample were excised from the EZBlue gel and 
subjected to MALDI-TOF analysis by the University of Manchester‟s core facility (Figure 
4.21B). Both bands were identified as Beta crystallin B1. 
 
 
Figure 4.20. Mass spectrometry of putative mTmem114 band from mouse lens. A) 
Lysates from mouse lens epithelium were run on SDS-PAGE gels and EZBlue stained (right hand side) 
or detected by western blot (left hand side) The corresponding band detected by the anti-mTmem114 
antibody (arrow) by western blot was extracted from the EZBlue gel and MALDI-TOF analysis was 
performed. B) MALDI-TOF results. The resulting peptides were matched against the Uniprot mouse 
database. Peptides from three crystalline proteins were identified. 
 
 
Figure 4.21. Western blot for Tmem114 in purified bovine lens fibre samples. A) A band of 
similar MW to that found in the mouse lens was identified in all three purified bovine lens fibre samples. 
A band of greater MW was also identified in the cortex membrane and cystoskeleton sample, but this 
band was also detected by the pre-immune bleed suggesting it is non-specific. B) MALDI-TOF analysis 
for two bands detected in the lens cortical fibre membrane sample. Bands were compared to a EZBlue 
stained gel of the same lysate. Both bands were identified as Beta crystallin B1.  
B A 
Chapter 4 
 
  
115 
 
 
A targeted approach was then performed using an orbitrap mass spectrometer at the 
Fingerprints Proteomics Facility at the University of Dundee. The sequence of mTmem114 
was built into an inclusion list and this sequence was searched for in the list of all peptides 
detected in the submitted band from a mouse lens epithelium lysate as in Figure 4.20. The 
predominant results were for crystallins. mTmem114 was not detected in the sample (Figure 
4.22). 
 
 
Figure 4.22. Mass spectrometry of putative mTmem114 band isolated from mouse lens 
epithelium sample using an Obitrap mass spectrometer. Orbitrap results from submitted band 
using the International Protein Index (IPI) database 
 
 
4.7.3 Endogenous localisation of mTmem114  
The use of the anti-mTmem114 antibody in western blotting against mouse tissue did not 
identify mTmem114, however this may have been due to low levels of expression and/or 
expression in a subset of cells. To test this hypothesis the antibody was used for 
immunohistochemistry (IHC) on sections of paraffin-embedded mouse eyes and on mouse 
lens cryosections. Labelling of the lens epithelium was predominantly in the apical membrane, 
with some lateral staining, where it colocalised with F-actin (Figure 4.23Ai). Labelling was also 
observed in the both the cortical and nuclear lens fibres (Figure 4.23Aii). However, similar 
labelling patterns were observed with the pre-immune bleed (Figure 4.23B). 
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Figure 4.23. Anti-mTmem114 immunohistochemical labelling of adult mouse lens. A) 
labelling of adult mouse lens with mTmem114 antibody and rhodamine-labelled phalloidin. i) In an 
isolated lens epithelium sample, F-actin (red) was localised at all cell membranes. Tmem114 labelling 
(green) was present at the apical and lateral membrane, but was not present at the basal membrane. ii) 
In both cortical and nuclear fibres, labelling for Tmem114 (green) was similar to that of F-actin (red). B. 
Labelling of cortical lens fibres with pre-immune bleed and anti-mTmem114 final bleed.  
 
 
4.8 Discussion 
4.8.1 mRNA expression  
Expression of TMEM114 was not detected in the human embryonic kidney (HEK) cell line or 
in the canine MDCK II cell line which are of kidney epithelium origin. Expression of TMEM114 
was also not detected in the adult lens epithelial cell line FHL124. This was unexpected as the 
properties of FHL124 cells are considered very similar to those of freshly obtained lens 
epithelial cells (Lauf et al. 2008) and Tmem114 is expressed in the mouse lens epithelium 
(Jamieson et al. 2007). The morphology of this cell line does not reflect that of in vivo lens 
epithelium, suggesting that some changes have occurred during establishment of the cell line. 
Thus, TMEM114 expression may have been lost during establishment of the FHL124 cell line. 
Alternatively, the specific cells from which the cell line developed did not express TMEM114. 
TMEM114 expression was detected in the developing human eye (Figure 4.1) and the 
expression was similar to that of murine Tmem114 (Figure 1.6) (Jamieson et al. 2007). 
Expression of TMEM114 was detected at CS21 (equivalent to murine stage E14), which 
correlates with onset of expression at E13.5 in mouse. As was identified in mouse, expression 
of TMEM114 increased with development. In mouse there is a marked increase in Tmem114 
expression postnatally (Jamieson et al. 2007). Postnatal human samples were not available 
for testing so expression in the adult has not been confirmed.  
i 
ii 
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4.8.2 Custom antibody testing 
Two custom polyclonal antibody projects were undertaken using the 14 amino acids of the C-
terminus of murine Tmem114 as the epitope. Although one antibody (#4672) failed to detect 
transfected mTmem114, the other (#4671) recognised transfected mTmem114 (Figures 4.4, 
4.5). The bands detected by the antibody were equivalent to those detected by an anti-V5 
antibody used against cells transfected with mTmem114-V5. The specificity of the antibody 
was shown by pre-incubating the anti-sera against the peptide antigen, and when this was 
done the antibody failed to detect the specific mTmem114 bands on the western blot (Figure 
4.7). The non-specific bands remained, confirming that the peptide specifically inhibited 
detection of mTmem114.  
 
The purified antibody, although functional, required high concentrations (1:50 for western blot 
and 1:20 for immunofluorescence). The antibody production schedule was protracted (Section 
2.6.1.1) and the titres of the final serum and purified antibody were significantly lower than the 
initial sera according to the ELISA results (Figure 4.6). The final bleed was taken 7 days post-
immunisation, short of the recommended 10-14 days (Harlow and Lane 1988). This sera 
however still proved functional at a dilution of 1:1000. Thus it was unexpected that the purified 
antibody was very weak. The use of an elution buffer that was too severe may have been 
responsible for this, or the fact that the purity of the peptide used was poor (Section 2.6.1.1) 
may have affected the affinity purification. 
 
In the V5-tagged construct of mTmem114 the V5-epitope was positioned at the C-terminus of 
Tmem114, immediately downstream of the antibody epitope. The Tmem114 antibody failed to 
detect mTmem114-V5 suggesting that the V5 epitope blocked access of the antibody to the 
mTmem114 epitope. This further suggests that the antibody is specific to the C-terminus of 
mTmem114. This specificity should allow differential labeling of tagged and untagged 
Tmem114. However, although the antibody could detect mTmem114 when heterologously 
overexpressed, it failed to detect mTmem114 in the adult lens. Non-specific labeling was 
observed when the antibody was used against adult mouse tissue. This non-specificity may 
have masked the detection of low expression levels of mTmem114.  
 
4.8.3 Glycosylation of mTmem114 
N-linked glycosylation of proteins can serve many purposes including protein folding and 
maintenance of correct conformation, intracellular trafficking and cell surface expression 
(Helenius 1994; Gahmberg and Tolvanen 1996). N-linked glycosylation of extracellular sites of 
membrane proteins occurs in a co-translational fashion in the lumen of the ER (Weerapana 
and Imperiali 2006). In the ER lumen, the core oligosaccharide, composed of glucose (Glc), 
mannose (Man) and N-acetyl glucosamine (GlcNAc) (Glc3Man9GlcNAc2) is added to 
asparagine residues in the consenus motif N-X-S/T (Helenius and Aebi 2004).  Removal of 
two of the three glucoses by glucosidases I and II occurs almost immediately, leaving a single 
glucose on the glycoprotein (Trombetta 2003). The ER resident chaperones calnexin and 
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calreticulin interact only with the monoglucosylated form of the glycoprotein (Zapun et al. 
1997; Vassilakos et al. 1998). The interaction with calnexin and calreticuin is terminated by 
cleavage of the remaining glucose by glucosidase II. If the released glycoprotein is correctly 
folded, it exits the ER. However, if after release from the chaperones, the glycoprotein has not 
adopted its native conformation, a single glucose is added back to the oligosaccharide by 
UDP-glucose:glycoprotein glucosyltransferase (UGGT1), facilitating binding of calnexin and 
calreticulin  (Ritter et al. 2005). This cycle of binding, release and re-binding continues and 
when the protein is correctly folded it exits the ER (Ellgaard and Helenius 2003). These 
proteins are then exported to the Golgi apparatus where the majority of glycoproteins undergo 
further processing of their sugar residues (Vagin et al. 2009). The mannose-based 
oligosaccharides, which are sensitive to Endo H digestion, are removed and replaced with 
more complex oligosaccharides which are Endo H insensitive (Helenius and Aebi 2004). 
However, if after multiple cycles the glycoprotein remains misfolded, a single mannose is 
cleaved by ER 1,2-mannosidase I which promotes association with ER degradation-
enhancing 1,2-mannosidase-like protein (EDEM) (Hosokawa et al. 2001), triggering ER-
associated degradation (ERAD) of the misfolded protein (Molinari et al. 2003; Oda et al. 
2003).  
 
When mTmem114 was detected by western blot three main isoforms were identified. A diffuse 
band at 40-45 kDa was sensitive to PNGase F but not Endo H digestion (Figure 4.13A,C) 
suggesting it represented the mature isoform with complex carbohydrates. An isoform at ~30 
kDa, which when resolved further appeared as two bands, was sensitive to Endo H digestion 
suggesting it contained mannose oligosaccharides (Figure 4.13C). This represents an 
intermediate isoform in the endoplasmic reticulum before export. A third isoform of ~23 kDa 
was approximately the same size as the predicted molecular mass of mTmem114. Treating 
mTmem114 with de-glycosylating enzymes increased the intensity of this band suggesting it 
represents the unglycosylated form of the protein. As the addition of oligosaccharides is a co-
translational event, the detection of Tmem114 in an unglycosylated state suggests that the 
protein was not being processed correctly by the MDCK II cells. This is most likely due to the 
high levels of overexpression in the transiently transfected cells, as the unglycosylated 
isoform was not present in the stable cell lines which had moderate levels of expression of 
mTmem114 (Figure 4.10A).  
 
The glycosylated sites in Tmem114 were identified by mutating the predicted glycosylation 
sites by SDM. The single mutants (N54K and N88K) were detected in three isoforms but had 
a reduced molecular mass compared to the wildtype (Figure 4.15). The double mutant was 
detected at ~23 kDa, the same mass as the de-glycosylated wildtype protein, confirming that 
this mutant is unglycosylated. 
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4.8.4 Localisation of mTmem114 
The localisation of the predicted transmembrane protein mTmem114 at the plasma 
membrane was confirmed by immunofluorescence in vitro. Membrane localisation was found 
to be cell-type dependent. When heterologously expressed in the lens epithelial cell line 
FHL124, mTmem114-V5 was detected in the cytoplasm, with strong perinuclear staining 
(Figure 4.8). No membrane localisation was observed. However, as previously mentioned, the 
morphology of this cell line does not reflect that of in vivo lens epithelium, and this may have 
affected localisation. Other lens epithelial cell lines could have been used to detect 
localisation. HLE-B3 cells (ATCC CRL-11421) were derived from an infant‟s lens and although 
they display an epithelial morphology, they fail to polarise (Andley et al. 1994). A 
physiologically relevant cell model for studying mTmem114 localisation requires the cell line to 
be polarised. Using rat lens epithelial explants, Stump and colleagues (2006) showed that 
treating non-polarised lens epithelial cells with lithium chloride (LiCl) promoted polarization. 
However, the ability to transfect these cells was not shown.  
 
Polarised cells such as MDCK II cells are recommended for studying the localisation of 
membrane proteins (van Beest et al. 2006). Polarised cells have distinct apical and 
basolateral domains, demarcated by tight junctions. During polarisation, adherens junctions 
form between opposing cells (Yonemura et al. 1995). ZO-1 is recruited to this contact site 
where it dimerises and functions to polymerise claudins (Itoh et al. 1999; Umeda et al. 2006). 
This polymerisation is necessary for tight junction formation (Umeda et al. 2006). The 
polymerised claudins and ZO proteins then form a distinct junctional complex, the tight 
junction, apical to the cadherin-based adherens junction. Once tight junctions are formed, ZO-
1 localises specifically to the junction (Miyoshi and Takai 2005). Thus, the localisation of ZO-1 
distinct and apical to that of E-cadherin can serve as a marker for tight junctions. When MDCK 
II cells were cultured on plastic surfaces, ZO-1 colocalised with E-cadherin at the lateral 
border, indicating that tight junctions had not formed (Figure 4.11). However, by culturing the 
cells on the transwell porous filters, which substitute the extracellular matrix on which 
polarised epithelial cells lie in vivo (Mostov et al. 2003), the MDCK II cells polarise and ZO-1 
localises to the tight junction, apical to the adherens junction (Figure 4.11).  
 
TMEM114 shows homology to proteins which localise to tight junctions in MDCK II cells and in 
situ (Section 3.10.2.6) (Notterpek et al. 2001; Ruffer and Gerke 2004; Sugiyama et al. 2008). 
Therefore, localisation of Tmem114 to the tight junction may have been predicted. However 
mTmem114 localised to the lateral and apical cell membranes and did not colocalise with the 
tight junction marker ZO-1 (Figure 4.12A). Both tagged and untagged mTmem114 displayed 
the same localisation, confirming both the specificity of the custom antibody and that the V5 
epitope does not affect localisation of the protein (Figure 4.12B,C). The cytoplasmic C-termini 
of claudins, which includes the PDZ binding motif which interacts with ZO-1, target and 
stabilize localization at the tight junction (Itoh et al. 1999; Ruffer and Gerke 2004). Loss of the 
C-terminus results in intracellular retention (Ruffer and Gerke 2004). The C-terminus of 
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TMEM114 is shorter than those of claudins and shows little similarity to them (Figure 3.7). The 
V5-tag was attached to the final C-terminal amino acid and the western blot data suggests 
that the V5 epitope blocks the anti-mTmem114 antibody epitope of Tmem114 which also 
located at the C-terminal of the protein. As both the tagged and untagged proteins have the 
same localisation this suggests that the amino acids in the C-terminal epitope are not involved 
in membrane localisation.   
 
Although lateral membrane localisation of mTmem114 was detected, expression was 
predominantly localised to the apical cell membrane (Figure 4.12B).  The apical membrane of 
epithelia is made up of a base membrane and protruding microvilli (Roper et al. 2000; 
Giepmans and van Ijzendoorn 2009). To determine if mTmem114 specifically localised to 
either membrane segment, immunoelectron microscopy using nano-gold labelled anti-
mTmem114 antibody was performed in MDCK II cells stably expressing mTmem114. 
Although labelling was observed in the microvilli, with some apical cytoplasmic labelling, 
background levels of labelling were too high for the results to be unambiguous.  
 
Apical localisation of proteins is associated with a number of motifs which typically lie in the 
extracellular domains or in transmembrane domains (Rodriguez-Boulan and Musch 2005; 
Cullinane et al. 2010). The addition of N-linked (Scheiffele et al. 1995) and O-linked 
oligosaccharides (Alfalah et al. 1999) and GPI anchors (Sharom and Lehto 2002) are 
associated with apical trafficking. mTmem114 contains two N-linked glycosylation sites 
(Section 4.4.2) and the absence of N-linked oligosaccharides at both sites resulted in 
intracellular localisation, possibly due to misfolding and retention in the ER. A blot of the 
unglycosylated mutant identified a second band at 40 kDa which may represent a dimer of the 
misfolded protein (Figure 4.15B). 
  
The presence of oligosaccharides at a single site resulted in lateral membrane localisation, 
but the presence of oligosaccharides at both sites was necessary for apical membrane 
localisation. The single glycosylation mutant proteins were also detected in the cytoplasm 
(Figure 4.16) and the single mutants had a higher proportion of Endo H sensitive isoforms 
than wildtype Tmem114 (Figure 4.15B). Endo H sensitivity is an indicator of ER localisation. 
Thus, although some of the single glycosylated proteins were reaching the plasma 
membrane, a significant proportion were present in the ER. This implies that both 
glycosylation sites are necessary for efficient membrane trafficking of Tmem114, supported by 
the fact that both glycosylation sites are evolutionarily conserved. Only when both sites are 
glycosylated does Tmem114 localise to the apical cell membrane suggesting that the apical 
localisation is functionally significant. 
 
The NHS-A protein is currently the only protein localised at tight junctions that is associated 
with congenital cataract (Sharma et al. 2006). Although the localisation of mTmem114 to tight 
junctions was not detected, its localisation suggests it may be part of the apical junctional 
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complex. mTmem114 is expressed in cells of the central lens epithelium and epithelial cells at 
the lens equator (Jamieson et al. 2007).  Due to the apical localisation of mTmem114 in the 
polarised MDCK II cells a similar localisation of mTmem114 in the lens epithelium was 
postulated. This was investigated using the custom polyclonal antibody to probe sectioned 
adult mouse lenses. However, although labelling was observed with the antibody, similar 
labelling was also observed with the pre-immune serum (Figure 4.22B). To determine if this 
was due to non-specific binding of the fluorescently labelled secondary antibody, or 
autofluorescence, a rabbit antibody isotype control was used in place of the primary antibody. 
No staining was observed with this isotype control confirming that the staining was not due to 
the secondary antibody or due to autofluorescence. Thus the observed labelling was likely to 
have been due to non-specific binding of an antibody present in the serum.  
 
4.8.5 Signal peptide of Tmem114 
Signal peptides are typically 20-30 amino acids in length and show little sequence 
conservation (Hegde and Bernstein 2006). There is a conserved structure to signal peptides, 
with a basic N-terminal domain (N region), followed by a hydrophobic domain (H region) and a 
slightly polar C region which contains the cleavage site (Nielsen and Krogh 1998). Signal 
peptides of nascent polypeptides emerging from the ribosome are recognised by a signal 
recognition particle (SRP) and the rate of translation is slowed until the nascent 
polypeptide/ribosome complex is targeted to the ER (Jiang et al. 2008). The growing 
polypeptide chain enters the lipid bilayer of the ER membrane via the translocon and the 
signal peptide is cleaved.    
 
Transmembrane domains are hydrophobic regions, which when present near the N-terminus 
of a protein, may be mis-annotated as signal peptides (Reynolds et al. 2008). These domains 
are recongnised by SRP for targeting to the ER (Keenan et al. 2001). In silico predictions 
using Philius (Section 3.3.3), which is designed specifically to overcome such mis-annotation 
of signal peptides in transmembrane proteins, suggested that Tmem114 has a signal peptide, 
although confidence in the prediction was only 66 %. To determine if the signal peptide of 
Tmem114 is cleaved, Tmem114 lacking its signal peptide was cloned. When both wildtype 
and signal peptide mutant were detected by western blot, the signal peptide mutant was 
detected at a lower molecular mass than the wildtype confirming that the signal peptide is not 
cleaved. Thus, Tmem114 retains TMD1 and has a tetraspan topology similar to the other 
Pfam00822 proteins. 
 
 
4.9 Conclusion 
Although this study has confirmed that Tmem114 is a transmembrane protein and showed 
that N-linked glycosylation is required for localisation at the membrane, the functional role of 
Tmem114 at the cell membrane remains to be elucidated. It is clear that Tmem114 is not a 
typical claudin as in polarised MDCK II cells it does not localise to the tight junction. This 
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was not unexpected as the C-terminus of Tmem114 shows no similarity to the C-termini of 
claudins, which are necessary for tight junction localisation (Ruffer and Gerke 2004; Umeda et 
al. 2006)    
 
Although Tmem114 did not localise to the tight junction, by localising to the lateral cell 
membrane it may have a role in barrier formation between cells. The effect of a claudin on 
barrier function can be determined by overexpressing or knocking down the expression of the 
claudin of interest in MDCK II cells on transwell membranes. By measuring the transepithelial 
resistance of the cell monolayer one can determine the effect of expression of the claudin on 
paracellular permeability (Furuse et al. 2001). The effect of mTmem114 on transepithelial 
resistance was not measured as the stable cell lines that were created were not clonal. This 
would have affected the integrity of the barrier as the monolayer would be constituted of 
Tmem114 expressing and non-expressing cells.    
 
What is possible to conclude is that Tmem114 and other members of Pfam00822 are 
expressed in polarised tissues. Although distinct in function, neurons (Hung et al. 2007) and 
epithelial cells (Horne-Badovinac and Bilder 2008) are both polarised. The lens develops from 
a single layer of polarised epithelial cells – the lens vesicle. In the lens the epithelial cells are 
polarised and the differentiated fibres retain this polarity (Lo et al. 2000; Zampighi et al. 2000). 
Expression of Tmem114 occurs in both the central and equatorial epithelium of the lens 
(Jamieson et al. 2007). Epithelial cells at above the equator, where Tmem114 expression is 
highest (Jamieson et al. 2007) lack tight junctions and are in contact with newly differentiating 
fibre cells at the epithelial-fibre interface (Zampighi et al. 2000). 
 
At the epithelial-fibre interface, the apical membranes of the differentiating fibres are in 
contact with the apical membranes of the lens epithelial cells (Figure 1.3) (Kuszak et al. 
1995). The apical and lateral localisation of Tmem114 in a model polarised epithelial cell line 
and the expression of Tmem114 in the epithelial cells of this region is suggestive of a role in 
the epithelial fibre interface. Posterior to the epithelial-fibre interface lies the modiolus or lens 
fulcrum, a structure formed from the joining of the apical ends of newly differentiating epithelial 
cells which have begun to elongate (Figure 1.3) (Zampighi et al. 2000; Bassnett 2005). The 
elongating cells also express Tmem114  (Jamieson et al. 2007) suggesting that Tmem114 
may have a role in the formation of the lens fulcrum. These hypotheses could not be tested as 
the antibody generated did not function in situ. 
 
If Tmem114 functions in the epithelial-fibre interface and/or the lens fulcrum, it may require 
the adhesive properties of other members of the Pfam00822 family. Claudins, EMP-1, MP20 
and the more distantly related calcium channel γ subunits contain the W-GLW-C-C motif and 
have the ability to act as adhesion molecules in mouse fibroblast L cells (Section 3.10.2.6). 
Unfortunately, due to time constraints, the adhesive capability of Tmem114 in L cells was not 
tested. If adhesive properties are shown it would suggest a possible role in adhesion 
Chapter 4 
 
  
123 
between lens epithelial and fibre cells. The localisation of Tmem114 in the correct positions of 
the lens would support this. Confirmation of the localisation would require the production of an 
antibody that functioned in situ. The functional role of Tmem114 in vivo may be identified by 
creating an animal model. As of October 2010, no knockout mouse is available, but Tmem114 
knockout embryonic stem cell colonies have been created 
(http://www.knockoutmouse.org/genedetails/MGI:1921970).  
 
Tmem114 is also expressed in the cerebellum (Jamieson et al. 2007), where the calcium 
channel γ2 subunit stargazin is expressed (Tomita et al. 2003). Stargazin acts as a TARP, 
mediating the membrane delivery of AMPA receptors (Chen et al. 2000). Delivery of AMPA 
receptors to the synapse is dependent of PDZ binding domains (Tomita et al. 2005). Although 
Tmem114 lacks the PDZ binding domains found in claudins and TARPs (Section 3.10.2.5), as 
it has relatively high levels of amino acid identity with the TARPs (Table 3.2), it may have the 
ability to traffic proteins to the membrane. To determine if Tmem114 functions to traffic 
proteins, pull-down experiments using lysates from lenses or cerebella could be performed.  
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5.1 Introduction 
The in silico analysis performed in chapter 3 suggests that TMLP1 is a transmembrane 
protein expressed in the brain. However, to date, no experimental analysis has been 
performed on this novel gene. There were two main aims in this chapter: to determine the 
expression pattern of murine Tmlp1 at the mRNA level by RT-PCR, and to determine the 
tissue specific expression as well as the cellular localisation of the predicted transmembrane 
protein Tmlp1 using custom anti-Tmlp1 polyclonal antibodies. 
 
5.2 Expression of Tmlp1  
5.2.1 Tmlp1 expression in mouse 
RT-PCR was used to determine the expression pattern of Tmlp1 in the adult mouse. 
Expression of Tmlp1 was detected in the brain, eye, lung, stomach and kidney, but was not 
detected in the liver or intestine (Figure 5.1A). Tmlp1 is also expressed in the developing brain 
and developing eye (Figure 5.1B). Expression in the eye was found to increase at later 
developmental stages, reaching a peak during adulthood. In the adult lens, expression is 
highest in the lens epithelium, with lower levels detected in the lens fibres. 
 
 
Figure 5.1. Expression profile of murine Tmlp1 detected by RT-PCR. Expression of 
mTmlp1 was detected by amplifying cDNA with primers amplying from exon 1 to exon 4.A) 
Expression in the adult mouse. B) Expression pattern in the developing and adult brain and eye. 
Detection of the housekeeping gene Hprt was used as a control for equal cDNA loading in the RT-PCR 
reactions. The endpoint of all PCRs was determined to be within the exponential phase as demonstrated 
by the linearities for each reaction (triangle). „RT-‟ are samples to which no reverse transcriptase was 
added. H20 is a no template control.   
 
5.2.2 TMLP1 expression in human development 
The expression pattern of TMLP1 in a select panel of human embryonic eye and neural tissue 
was determined by RT-PCR. TMLP1 expression was detected in the hindbrain at CS21 
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(Figure 5.2). TMLP1 expression was also detected in the eye at foetal stage 2 (F2), but not at 
the earlier stage of Carnegie Stage 21 (CS21). In the spinal cord, expression was detected at 
F2 but not at the earlier stages of CS21 and F1. The primers used to amplify TMLP1 
encompass exon 1 to exon 4. Three different isoforms were detected in the different tissues. 
Sequencing of the amplicons confirmed that they were alternatively spliced isoforms of 
TMLP1. In the eye, the full-length isoform and an isoform which lacked exons 2 and 3 were 
expressed. This shorter isoform was also expressed in the hindbrain. The F2 spinal cord had 
weak expression of an isoform that lacked exon 2 only. The alternatively spliced isoforms 
produce in-frame shortened isoforms of TMLP1 with alternative topologies (Figure 5.3). 
 
Figure 5.2. Expression profile of TMLP1 in developing eye and neural tissues.  
Expression of TMLP1 was detected by amplifying cDNA with primers amplifying from exon 1 to 
exon 4. TMLP1 was expressed in the hindbrain at Carnegie stage 21 (CS21) in a splice isoform which 
lacks exons two and three. At Foetal stage two (F2) TMLP1 was expressed in the eye and spinal cord. 
Expression in the spinal cord was weak and was restricted to a splice isoform which lacks exon 2. In the 
eye TMLP1 was in two isoforms: full length TMLP1 and TMLP1 which lacked exons 2 and 3.  Detection 
of the housekeeping gene GAPDH was used as a control for equal cDNA loading in the RT-PCR 
reactions. The endpoint of all PCRs was determined to be within the exponential phase as demonstrated 
by the linearities for each reaction (triangle). H20 is a no template control. Lane 4 is the DNA marker 
Hyperladder IV. Bands are of 100 bp increments (100-1000 bp).  
Chapter 5 
 
  
127 
 
Figure 5.3. Predicted topologies of full-length TMLP1 and the splice variants lacking 
exon two or exons two and three. The splice isoform lacking exon 2 (TMLP1 Δ2) maintains the 
same topology as full-length TMLP1 but the altered splice site results in the incorporation of a valine (V) 
(underlined) in place of glycine (G) at p.64. The isoform lacking exons 2 and 3 (TMLP1 Δ2,3) encodes a 
protein 73 amino acids shorter than the predicted full length protein. This isoform is predicted to have 
three transmembrane domains (bold). Alternate exons are in black and blue. Amino acids encoded by 
overlapping splice are coloured red. 
                                                                                 
 
5.2.3 TMLP1 expression in cell lines 
Expression of TMLP1 was not detected in the human lens cell line FHL124 or HEK293 cells 
by RT-PCR (data not shown). Canine Tmlp1 (XM_548670) was not detected in MDCK II cells 
(data not shown). 
 
5.2.4 Cloning of wildtype and mutant isoforms of murine Tmlp1 
The coding sequence of Tmlp1 was amplified from murine cDNA and cloned into the pGEM-T 
easy vector. The full-length wildtype Tmlp1 clone was subsequently used as a template to 
generate a mutant isoform lacking the predicted signal peptide (amino acids 2-29) (Tmlp1-
SPM). Tmlp1-SPM was cloned by amplifying the coding sequence downstream of the 
predicted cleavage site. C-terminal V5-tagged constructs were created by amplifying the 
template DNA with a reverse primer which contained the sequence encoding the V5 epitope 
followed by a TGA termination codon. All four coding sequences were subsequently cloned 
from pGEM-T easy into the expression vector pcDNA3.1(-) and bi-directionally sequenced to 
confirm that the sequence was correct and in-frame. 
 
 
5.3 Detection by western blot  
5.3.1 V5-tagged Tmlp1 and Tmlp1-SPM 
MDCK II cells transfected with wildtype V5-tagged mTmlp1 (mTmlp1-V5) and the V5-tagged 
signal peptide mutant (mTmlp1-SPM-V5) were lysed, run on an SDS-PAGE gel and detected 
by western blot (Figure 5.4). mTmlp1-V5, which has a predicted molecular mass of 23.3 kDa, 
was detected in four isoforms at approximately 19, 22, 23, and 27 kDa. The most prominent 
isoform was at ~19 kDa. mTmlp1-SPM-V5, which has a predicted molecular mass of 20.9 kDa 
was detected at ~21 kDa.  
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The detection of multiple isoforms of Tmlp1 by western blot (Figure 5.4) was suggestive of co-
translation or post-translation modifications. Although mTmlp1 does not contain predicted N-
glycosylation sites, the banding pattern of Tmlp1 was similar to that of the glycosylated protein 
Tmem114-V5 (Figure 5.4). Therefore, the presence of N-linked oligosaccharides was tested 
using PNGase F and tunicamycin. Treating transfected cells with the glycosylation inhibitor 
tunicamycin resulted in a shift to the 19 kDa isoform suggesting that mTmlp1 is glycosylated 
(Figure 5.5A). Treatment of mTmlp1 lysates with an enzyme that cleaved N-linked 
oligosaccharides (PNGase F) also resulted in a shift to the 19 kDa isoform. To determine if 
the N-linked oligosaccharides were mature complex oligosaccharides or immature mannose-
rich oligosaccharides mTmlp1 lysate was treated with the enzyme Endo H which resulted in a 
shift to the 19 kDa isoform (Figure 5.5C). Thus the fastest migrating isoform (19 kDa) 
represents the unglycosylated form of mTmlp1-V5. Unexpectedly, this unglycosylated isoform 
migrated faster than Tmlp1-V5 lacking its signal peptide (21 kDa). However, on prolonged 
exposure of Tmlp1-SPM-V5, a faster migrating isoform was identified at ~17 kDa (Figure 
5.5B). The slower 21 kDa migrating isoform was not formed in the presence of tunicamycin 
and Tmlp1-SPM-V5 was sensitive to both PNGase F (Figure 5.5B) and Endo H (Figure 5.5C) 
digestion indicating it contained N-linked mannose-rich oligosaccharides.  
 
If the predicted signal peptide of Tmlp1 is cleaved, the de-glycosylated isoforms of Tmlp1-V5 
and Tmlp1-SPM-V5 should migrate at the same speed on an SDS-PAGE gel. However, the 
deglycosylated isoform of Tmlp1-SPM-V5 migrated faster than the deglyosylated isoform of 
the full length Tmlp1-V5 (Figure 5.5C) indicating that the signal peptide of Tmlp1 is not 
cleaved. 
 
 
Figure 5.3. Detection of MDCK II 
cells transfected with V5-tagged 
wildtype (mTmlp1-V5) and signal 
peptide mutant Tmlp1 (mTmlp1-
SPM-V5) by western blot. Tmlp1-V5 
was detected in four isoforms (left braces). 
Tmlp1_SPM-V5 was detected at 21 kDa 
(right brace). V5-tagged Tmem114 was 
used as a positive control.  
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Figure 5.5. Testing of Tmlp1 and Tmlp1-SPM for the presence of N-linked 
oligosaccharides. MDCK II cells were transfected with V5-tagged Tmlp1 (A, C) or V5-tagged Tmlp1 
signal peptide mutant (SPM) (B, C) were treated during culture or post-lysis to determine the presence of 
N-linked oligosaccharides. Tunicamycin prevents the addition of N-linked oligosaccharides. PNGase F 
cleaves all N-linked oligosaccharides from proteins. Endo H cleaves N-linked mannose-rich 
oligosaccharides or hybrid oligosaccharides, but not complex oligosaccharides processed in the Golgi 
Apparatus. A) N-linked glycosylation of Tmlp1-V5. Untreated Tmlp1-V5 is detected in three isoforms 
from 19 kDa to ~28 kDa. When transfected cells are grown in the presence of tunicamycin Tmlp1-V5 is 
detected in the 19 kDa isoform only. Tmlp1 lysates are sensitive to PNGase F, being detected in the 19 
kDa isoform only. B) N-linked glycosylation of mTmlp1-SPM-V5. Untreated Tmlp1-SPM-V5 is detected in 
two isoforms at 17 kDa and 20 kDa. When transfected cells are grown in the presence of tunicamycin 
Tmlp1-V5 is detected in the 17 kDa isoform only. Tmlp1 lysates are sensitive to PNGase F, being 
detected in the 17 kDa isoform only.  C) Endo H treatment of Tmlp1-V5 and Tmlp1-SPM-V5. Tmlp1-V5 
and Tmlp1-SPM-V5 are sensitive to Endo H digestion as seen by the shift to the fastest migrating 
isoform.  
 
 
5.3.2 Testing of custom polyclonal antibodies to Tmlp1 
5.3.2.1 Epitope design 
The final C-terminal 14 residues of mTmlp1 had previously been selected as the epitope for 
polyclonal custom antibody generation. This epitope is unique to Tmlp1 and it is predicted to 
be accessible as it does not lie in transmembrane domain (Figure 5.6). As discussed in 
section 3.3.6 this intracellular C-terminus is poorly conserved in mammals. The C-terminus of 
rat Tmlp1 is similar to that of mouse Tmlp1, possibly facilitating use of the antibody to detect 
rat Tmlp1 (Figure 5.6).  
 
 
Figure 5.6. Multiple alignment of the C-terminus of Tmlp1 orthologues. The epitope used 
for custom antibody production is highlighted in the red box. This epitope is conserved in rat (Rattus 
norvegicus), but is clearly distinct to the C-terminus of primates (Homo sapiens, Macaca mulatta). 
Homo sapiens 
Macaca mulatta 
Mus musculus 
Rattus norvegicus 
Bos taurus 
Canis familiaris 
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5.3.2.2 Sigma custom polyclonal antibody generation 
Sigma-Aldrich synthesised and purified the designed KLH-conjugated peptides (purity 66 %) 
which were then used to immunise two New Zealand white rabbits (#4673 and #4674). The 
initial test sera were then compared to the pre-immune serum for their reactivity to transfected 
mTmlp1 by western blot. At the time of testing, a V5-tagged positive control had not been 
cloned, to aid in the identification of specific bands between the transfected to non-transfected 
cells. 
 
 
Figure 5.7. Testing of the #4673 and #4674 anti-mTmlp1 sera. Sera were tested on non-
transfected MDCK II cells (NT) and MDCK II cells transfected with untagged Tmlp1 (Tmlp1). A single 
band of ~19 kDa (brace) is detected in the transfected cells by sera from both rabbits. This band was not 
detected in the non-transfected cells (NT) and was not detected by the pre-immune bleed. 
 
Initial test sera from both rabbits detected a specific band at ~19 kDa in Tmlp1-transfected 
cells that was not detected with the sera of the pre-immunised rabbits (Figure 5.7). This was 
similar in mass to the predicted molecular mass of mTmlp1 (22 kDa). As the signal was 
stronger with the test sera from rabbit #4674, sera from this rabbit was chosen for antibody 
purification. The specific band at 19 kDa detected by the initial sera was also detected by the 
fourth test sera and final sera (Figure 5.8A). However this band was not detected by the 
purified antibody at concentrations as high as 1:100 (Figure 5.8A). The specificity of the final 
test sera was confirmed using peptide incubation. The final test sera detected full-length and 
the signal peptide mutant isoform of Tmlp1 (Figure 5.8B). When peptide pre-incubation was 
performed, the sera failed to detect two transfected isoforms of mTmlp1 (Figure 5.8B), 
confirming that the antibody is specific. Non-specific bands at 35 kDa and above 40 kDa 
remained in the pre-incubated samples.  
 
The purified antibody failed to detect the 19 kDa band at dilutions as high as 1:50 dilution, and 
the ELISA results show that the purified antibody titre was significantly lower than that of the 
initial test sera (Figure 5.9).  
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Figure 5.8. Testing of #4674 bleeds and purified antibody in transfected MDCK II cells.  
A) Comparison on Tmlp1-transfected to non-transfected cells.  A single band of ~19 kDa (brace) is 
detected by all bleeds in the Tmlp1 transfected cells, but is not detected by the affinity purified antibody. 
B) Peptide incubation. Pre-incubation of the final bleed with the peptide epitope ablated the detection of 
the Tmlp1 bands (braces), confirming they represent mTmlp1. Detection of the Tmlp1 signal peptide 
mutant (Tmlp1-SPM) bands was also prevented by pre-incubation with the peptide epitope. 
 
 
Figure 5.9. ELISA results for rabbit #4674 sera and purified antibody against mTmlp1. At 
a dilution of 1:1000, reads for all tested post-immunised sera were greater than pre-immunised serum 
(blue). The final bleed (orange) and purified antibody (green) were much weaker than Bleed 2 (red). 
 
5.3.2.3 NEP custom polyclonal antibody generation 
Due to the failure of the antibody purification process, custom polyclonal antibody generation 
was initiated with another company, New England Peptide (NEP) (Section 2.6.1.2).  The same 
C-terminal 14 residues of mTmlp1 were used as the epitope. The synthesised KLH-
conjugated peptide was >85 % pure and was used to immunise two New Zealand white 
rabbits (#4142 and #4144). Test sera were used to probe MDCK II cells transfected with 
Tmlp1. The Sigma-Aldrich final serum was used as a positive control for the presence of 
Tmlp1. Test sera from rabbit #4142 failed to detect Tmlp1 (Figure 5.10A). The sera from 
rabbit #4144 detected a single band at 19 kDa comparable to that detected by the Sigma-
Aldrich antibody at dilutions of 1:1000 (Figure 5.10B).  
A B 
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Pre-incubating the final test serum from #4144 with the peptide epitope resulted in ablation of 
the band at 19 kDa indicating the band was specific to Tmlp1 (Figure 5.11A). This final serum 
from #4144 was affinity purified using the peptide epitope. The purified antibody was 
functional at a 1:200 dilution (Figure 5.11B). Figure 5.11B shows that the final sera from 
Sigma, the purified NEP antibody detect bands which match those of V5-tagged Tmlp1, 
although a background band at ~34 kDa was observed. 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.10. Testing of the #4142 and #4144 anti-mTmlp1 sera. Non-transfected MDCK II 
cells or MDCK II cells were transfected with mTmlp1, were lysed, run on SDS-PAGE gels and detected 
by western blot. A) Sera from rabbit #4142 failed to detect transfected Tmlp1, which was detected by the 
Sigma antibody at a dilution of 1:1000. B) Sera from rabbit #4144 detected a single band of ~19 kDa 
which was also detected by the Sigma antibody. This band was not detected in the non-transfected (NT) 
cells. 
 
 
Figure 5.11. Confirming the specificity of the NEP anti-Tmlp1 antibody against 
transfected MDCK II cells. A) Peptide incubation. The final sera from rabbit 4144 detected two 
isoforms at 17 kDa and 19 kDa (braces) as well as some other slower migrating bands in Tmlp1 
transfected MDCK II cells. Pre-incubation of the antibody with the peptide antigen blocked detection of 
the 17 kDa and the 19 kDa bands, but not the other bands, confirming that the 17 kDa and 19 kDa 
bands are specific. B) Comparison of isoforms of Tmlp1 detected by the Sigma antibody and NEP 
purified antibody and the V5-tagged Tmlp1 detected with the V5 antibody. Braces on left hand side: 
Tmlp1 isoforms. Braces on right hand side: Tmlp1-SPM isoforms.  
A B 
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5.2.4 Use of custom polyclonal antibodies to detect endogenous Tmlp1 
After confirming the specificity of the purified antibody to the C-terminal epitope and optimising 
the concentration required for detection by western blot, the anti-Tmlp1 NEP purified antibody 
was used to probe lysates from a variety of mouse tissues. Bands were identified in a number 
of tissues, with most tissues displaying more than one band (Figure 5.12). The lens tissue 
contained a single band of ~20 kDa, close in molecular mass to the transfected Tmlp1 band. 
This 20 kDa lens band was not present in the whole eye sample suggesting it was enriched in 
the lens. However, pre-incubation with the peptide epitope did not prevent detection of the 
band in the lens suggesting it was non-specific (Figure 5.13B). No mouse brain lysate was 
available for testing, but a rat brain homogenate was available. Therefore, as the region of 
mouse Tmlp1 which was used to generate the custom antibodies was similar to that of rat 
Tmlp1 (Figure 5.6), a rat brain homogenate was probed with the anti-Tmlp1 antisera. Although 
the single band in the mouse lens sample was detected, no bands of the correct size were 
identified in rat brain homogenate (Figure 5.13A).  
 
 
 
Figure 5.12. Western blot using the NEP anti-Tmlp1 purified antibody against a panel of 
adult mouse tissues. This blot was dual-probed for Tmlp1 and β-actin labelling. The housekeeping 
protein β-actin, detected at 44 kDa, was used as a loading control. All other bands are attributed to the 
Tmlp1 purified antisera. 
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Figure 5.13. Western blots using anti-Tmlp1 antibody against rat brain, mouse lens and 
mouse liver. A) Tmlp1 transfected in MDCK II cells is detected in three isoforms (brace) and is mainly 
detected in the 17 kDa isoform (asterisk). Other bands represent background labelling. No similar bands 
were detected in rat brain lysates. A solitary band is detected in the mouse lens lysate at 24 kDa. B) 
Peptide pre-incubation with anti-Tmlp1 antibody. Tmlp1 transfected in MDCK II cells is detected at 17 
kDa (asterisked brace) but is not detected when the antibody is pre-incubated with the peptide antigen. 
The bands detected in the liver (25 kDa, 35 kDa) and lens lysates (24 kDa) were present when the 
antibody was pre-incubated with the peptide antigen suggesting the bands were non-specific.   
 
 
5.4 Localisation of mTmlp1-V5 and untagged mTmlp1 in MDCK II cells 
The in silico analysis performed in chapter 3 suggested that Tmlp1 is a transmembrane 
protein (Table 3.1).  Multiple unsuccessful attempts were made at creating stable MDCK II 
cells expressing V5-tagged or untagged Tmlp1. Therefore, transient transfections of Tmlp1 in 
MDCK II cells were used to determine the cellular localisation of the protein. V5-tagged Tmlp1 
displayed an intracellular localisation pattern in transiently transfected polarised MDCK II cells 
(Figure 5.14Ai, ii). Untagged Tmlp1 detected with NEP purified anti-Tmlp1 antibody had a 
similar distribution to that of V5-tagged Tmlp1 (Figure 5.14B). The intracellular staining pattern 
resembled that of the ER, but as previously mentioned (Section 4.5.3) an antibody that 
detected the canine ER was not available to test for colocalisation of Tmlp1 with the ER. As 
Tmlp1 had a similar intracellular localisation when detected with both the anti-V5 antibody and 
the NEP purified anti-Tmlp1 antibody it was hypothesised that a) the localisation of V5-tagged 
Tmlp1 was not affected by the presence of the V5-tag, and b) the NEP purified anti-Tmlp1 
antibody specifically detected Tmlp1 by immunofluorescence. Consistently, the number of 
cells expressing Tmlp1-V5 or Tmlp1 was found to be lower than for other constructs 
transfected at the same concentration.  
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Polarised MDCK II cells transfected with untagged Tmlp1. Untagged Tmlp1 detected with anti-Tmlp1 
purified antibody (green) localises predominantly in an intracellular manner with some localisation at the 
plasma membrane. Z-stack images to the right of each panel show Y-Z cross-sections through the 
dashed pink line in the X-Y composite images. The left and right sides show the basal and apical 
membranes, respectively. Bar = 10 μm. Cells were fixed with 1:1 methanol:acetone and viewed by 
confocal microscopy. 
 
 
5.5 Discussion 
5.5.1 Expression of TMLP1 
Expressed sequence tags (ESTs) for TMLP1 have only been reported in adult human tissue 
(hippocampus and hypothalamus) and in embryonic stem cells (Unigene Hs.632228) (Section 
3.7). To determine if TMLP1 is also expressed in neural tissue during embryonic 
development, a panel of human cDNA from various central nervous system (CNS) tissues and 
eyes of different developmental stages was analysed for expression of TMLP1 by RT-PCR. 
Interestingly, multiple splice isoforms were identified which matched those previously reported 
in EST databases. Although a TMLP1 EST is reported from the adult hypothalamus 
(DB496856.1), expression was not detected in the developing diencephalons (which contain 
the hypothalamus). This may be due to the low levels of expression in the hypothalamus 
being diluted by the other tissues of the diencephalon or that expression in the hypothalamus 
is restricted to adult stages.  
 
The earliest expression of TMLP1 was detected in the hindbrain at CS21. This isoform lacked 
Figure 5.13. Localisation of Tmlp1 in MDCK II 
cells. A) Polarised MDCK II cells transfected with 
Tmlp1-V5. i) V5-tagged Tmlp1 detected with anti-V5 
antibody (green) localises predominantly in an 
intracellular manner. Some cells display strong 
perinuclear staining (*). The Z-stack image to the right 
hand side shows that Tmlp1-V5 does not colocalise 
with the tight junction marker ZO-1 (red). ii) i) V5-
tagged Tmlp1 (green) localises predominantly in an 
intracellular  manner  which  surrounds  the nucleus. 
B)  
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exons two and three. An EST of the same splice form is present in the adult hippocampus 
(BC042066). Exons two and three encode the latter part of ECL1, TMD2 and part of TMD3 
(Figure 5.3). The omission of exons 2 and 3 does not alter the frame of the protein, but results 
in the loss of domains found in the full-length protein. Thus, the resulting protein has three 
instead of four predicted TMDs; TMD2 is lost whilst TMD3 extends to include what was part of 
ECL2 (Figure 5.3). Additionally the smaller isoform is predicted to have an extracellular 
instead of intracellular C-terminus. Although many of the claudins and the TARPs contain 
protein interacting domains in their intracellular C-termini (Itoh et al. 1999; Schnell et al. 2002), 
these motifs are not present in the intracellular C-terminus of Tmlp1 (Section 3.3.6). This 
suggests two possibilities: 1) the C-terminus has an important function which can be 
performed inside or outside the plasma membrane; 2) TMLP1 does not contain interacting 
domains in its C-terminus and it becoming extracellular has no effect on protein function.  
 
Any functional difference between the wildtype and the alternatively spliced isoform may be 
due to loss of latter half of ECL1. Loss of this region results in the loss of the second cysteine 
of the W-GLW-C-C motif. Also the alternatively spliced isoform has an altered membrane 
topology which results in the LW-C residues forming part of TMD2. Thus, this isoform lacks 
the signature motif (W-GLW-C-C) of the Pfam00822 family. A study which used peptides of 
the first half of ECL1 (includes W-GLW) and the second half of ECL1 (includes C-C) of 
claudin-1 showed that the latter peptide interacts with full-length claudin-1 and disrupts tight 
junction assembly (Mrsny et al. 2008). Thus, the latter half of ECL1 in claudins is functionally 
important for oligomerisation. Introducing hemagglutinin tags into the end, but not the middle, 
of ECL1 of the γ2 subunit prevents its interaction with AMPARs, suggesting that these 
residues mediate the interaction with AMPARs (Tomita et al. 2004). Omission of this domain 
in TMLP1 due to alternative splicing is likely to be functionally significant, possibly affecting its 
ability to interact with itself or other proteins with the W-GLW-C-C motif. 
 
The short isoform lacking exons 2 and 3 was also detected in the foetal stage 2 eye where it 
was co-expressed with the full-length TMLP1. Expression of TMLP1 was not detected at the 
earlier stages of CS16 and CS21. Expression of the full length isoform had not previously 
been reported and its detection confirms the predicted exonic structure in Figures 3.19 and 
3.22 (based on the now obsolete Genbank accession XM_211287.4). As described in section 
3.9, the TMLP1 locus loc283999 is predicted to encode two distinct proteins, encoded by 
exons 1, 3 ,4 and 5 (Figure 3.21); ENSP00000364084 is a 194 amino acid splice isoform of 
TMLP1, ENSP00000402790 is a 394 amino acid protein encoded by the same transcript 
translated in a different frame.  ENSP00000402790 is a predicted globular protein (Philius) 
that has no known homologous proteins. Section 3.9 describes how the retention of exon 2 
does not alter the frame of TMLP1 but results in a premature stop codon in 
ENSP00000402790. Therefore the detection of the expression of an amplicon containing 
exons 1, 2, 3 and 4 by RT-PCR confirms that TMLP1 is the protein encoded at this locus.  
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The spinal cord at developmental stage foetal stage 2 showed weak expression of the isoform 
that lacked exon 2 (the 194 amino acid isoform of TMLP1 ENSP00000364084). Omission of 
exon 2 results in the loss of the latter half of ECL1, a region which includes the second 
cysteine of the W-GLW-C-C motif. As discussed previously this may affect the protein‟s ability 
to interact with itself and other proteins. An investigation into the prevalence of alternative 
splice variants in transmembrane proteins in the human genome found that splice variants 
were common (Cline et al. 2004). Of the 15 proteins with four transmembrane domains tested, 
13 showed alternative splice variants with differing transmembrane architectures (Cline et al. 
2004). Thus the identification of TMLP1 isoforms with different transmembrane topologies is 
not unusual. The γ6 calcium channel subunit is also expressed in three isoforms – full length, 
without exon 2, and without exons 2 and 3 with the consequent loss of predicted 
transmembrane domains (Burgess et al., 2001). The full-length isoform of Cacng6 is 
expressed in rat skeletal muscle (Chu et al., 2001). Expression of CACNG6 in the human 
brain is present in all three isoforms, predominantly in the isoform lacking only exon 2 
(Burgess et al., 2001). However, the functional significance of the alternative isoforms of γ6 
remains to be elucidated. 
 
5.5.2 Expression of murine Tmlp1 
Expression of murine Tmlp1 had not previously been reported in any database (Section 3.7). 
Full-length Tmlp1 was detected by RT-PCR but no additional alternatively spliced variants 
were identified. Tmlp1 was detected in the brain, eye, lung, stomach and, at very low levels, in 
the kidney (Figure 5.1A). The concentration of RNA extracted from heart and muscle 
repeatedly was weak so these tissues were not tested. Expression of Tmlp1 was also 
detected in the developing brain and eye (Figure 5.1B), similar to the expression of TMLP1 in 
humans (Figure 5.2).  In the lens, Tmlp1 was expressed in the epithelium and to a lesser 
extent in the fibres.  
 
Translation of the full-length murine Tmlp1 sequence in other frames does not produce a 
protein similar to the globular protein ENSP00000402790 (data not shown) further confirming 
that Tmlp1 is the protein encoded by this locus. 
 
To determine the expression pattern of Tmlp1, custom rabbit polyclonal antibodies were 
generated against the final 14 amino acids of the intracellular C-terminus. The sera generated 
by Sigma-Aldrich detected transfected Tmlp1 however the purified antibody did not (Figure 
5.8A). Therefore a second rabbit polyclonal antibody was generated by New England Peptide 
(NEP). The purified antibody detected transfected Tmlp1 when used at dilutions of 1:200 
(Figure 5.11B). A panel of adult mouse tissues were probed with the anti-Tmlp1 antibodies to 
investigate the expression pattern of Tmlp1. Bands were present in the majority of tissues 
tested, including some that were negative for expression of Tmlp1 at the mRNA level (Figure 
5.1A). However, the molecular mass of the bands detected was much larger than expected 
and no two tissues had the same bands, suggesting that the bands were non-specific (Figure 
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5.12). A single band was present in the lens sample that was not present in the whole eye 
sample suggesting the protein was enriched in the lens. However the lens band could not be 
competed out by peptide pre-incubation, suggesting the band may be non-specific (Figure 
5.13B).  
 
Thus, although the anti-Tmlp1 antibodies generated were able to detect Tmlp1 when it was 
over-expressed in cell lines, Tmlp1 was not detected in tissue. Expression at the mRNA level 
is low as detection by RT-PCR required a large number of PCR cycles. Assuming this 
correlated with low levels of protein expression this may explain why the anti-Tmlp1 
antibodies were unable to detect Tmlp1 in situ. An alternative explanation is that Tmlp1 is 
unstable and is rapidly degraded before detection. However, unstable proteins tend to be rich 
in amino acids that can be phosphorylated (Yen et al. 2008) and Tmlp1 has few predicted 
phosphorylation sites (Figure 3.9). 
 
5.5.3 In vitro detection of Tmlp1 
Tmlp1 has a predicted molecular mass of 22 kDa, and with cleavage of its predicted signal 
peptide it has a predicted molecular mass of 19.1 kDa. When Tmlp1 was detected by western 
blot it was detected at approximately 19 kDa, suggesting the signal peptide was cleaved. To 
determine if this hypothesis was correct, Tmlp1 was cloned without its signal peptide. When 
the signal peptide mutant (Tmlp1-SPM) was detected by western blot it was detected at a 
lower molecular mass than the wildtype Tmlp1. This suggests that the signal peptide is not 
cleaved (Figure 5.5C). Thus, similar to the claudins and voltage dependent calcium channel γ 
subunits, the N-terminus of Tmlp1 is a signal anchor and not a signal peptide.  
 
Although Tmlp1 was detected at lower molecular mass (19 kDa) than predicted (23.3 kDa), 
Tmem114-V5 was also detected at a smaller molecular mass (22 kDa) than expected (25.7 
kDa) (Figure 5.4). The protein markers used are predicted to be 95% accurate 
(http://www.bio-rad.com/webroot/web/pdf/lsr/literature/Bulletin_4110025.pdf) which does not 
account for the 4 kDa difference between the expected and the observed molecular masses.  
Therefore the difference may be due to the properties of the amino acids in the protein 
affecting its gel resolution. Proteins with hydrophobic domains, such as transmembrane 
proteins, generally bind more SDS than hydrophilic proteins, which speeds up migration (Rath 
et al. 2009).  
 
Several isoforms of Tmlp1 were detected from cells transiently transfected with Tmlp1 (Figure 
5.5). The higher molecular mass isoforms were sensitive to digestion by enzymes that cleave 
N-linked oligosaccharides, suggesting that the protein is N-glycosylated. This finding was 
unexpected as no N-linked glycosylation sites were predicted in murine Tmlp1 (Figure 3.4). 
The majority of the protein detected was in the non-glycosylated form suggesting that the N-
linked glycosylation process was inefficient. Typically oligosaccharides are added to 
asparagine residues (N) that are followed by any amino acid (except proline) and then a 
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serine or threonie (N-X-S/T) (Gavel and von Heijne 1990). Oligosaccharides  may also be 
added to asparagines in the motif N-X-C but this is a rare occurrence (Giuffrida et al. 1997) 
and occurs less efficiently than at N-X-S/T sites (Breuer et al. 2001). Tmlp1 contains a 
potential N-X-C site in ECL1 at p.N61 (NSCV). This N-X-C site is also present in rat, which 
also lacks N-X-S/T sites (Figure 3.4). The asparagine at p.N61 is located four amino acids 
downstream, and two amino acids upstream, of the cysteine residues in the W-GLW-C-C 
motif (Figure 3.4). As discussed in section 3.10.4, it has been postulated, but never 
demonstrated, that the cysteine residues of this motif in claudins and Pfam00822 members 
form disulphide bonds.  
 
Both N-linked glycosylation (Kaplan et al. 1987) and disulphide bond formation (Chakravarthi 
et al., 2007) occur in a co-translational fashion in the ER lumen. The enzyme oligosaccharyl 
transferase, which adds the initial oligosaccharide (tetradecasaccharide)  to the asparagine 
residue, is thought to interact with the hydroxyl group of the serine/threonine of the N-X-S/T 
motif (Bause and Legler 1981). It has been postulated that the sulphydryl group (SH) of the 
cysteine in N-X-C can act in place of the hydroxyl group (OH) on the serine or threonine 
residues for hydrogen bonding with oligosaccharyl transferase, albeit less efficiently (Breuer et 
al. 2001). If oligosaccharyl transferase binds the SH group before disulphide bonds form, 
disulphide bond formation may be prevented. Inversely, formation of the disulphide bond may 
prevent glycosylation of the asparagine residue. Prevention of disulphide formation in the 
haemagglutinin-neuraminidase (HN) of Newcastle disease virus results in glycosylation of an 
asparagine site between the cysteines that is not normally glycosylated (McGinnes and 
Morrison 1997). A similar effect is thought to occur with the human receptor activity modifying 
protein-3 (RAMP3), as blocking of disulphide bond formation increases N-linked glycosylation 
(Flahaut et al., 2003).  Mutating the first of the two cysteine residues may establish if the 
cysteine residues form a disulphide bridge and if so, determine if prevention of disulphide 
bride formation promotes glycosylation at the p.N61 site.  
 
The significance of the N-X-C site in Tmlp1 is unknown. There is an equivalent N-X-C site in 
the human orthologue at p.N66 that encompasses the second cysteine of the W-GLW-C-C 
motif (Figure 3.3). However, human TMLP1 also contains a N-X-S/T site at p.N41 and so if 
human TMLP1 is glycosylated in vivo it is likely to be at this site and not at the N-X-C site as 
glycosylation is more efficient at N-X-S/T sites than N-X-C sites (Breuer et al. 2001).  
 
5.5.4 Localisation of Tmlp1 
N-linked oligosaccharides covalently linked to Tmlp1 were sensitive to Endo H. Endo H 
cleaves N-linked oligosaccharides that have not undergone further processing to complex 
oligosaccharides in the Golgi apparatus, inferring that the protein has not been processed 
beyond the ER. When the localisation of Tmlp1 was investigated in MDCK II cells, Tmlp1 was 
localised in the cytoplasm in a reticulate pattern indicative of the ER (Figure 5.14). As 
previously mentioned in section 4.5.3 the ER antibodies tested did not label the ER in the 
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canine-derived MDCK II cells, preventing colocalisation experiments being performed. 
However, the sensitivity to Endo H digestion confirms the ER localisation of Tmlp1. Integral 
membrane proteins of the ER may also be glycosylated (Kornmann et al., 2009).  Human 
pancreas-specific protein disulfide-isomerase (PDIp), an ER chaperone, is N-glycosylated 
(Desilva et al. 1997). Maintenance of mitochondrial morphology 1 (MMM1), previously thought 
to be a mitochondrial protein, was re-annotated as an integral ER membrane protein due to its 
localisation and sensitivity to Endo H (Kornmann et al., 2009). Thus, Tmlp1 may be an N-
linked glycosylated integral ER membrane protein. 
 
However, misfolded plasma membrane proteins may also be retained in the ER (Hwa et al. 
1997; Choi et al. 2005; Gallagher et al. 2007). As discussed in section 4.8.3 glycosylation of 
proteins may be required for correct folding and trafficking of membrane proteins and Tmlp1 
was predominantly detected in the non-glycosylated isoform. If Tmlp1 is being misfolded due 
to a lack of glycosylation it may be retained in the ER. Misfolded proteins retained in the ER 
are detected and degraded by ER-associated degradation (ERAD), a proteasome dependent 
degradation pathway (Gelman et al. 2002; Meusser et al. 2005).  There were a number of 
indicators that Tmlp1 was being degraded. Repeatedly, when detected by 
immunofluorescence, very few cells were positive for Tmlp1 expression. Also, numerous 
unsuccessful attempts were made to create stable cell lines expressing Tmlp1 or Tmlp1-V5. 
In contrast, transiently transfected Tmlp1 and Tmlp1-V5 were detected at high levels of 
expression. With the more moderate levels of expression associated with stable transfections, 
the cellular machinery may efficiently degrade the misfolded protein. The vector backbone, 
cells and transfection procedure used to express Tmlp1 were the same as used for 
Tmem114, suggesting that the low levels of protein detected was due to something inherent in 
Tmlp1 and not some other factor.  
 
When studying the cellular localisation of a protein the choice of an appropriate cell line is 
important (Davidson et al. 2009). As Tmlp1 is expressed in epithelium of the lens and in other 
epithelial tissues (lung, stomach, and kidney) MDCK II cells were chosen to study its 
localisation as these cells are a model epithelial cell system. As Tmlp1 was also expressed in 
regions of the brain perhaps a neuronal cell line such as HT-22 cells (Sarkar et al. 2008) 
would correctly process Tmlp1. Or perhaps a murine cell line such as L cell fibroblasts 
(Kubota et al. 1999) would correctly process murine Tmlp1.  
 
5.5.5 Limitations and future directions 
The study of murine Tmlp1 has revealed little in terms of functional aspects of the protein. 
However, there were a number of reasons for studying murine Tmlp1 and not the human 
orthologue. Firstly, the antibodies had previously been designed against murine Tmlp1 to 
facilitate their use for western blotting and immunohistochemistry with mouse tissue. While the 
C-terminus of Tmlp1 was a good choice of epitope in respect of the fact that because it would 
detect all splice variants, it limited the study to murine tissue as the C-terminus is not 
Chapter 5 
 
  
141 
conserved (Figure 5.6). However, there are no regions other than the transmembrane 
domains which show enough conservation between mouse and human for the antibody to 
detect both proteins. The region surrounding the G-LW-C-C is the most similar but using this 
region as the epitope may have resulted in non-specificity as it may detect other Pfam00822 
proteins. Also, the predicted presence of glycosylation sites and disulphide bond sites may 
have resulted in a tertiary structure which would block access to the epitope. The second 
reason for studying murine Tmlp1 was that murine cDNA was widely available, allowing 
Tmlp1 to be cloned.  The panel of human cDNAs only became available half-way through this 
study, by which point the antibodies directed against the C-terminus of murine Tmlp1 had 
been generated and the murine orthologues had been cloned. No full-length IMAGE clone for 
human TMLP1 exists.  
 
With more time and resources, and the data generated from studying Tmlp1, it would be 
desirable to characterise the human orthologue. All three isoforms of TMLP1 detected by RT-
PCR could be cloned, initially with a V5 tag. The presence of N-linked oligosaccharides could 
be detected using de-glycosylating enzymes and if glycosylation was confirmed, the 
glycosylated site (predicted to be p.N41) could be identified by creating mutant protein. The 
localisation of each of the three TMLP1 isoforms could then be investigated, initially in MDCK 
II cells, and then in neuronal cells. If TMLP1 is glycosylated at the predicted site and correctly 
processed (i.e. the majority of the protein in the glycosylated form) then one could be 
confident in the localisation of the protein. As the C-terminus of the TMLP1 isoform lacking 
exons 2 and 3 is predicted to be extracellular, positioning the V5 tag at the C-terminus could 
determine if the C-terminus is extracellular or not by permeabilising the cells before labelling.  
 
With sufficient resources the expression profile of TMLP1 could also be investigated more 
extensively in developing eye and CNS tissues. The genes encoding the γ1 and γ6 subunits 
are expressed in skeletal muscle (Sandoval et al. 2007) and skeletal and cardiac muscle (Chu 
et al. 2001), respectively. In vitro γ1 and γ6 interact with voltage dependent calcium channels 
expressed in their representative tissues (Arikkath et al. 2003; Hansen et al. 2004). These 
tissues were not tested for Tmlp1 expression as the extracted RNA was of poor quality. A 
wide range of adult and developing human cDNA samples could be used to create a more 
complete expression profile, which may show tissue specificity of the different isoforms. Once 
the tissues expressing TMLP1 are identified, in situ hybridisation could be performed to 
determine a more precise spatial expression pattern. 
 
To determine a functional role for TMLP1 the knowledge of which tissues it is expressed in 
could be utilised to determine the localisation and post-translational modifications in an 
appropriate cell line (as previously discussed) and to identify interaction partners. The latter 
could be performed using a targeted approach such as co-immunoprecipitation with calcium 
channel subunits expressed in the tissues identified, or using a non-targeted approach such 
as pull-downs. Human lens epithelial cells express a number of α-subunits (Cav1.2, Cav3.1, 
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Cav3.2, and Cav3.3), and in vitro blocking of voltage dependent calcium channel activity 
decreases the rate of proliferation of cultured HLE-B3 cells (Meissner and Noack 2008). 
Tmlp1 is expressed in the lens epithelium (Figure 5.1).  Future co-immunoprecipitation 
experiments using lysates of HLE-B3 cells transfected with TMLP1 may identify an interaction 
between TMLP1 and the endogenously expressed voltage dependent calcium channels.  
 
Bioinformatic analysis (chapter 3) showed that TMLP1 is similar to the calcium channel γ6 
subunit, which modulates Cav3.1 activity in vitro (Hansen et al. 2004). The ability of Tmlp1 to 
modulate voltage dependent calcium channel activity was not tested for two main reasons. 
Firstly, Tmlp1 localised to the ER whereas voltage dependent calcium channel subunits 
localise to the plasma membrane (Brice and Dolphin 1999). Secondly, to test the ability of 
Tmlp1 to modulate calcium channel activity would have required the creation of cell lines 
expressing the α-, β-, and α2δ-subunits. There are a number of α-subunits which can be 
tissue-specific, requiring the creation of multiple cell lines. After consulting a researcher of 
voltage dependent calcium channels at the University of Manchester (Dr Liz Fitzgerald) it was 
decided that pursuing this area of research would be unwise considering the time required 
and the number of α-subunits that would need to be tested.  
 
 
5.6 Conclusion 
This study has identified that TMLP1 is temporally and developmentally expressed in a wide 
variety of tissues. Such a wide expanse of tissue expression has also been established for the 
voltage dependent calcium channel γ subunits (Burgess et al. 2001) and for some claudins 
(Hewitt et al. 2006). Interestingly, three different splice isoforms were identified, and the 
presumptive full-length isoform, that was not annotated in any current database, was 
detected. Expression of the full-length isoform confirms that TMLP1 is expressed from 
loc283999. Although the custom antibodies generated detected murine Tmlp1 in vitro, Tmlp1 
was not detected in vivo. The failure to detect murine Tmlp1, coupled with the unclear state of 
glycosylation of murine Tmlp1 limited the study. However, creating an antibody specific to 
human TMLP1, which would enable the study of the different isoforms, would have limited the 
work to in vitro analysis.  
 
TMLP1 is a novel gene expressed in a number of tissues in the developing embryo and in the 
adult and its functional characterisation may reveal insights into eye and brain development. 
To proceed with the characterisation of TMLP1, V5-tagged constructs of all three splice 
isoforms could be cloned and expressed in epithelial and neuronal cell lines to study their 
localisation and possible interacting partners. With further time and resources the effects of 
TMLP1 expression on voltage dependent calcium channel activity would also merit 
investigation.   
 
The knockout mouse project (http://www.knockoutmouse.org) currently (as of October 2010) 
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has knockout stem cells for Tmlp1. A knockout mouse may be a useful resource, but as 
discussed previously, murine Tmlp1 may not be representative of human TMLP1. However, if 
the N-X-S/T glycosylation site present in primates and ungulates is functionally significant it is 
surprising that it is not present in rodents. Due to the fact that a Tmlp1 orthologue in Xenopus 
was not identified and the presence of a Tmlp1 orthologue in zebrafish is unknown, animal 
models for Tmlp1 do not provide a good avenue for investigating Tmlp1 function. 
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Chapter 6: Knockdown of Tmem114 in Xenopus 
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6.1 Introduction  
To investigate the functional role of Tmem114 in vivo, a knockdown model was created. The 
African clawed frog Xenopus tropicalis was chosen to create the model for a number of 
reasons. Offspring are produced in large numbers and are amenable to knockdown of protein 
expression using antisense morpholinos. The embryos have a short developmental time and 
their development is external facilitating monitoring of phenotypes at all developmental 
stages. Morpholinos are modified DNA oligonucleotides that bind to complementary 
sequences in the target mRNA. Binding to the mRNA blocks translation by the ribosome by 
steric hindrance (Heasman et al. 2000). This results in the knockdown of target protein 
expression. Morpholinos are easily injected into Xenopus zygotes allowing the knockdown of 
a specific protein in the developing embryo. 
 
6.2 Expression of xtTmem114 in Xenopus tropicalis development 
Before attempting to create an animal model for Tmem114, it was necessary to confirm that 
Tmem114 was expressed in developing X. tropicalis using RT-PCR and in situ hybridisation 
experiments were performed.  
 
6.2.1 RT-PCR in stage and tissue series 
RT-PCR using primers that crossed the first intron of Tmem114 in X. tropicalis (xtTmem114) 
were used to detect expression in a stage series of developing embryos (Figure 6.1 A). The 
forward primer was designed to the 5‟UTR and encompassed the morphlino binding sites 
(Sections 6.3.1 and 6.3.2). Maternal expression of xtTmem114 was detected at stages 1-7, 
but transcription by the developing embryo does not occur until stage 23, when it is weakly 
expressed. Expression is upregulated in later stages. To determine which tissues xtTmem114 
is expressed, a panel of cDNA from various adult tissues was used for RT-PCR. Expression 
was observed in the eye, lung and intestine (Figure 6.1B). Expression in the developing eye 
was also detected at similar levels to that in the adult eye (Figure 6.1C). 
 
6.2.2 In situ hybridisation 
To determine the expression of Tmem114 in different tissues in the developing embryo, in situ 
hybridisation was performed. Two probes were used on separate occasions. Initially, probes 
transcribed from full-length xtTmem114 were used but there appeared to be no difference in 
the staining pattern between the antisense and the sense (negative control) probes. Staining 
was observed but this appeared to be due to probe trapping. To improve tissue penetration of 
the probe, a shorter probe was then used. This probe was based on the only X. tropicalis 
Tmem114 EST (Genbank accession CX373776, IMAGE: 7632995), which includes exons 3 
and 4. However, no staining difference was seen between the antisense and sense probes 
(Figure 6.2A). The lens specific gene Lim2 was used as a marker for the lens and as a 
positive control for the in situ hybridisation experiments. Figure 6.2B clearly demonstrates that 
xtLim2 is expressed in the lens and the staining was specific to the antisense probe, 
confirming that the protocol used could detect expression of genes in the lens.  
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Figure 6.1. Expression of xtTmem114 in developing and adult X. tropicalis. A) Expression 
in the developing whole embryo. Maternal expression was detected (stages 1-7). Expression in the 
developing embryo is restricted to later developmental stages. B) Expression in adult tissues.  
Expression was detected in the adult eye, lung and intestine. C) Expression in the developing and adult 
eye. Detection of the housekeeping gene Gapdh was used as a control for equal cDNA loading in the 
RT-PCR reactions. The linearity for each reaction is indicated (triangle). 40- and Eye RT- represent 
samples to which no reverse transcriptase was added. H20 represents a no template control.   
 
 
 
Figure 6.2. Developmental expression analysis by in situ hybridisation. A) xtTmem114. No 
difference in staining was observed between the antisense and sense (negative control) probes based 
on the xtTmem114 EST CX373776. B) xtLim2. Staining with the antisense probe was detected in the 
lens and a single rhombencephalon. Diffuse staining was detected with the sense probe. 
A 
B 
C 
sense 
antisense 
sense 
antisense 
A     xtTmem114 
B     xtLim2 
Stage 23 Stage 28 Stage 32 Stage 35 
Stage 25 Stage 37 Stage 40 
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6.3 Morpholino knockdown of xtTmem114 
To knock down expression of Tmem114, morpholinos were designed to block translation of 
Tmem114 mRNA. Searches were performed with morpholino sequences against sequence 
databases to identify possible cross-reaction before being synthesised. 
 
6.3.1 Morpholino 1 
6.3.1.1 Design and optimisation 
Morpholino 1 (MO1) was 25 nucleotides in length and was designed to bind across the 
translation start site, binding from 3 nucleotides upstream of the A of the translation start site 
(AUG) to 21 nucleotides downstream (Figure 6.3A). Initially, a range of concentrations up to 
20 ng of MO1 were injected in order to ascertain what levels were toxic to the embryo. Doses 
up to 10 ng had normal levels of embryo survival (Figure 6.3C). When the developing 
embryos reached at least stage 40, phenotypes were observed and scored. Bilateral and 
unilateral microphthalmia were observed in a dose dependent manner (Figure 6.3B,D). Other 
ocular anomalies such as coloboma occured at much lower frequencies (Figure 6.4A iv).  
 
6.3.1.2 Unilateral injections 
To increase the sensitivity of scoring for microphthalmia, unilateral injections were performed. 
Unilateral injections of morpholino create a unilateral knockdown allowing comparison with the 
uninjected side as an internal control. As survival rates were greatest for 10 ng bilateral 
injections of MO1 (Figure 6.3C), 5ng of MO1 was chosen as the optimal dose for unilateral 
injections. 5 ng of MO1 when injected unilaterally resulted in 39 % of embryos displaying an 
observable difference in eye size (Figure 6.4). 
 
6.3.1.3 EGFP injections 
To confirm the observed phenotype developed on the injected half of the embryo, MO1 was 
co-injected unilaterally with a plasmid expressing enhanced green fluorescent protein (EGFP). 
Embryos were visualised using a fluorescent microscope at stage 30-33. At later stages 
EGFP expression was lost. Figure 6.5 is a representative image displaying that the 
microphthalmia associated with the EGFP injected side of the embryo.  
 
6.3.1.4 Increased defects in gut development in MO-injected embryos 
When injections were performed with higher doses of MO1 an increase in gut developmental 
defects was observed (Figure 6.6). The developing gut typically forms a coil structure formed 
from two external anticlockwise loops with a small inner clockwise loop (Chalmers and Slack 
1998) (Figure 6.6 A). Embryos injected with 15 ng of MO1 bilaterally or 7.5 ng of MO1 
unilaterally displayed defects in gut development at a frequency of 51 % and 24 % 
respectively, compared to 7 % of uninjected embryos (Figure 6.6B). The majority of the 
morphants had uncoiled guts which developed as a single curved tube whilst others formed 
more bulbous structures (Figure 6.6A).  
 
Chapter 6 
 
  
148 
 
 
Figure 6.3. Bilateral injections of MO1. A) Binding site for MO1. MO1 (red) binds three bases of 
the 5‟ UTR (lower case) and the first 22 nucleotides of the coding sequence of xtTmem114 (upper case, 
bold). B) Frequency of eye defects (%) observed in uninjected embryos and embryos injected with MO1. 
Frequency of eye defects was dose dependent C) Survival rates of embryos for each dose. D) Data for 
the 3 independent experiments for 5ng and 10 ng MO1 injections 
B 
aacacaggaacaaguggauuccucuucuguaucugcaAUGAAGCUGAAACUGAGUAUGUUAUCUGUCUU
U CGTTACTTCGACTTTGACTCATACA 
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3 independent experiments  1 experiment 
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Figure 6.4. Unilateral injection of 5 ng MO1. A) Injected embryos displaying unilateral 
microphthalmic eyes (ii, iii) (arrowhead). On rare occasions embryos displayed unilateral retinal 
coloboma (iv) (arrowhead). B) Frequency of unilateral microphthalmia observed uninjected embryos and 
in embryos unilaterally injected with 5 ng MO1. C) Data for the 3 independent experiments for 5ng 
unilateral injections 
 
 
 
Figure 6.5. Unilateral co-injection of EGFP with 5 ng MO1. An MO1/EGFP injected embryo 
visualised under white light (left) and GFP filter (right) confirms the phenotype is observed on the MO1 
injected side.  
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Figure 6.6. Gut defects in MO1-injected embryos. A) Embryos injected with 15 ng MO1 
displaying defects in gut development. Gut morphology is illustrated to the right of the embryos which 
display their ventral surface. The correctly developed guts (green illustrations) of uninjected embryos 
form a coiled structure of antisense loops. The morphants displayed failure of the coil to form correctly, 
formation of a singular tubular gut or formation of a bulbous structure (red illustrations). B) Frequency of 
eye and gut defects observed in embryos injected unilaterally with 7.5 ng MO1 and bilaterally with 15 ng 
MO1. Data presented is from a single experiment. Eye only = unilateral eye defects with no other 
abnormalities. Gut only = Abnormal gut development with no other abnormalities. Eye and gut = 
Unilateral microphthalmia with gut abnormalities. 
 
Eye and gut defects in uninjected embryos and embryos injected with MO1 B 
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6.3.1.5 Knockdown of xtTmem114 with morpholino in vitro 
The ability of MO1 to prevent translation of xtTmem114 was tested in vitro, as the custom 
polyclonal antibody to mTmem114 does not detect xtTmem114 (data not shown). Full-length 
xtTmem114 including 23 nucleotides of the upstream 5‟UTR was cloned with a C-terminal V5 
tag. When transcribed and translated in vitro multiple bands between 10 and 18 kDa were 
detected by western blot (Figure 6.7). These bands were not present when no in vitro 
transcribed RNA was added to the in vitro translation reaction (Figure 6.7, negative control). 
To test if MO1 blocks translation of these xtTmem114 products, MO1 was added to the in vitro 
translation reaction at a final concentration similar to that of the final concentration of MO1 in 
the injected embryo (Hilton et al. 2007). A separate reaction using a standard control 
morpholino at the same concentration was also performed. Detection of the protein bands 
was not prevented by addition of MO1 (Figure 6.7).  
 
The V5-tagged xtTmem114 has a predicted molecular mass of 24.8 kDa, but the bands 
detected were of a lower molecular mass (12-18 kDa). When the coding sequence of this 
construct is translated in silico seven isoforms which end in an in-frame V5-tag are produced 
ranging from full-length (24.8 kDa) to 10.5 kDa (Figure 6.8). The bands detected by western 
blot are similar in molecular mass to the predicted molecular mass of the four putative 
isoforms (10.5 kDa, 12.6 kDa, 14.7 kDa, 18.3 kDa). This suggests that the translational 
machinery was utilising alternative start codons producing shorter isoforms, that were not 
blocked by MO1 which targets only the true start codon. 
 
 
Figure 6.7. Detection of in vitro translated 
products by western blot. Non-specific bands at 
25 kDa, 30 kDa and 34 kDa were detected in all 
samples. Three major bands between 12 and 18 kDa 
and one minor band of 10.5 kDa were detected. These 
bands were not detected when no RNA was added to 
the in vitro translation reaction (-ve control). 
Expression of these isoforms was not prevented by 
addition of xtTmem114 MO1 or a standard control MO.  
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A 
 
>pGEM_xtTmem114-V5 
taatacgactcactatagggcgaattgggcccgacgtcgcatgctcccggccgccatggcggccgcgggaattcgat
tTGGATTCCTCTTCTGTATCTGCAATGAAGCTGAAACTGAGTATGTTATCTGTCTTTGTTGCTGTGGTTGGCATATT
AAGTTTCATATCATTAGTTGTTGCTATTGGAACTGATTTTTGGTATATTATTGATGCGTCCAGACTGGAAAAGATCA
CCAATTTCTCTGATCCATTAAGTTCCCATTCAGGACTCTGGAGGATGTGTAAATTTAAGAACAAATGTCTCCCTCTG
ATAAATCCCTTTCGGCTTGGGAACTTAAACTTCACTGATTCACAGAAACAGCTTTTGAGTATGCATGGAACACTAGT
GATTTTACTACCACTTAGCCTAATCTTGATGATATTTGGAGGAATGACTGGGTTTGTTAGTATTCTTGCAAGAGCTT
ATCTACTTCTGCTTTTGACCGGAATGCTTTTCCTGTTTGGCGCACTAGTAACATTAACGGGAATCAGCATCTACATT
GCCTACTCTGCTGCTGCATTTAAAGATGCCGTTTGCATCTTAGGGAACAAAATTCTGGAAGATATTGACATACAATT
TGGCTGGTCCTTGGCTCTGGCATGGATATCATTTATTACAGAGATTCTCACAGGGATAGCCTTCCTGGTGGCTGCCA
GAGTAACTGGGTTAAAAAGAAGAAGACGGGAGCAGGTTATAGGTAAGCCTATCCCTAACCCTCTCCTCGGTCTCGAT
TCTACGTGA  
-----------------------------------------------------------------------------
---- 
B 
 
24.8 kDa MKLKLSMLSVFVAVVGILSFISLVVAIGTDFWYIIDASRLEKITNFSDPLSSHSGLWRMCKFKNKC
LPLINPFRLGNLNFTDSQKQLLSMHGTLVILLPLSLILMIFGGMTGFVSILARAYLLLLLTGMLFL
FGALVTLTGISIYIAYSAAAFKDAVCILGNKILEDIDIQFGWSLALAWISFITEILTGIAFLVAAR
VTGLKRRRREQVIGKPIPNPLLGLDST 
 
24 kDa MLSVFVAVVGILSFISLVVAIGTDFWYIIDASRLEKITNFSDPLSSHSGLWRMCKFKNKCLPLINP
FRLGNLNFTDSQKQLLSMHGTLVILLPLSLILMIFGGMTGFVSILARAYLLLLLTGMLFLFGALVT
LTGISIYIAYSAAAFKDAVCILGNKILEDIDIQFGWSLALAWISFITEILTGIAFLVAARVTGLKR
RRREQVIGKPIPNPLLGLDST 
 
*18.3kDa MCKFKNKCLPLINPFRLGNLNFTDSQKQLLSMHGTLVILLPLSLILMIFGGMTGFVSILARAYLLL
LLTGMLFLFGALVTLTGISIYIAYSAAAFKDAVCILGNKILEDIDIQFGWSLALAWISFITEILTG
IAFLVAARVTGLKRRRREQVIGKPIPNPLLGLDST 
 
*14.7 kDa MHGTLVILLPLSLILMIFGGMTGFVSILARAYLLLLLTGMLFLFGALVTLTGISIYIAYSAAAFKD
AVCILGNKILEDIDIQFGWSLALAWISFITEILTGIAFLVAARVTGLKRRRREQVIGKPIPNPLLG
LDST 
 
13.1 kDa MIFGGMTGFVSILARAYLLLLLTGMLFLFGALVTLTGISIYIAYSAAAFKDAVCILGNKILEDIDI
QFGWSLALAWISFITEILTGIAFLVAARVTGLKRRRREQVIGKPIPNPLLGLDST 
 
*12.6 kDa MTGFVSILARAYLLLLLTGMLFLFGALVTLTGISIYIAYSAAAFKDAVCILGNKILEDIDIQFGWS
LALAWISFITEILTGIAFLVAARVTGLKRRRREQVIGKPIPNPLLGLDST 
 
*10.5 kDa MLFLFGALVTLTGISIYIAYSAAAFKDAVCILGNKILEDIDIQFGWSLALAWISFITEILTGIAFL
VAARVTGLKRRRREQVIGKPIPNPLLGLDST 
 
Figure 6.8. Possible translation start sites in pGEM-xtTmem114-V5 and the predicted 
protein products which may produce in-frame V5-tagged proteins. A) xtTmem114 (upper 
case) was in vitro transcribed from the T7 promoter (bold) of pGEM T easy (lower case). Blue = 5‟UTR 
sequence. Green highlight = Translation start site for xtTmem114. Yellow highlight = possible alternative 
start sites that encode in-frame products. Red highlight = possible alternative start site that encodes out-
of-frame products. TGA = stop codon. Underline = V5 tag. B) Translated sequences from putative 
transcripts which encode V5 tags and their predicted molecular weight. * Predicted to represent the 
bands detected by western blot. Underline = V5 tag. Sequences translated using Expasy translate tool 
(http://www.expasy.ch/tools/dna.html). Molecular weight predicted by the Expasy pI/Mw tool 
(http://www.expasy.ch/tools/pi_tool.html). 
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6.3.2 Morpholino 2 
A second morpholino (MO2) designed to bind immediately upstream of the binding site for 
MO1 was generated to further confirm the phenotype observed (Figure 6.9A). Embryos 
unilaterally injected with 7.5 ng MO2 displayed unilateral microphthalmia at a frequency of 59 
% compared to 4.8 % in uninjected embryos (Figure 6.9 B,C,D). Gut and/or eye abnormalities 
were observed in more than 81 % of MO2 injected in comparison with 19 % of uninjected 
(Figure 6.10). The level of gut abnormalities (13.8 %) was consistently higher than the levels 
of unilateral microphthalmia observed (4.8 %) in uninjected embryos. This level was relatively 
low when compared to the levels in the MO2 injected embryos (51 %). 
 
Figure 6.9. Second morpholino (MO2) directed against the 5’UTR of Tmem114. A) 
Binding sites of MO2. MO2 (blue) binds the 5‟UTR (lower case) of xtTmem114 four bases upstream 
of the translation start site (AUG). Coding sequence of xtTmem114 is in upper case and bold. B) 
Injected Embryo injected unilaterally with 7.5 ng MO2 displaying microphthalmic eye (arrowhead). C) 
Frequency of unilateral microphthalmia observed in embryos unilaterally injected with 7.5 ng MO2. D) 
Data for the 5 independent experiments.  
 
A 
B C 
D 
aacacaggaacaaguggauuccucuucuguaucugcaAUGAAGCUGAAACUGAGUAUGUUAUCUGUCUUU 
 TGTTCACCTAAGGAGAAGACATAGA 
Frequency of unilateral microphthalmia   
% 
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Figure 6.10. Gut defects in MO2-injected embryos. A) Frequency of eye and gut defects 
observed in embryos unilaterally injected with 7.5 ng MO2. B) Data for the 3 independent experiments. 
Eye only = unilateral eye defects with no other abnormalities. Gut only = Abnormal gut development with 
no other abnormalities. Eye and gut = Unilateral microphthalmia with gut abnormalities. 
 
 
6.3.3 Structure of the microphthalmic eyes 
To investigate the effect of knockdown of xtTmem114 expression on the structure of the eye, 
embryos which were unilaterally injected with 7.5 ng of MO2 were sorted into those displaying 
unilateral microphthalmia of the right eye and those displaying unilateral microphthalmia of the 
left eye. The sorted embryos were embedded in paraffin, sectioned and stained with 
haematoxylin and eosin (H&E). Comparing both eyes of the microphthalmic embryos revealed 
no observable difference between the uninjected and injected eye other than overall eye size 
(Figure 6.11). The lenses were clear and comparable in size although the finer cellular 
A 
B 
Eye and gut defects in embryos injected with MO2 
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structure of the lens could not be determined in the sections obtained. In the retina, there was 
no difference in the structure of the ganglion cell layer, inner and outer plexiform layer, inner 
and outer nuclear layer, the outer segment of the photoreceptors or in the retinal pigmented 
epithelium (RPE). No differences were observed in the cornea. 
 
Figure 6.11. Sectioned microphthalmic (A) and normal (B) eye of a stage 43 embryo. No 
structural differences are detectable between the two eyes. Co = cornea, le = lens, gl = ganglion layer, 
ipl = inner plexiform layer, inl = inner nuclear layer, opl = outer plexiform layer, onl = outer nuclear layer, 
os = outersegments of photoreceptors, rpe = retinal pigmented epithelium. Images were taken at 20 x 
magnification.  
 
 
6.3.4 Attempt at rescue of phenotype 
Murine Tmem114 (mTmem114) differs from xtTmem114 in the binding regions of the 
xtTmem114 MOs (Figure 6.12A). Therefore, the morpholinos should have no effect on 
translation of mTmem114. If mTmem114 and xtTmem114 are functionally conserved then 
heterologous expression of mTmem114 should compensate for the loss of endogenous 
xtTmem114 expression caused by the morpholinos and rescue the phenotype observed in the 
MO injected embryos. Before attempting a phenotypic rescue mTmem114-V5 was 
overexpressed in embryos to determine if such expression was tolerated by the embryos. 
Varying amounts of V5-tagged mTmem114 were injected into embryos to determine at what 
dose no observable phenotypes were detected. A marked increase in the number of embryos 
failing to develop past gastrulation was observed. At doses of 100 pg and 200 pg, 37 % and 
61 % of embryos, respectively, displayed gastrulation-specific defects such as exogastrulation 
(Figure 6.12B). Higher frequencies of grossly abnormal or dead embryos were also observed. 
 
co 
gl opl os onl rpe 
A  B 
inl ipl 
lens 
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Figure 6.12. Overexpression of mTmem114-V5. A) Comparison of the region surrounding the 
translation start sites of xtTmem114 and mTmem114. Identical residues are marked by an asterisk. The 
binding site for MO1 (red) in xtTmem114 has 11 identical nucleotides of 25 when compared to 
mTmem114. The binding site for MO2 (blue) in the 5‟UTR (lower case) shows little conservation. B) 
Phenotypes observed with injection of mTmem114-V5. A marked increase in the number of abnormal 
and exogastrulated embryos was observed with injection of mTmem114-V5. Data presented is from a 
single experiment.   
 
To determine if the observed phenotypes correlated with mTmem114-V5 expression, 
uninjected and mTmem114-V5 injected embryos were lysed and protein expression was 
detected by western blot. Prior to western blotting, the membrane was stained with Ponceau 
S confirming protein transfer to the membrane (Figure 6.13A). Subsequently, V5 expression 
was analysed by western blot. All samples tested were negative for V5 indicating the injected 
mRNA was not being translated (Figure 6.13B).  
 
To check the integrity of the mRNA injected, total RNA was extracted from injected embryos 
and cDNA was made. The presence of mTmem114-V5 was detected by RT-PCR using 
primers specific for mTmem114 (Figure 6.13C). mTmem114 was detected in the cDNA from 
injected samples, but not in the uninjected samples or in negative control samples to which 
RNA was added but reverse transcriptase was not.  
xtTmem114 aacaaguggauuccucuucuguaucugcaAUGAAGCUGAAACUGAGUAUGUUAUCUGUC 
           TGTTCACCTAAGGAGAAGACATAGACGTTACTTCGACTTTGACTCATACA 
mTmem114  gccggcgcccgggggcccaacgcugggagAUGCGGGUGCGCCUGGGCGCUCUGGCGGGA 
            *            *       *  *  ***  * **   *** *     *  * *   
 
     
A 
B 
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Figure 6.13. Detection of the overexpression of mTmem114-V5 mRNA. A) Detection of 
mTmem114-V5 by western blot. mTmem114-V5 was not detected in the injected (100 pg or 200 pg 
RNA) or uninjected (U) embryos, but was detected in the lysate of mTmem114-V5 transfected cells. The 
Ponceau S stained membrane demonstrates that similar levels of protein were present in all samples. B) 
Detection of mTmem114-V5 by RT-PCR with primers amplifying exons 1 and 2. Expression of 
mTmem114-V5 was detected in the embryos injected with 100 pg mTmem114-V5 mRNA and higher 
levels of expression were detected in the embryos injected with 200 pg mTmem114-V5 mRNA. 
Expression was not detected in the uninjected embryos. Detection of the housekeeping gene GAPDH 
was used as a control for equal cDNA loading in the RT-PCR reactions. The endpoint of all PCRs was 
determined to be within the exponential phase as demonstrated by the linearities for each reaction 
(triangle). H20 represents a no template control.   
 
 
6.4 Discussion  
6.4.1 Early developmental expression of xtTmem114 
Expression of xtTmem114 was detected at specific stages of development (Figure 6.1). In 
early Xenopus development RNA synthesis does not occur until the midblastula stage (stage 
8). Until this point, protein expression is dependent on maternally inherited mRNA and protein 
(Newport and Kirschner 1982). The maternally expressed mRNAs are translated at specific 
times which are thought to be associated with the adenylation state of the mRNAs 
(Graindorge et al. 2006). The maternal expression of Tmem114 detected in X. tropicalis had 
not previously been described in other species. This early expression in X. tropicalis is 
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suggestive of a functional role prior to gastrulation in which case the injection of morpholinos 
may disrupt blastula development. A reduction in embryo survival was observed with the 
increase in MO dose (Figure 6.3C), which may suggest that knockdown of Tmem114 was 
lethal to the embryos, but may have been due to non-specific effects caused by the injection 
or by non-specific toxicity associated with the high concentrations of morpholino, or by poor 
quality of the embryos (discussed in Section 6.4.4).  
 
When mTmem114-V5 was heterologously expressed in developing embryos gastrulation 
defects were observed. This suggested that expression of Tmem114 may inhibit gastrulation. 
Gastrulation involves the organisation of cells of the blastula into the three germ layers: 
endoderm, mesoderm and ectoderm. This involves highly co-ordinated cell movement which 
is dependent on cell-cell and cell-extracellular matrix adhesion (Steinberg 1996). Improper 
expression of a protein with adhesive properties may disrupt the co-ordinated cell movement 
involved in gastrulation. Overexpression of claudins in Xenopus increases cell-cell adhesion 
and impairs gastrulation (Brizuela et al. 2001; Chang et al. 2010). Tmem114 is similar to a 
number of proteins with adhesive properties (Section 3.10.2.6) and therefore, expression of 
Tmem114 at gastrulation, when it is not normally expressed, may alter the cell-cell adhesions, 
affecting the movement of cells necessary for successful gastrulation. However, the link 
between mTmem114-V5 overexpression and exogastrulation could not be proved. Although 
the injected mTmem114-V5 mRNA appeared stable (as it was detected by RT-PCR) 
translation to Tmem114-V5 could not be detected by western blot. This indicated that the 
phenotype observed may have been due to toxicity of the injected mRNA or due to the 
injection procedure itself, and not due to expression of mTmem114. Attempts were also made 
to inject plasmid DNA encoding mTmem114-V5 but this also was not detected by western blot 
(data not shown). 
 
With further time and resources the overexpression of mTmem114-V5 could have been 
optimised. Once overexpression had been successfully achieved, a rescue of the phenotype 
could be attempted. Rescue of a phenotype by expression of the target mRNA is the most 
stringent test of specificity of the phenotype observed in knockdown models. A more 
extensive investigation of the effect of xtTmem114 MOs on early development may identify 
the early functional role. The dissection of the early embryos into animal and vegetal 
hemispheres may also detect if expression of xtTmem114 is localised to specific poles.  
 
6.4.2 Zygotic expression of xtTmem114 
Weak zygotic expression of xtTmem114 began at stage 23, approximately the time of 
interaction between the presumptive lens ectoderm (PLE) and the optic vesicle (Ishibashi and 
Yasuda 2001; Henry et al. 2008). Expression in the eye at later developmental stages (45, 47) 
was shown by RT-PCR, but expression at earlier stages could not be tested by RT-PCR as 
the tissues were too small to dissect. Attempts were made to detect expression by in situ 
hybridisation, but although the protocol worked, as shown by the staining for xtLim2, specific 
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staining for xtTmem114 could not be detected. The background staining seen with both 
antisense and sense probes was suggestive of trapping of reagents in cavities (“probe 
trapping”) which may have been due to low levels of expression of xtTmem114 or due to the 
chemistry of the probes used. A similar staining pattern was observed with the sense xtLim2 
probe confirming that the staining observed was non-specific.   
 
Expression of xtTmem114 restarts at stage 37 at higher levels than earlier developmental 
stages. This may represent upregulation of expression in the eye, as seen in mouse 
(Jamieson et al. 2007) or may represent a more widespread expression of the gene. The 
increase in expression coincides with two major developments in the eye: at stage 35/36, the 
cavity of the lens vesicle begins to be filled by the elongating primary fibre cells and the retina 
begins to differentiate into its specific layers (Henry et al. 2008). By stage 41 the primary lens 
cells have filled the lumen of the lens vesicle (Henry et al. 2008), the equivalent of E13.5 in 
mouse (Faber et al. 2002). Expression of murine Tmem114 begins at E13.5 and increases 
thereafter (Jamieson et al. 2007). Expression in Xenopus therefore occurs slightly earlier than 
in mouse, but expression is increased at stage 40, approximately the equivalent stage of 
onset of murine expression.  
 
The earliest detection of mTmem114 expression in the developing mouse eye is detected at 
E13.5 (Jamieson et al. 2007), the equivalent stage of development as stage 41 in Xenopus. In 
Xenopus, the expression at stages 23-26 (the time of PLE/optic vesicle contact) was much 
lower than at 37-40. Therefore, expression in the developing PLE in mouse may also be 
occurring, but was not detected due to the low levels of expression. 
 
Expression of xtTmem114 was also detected in the adult intestine, but developing tissues 
were not tested. The major development of the digestive system takes place form stage 36 
onwards (Estabel et al. 2003) and at stage 40 the gut is formed of a simple tube, with the 
formation of coiled loops occurring at approximately stage 43 (Chalmers and Slack 1998). In 
the adult xtTmem114 is also expressed in the lung. In the developing embryo external gills 
begin to develop at stage 36 (Segerdell et al. 2008) and at stage 46 the external gills are 
replaced by internal gills which later in development are replaced by lungs (Estabel et al. 
2003). 
 
Developmental, but not adult, expression of murine Tmem114 has been reported in kidney 
and developmental kidney defects were identified in patients with the balanced translocation 
through the putative promoter of TMEM114 (Jamieson et al. 2007). Expression in the kidney 
of adult X. tropicalis was not detected. During kidney development in X. tropicalis, the 
pronephros begins to function at stage 36 (Chan and Asashima 2006) and this is followed by 
a wave of gene expression (Brandli 1999). This coincides with the onset of xtTmem114 
expression, suggesting a possible role in kidney development. The failure of the in situ 
hybridisation means that this hypothesis could not be tested. 
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Thus, the onset of xtTmem114 expression at stage 37 may represent expression in the eye, 
kidney, gill or intestine or may represent expression in a number of these developing tissues. 
Determination of spatial expression of xtTmem114 at this stage will require in situ 
hybridisation. 
 
6.4.3 Knockdown of xtTmem114 results in microphthalmia 
The xtTmem114 MO injected embryos displayed the developmental ocular defect 
microphthalmia. Microphthalmia was observed in 39 % of MO1 unilateral injected embryos 
and 59 % of MO2 unilateral injected embryos, with background (uninjected) frequencies of 
2.9-4.8 %. Although background frequencies were higher than from other published work from 
the laboratory (1.8-2.4 %) (Hilton et al. 2007), frequencies were in line with other published 
work. Other published work reporting eye defects in the range of 65-77 % reported 
frequencies of 3-9 % in control MO injected embryos (Elkins and Henry 2006; Hanel and 
Hensey 2006; Wang et al. 2009b). 
 
Although phenotypes were scored after stage 40 when the eyes of the embryos were 
relatively large, presentation of the phenotype preceded stage 37, as shown in the 
EGFP/MO1 injected embryos (Figure 6.5).  This suggests that the phenotype was due to 
knockdown of expression at the earlier stages of 23-26, rather than when expression restarts 
at stage 37. This implies that xtTmem114 is expressed in the eye at the stages of 23-26. In 
Xenopus the PLE is in contact with the optic vesicle at these stages and its thickening to form 
the lens placode occurs at stage 27 (Ishibashi and Yasuda 2001). Thus xtTmem114 
expression precedes lens placode formation but occurs at the time of its precursor tissue.  
 
Impaired lens formation is a major cause of microphthalmia (Landel et al. 1988; van 
Raamsdonk and Tilghman 2000) and in humans seven of the eight genes which are known to 
cause isolated microphthalmia/anophthalmia encode transcription factors required for lens 
formation (reviewed in Becker et al., 2010). Reduction of the size of lens placode caused by 
haploinsufficiency for Pax6, a gene essential for lens placode formation (Grindley et al. 1995) 
results in the formation of a small lens causing microphthalmia (van Raamsdonk and 
Tilghman 2000). Cases of microphthalmia in which lens development is defective at later 
stages, such as the disrupted elongation of lens fibre cells (Oda et al. 1980), or a decrease in 
the number of fibre cells (White et al. 1998) also decreases the size of the lens relative to the 
remainder of eye.  
 
As the lens placode is key to development of the whole eye, disrupting development of the 
PLE may have resulted in the overall reduction in eye size. Disruption of PLE development by 
a conditional knockout of the transcription factor Six3 prevents development of the lens 
placode and lens (Liu et al. 2006b). The lenses of the xtTmem114 MO microphthalmic eyes 
were of normal size relative to the remainder of the eye, i.e., the affected eye showed a 
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reduction in size in all tissues and not specifically the lens. This suggests that the defect in 
development caused by the MOs delayed growth of the whole eye rather than inhibiting 
development of the lens. 
 
TMEM114 is associated with early onset dominant cataract through its proximity to a balanced 
translocation (Jamieson et al. 2007). The breakpoint of the translocation transects the 
predicted promoter of TMEM114.  However, no association was identified between coding 
sequence variants in TMEM114 and autosomal dominant congenital cataract (Jamieson et al. 
2007). The microphthalmic lenses of Tmem114 MO injected embryos showed no sign of 
opacification and cataract was not observed in any of the other morphants. Cataract, although 
rarely reported, is detectable in MO-injected Xenopus (Dirscherl et al. 2005). Thus, coding 
sequence variants in TMEM114 and knockdown of Tmem114 have not been shown to result 
in cataract. However, the effect of the balanced translocation on TMEM114 expression is 
unknown. If the effect was to inhibit expression of TMEM114, one may have expected to 
observed cataract in the morphants. As this did not occur it is possible that the translocation 
has the effect of dysregulating expression of TMEM114, with expression or over-expression 
occurring at the wrong time or place. The effect of mutations on promoter activity can be 
tested with luciferase assays, with luciferase expression controlled by the promoter of interest. 
Although both wildtype and mutant promoter fragments could have been cloned, the lack of a 
suitable cell system in which to perform the luciferase assays prevented the experiment from 
being pursued. As described in section 4.2.2, endogenous TMEM114 expression was not 
detected in any of the cell lines tested.  
 
The knockdown/knockout of a number of genes in which missense mutations in humans result 
in cataracts causes microphthalmia. Missense mutations in the gap junction protein connexin 
50 (Cx50) are associated with a variety of forms of dominant congenital cataract (Schmidt et 
al. 2008; Vanita et al. 2008; Wang et al. 2009a; Gao et al. 2010).  Cx50 knockout mice display 
congenital cataract and microphthalmia (White et al. 1998; Rong et al. 2002). Microphthalmia 
also presents in some mice and rats homozygous for missense mutations in Cx50 (Liska et al. 
2008; Bakthavachalu et al. 2010). Knockout of Pitx3 results in microphthalmia due to failure of 
the lens to develop (aphakia) (Rieger et al. 2001) and homozygous frameshift mutations in 
PITX3 cause microphthalmia and neurological defects (Bidinost et al. 2006).  Knockout of αA-
crystallin in mouse results in cataract and microphthalmia (Brady et al. 1997). Interestingly 
homozygous missense mutations affecting residue p.R54 of αA-crystallin in mouse have 
different effects. Both p.R54C and p.R54H (Chang et al. 1999) mice display cataract but the 
p.R54C mouse also displays microphthalmia (Xia et al. 2006). The substitution of histidine for 
arginine replaces a positively charged amino acid with another positively charged amino acid. 
But, altering the positively charged arginine (R) to the non polar cysteine results in the more 
severe phenotype microphthalmia. This suggests that loss of protein or proteins with severe 
amino acid alterations are associated with microphthalmia.  
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In conclusion, knockdown of xtTmem114 in Xenopus results in microphthalmia and biallelic 
missense or non-sense mutations in a number of genes expressed in the lens are associated 
with microphthalmia. Therefore one may expect to find biallelic missense or non-sense 
mutations in TMEM114 associated with microphthalmia in humans. This hypothesis is tested 
in Chapter 7.  
 
6.4.4 Knockdown of xtTmem114 is associated with an increase in gut defects 
An increased number of embryos displaying abnormal guts were observed with injection of 
MO1. This was followed up with three independent experiments with injection of MO2 also 
resulting in an increased frequency of abnormal gut development. Expression of xtTmem114 
was detected in the adult intestine supporting a role for xtTmem114 in this tissue. As 
discussed above there was a marked increase in expression of xtTmem114 from stage 37. At 
this stage the gut is simple but is beginning to develop. By stage 43 the gut has lengthened, 
has begun to forms its cavity, and has formed its coiled structure which further develops with 
time (Chalmers and Slack 1998; Chalmers and Slack 2000). Although the increase in 
expression of xtTmem114 coincides with this stage of gut development, the failure of the guts 
to coil in the MO injected embryos is not likely to be due to inhibition of expression at such late 
a stage of development. MOs become more dilute as the embryo grows and so phenotypic 
effects are usually due to inhibition at earlier stages. Gut coiling has also been shown to 
sensitive at earlier stages of development, particularly at stage 25 (Zeynali and Dixon 1998) 
which coincides with the earlier expression of xtTmem114.  
 
Even though gut development is well documented and used as a marker for embryo staging 
(Nieuwkoop and Faber 1967) there was consistently a high background rate of gut defects in 
the uninjected embryos (7.4 %-23.5 %). Previous work published by this laboratory had 
background gut defect frequencies of 5-6 %, compared to background levels of eye defects of 
<1 % (Hilton et al. 2007). This suggests that gut development was particularly sensitive to 
perturbation. To determine if the observed increase in frequency of gut abnormalities was due 
specifically to the xtTmem114 MOs a number of control experiments could have been 
performed. Embryos could have been injected with the same concentration of control 
morpholino to determine if the effect was due to injection of oligonucleotides or injected with 
water to determine if the effect was due to the injection procedure itself.  
 
Although the expression in the adult intestine is suggestive of expression in the developing 
intestine, this developmental expression has not been determined. Also, the effect of 
morpholinos decreases with the number of cell divisions occurring as the morpholino 
becomes more dilute with each cell division. Thus, when xtTmem114 expression is at its peak 
(~stage 40), the morpholino is likely to be nearing its most dilute state. Also, Tmem114 
expression has only been detected in epithelial tissues, but although gut development begins 
earlier, the intestinal epithelium is not formed until stage 45 (Chalmers and Slack 2000). Thus 
there are a number of questions that need answering before the association between 
knockdown of xtTmem114 and defects in gut development is confirmed. 
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It is common that the quality of embryos varies from batch to batch, especially if the females 
used are old or not ovulating regularly (Tomlinson et al. 2005). This can affect the numbers of 
embryos surviving through gastrulation and those that do may have an increased rate of 
abnormalities or be more susceptible to perturbation. For this reason data from three or more 
independent experiments using different females are performed. The initial dose optimisation 
experiments for MO1 using 15 ng and 20 ng injections had low survival rates of the uninjected 
(~50 %) and very low survival rates for the injected (~ 15 %). But these doses were only 
tested once. Based on this data 10 ng was chosen as the optimal dose (5 ng for unilateral 
injections). However, repetition of the higher doses may have identified that these doses are 
tolerable to the embryos and an increased dose may have increased the numbers of embryos 
displaying microphthalmia from the moderate but significant level of 39 %. 
 
Using MO1, 39 % of embryos displayed microphthalmia and using a higher dose of MO2, 59 
% of embryos displayed microphthalmia. Thus, complete penetrance of the phenotype was 
not observed. However, as the majority (80 %) of MOs from Gene Tools are reported to 
achieve 70-98 % knockdown of their specific targets (Summerton 2007), one cannot expect to 
achieve phenotypes in 100 % of MO injected embryos. As discussed above, the lower rate of 
microphthalmia with MO1 may be due to using a sub-optimal dose. The co-injection of EGFP 
with the MOs routinely would have allowed selection of embryos specifically with EGFP/MO 
located in the early developing eye which may have increased the frequency of 
microphthalmia detected. However, the co-expression of EGFP may have been a confounder 
so this was not performed. Injections can also be performed at later stages, e.g. injection into 
the animal region of dorsal blastomeres at the 16 cell stage specifically targets the brain, eyes 
and olfactory tissues (Moody 1987; Ciesiolka et al. 2004). But this strategy requires more time 
and expertise and reduces the number of injections being performed.  
 
6.4.5 Limitations of this study 
There were two major limitations to this study: the failure of the in situ hybridisation for 
xtTmem114 and the inability to confirm that MO1 and MO2 block translation of their targets. 
Although the temporal expression of xtTmem114 was successfully determined in this study, 
there was only limited spatial expression determined by RT-PCR. A successful in situ 
hybridisation would have aided this study in numerous ways. The expression at stages 23-26 
is likely to occur in the PLE due to the expression of mTmem114 in the lens and that 
microphthalmia is observed before the later onset of expression at stage 37. Wholemount in 
situ hybridisations at a range of stages from 20-30 would have confirmed this hypothesis as 
true or false. There is large increase in expression of xtTmem114 at stage 37 which coincides 
with developmental processes in the eye, kidney and intestine. A functional in situ 
hybridisation at this stage would have determined the tissue(s) in which it is expressed at this 
stage. 
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Due to the lack of an antibody that detected xtTmem114 the knockdown of xtTmem114 could 
not be shown in vivo. Therefore an alternative approach based on the in vitro translation of 
V5-tagged xtTmem114 was used. However, xtTmem114 contains a number of potential ATG 
initiation codons, and when detected by western blot, it was apparent that translation was 
being initiated downstream of the “true” initiation codon. Therefore, the addition of MO1 had 
no effect as the ribosome was binding at an alternative site. If time permitted an alternative 
approach could have been taken to prove that the MOs bind their targets and knockdown 
expression. The 5‟UTR of xtTmem114 could have been cloned upstream of a protein such as 
GFP. As shown in figure 6.5, X. tropicalis embryos readily transcribe and translate GFP from 
injected circular plasmids. The ability of MO2, which binds the 5‟UTR of xtTmem114 to 
knockdown expression of its target could be tested by co-injecting the xtTmem114-
5‟UTR/GFP construct with and without MO2. As a further control, MO2 should not prevent 
translation of GFP which lacked the 5‟UTR of xtTmem114. This method has previously been 
used to prove efficacy of morpholinos in vivo (Jia et al. 2008).  However, although the 
knockdown of xtTmem114 was not demonstrated, the observation of similar phenotypes with 
MO1 and MO2 which have independent targets was suggestive of specificity.  
 
Another limitation of the study was that a control MO was not used. Injection of scrambled 
MOs or standard control MOs available commercially act as a better control than using 
uninjected embyros as it controls for the injection procedure itself and it acts as a control for 
the injection of the 25bp oligonucleotide. However, injecting control MOs in the same 
experiments as the test MOs halves the number of test embryos injected. Previous MO work 
in the laboratory showed little difference in the rates of defects between MO, water and 
uninjected embryos (Hilton et al. 2007). For this reason, control MOs were not employed.  
 
6.5 Conclusion 
The use of X. tropicalis as an animal model has confirmed the role of Tmem114 in eye 
development but has also uncovered questions that remain to be answered. Maternal 
expression of xtTmem114 was detected but the functional role for this is yet to be determined. 
The conservation of this maternal expression also remains to be identified. The data 
generated suggests that xtTmem114 is expressed in the early stages of eye development, 
earlier than reported in mouse (Jamieson et al. 2007). This has led to the hypothesis that 
TMEM114 may be associated with microphthalmia in humans, a hypothesis which is tested in 
chapter 7. The detection of expression in the intestine and the lung suggests a more 
widespread expression pattern than previously detected. In the lens Tmem114 is expressed in 
the epithelial cell layer (Jamieson et al. 2007). The lung and the intestine are also epithelial 
tissues. If the hypothesis that TMEM114 is associated with microphthalmia in humans is 
correct, one may expect to find the microphthalmia occurring in association with other non-
ocular anomalies.  
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7.1 Introduction 
Knockdown of Tmem114 in Xenopus tropicalis resulted in microphthalmia (Chapter 6) and the 
expression of TMEM114 in the developing human eye (Figure 4.1) suggested a role in eye 
development. TMEM114 is located at a locus associated with isolated microphthalmia with 
cataract (MCOPCT1, OMIM 156850). Therefore mutations were sought in a panel of patients 
with microphthalmia to determine if mutations in TMEM114 are associated with 
microphthalmia in humans. 
 
7.2 Screening of microphthalmia cohort for mutations in TMEM114 
This panel consisted of 77 patients with the congenital structural eye defects microphthalmia 
(small eye), anophthalmia (absence of ocular tissue in the orbit) and coloboma (failure of part 
of the fetal fissure to close) (Table 7.1). Some of these phenotypes were in isolation, but the 
majority of patients had other ocular and non-ocular phenotypes (Full list of clinical 
phenotypes available in Table 9.14). The microphthalmia/anophthalmia/coloboma (MAC) 
patients were screened for mutations in the coding sequence and flanking intronic sequences 
of TMEM114. Three patients were identified to have heterozygous missense variants (Figure 
7.1) and a number of SNPs were identified in patients and in controls (Table 7.2).  
 
Table 7.1. Clinical phenotypes of 77 MAC patients screened for mutations in TMEM114. 
n = number of patients. NS = number of patients with non-syndromic (eye only) phenotypes. Total = 
combined numbers of bilateral cases (unilateral anophthalmia with contralateral anophthalmia are 
considered bilateral microphthalmia). 
Phenotype n NS   Total  
Bilateral anophthalmia  13 6 13 
Unilateral anophthalmia with contralateral microphthalmia 12 7  
Unilateral anophthalmia with contralateral microphthalmia & coloboma 2 1  
Bilateral microphthalmia 19 8   48 
Bilateral microphthalmia with bilateral colobomata  11 9  
Bilateral microphthalmia with unilateral coloboma 4 3  
Unilateral microphthalmia  3 1  
Unilateral microphthalmia with contralateral coloboma 4 1  
Bilateral colobomata  3 2 
8 
Bilateral colobomata with unilateral microphthalmia 5 5 
Unilateral coloboma  1 0  
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Figure 7.1. Missense variants identified in patients with microphthalmia. A) Heterozygous 
G>A change at position 5 (arrow) resulting in substitution of glutamine for arginine B) Heterozygous C>T 
change at position 134 (arrow) resulting in substitution of lysine for proline. C) Heterozygous C>T 
change at position 440 (arrow) resulting in substitution of valine for alanine. Bar indicates intronic 
sequence. Phenotypes and ethnicity of the affected individuals are presented on the right. 
 
 
The variant c.134C>T, resulting in the substitution of non-polar proline with the non-polar 
leucine (p.P45L), was identified in a patient with bilateral microphthalmia, coloboma and 
retinal dystrophy (Figure 7.1 B). The affected proline residue, located in ECL1, is conserved in 
mammals, although the surrounding amino acids show little conservation (Figure 7.2). 
Parental DNA was unavailable for testing. This variant was identified in one of 224 white 
European control chromosomes tested, which suggests that it is a rare non-pathogenic variant 
(Table 7.2).  
 
A c.5G>A transition resulting in an arginine to glutamine substitution (p.R2Q) was identified in 
a patient with bilateral microphthalmia, retinal coloboma and congenital kidney defects as well 
as other anomalies (Figure 7.1A). Parental DNA was unavailable for testing as was 
information on their affected status. This variant was absent from 224 white European control 
chromosomes screened by direct sequencing. The arginine at position 2 in TMEM114 is 
conserved down to chick and is located in the predicted short intracellular N-terminus of 
TMEM114 (Figure 7.2). The potential functional effect of p.R2Q was investigated using tools 
which predict the effect of non-synonymous substitutions on protein function. Supportive of 
the mutations pathogenicity in vivo PolyPhen (Ramensky et al. 2002) predicted the 
substitution as “probably damaging” and SIFT (Kumar et al. 2009) predicted that the change 
would be “not tolerated”.  
c.5g>a p.R2Q 
> bilateral microphthalmia, retinal coloboma 
> absent right kidney, cystic dysplastic left 
kidney, bilateral cryptorchidism, adducted 
left thumb, pseudoarthrosis of right clavicle  
> Ethnicity: Vietnamese 
c.134c>t p.P45L 
> bilateral microphthalmia, colobomas, 
retinal dystrophy.   
> Ethnicity: unknown 
c.440c>t p.A147V 
> bilateral anophthalmia, optic nerve 
hypoplasia, atrophic chiasm 
> interhemispheric cyst, corpus callosum 
agenesis, Dandy Walker malformation, 
seizures, dysplastic cup shaped ears, 
extended abdomen. 
> Ethnicity: unknown 
Phenotype 
Chapter 7 
 
  
168 
 
The third variant identified, c.440C>T changes the first nucleotide in exon 4 resulting in the 
substitution of the highly conserved non-polar alanine with the non-polar valine (p.A147V) in 
TMD3 (Figure 7.1C). This patient had bilateral anophthalmia, hypoplasia of both globes, optic 
nerve hypoplasia and multiple non-ocular anomalies (atrophic chiasm, interhemispheric cyst, 
corpus callosum agenesis, Dandy Walker malformation, seizures, dysplastic cup shaped ears 
and extended abdomen). Sequencing of the unaffected parents of this individual identified the 
same c.440C>T variant in the patient‟s unaffected mother confirming that the variant is not the 
causative mutation in this patient. This variant disrupts an Nco I site (CCATGG). The Nco I 
digested exon four fragment from the patient was detected as two bands of 372 bp 
(undigested) and 301 bp (digested), indicating heterozygosity at the Nco I site (Figure 7.3). 
However, all of the 160 white European control chromosomes screened were sensitive to Nco 
I digestion indicating they were wildtype for the Nco I site.  
 
Two non-coding variants and one synonymous substitution were also identified in the panel. 
The c.13C>T variant does not alter the encoded amino acid suggesting it is a SNP. A C>T 
variant in the 5‟UTR, 24 nucleotides upstream of the A of the initiation codon was present in 
patients in heterozygous and homozygous states but was also identified in controls 
heterozygous and homozygous states suggesting it was a SNP. The c.440-7C>G change in at 
the end of intron three has previously been reported as a SNP in the database dbSNP 
(rs62018861). 
 
Table 7.2. Variants identified in the coding and non-coding regions of TMEM114 in MAC 
patients and controls. H/h = heterozygous. h/h homozygous. * = tested by Nco I digestion. ^ = 
rs62018861  
 
     
  
Variants 
 
Nucleotide         Protein 
Prevalence  
in H/h 
state 
Prevalence 
in h/h state 
Prevalence 
in H/h 
state 
Prevalence 
in h/h state 
Exon1 -24C>T - 20/77 6/77 36/112 1/112 
Exon1 c.5G>A p.R2Q 1/77 0/77 0/112 0/112 
Exon1 c.13C>T p.L5L 1/77 0/77 0/112 0/112 
Exon1 c.134C>T p.P45L 1/77 0/77 1/112 0/112 
Intron3 c.440-7C>G^ - 16/77 3/77 not tested not tested 
Exon4 c.440C>T p.A147V 1/77 0/77 0/80* 0/80* 
 
    Patients         Controls 
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A 
H. sapiens         MRVHLGGLAGAAALTGALSFVLLAAAIGTDFWYIIDTERLERT--------GPGAQDLLGS 53 
M. mulatta         MRVHLGGLAGAAALTGALSFVLLAAAIGTDFWYIIDTERLERS--------GPGAQDLLGS 53 
M. musculus        MRVRLGALAGAAALSGALSFVLLAAAIGTDFWYIIDTERLERS-SQRMRDQGP-------- 52 
R. norvegicus      MRVRLGALAGAAALSGALSFVLLAAAIGTDFWYIIDTERLEKS-SPRMRDQGP-------- 52 
B. taurus          MRVHLGALAGAAALTGALSFVLLAAAIGTDFWYIIDTERLERG--------GPGARGPVGA 53 
M. domestica       MRVRLGALAGAAALTGALSFVLLAAAIGTDFWYIIDTARLEQRRPGASGARDPGGSSTDS- 60 
G. gallus          MRVSLSVLSLLVALVGASSFVFLVVAIATDFWYIIDASRLETATN---------------- 45 
X. tropicalis      MKLKLSMLSVFVAVVGILSFISLVVAIGTDFWYIIDASRLEKITN---------------- 45 
D. rerio           MKVTFTGLAGFVAVFGVLSFIGLVLAIGTDFWYIIDTSKRENSSS---------------- 45 
                   *:: :  *:  .*: *  **: *. **.********: : *                    
 
H. sapiens         INRSQPEPLSSHSGLWRTCRVQSPCTPLMNPFRLENVTVSESSRQLLTMHGTFVILLPLS 113 
M. mulatta         INRSQLEPLSSHSGLWRTCRVQSPCTPLMNPFWLENVTVSESSRQLLTMHGTFVILLPLS 113 
M. musculus        ANRSQQEPLSSHSGLWRTCRVQSSCTPLMNPFWQENVTVSDSSRQLLTMHGTFVILLPLS 112 
R. norvegicus      VNRSQSEPLSSHSGLWRTCRVQSTCTPLMNPFWQENVTVSDSSKQLLTMHGTFVILLPLS 112 
B. taurus          NNRSQLEPLSSHSGLWRTCRVQSPCAPLMNPFWQENVTVSDSSRQLLTMHGTFVILLPLS 113 
M. domestic        LNHSQPEPLSSHSGLWRTCRVQSKCTPLMNPFWQENVTVSDSDRQLLTMHGTFVILLPLS 120 
G. gallus          ----GTAALSSHSGLWRTCRLRSKCYPLINPFWYENANITDSHRQLLYMHGTFVILMPLS 101 
X. tropicalis      ----FSDPLSSHSGLWRMCKFKNKCLPLINPFRLGNLNFTDSQKQLLSMHGTLVILLPLS 101 
D. rerio           ------VSLSSHSGLWRTCNFHNQCWPFMNPFGAG-RNLSDSQRQILNMQGTFIILLPLS 98                          
                          .********* *..:. * *::***     ..::* :*:* *:**::**:*** 
 
H. sapiens         LILMVFGGMTGFLSFLLQAYLLLLLTGILFLFGAMVTLAGISVYIAYSAAAFREALCLLE 173 
M. mulatta         LILMVFGGMTGFLSFLLRAYLLLLLTGTLFLFGAMVTLAGISVYIAYSAAAFREALCLLE 173 
M. musculus        LIVMVFGGMTGFLSFLLRAHLLLLLTGILFLFGAMVTLTGISIYIAYSAVAFREAVCLLE 172 
R. norvegicus      LIVMVFGGMTGFLSFLLRAHLLLLLTGTLFLFGAMVTLTGISIYIAYSAVAFREAMCLLE 172 
B. taurus          LILMVFGGMTGFLSFLLRASCLLLLTGTLFLFGALVTLAGISVYIAYSAAAFQEALCLLQ 173 
M. domestica       LILMVFGGMTGFISILARAYLLLLMTGMLFLFGALVTLAGISVYIAYSAAAFQEAVCLLE 180 
G. gallus          LILMIFGGMTGFISILARAYLLLLMTGLLFLFGALVTLTGIGVYIAYSAAAFEEAVCLLR 161 
X. tropicalis      LILMIFGGMTGFVSILARAYLLLLLTGMLFLFGALVTLTGISIYIAYSAAAFKDAVCILG 161 
D. rerio           VILLFVGGMLGFISLLARAYVLLLLTGVLLLFGAVLSLAGICVYMAYSAAAFREAVDISG 158 
                   :*::..*** **:*:* :*  ***:** *:****:::*:** :*:****.**.:*: ::   
 
H. sapiens         EKALLDQVDISFGWSLALGWISFIAELLTGAAFLAAARELSLRRRQDQAI- 223 
M. mulatta         EKALLDQVDIHFGWSLALGWISFIAELLTGGAFLAAARELSLRRRQDQAI- 223 
M. musculus        ERALLDQVDIRFGWSLALGWISFVSELLTGVVFLAAARALSLSQRQDQAI- 222 
R. norvegicus      ERALLDQVDIRFGWSLALGWISFVSELLTGVVFLAAARVTNLSQRQEQAI- 222 
B. taurus          EKTLLDQVDIRFGWSLALGWVSCVAELLTGATFLVAARVLSLRRRQDQAI- 223 
M. domestica       EKDLLDQVDIRFGWSLALGWISFISELLTGAAFLLAARMVGLKRRQDQAI- 230 
G. gallus          SKDVLVEIDIRFGWSLALVWISFVAEVITGAAFLLAARVVGLKQQHEQEL- 211 
X. tropicalis      NK-ILEDIDIQFGWSLALAWISFITEILTGIAFLVAARVTGLKRRRREQVI 211 
D. rerio           HK-TLQDIEIYFGWSLILASVSFVGELCTAVAFLLTSVKVSQQTNQEQDE- 207 
                     :  * :::* ***** *  :* : *: *. .** ::   .   .: :  
 
 
 
 
 
 
B Figure 7.2. Conservation and 
location of the affected residues. A) 
Multiple alignment of TMEM114 
orthologues. p.R2 is conserved to chick. 
p.P45 is conserved in mammals but is 
located in a non-conserved region. p.A147 
is conserved in all species and is the first 
amino acid encoded by exon 4. Variants 
are highlighted in yellow. Alternate exons 
are coloured in black and blue font. Amino 
acids bridging two exons are in red font. B) 
Location of affected residues. p.R2 is 
located in the intracellular N-terminus. 
p.P45 is located in the 1
st
 extracellular loop. 
p.A147 is located in the 3
rd
 transmembrane 
domain. Topology predicted by TMHMM. 
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Figure 7.3 Screening for the c.440C>T variant in patients and controls by Nco I 
digestion. The c.440C>T variant disrupts and Nco I restriction site in exon 4 of TMEM114. In control 
DNA Nco I treatment digested the DNA forming a 301 bp DNA fragment, compared to the 372 bp 
fragment in the non-treated sample (NT). The amplicon from the patient identified to be heterozygous for 
the c.440C>T variant produced two bands of 372 bp and 301 bp when digested with Nco I indicating that 
the Nco I site was disrupted on one allele. 
 
 
7.3 Functional analysis 
The panel screened was from an external source and there was a delay in acquiring 
information regarding the patients and acquiring parental DNA samples. Therefore, before the 
appropriate controls had been screened, in vitro analysis was undertaken to determine if the 
mutations identified had functional effects on the TMEM114. To assess the potential 
pathogenic consequences of the human TMEM114 variants identified, mutations were 
introduced at the equivalent site in mTmem114-V5 using SDM (Figure 7.4). The murine 
equivalent of p.A147V, p.A146V, had previously been cloned (Urquhart, unpublished) due to 
the presence of this variant in patients with autosomal dominant congenital cataract (ADCC) 
(Jamieson et al. 2007).  
 
7.3.1 Expression levels 
Expression levels of the variants p.R2Q, p.P52L and p.A146V were compared by transfecting 
into MDCK II cells and detecting by western blot. Forty eight hours post-transfection the 
p.R2Q variant and the p.P52L (murine equivalent of p.P45L) had similar expression levels and 
pattern to the wildtype (Figure 7.5A). Unexpectedly, the p.A146V isoform (murine equivalent 
of p.A147V) was not detected in the 40-45 kDa isoform, but was detected predominantly in 
the intermediate isoform at ~32 kDa (Figure 7.5A). This variant was sensitive to digestion by 
Endo H which cleaves mannose-rich oligosaccharides, which are typical of glycoproteins that 
have not been trafficked beyond the ER (Figure 7.5B).  
 
Chapter 7 
 
  
171 
 
Figure 7.4. Sequence chromatograms of the mTmem114-V5 mutants created by site-
directed mutagenesis. Mutations (asterisks) were created at the equivalent sites of murine 
Tmem114 
 
 
 
Figure 7.5. Detection of wildtype and missense isoforms of C-terminal V5 tagged 
Tmem114 by western blot. A) Expression of wildtype and missense isoforms in MDCK II cells. 
Tmem114 is detected in three main isoforms; unglycosylated (23 kDa), with covalently linked mannose-
rich oligosaccharides (32 kDa), and with covalently linked complex oligosaccharides (40-45 kDa). p.R2Q 
and p.P52L are expressed at similar levels to wildtype Tmem114 (when normalised to the housekeeping 
protein GAPDH). p.A146V is expressed predominantly in the mannose-rich 32 kDa isoform. B) Endo H 
digestion of wildtype and p.A146V. Non-treated (NT) p.A146V is detected at 32 kDa. Endo H treatment 
of p.A146V results in a shift to the unglycosylated form (23 kDa) of Tmem114. Endo H treatment of 
wildtype Tmem114 results in a shift of the mannose-rich oligosaccharide isoform, but not the complex 
oligosaccharide isoform. 
 
 
7.3.2 Localisation of variants in polarised MDCK II cells 
To determine if the missense mutations had effects on the localisation of Tmem114, the 
localisation of the V5-tagged variants was sought in polarised MDCK II cells. The p.R2Q and 
p.P45L variants localised to the lateral and apical cell membrane, comparable to that of 
p.R2Q p.P52L p.A146V 
wildtype 
mutant 
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wildtype Tmem114 (Figure 7.6). When V5-tagged p.A146V was expressed in polarised MDCK 
II cells it displayed a predominantly perinuclear localisation. Co-staining with the membrane 
protein E-cadherin confirmed p.A146V does not localise at the cell membrane (Figure 7.7A). 
The staining pattern of p.A146V was indicative of ER localisation.  This could not be directly 
demonstrated because, as mentioned in section 4.5.3, it was not possible to optimise an ER 
antibody for MDCK II cells. Using the Golgi apparatus marker GM-130 revealed that p.A146V-
V5 is not localised to the Golgi apparatus (Figure 7.7B). This lack of colocalisation with the 
Golgi apparatus and the plasma membrane supports the conclusion that p.A146V-V5 does 
not undergo further processing of its N-linked oligosaccharides, as shown by its sensitivity to 
Endo H digestion (Section 7.2.1). 
 
 
Figure 7.6. Localisation of wildtype and missense isoforms of V5-tagged mTmem114 in 
polarised MDCK II cells. Transfected cells were polarized on transwell filters and labeled with anti-
V5 antibody (green) 48 hours post-transfection. Wildtype mTmem114-V5 localises to the plasma 
membrane. The variants p.R2Q and p.P52L also localise to the plasma membrane. The missense 
isoform p.A146V does not localise to the plasma membrane and is retained in the cytoplasm. Nuclei are 
stained with DAPI (blue). Bar = 10 μm. Cells were fixed with 1:1 methanol:acetone and viewed by 
confocal microscopy. 
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Figure 7.7. Localisation of mTmem114 p.A146V-V5 in MDCK II cells. A) mTmem114 
p.A146V-V5 (red) fails to localise to the cell membrane labelled with E-cadherin (green). Nuclei are 
stained with DAPI (blue). B) mTmem114 p.A147V-V5 (green) does not colocalise with the Golgi 
apparatus marker GM130 (red). Bar = 10 μm. Cells were fixed with 1:1 methanol:acetone and viewed by 
confocal microscopy. 
 
7.3.3 Effects of p.A146V on wildtype Tmem114 
Missense mutations which result in retention of the mutant protein in intraceullular organelles 
have the potential to act in a dominant-negative manner by inhibiting the trafficking of wildtype 
protein (Saliba et al. 2002). To determine if expression of p.A146V-V5 influences the 
localisation of wildtype mTmem114, untagged wildtype mTmem114 was co-transfected with 
V5-tagged p.A146V into polarised MDCK II cells and visualised by immunofluorescence. As 
previously demonstrated in figure 4.4, the V5-epitope prevents detection by the custom 
polyclonal antibody. Cells co-transfected with untagged wildtype mTmem114 and p.A146V-V5 
and labelled with anti-Tmem114 antisera (i.e. detecting the wildtype isoform only) displayed 
plasma membrane staining (Figure 7.8Ai). Co-transfected cells labelled with anti-V5 antibody 
(detecting the p.A146V isoform only) displayed cytoplasmic staining (Figure 7.8Aii). Cells 
transfected with p.A146-V5 alone and labelled with anti-Tmem114 antisera showed very low 
levels of background staining (Figure 7.8Aiii). This confirms that the anti-Tmem114 antisera 
was specifically detecting the untagged protein.  
 
In co-transfected cells labelled with both anti-Tmem114 anti-sera and anti-V5 antisera, the 
wildtype untagged protein was detected at the cell membrane whilst the mutant protein was 
retained in the cytoplasm (Figure 7.8B). Therefore, co-transfection of p.A146V Tmem114 had 
no effect on the trafficking of the wildtype protein.  
 
A B 
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Figure 7.8. Co-transfection of wildtype mTmem114 and p.A146V-V5 in MDCK II cells. A. 
i) In co-transfected cells, anti-Tmem114 antisera (green) detects only the untagged wildtype isoform and 
shows only plasma membrane staining. ii) In co-transfected cells, anti-V5 antibody (red) detects only the 
p.A146V isofrom and shows cytoplasmic but not plasma membrane staining. iii) In cells only transfected 
with the p.A146V-V5 isofrom, anti-Tmem114 antisera (green) only detects very low levels of background 
staining due to epitope masking. B) Dual staining with anti-mTmem114 and V5 antibodies in co-
transfected cells. Dual-labelled cells for anti-Tmem114 (green) (i), anti-V5 (red) (ii), and the merged 
image (iii). In co-transfected cells, wildtype Tmem114 localises to the plasma membrane, but p.A146V-
V5 is retained in the cytoplasm. Nuclei are stained with DAPI (blue). Bar = 10 μm. Cells were fixed with 
1:1 methanol:acetone and viewed by confocal microscopy. 
 
 
7.4 Possible effect of c.440C>T on splicing 
The nucleotide c.440C is the first nucleotide of exon 4 of TMEM114 and therefore at the 
intron-exon boundary. Mutations at intron/exon boundaries can affect the splicing of 
transcripts and are a common source of mutation in human disease (Ars et al. 2000; Schmid 
et al. 2010).  To investigate if the sequence variant c.440C>T has an effect on the splicing of 
TMEM114, bioinformatic splicing prediction programs were used to predict possible splicing 
differences between the wildtype and c.440C>T isoforms. Of the 4 programs used, two (PESX 
and FAS-ESS) did not detect any difference between the 2 sequences. ESEfinder predicted 
the loss of a SRp40 site and the gain of a SRp55 site in the variant sequence and the 
program Rescue-ESE predicted the loss of an exon splice-enhancing site in the variant 
sequence (Figure 7.9). 
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Figure 7.9. Predicted splice factor binding sites in wildtype and c.440C>T TMEM114. 
Wiltype TMEM114 (top) contains an SRp40 binding site and an AAGCCA binding motif that are lost by 
the alteration of C>T at nucleotide c.440 (bottom, in red). The mutant sequence contains a predicted 
SRp55 site not present in the wildtype. Intron 3 (highlighted in yellow) and exon 4 (blue font). Variant 
nucleotide is highlighted in red font.  
 
 
7.5 Discussion 
7.5.1 Prevalence and etiology of microphthalmia 
As discussed in section 6.4.3, a number of genes associated with congenital cataract are also 
associated with microphthalmia. The To3 mouse is homozygous for missense mutations in 
Lim2, a gene homologous to Tmem114, displays microphthalmia (Steele et al. 1997). 
TMEM114 is located at a locus associated with isolated microphthalmia with cataract 
(MCOPCT1). This data, taken in conjunction with what has been identified in this study (that 
TMEM114 is expressed in the developing human eye (Figure 4.1) and knockdown of 
xtTmem114 results in microphthalmia (Chapter 6) makes TMEM114 a good candidate for 
association with microphthalmia.  
 
Microphthalmia is a congenital ocular developmental defect responsible for 3.2-11.2 % of 
blindness in children (Fujiki et al. 1982; Fraunfelder et al. 1985; Traboulsi 1999), with an 
estimated prevalence of 5-14 per 100,000 live births (Morrison et al. 2002; Kallen and 
Tornqvist 2005; Shah et al. 2010). Microphthalmia is often associated with other ocular 
defects such as cataract (Billingsley et al. 2006) and coloboma (Aijaz et al. 2004), as well as 
with non-ocular defects such as mental retardation and cardiac anomalies in syndromes such 
as CHARGE syndrome (OMIM 214800) and Lenz microphthalmia syndrome (OMIM 309800). 
 
Although a number of causative genes have been identified for microphthalmia (e.g. SOX2, 
PAX6, VSX2) the genetic etiology of the majority of cases remains unknown (Verma and 
Fitzpatrick 2007; Chao et al. 2010). The majority of the genes currently associated with 
microphthalmia and anophthalmia encode transcription factors, which typically lead to more 
systemic phenotypes than microphthalmia and anophthalmia alone. Isolated cases of 
microphthalmia and anophthalmia are in the minority (Morrison et al. 2002) and relatively few 
genes have been identified. Homozygous mutations in the homeobox gene VSX2/CHX10 
(Burkitt Wright et al. 2010; Iseri et al. 2010) and compound heterozygous mutations in another 
homeobox gene RAX (Voronina et al. 2004; Lequeux et al. 2008) have been associated with 
recessive forms of isolated microphthalmia. Biallelic mutations in FOXE3, a transcription 
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factor with a role in the proliferation and differentiation of lens cells (Medina-Martinez et al. 
2005), are associated with recessive microphthalmia in multiple ethnic groups (Reis et al. 
2010b). The homeobox gene SIX6 is located in a locus associated with isolated 
microphthalmia (14q32; OMIM 251600). Although a sequence variant in SIX6 has been 
identified in a case of microphthalmia, pathogenicity of the variant has not been demonstrated 
(Gallardo et al. 2004).  
 
7.5.2 Variants identified in TMEM114 
The panel of 77 patients screened here contained 48 cases of bilateral isolated or syndromic 
microphthalmia and 13 cases of bilateral isolated or syndromic anophthalmia. A c.5G>A 
transition resulting in an arginine to glutamine substitution (p.R2Q) was identified in a patient 
with bilateral microphthalmia, retinal coloboma, kidney defects and other non-ocular 
anomalies such as bilateral cryptorchidism, adducted left thumb, and pseudoarthrosis of the 
right clavicle. This variant was found to be absent from 224 control chromosomes tested. 
Unfortunately, parental DNA and clinical information was unavailable making the significance 
of their affected status uncertain.  The p.R2Q variant identified is predicted to be damaging 
according to the prediction tools PolyPhen2 and SIFT. As discussed in section 4.8.5 the N-
terminal region (the “N domain”) of signal sequences are basic. Substitution of the basic 
arginine residue at p.R2 with a polar glutamine residue may have altered the N domain, 
possibly reducing the efficiency of insertion into the ER membrane. However, in polarized 
MDCK II cells the expression and localisation of p.R2Q variant was similar to that of wildtype 
Tmem114 (Figure 7.6). 
 
A heterozygous arginine to glutamine missense mutation in the intracellular N-terminus of 
bestrophin-1, also close to the first predicted transmembrane domain (TMD), is associated 
with the autosomal dominant retinal disorder Best disease (Marquardt et al. 1998), supporting 
the likely pathogenicity of the p.R2Q variant in TMEM114. The function of the intracellular N-
terminus of TMEM114 is unknown. Although short, the N-terminus may contain protein 
interaction domains which are disrupted by the arginine to glutamine substitution. 
 
In addition to the ocular defects, the patient is also reported to display kidney defects, with an 
absent right kidney and a cystic dysplastic left kidney. Developmental kidney defects were 
also observed in individuals with cataracts carrying the balanced translocation upstream of 
TMEM114 (Jamieson et al. 2007). These kidney phenotypes and the weak expression of 
Tmem114 in the developing kidney (Jamieson et al. 2007) suggest a putative role for 
TMEM114 in kidney development.  Biallelic mutations in STRA6, involved in vitamin A 
metabolism, are associated with microphthalmia with a duplicated kidney collecting system, 
although parental DNA was available to confirm the inheritance pattern (White et al. 2008). 
Expression of Tmem114 was also detected in the mouse testis (Jamieson et al. 2007) and the 
p.R2Q patient also presented with bilateral cryptorchidism (failure of the testes to descend 
into
 
the scrotal sac). However, bilateral cryptorchidism is the most frequent congential 
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defect in males, with an estimated prevalence of 2-4 % of live male births (Barthold and 
Gonzalez 2003). 
 
The absence of the p.R2Q variant in 224 control chromosomes is suggestive of pathogenicity, 
but the limited scope of the functional assays available means that the functional effect of the 
mutation remains to be elucidated. To strengthen confidence in this finding, it would be helpful 
to screen the proband‟s DNA for mutations in STRA6 in order to eliminate this as a potential 
cause of their condition.  
 
7.5.3 Identification of the missense variant p.A147V 
The missense variant c.440C>T (p.A147V) was identified in a patient with bilateral 
anophthalmia, hypoplasia of both globes, optic nerve hypoplasia and multiple non-ocular 
defects. The severe systemic phenotype suggested that the missense mutation was unlikely 
to be the causative mutation and this was confirmed by finding the same variant in the 
unaffected mother. Interestingly, the p.A147V variant was identified three times in a 
heterozygous state in a panel of 130 ADCC patients (Jamieson et al. 2007). However, in one 
of the families it was absent from an affected family member, suggesting it is a polymorphism 
(Jamieson et al. 2007). However, although previously reported as a polymorphism, this variant 
was found absent from 160 control chromosomes tested.  
 
The mislocalisation of the murine equivalent of p.A147V, p.A146V, was not expected as the 
variant had been reported as a SNP (Jamieson et al. 2007). When expressed in MDCK II cells 
p.A146V displayed an intracellular localisation indicative of ER localisation. This ER 
localisation was confirmed by the fact that p.A146V was sensitive to Endo H digestion. 
Integral membrane glycoproteins are translated in the ER and exit the ER when they have 
been folded into the correct conformation by ER resident chaperones (Dejgaard et al. 2004). 
Mutations in TMDs of membrane proteins may disrupt their native conformation, leading to 
incomplete folding or misfolding (Hwa et al. 1997; Choi et al. 2005; Gallagher et al. 2007). 
Proteins which remain misfolded after repeated cycles of chaperone binding are targeted for 
ER-associated degradation (ERAD). ERAD is a quality control system which targets misfolded 
or unassembled proteins within the ER lumen for degradation via the cytoplasmic ubiquitin-
proteasome system (Gelman et al. 2002; Meusser et al. 2005). However, severely misfolded 
proteins may aggregate in the cell triggering the unfolded protein response (UPR) (Roboti et 
al. 2009). The UPR is a stress response that induces expression of chaperones to promote 
folding (Friedlander et al. 2000; Okada et al. 2002) and halts protein translation to prevent 
protein build up in the ER (Okada et al. 2002; Ron 2002). 
  
The 40-45 kDa Endo H insensitive isoform of Tmem114, which localises to the cell 
membrane, was not detected in the p.A146V lysate. This suggested that p.A146V was either 
being trafficked through the Golgi apparatus to the plasma membrane but was being rapidly 
degraded, or it was not being trafficked and was being retained in the ER. Some misfolded 
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proteins escape the ER quality control system and are trafficked to the plasma membrane. 
However, the lysosomal degradation system detects and degrades misfolded proteins that 
have been transported to the Golgi apparatus (Arvan et al. 2002) or plasma membrane (Luzio 
et al. 2007). Lysosomes are membrane-bound organelles that contain multiple hydrolytic 
enzymes to degrade misfolded proteins.  
 
Different mutations in the same protein which affect protein folding may be processed in very 
different ways and yet still result in the same phenotype as is the case for mutations in 
claudin-16 which cause familial hypomagnesemia with hypercalciuria and nephrocalcinosis 
(FHHNC) (Kausalya et al. 2006). If p.A146V was being retained in the ER it may be degraded 
via the proteasome or the misfolded protein may have formed multimers and aggregated. 
Such protein aggregates fail to resolve on SDS-PAGE gels and are retained in the stacking 
gel (Goldberg et al. 2001; Mishra et al. 2008). No such aggregates were identified in the 
p.A146V-V5 lysates.  
 
The majority of cellular proteins are routinely being turned over at rates which are protein 
dependent.  Protein turnover involves degradation of the cellular protein and its replacement 
by newly synthesised protein. Misfolded proteins degraded by the cellular machinery are 
degraded much more rapidly than the correctly folded proteins. The alanine to valine 
substitution at p.A147 may disrupt the conformation of TMEM114 resulting in its misfolding 
leading it to be more rapidly degraded than the wildtype. A heterozygous alanine to valine 
mutation in a TMD of rhodopsin which results in misfolding (Hwa et al. 1997) is associated 
with the retinal disease retinitis pigmentosa (RP) (Fuchs et al. 1994). Although alanine and 
valine are both hydrophobic, valine has a larger sidechain which results in the disruption of 
residues in another TMD (Stojanovic et al. 2003).  
 
To determine if p.A147V is being degraded at a faster rate than the wildtype, pulse-chase 
experiments could be performed. Pulse-chase experiments involve the cellular proteins being 
radiolabeled for a set period of time (the pulse) followed by a period of time when protein 
synthesis occurs without radiolabeled amino acids (the chase). The degradation of the 
radiolabeled protein can then be monitored over time. Pulse-chase analysis, would determine 
the rate of turnover of wildtype Tmem114 and then the rate of degradation of p.A146V could 
then be determined and compared to the wildtype. If a more rapid rate of degradation was 
confirmed, the pathway by which p.A146V is being degraded could be determined using 
proteasome and lysosome inhibitors and detecting changes in expression levels (Roboti et al. 
2009).  
 
The identification of the molecular effect of the alanine to valine substitution on the folding of 
TMEM114, i.e., whether it is rapidly degraded by the proteasome or lysosome or if it is not 
degraded efficiently leading to a cytotoxic build up of misfolded protein, is important in terms 
of disease. 
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7.5.4 The p.A147V variant and dominant disease 
The identification of the p.A147V variant in three patients with ADCC suggests that, 1) it is a 
rare polymorphism and has no association with congenital cataract or, 2) it is has a dominant 
effect and the family member with ADCC in which this variant was not detected was either a 
phenocopy or was heterozygous for c.440C>T but the variant was not detected due to allelic 
dropout. Although both latter options are unlikely, such occurrences are not without 
precedence (Bidinost et al. 2006; Tester et al. 2006). 
 
ER-retained misfolded proteins exert a dominant negative effect via two main mechanisms. 
Firstly, by preventing trafficking of the wildtype protein to its correct destination, or secondly, 
by creating a build-up of misfolded protein in the ER that triggers the unfolded protein 
response (UPR). To investigate the first possibility wildtype and p.A146V Tmem114 were co-
transfected in polarised MDCK II cells. Co-transfection of the p.A146V mutant isoform had no 
effect on the localisation of wildtype Tmem114. The possibly that p.A146V forms stable 
aggregates in the ER and triggers UPR has yet to be determined. However, as previously 
discussed the lack of aggregates resolving on SDS-PAGE gels suggests this phenomenon is 
not occurring. Future pulse chase experiments investigating the degradation rates of wildtype 
and p.A146V Tmem114 would more comprehensively address this possibility.  
 
Heterozygous mutations may also have a dominant effect as a result of haploinsufficiency. 
The appearance of the p.A147V variant in the heterozygous state in the unaffected mother of 
a patient with microphthalmia suggests that individuals who are haploinsufficient for wildtype 
TMEM114 are asymptomatic. This also implies that the p.A147V variant in a heterozygous 
state is not associated with pre-senile cataract or other ocular disease.  
 
7.5.5 Association of p.A147V with age-related cataract?  
Age-related cataract occurs due to the misfolding and aggregation of protein which 
accumulates over the lifetime of an individual (Andley 2009). Although heritability of age-
related cataract is well established (Hammond et al. 2001) there are few genetic variations 
associated with age-related cataract, although the number of associations are increasing (Jun 
et al. 2009; Zhou et al. 2010; Zuercher et al. 2010). Lifelong expression of misfolded p.A147V 
in combination with other misfolded proteins that naturally accumulate over time may result in 
age-related cataract. Therefore, mutations in TMEM114 may be a contributing factor in age-
related cataract. 
 
7.5.6 Association of p.A147V with recessive disease? 
Although the p.A147V variant does not appear to act in a dominant manner, its mislocalisation 
and possible degradation would suggest it is non-functional. Co-transfection with wildtype 
Tmem114 did not rescue the localisation of p.A146V, suggesting that this variant acts in a 
recessive manner. In the previous chapter it was demonstrated that knockdown of 
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xtTmem114 in vivo results in microphthalmia, suggesting that a lack of functional Tmem114 
causes ocular disease. Therefore it is possible that recessive TMEM114 mutations are 
associated with ocular phenotypes, as is the case for missense mutations in the TMD of LIM2 
(Pras et al. 2002; Ponnam et al. 2008). Unfortunately, no panels of recessive cataract or 
microphthalmia were available to test this hypothesis.  
 
7.5.7 Splicing effect of the c.440 C>T variant  
The alanine to valine substitution at p.A147 is caused by the c.440C>T variant at the first 
nucleotide of exon three. The functional investigation into the c.440C>T variant in this chapter 
was based on the amino acid substitution. However, the altered nucleotide‟s location at an 
intron/exon boundary suggested that the DNA variation it may affect splicing. Splice site 
prediction tools identified that the mutation results in the loss of some splicing factor binding 
sites that may cause a failure of splicing or aberrant splicing at a cryptic splice site. This could 
have been tested using an ex vivo splice assay but due to time restrictions this was not 
possible.  
 
Missense mutations in the coding sequence of the RPE gene BEST1 which cause autosomal 
dominant vitreoretinalchoroidopathy (ADVIRC) have been demonstrated in vitro to cause 
misplicing resulting in the produciton of deletion isoforms (Yardley et al. 2004). The missense 
mutations are predicted to result in the production of two isoforms from a single allele in vivo: 
the missense isoform and a deletion isoform caused by exon skipping (Yardley et al. 2004). 
The phenotype of ADVIRC patients with missense splice site mutations is distinct to those 
with the heterozygous missense mutations in BEST1 that cause Best disease. Aberrant 
splicing of TMEM114 due to the c.440C>T variant may result in the production of a mutant 
protein with more severe functional consequenses than caused by the straightforward 
p.A147V missense isoform.  
 
Alternatively the c.440C>T variant may prevent splicing of intron 3 resulting in a premature 
stop codon, which may lead to nonsense mediated decay. Thus, if the c.440C>T variant has 
an effect on splicing, the pathogenic mechanism may result from loss- or gain- of function. If 
the c.440C>T change does alter splicing, the mis-spliced isoform or the missense mutation 
isoform may not be produced exclusively and there may be a mixed population of protein 
products. It is likely that the proportions would be determined by the splicing machinery of the 
individual and so the c.440C>T variant may show altered penetrance depending on the 
genetic background of the individual. 
 
7.5.8 Limitations of the TMEM114 sequencing strategy 
As with the majority of sequencing strategies used to detect mutations there were a number of 
limitations. Only the coding exonic sequences and the surrounding intron/exon boundaries 
and 70 bp of 5‟UTR were sequenced. The primers used previously to detect mutations in 
TMEM114 (Jamieson et al. 2007) had binding sites close to intron/exon boundaries. 
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Sequences close to the primer binding site (within 50 bases) are often not read as the short 
amplicons produced may be removed during the purification process. Therefore, if sequences 
were read in only one direction, the use of these primers (positioned close to the intron/exon 
boundaries) may have resulted in splice site altering variants in the intronic regions being 
missed. To overcome this potential problem, new primers were designed to amplify from 
deeper within the introns. This had the advantage of producing a clearer sequence trace for 
the exonic sequences and their proximal intronic sequences. The possible disadvantage of 
this strategy is that the intronic regions chosen may harbour SNPs which might result in allelic 
dropout. This would result in the sequencing of a single allele for which the patient would 
appear homozygous for the wildtype sequence.   
 
The breakpoint on chromosome 16 in the balanced translocation t(16;22)(p13.3;q11.2) 
associated with juvenile onset cataract is located 673 bp upstream of the predicted 
transcription start site, and 151 bp upstream of the translation start site of TMEM114 
(Jamieson et al. 2007). Extending the upstream region of TMEM114 that was sequenced may 
have identified sequence variants in the 5‟UTR or in the putative promoter that alter regulatory 
elements. However, although regulatory elements may be close to the coding sequence of 
genes, e.g. in hereditary hyperferritinemia cataract syndrome (HHCS), the causative 
mutations are located ~160 bp upstream in the 5‟UTR (Rochow et al. 2009), or much further 
away, e.g. regulatory elements in the transcription factor PAX6 have been identified up to 150 
kb away (Kleinjan et al. 2001).  
 
Deletions in the genes SOX2 (Reis et al. 2010a) and BCOR (Ng et al. 2004), and a large 
genomic deletion encompassing TMX3 (Chao et al. 2010) are associated with syndromic and 
non-syndromic microphthalmia, respectively.  It is possible that single allele deletions of 
coding sequence regions that presented as homozygous traces were missed. Also, as the 
focus of this sequencing strategy was on coding sequence variants, deletions of regulatory 
elements in the promoter, UTRs or introns would have been missed. To detect copy number 
variants (loss or gain of DNA) techniques such as multiplex ligation-dependent probe 
amplification (MLPA) could have been utilised. Due to time limitations, the strategy used 
focused only on PCR based detection methods. 
 
Once variants in patients are identified it is important to determine if the same variants are 
present in unaffected individuals of the same ethnicity. Whilst 224 control chromsomes were 
screened (typically giving over 80 % power to detect a variant with a frequency of 0.01 
(Collins and Schwartz 2002)) the controls were not ethnically matched. The c.5g>a (p.R2Q) 
variant was identified in a patient of Vietnamese origin (Figure 7.1).  As Vietnamese or 
southeast Asian controls were not available, controls of white European descent were 
screened. Screening of southeast Asian controls may have identified the c.5g>a (p.R2Q) 
variant, suggesting that it is a non-pathogenic variant found in this population. Thus, future 
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work should involve the acquisition and screeening of southeast Asian controls and the 
access of the data from the 1000 genomes project (www.1000genomes.org). 
 
7.6 Conclusion 
This study and a previous study (Jamieson et al. 2007) have failed to identify a direct link 
between mutations in TMEM114 and over 200 cases of human ocular disease. The in vivo in 
X. tropicalis data supports the hypothesis that the human orthologue of TMEM114 is a strong 
candidate for recessive microphthalmia. The inheritance pattern of the microphthalmia cases 
in the panel of patients screened for mutations in TMEM114 cases was unknown, but 
recessive cases are likely to represent a small fraction of the total number of the 48 cases 
(Reis et al. 2010b). To date, four loci (14q32, VSX2, RAX, FOXE3) have been associated with 
isolated autosomal recessive microphthalmia/anophthalmia (Bar-Yosef et al. 2004; Gallardo et 
al. 2004; Lequeux et al. 2008; Reis et al. 2010a), although more have been associated with 
syndromic forms. These four loci are estimated to account for less than 20 % of all cases 
(Reis et al. 2010b) suggesting there are more genes yet to be identified. Subsequent to its 
identification as a cause of autosomal recessive microphthalmia, screening of a panel of 198 
microphthalmia and anophthalmia patients failed to identify mutations in VSX2 (Morrison et al. 
2002). This suggests that even if mutations are not identified in one panel of patients, 
screening further panels may identify pathogenic mutations. Further support for this comes 
from other examples of ocular disease in which candidate genes were chosen due to the 
phenotype of mouse models. The gene PCDH21 was chosen for screening of patients with 
retinal dystrophies as Pcdh21 knockout mice display retinal degeneration (Rattner et al. 
2001). Screening of a panel of 279 patients with autosomal recessive retinal disease failed to 
identify mutations in PCDH21 (Bolz et al. 2005), but five years later mutations were identified 
in a homozygous or biallelic state in families with autosomal recessive retinal disease 
(Henderson et al. 2010; Ostergaard et al. 2010). Thus, TMEM114 remains a good candidate 
gene for microphthalmia. 
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Chapter 8: Discussion 
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8.1 Introduction 
The human genome has an estimated 21,257 protein-coding genes, the majority of which 
encode proteins of unknown function (http://www.ensembl.org/Homo_sapiens/Info/StatsTable) 
(October 2010). Characterising the function of these proteins is of vital importance to our 
understanding of biological processes at the molecular level.  With the advancement of high 
resolution SNP arrays and next generation sequencing, genes are readily being associated 
with human diseases (Daly et al. 2010; Johnston et al. 2010; Ng et al. 2010; Nishimura et al. 
2010). In this functional genomics era the major challenge is to understand the biological role 
of proteins and the functional significance of disease associated variants. This is paramount to 
the identification of disease pathways and it is only when the pathogenic mechanisms are 
understood can one begin to identify possible therapeutics.  
 
There are a number of ways to identify the function of a protein, and typically functional 
characterisation depends upon information gathered from multiple sources. The association 
with a disease may give clues as to the function, e.g. hereditary hyperferritinemia cataract 
syndrome patients have high serum ferritin levels, suggesting the gene associated with the 
disease is involved in ferritin production or regulation, as was the case (Beaumont et al. 
1995). Often, however, there is little specific information that can be inferred from the disease 
phenotype, e.g. an association with cataract may reveal a protein‟s role in the lens, but 
provides scant information regarding the molecular function of the protein. The existence of 
characterised homologues or orthologues can also give clues to the function of the protein of 
interest and suggest experiments which can be utilised to test the function of the new protein. 
The creation, or existence of, an animal model for an orthologous protein can greatly aid the 
understanding of a protein‟s function and the identification of interacting protein partners can 
illuminate molecular pathways.  
 
Many large publicly available databases containing information regarding DNA and protein 
expression and function are accessible online. Data from microarray-based expression 
studies can be useful to identify if the gene or interest is up- or down-regulated at different 
developmental time points or under different conditions such as after pharmaceutical 
treatment, or in diseased tissue (e.g. cancers). To date, major changes in the regulation of 
TMEM114 or TMLP1 have not been reported in microarray studies. Genome-wide association 
studies (GWAS), which compare the frequency of SNPs in disease and control populations, 
have been a useful tool to identify the genetic contributors to multigenic diseases (Rioux et al. 
2007; Sladek et al. 2007). GWAS may also identify previously undiscovered functions of a 
protein. The role of the oncogene BCL11A in foetal haemoglobin production was unknown 
until a GWAS study mapped a new F cell quantitative trait locus to BCL11A (Menzel et al. 
2007), even though a mouse model had previously been created (Liu et al. 2003) and the 
gene was well characterised in vitro (Liu et al. 2006a).  
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This discussion aims to give a brief overview of what has been achieved in this study in terms 
of the characterisation of TMEM114 and TMLP1 and discuss areas that merit further 
investigation.  
 
 
8.2 Homology to proteins of known function 
An initial approach to potentially identify the function of a protein is to identify homologous 
proteins of known function. This can subsequently be used to aid experimental design to test 
the function of the protein. The search for proteins homologous to TMEM114 identified a 
similar protein of unknown function, TMLP1. The predicted topologies and the presence of 
conserved motifs placed TMEM114 and TMLP1 in the Pfam00822 family of transmembrane 
proteins.  The relationship of TMEM114 and the newly identified TMLP1 to members of the 
Pfam00822 family was investigated in silico and in vitro in this study. TMEM114 and TMLP1, 
although similar in size to the tight junction claudin proteins, lack the PDZ-binding domains 
through which claudins interact with ZO proteins (Itoh et al. 1999). In polarised MDCK II cells, 
Tmem114 and Tmlp1 failed to colocalise with ZO-1 indicating they are likely to have distinct 
functions to claudins. 
 
In chapter 3 both TMEM114 and TMLP1 were shown to be more similar to voltage dependent 
calcium channel γ subunits, a family of eight proteins divided into two functionally distinct 
groups. γ1 and γ6 interact with and modulate the activity of voltage dependent calcium 
channel α-subunits (Cav) expressed in cardiac and skeletal muscle (Arikkath et al. 2003; 
Hansen et al. 2004; Lin et al. 2008). The determination of the ability of a protein to modulate 
calcium channel activity required resources which were not available, and so was not 
investigated in this study. If more evidence was accrued to strengthen the possibility that 
TMEM114 or TMLP1 interact with Cavs, then performing patch-clamp experiments to identify 
a modulating role in calcium channel activity would be an interesting area to pursue. The other 
voltage dependent calcium channel γ subunits, despite their name, have debatable effects on 
calcium channel activity. These γ subunits are expressed in the brain where they regulate 
trafficking and modify activity of AMPA receptors, and hence are known as transmembrane 
AMPA receptor regulatory proteins (TARPs) (Tomita et al. 2005). The TARPs contain key 
protein interaction domains in their C-termini required for AMPA receptor trafficking that are 
not present in the C-termini of TMEM114 or TMLP1.  
 
TMEM114 and TMLP1 contain the W-GLW-C-C motif in their extracellular loop 1, and 
claudins and other Pfam00822 proteins with this motif have roles in cell adhesion (Kubota et 
al. 1999; Grey et al. 2003). The voltage dependent calcium channel γ subunits have cell-cell 
adhesion capabilities in vitro, although this has yet to be demonstrated in vivo (Price et al. 
2005). The testing of this adhesion function, initially in vitro using L-cell fibroblasts, would 
determine if TMEM114 and TMLP1 have adhesive capacities. A positive result may suggest, 
although not necessarily infer, an adhesion role in vivo.  
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In mouse Tmem114 expression was detected at E13.5 (Jamieson et al. 2007). At this point in 
lens development the primary fibres have elongated and filled the lens vesicle. Expression of 
Tmem114 was upregulated postnatally (Jamieson et al. 2007) and although the formation of 
secondary lens fibres occurs throughout life, secondary fibre formation is much more active in 
the early postnatal period (White et al. 1998). Therefore the onset of Tmem114 expression 
coincides with when the elongating primary fibre cells reach the anterior lens epithelial cells, 
and the postnatal upregulation of Tmem114 coincides with the increased levels of secondary 
lens fibre cell differentiation (White et al. 1998; Jamieson et al. 2007).  Tmem114 localises 
predominantly to the apical cell membrane in polarised epithelial cells in vitro and in the lens 
expression was detected in the epithelium (Jamieson et al. 2007). The conserved adhesion 
properties in Pfam00822 proteins has lead to the hypothesis that TMEM114 acts as an 
adhesion molecule between the apical membrane of epithelial cells and fibre cells in the lens. 
An alternative hypothesis is that TMEM114 may be involved in secondary fibre cell 
proliferation or differentiation, as high levels of expression occur in the germinative region of 
the lens (Jamieson et al. 2007). The development of an antibody which detects endogenous 
Tmem114 would facilitate the precise localisation of Tmem114 in vivo. Using such an 
antibody, immunogold labelling and visualisation by electron microscopy may determine if 
Tmem114 is present in junctions between the cells. The generation of a knockout mouse may 
be the best means of testing these hypotheses (Section 8.3).  
 
 
8.3 Animal models 
The creation of animal models and the study of spontaneous animal mutants have greatly 
facilitated the identification of protein function and the aetiology of many diseases. Typically in 
animal models the loss of the particular protein is investigated. Thus, the functional role of a 
protein may be identified by determining the effect of loss of the protein on the animal‟s 
phenotype. An orthologue of TMLP1 was not identified in X. tropicalis and so the in vivo 
analysis in this study was restricted to TMEM114.  Knockdown of Tmem114 in X. tropicalis 
resulted in a small eye phenotype suggesting TMEM114 has a role in eye growth and 
development. Although X. tropicalis is a useful tool for investigating protein function (Section 
6.1), in evolutionary terms Xenopus is much more distant to humans than other animal 
models such as mouse. Also, morpholinos cause only a temporary and incomplete 
knockdown of the target protein. Knockout, i.e. the complete ablation, of a protein can be 
achieved in mouse by targeted recombination. Additionally, much more sophisticated 
phenotypic and behavioural analysis can also be performed in mouse than the simpler 
analysis performed with Xenopus (Boothby and Roberts 1995; Lambert et al. 2004). A murine 
model would be useful to test the role of Tmem114, particularly in the eye and brain, as subtle 
changes may not have been detected in Xenopus, and as the knockout is permanent non-
developmental phenotypes could also be detected.  
 
Chapter 8 
 
  
187 
Developmental, but not adult, expression of Tmem114 was also detected in the kidney and all 
of the ADCC patients with the t(16;22)(p13.3;q11.2) balanced translocation tested have 
developmental kidney defects (Jamieson et al. 2007). Developmental kidney defects were 
also reported in the TMEM114 p.R2Q patient. A Tmem114 knockout mouse would provide a 
useful tool to study the possible role of Tmem114 in kidney development.  
 
A number of tissues express Tmlp1 in mouse (Figure 5.1). However, as previously discussed 
mouse Tmlp1 lacks the N-X-S/T glycosylation site which is present in human TMLP1 (Figure 
3.4), and this appeared to affect trafficking of Tmlp1. This may complicate any analysis of a 
Tmlp1 knockout mouse as the extrapolation of data may be limited. It may be, however, that 
mice can efficiently process Tmlp1 without the need for N-linked glycans. Changes in the 
amino acid composition of Tmlp1 throughout evolution may have led to the need for a N-
linked glycan to stabilise the structure. Thus, although a Tmlp1 knockout may be a useful tool, 
the costs involved and the doubts over the translation of the findings from mice to humans 
would suggest that a Tmlp1 knockout would not be cost-effective at this time. Therefore, the 
focus would be to find interacting partners for human TMLP1 using the targeted or non-
targeted approaches discussed in section 8.5. Knockout mouse stem cells are available for 
both Tmem114 (Project: VG15800) and Tmlp1 (Project: 66468) 
(http://www.knockoutmouse.org/).   
 
 
8.4 Association with disease 
The association of sequence variants with disease can also aid in understanding protein 
function. The TMEM114 gene was identified through its proximity to a balanced translocation 
which was associated with ADCC (Jamieson et al. 2007), although a direct association 
between mutations in the coding sequence of TMEM114 and ADCC was not identified 
(Jamieson et al. 2007). The functional data generated in this study suggested that TMEM114 
represented a strong candidate for association with microphthalmia in humans. One 
heterozygous variant that was not present in controls was identified in a panel of MAC 
patients, but pathogenicity was not confirmed. Thus the association between TMEM114 and 
microphthalmia has yet to be demonstrated, as discussed in section 8.6.   
 
It is important to fully investigate the functional effects of mutations on protein function. For 
example heterozygous mutations may have a pathogenic effect by reducing the level of 
wildtype protein expressed (haploinsufficiency) or by having a dominant negative effect on the 
wildtype protein. Although in terms of genetic counselling how a dominant mutation exerts its 
effects is of little importance, in terms of possible future treatment it is imperative to distinguish 
between these effects as dominant negative effects may not be corrected simply by 
increasing gene expression by gene therapy or pharmacological means. The p.A147V variant, 
identified in ADCC patients (Jamieson et al. 2007) and in a patient with anophthalmia 
(Chapter 7) was also present in an unaffected relative implying it is a SNP. However, in vitro 
Chapter 8 
 
  
188 
this variant was retained in the ER possibly due to misfolding. The functional consequences of 
this ER retention remain to be investigated. Pulse-chase analysis could be utilised to 
determine if this p.A147V variant is rapidly degraded (and by which pathway) or if it is retained 
in the ER and causes ER stress.  
 
Although knockout mice can prove valuable tools, genetically they represent the null 
phenotype. Typically diseases are more complex than simply representing the null phenotype, 
often being caused by gain-of-function missense mutations (Botstein and Risch 2003). The in 
vitro data generated in this study revealed that the p.A147V variant does not appear to 
function like wildtype TMEM114. Creation of a knock-in mouse expressing p.A146V Tmem114 
(equivalent of human p.A147V) may answer a number of questions: does p.A146V in the 
heterozygous state cause congenital cataract or age-related cataract?; do mice homozygous 
for p.A146V present with microphthalmia or other congenital phenotypes?; does the C>T DNA 
change at the start of exon four, which causes the missense substitution, alter the splicing of 
Tmem114? If phenotypes were observed they could be correlated with characterisation of the 
mutant protein (i.e. pulse-chase analysis).  
 
An attempt to associate TMLP1 with human disease was not made as there was limited 
functional data to base a hypothesis on. However, its expression in the developing eye and 
brain suggest it may be a good candidate for screening if chromosome 17q25 is identified in a 
linkage study for association with developmental ocular or neurological disorders. 
 
 
8.5 Identification of interacting protein partners 
Another way to identify a possible function for a protein is to identify interacting protein 
partners to determine the pathway in which the protein functions. This area of research was 
not investigated in this study due to time restrictions. As the expression profile of Tmem114 
and Tmlp1 have been identified in this study and previously (Jamieson et al. 2007), lysates 
from these specific tissues could be used as a source of potentially interacting proteins. The 
TMEM114 and TMLP1 proteins could be tagged with glutathione S-transferase (GST) (Roh et 
al. 2002) to probe for interacting proteins in lysates of particular tissues. The Split-Ubiquitin 
Membrane Yeast Two-Hybrid system was successfully employed to identify interacting 
proteins for claudin-16 and claudin-19 (Hou et al. 2008).  
 
As transmembrane proteins expressed in the lens epithelium there is potential that TMEM114 
and TMLP1 may interact. An interaction between the two proteins could be investigated using 
a targeted approach such as co-immunoprecipitation or fluorescence resonance energy 
transfer (Blasig et al. 2006). Other possible interaction targets are the voltage dependent 
calcium channel α-subunits, as TMLP1 shares a number of common features with the γ6 
subunit which modulates Cav3.1 channel activity in vitro (Lin et al. 2008). Lens epithelial cells 
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express a number of Cav3.1 and other voltage dependent calcium channels (Meissner and 
Noack 2008) and these may represent good targets for interaction experiments. 
 
 
8.6 TMEM114 and congenital ocular disease 
Over 200 cases of congenital ocular disease have been screened for mutations in the coding 
sequence of TMEM114 without a clear association. The initial screening of 130 ADCC 
patients was based upon the fact that TMEM114 lies in close proximity to a balanced 
translocation t(16;22)(p13.3;q11.2) that associated with juvenile onset cataract (Jamieson et 
al. 2007). It was postulated that the translocation resulted in misexpression of TMEM114 
(Jamieson et al. 2007), but the molecular effect of the balanced translocation is unknown. To 
identify a possible effect of the balanced translocation on TMEM114 expression, some of the 
sequence at 16p13.3 upstream of TMEM114 from wildtype and translocated chromosomes 
could be cloned into luciferase reporter constructs. However, as the cell lines tested did not 
endogenously express TMEM114 (Section 4.2.2), an appropriate cell line will need to be 
identified. This experiment would also assume that the regulatory regions of TMEM114 are in 
close proximity to the transcription start site, which may not the case. This experiment also 
assumes that it is the dysregulation of TMEM114 expression that is associated with disease, 
and not that the translocated putative TMEM114 promoter is causing misexpression of other 
genes on chromosome 22q11.2.  
  
As discussed in section 7.6, mutations in TMEM114 appear not to be a common cause of 
congenital ocular disease and screening more patients, and perhaps a specific subset of 
patients (e.g. recessive cases), may identify causative mutations.  It is also possible that the 
phenotype observed in X. tropicalis knocked down for xtTmem114 is not representative of the 
human phenotype. The onset of expression of xtTmem114 occurrs at a stage of eye 
development earlier than was detected in mouse or humans, and hence the phenotype in X. 
tropicalis may be more severe. Although unlikely, TMEM114 mutations may contribute to 
digenic disease, in which mutations in two genes are required for pathogenicity. For example, 
both the peripherin/RDS and ROM1 genes encode transmembrane proteins expressed in the 
same retinal cells (Bascom et al. 1993) and the proteins form a multimeric complex with each 
other (Goldberg et al. 1995). Mutations in ROM1 alone have not been associated with retinal 
disease but a combination of heterozygous mutations in both peripherin/RDS and ROM1 are 
associated with retinitis pigmentosa (Kajiwara et al. 1994).  
 
Finally, for reasons such as compensation, mutations in TMEM114 may not be associated 
with congenital ocular disease at all. Developmental expression of Tmem114 is relatively 
weak when compared to its postnatal expression (Jamieson et al. 2007), suggesting that 
perhaps it is more likely that disease phenotypes associated with Tmem114 would be of later 
onset (e.g. age-related cataract). It may also be that a disease associated with mutations in 
either TMEM114 or TMLP1 are non-ocular as Tmem114 is also expressed in the 
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cerebellum, testis and developing kidney (Jamieson et al. 2007). In terms of cloned ESTs 
(Section 3.7), TMEM114 expression is highest in carcinoids of the lung (rare neuroendocrine 
tumors that represent 1-2 % of lung cancers (Hage et al. 2003)). Altered expression of 
claudins and other Pfam00822 proteins are associated with cancers (Beaudry et al. 2010b; 
Jung et al. 2010). Alteration of claudin expression is associated with lung carcinoids (Moldvay 
et al. 2007), although unlike TMEM114 expression, claudin expression was downregulated 
(Moldvay et al. 2007). The upregulation of TMEM114 as a cause or effect of carcinoid 
formation may be an interesting area to investigate.  
 
 
8.7 Conclusion 
The overall aim of this study was to characterise the function of the novel protein TMEM114. 
While progress was made and a role in eye development confirmed, the precise functional 
role remains to be elucidated. This study has predominantly focused on the ocular aspects of 
TMEM114 due to its association with ADCC (Jamieson et al. 2007) and the small eye 
phenotype observed in the xtTmem114 knockdown. The expression of Tmem114 and Tmlp1 
was also detected in other tissues and the role of these proteins in non-ocular tissues 
represent interesting areas to be pursued. The distinctions between TMEM114, TMLP1 and 
each of the other groups of proteins of known function in the Pfam00822 family made it 
difficult to identify a functional role for the proteins in such a short time-frame. With further in 
vitro and in vivo characterisation, combined with information accumulating from microarray, 
GWAS and massively parallel sequencing, the biological roles of TMEM114 and TMLP1 will 
be revealed.  
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9.1 Uniform Resource Locators (URL) for online resources 
9.1.1 Databases 
Ensembl  http://www.ensembl.org/ 
Genbank http://www.ncbi.nlm.nih.gov/genbank/ 
IPI  http://www.ebi.ac.uk/IPI/ 
OMIM  http://www.ncbi.nlm.nih.gov/omim/ 
Pfam  http://pfam.sanger.ac.uk/ 
Prosite  http://expasy.org/prosite/ 
Unigene http://www.ncbi.nlm.nih.gov/unigene/ 
Uniprot  http://www.uniprot.org/ 
 
9.1.2 Prediction tools 
Compute pI/MW http://expasy.org/tools/pi_tool.html 
CSS-Palm 2.0   http://csspalm.biocuckoo.org/ 
HMMTOP           http://www.enzim.hu/hmmtop/ 
NetNGlyc 1.0    http://www.cbs.dtu.dk/services/NetNGlyc/ 
NetOGlyc 3.1    http://www.cbs.dtu.dk/services/NetOGlyc/ 
NetPhos2.0   http://www.cbs.dtu.dk/services/NetPhos/ 
NetPhosK 1.0   http://www.cbs.dtu.dk/services/NetPhosK/ 
Philius   http://www.yeastrc.org/philius/pages/philius/runPhilius.jsp 
PolyPhen   http://genetics.bwh.harvard.edu/pph/ 
SIFT   http://sift.jcvi.org/ 
SignalP   http://www.cbs.dtu.dk/services/SignalP/ 
Sulfinator  http://expasy.org/tools/sulfinator/ 
TMHMM  http://www.cbs.dtu.dk/services/TMHMM/ 
TMMOD  http://liao.cis.udel.edu/website/servers/TMMOD/ 
TMPRED  http://www.ch.embnet.org/software/TMPRED_form.html 
TOPPRED  http://www.sbc.su.se/~erikw/toppred2/ 
 
9.1.3 Other tools 
ALIGN  http://xylian.igh.cnrs.fr/bin/align-guess.cgi 
Blast   http://blast.ncbi.nlm.nih.gov/ 
ClustalW http://www.ebi.ac.uk/Tools/clustalw2/index.html 
Translate http://expasy.org/tools/dna.html 
 
9.1.4 Downloaded Software 
BioEdit  http://www.mbio.ncsu.edu/bioedit/bioedit.html 
EZ-C1  http://www.nikon-instruments.jp/eng/service/download/DLList.aspx?CID=3 
Seaview  http://pbil.univ-lyon1.fr/software/seaview.html 
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9.2 Database accession numbers for DNA and protein sequences 
 
Table 9.1 Homo sapiens DNA and protein sequences 
Name DNA Protein sequences for 
alignments 
Ensembl accession 
numbers for gene 
structure 
TMEM114 NM_001146336.1 NP_001139808.1 - 
TMLP1 XM_941058.2 XP_946151.1 - 
CLARIN-1 - NP_777367.1 - 
CLAUDIN-1 - NP_066924.1 ENSP00000295522 
CLAUDIN-2 - NP_065117.1 ENSP00000336571 
CLAUDIN-3 - NP_001297.1 - 
CLAUDIN-4 - NP_001296.1 - 
CLAUDIN-5 - NP_003268.2 - 
CLAUDIN-6 - NP_067018.2 - 
CLAUDIN-7 - NP_001298.3 - 
CLAUDIN-8 - NP_955360.1 - 
CLAUDIN-9 - NP_066192.1 - 
CLAUDIN-10a - NP_878268.1 - 
CLAUDIN-10b - NP_008915.1 - 
CLAUDIN-11 - NP_005593.2 - 
CLAUDIN-12 - NP_036261.1 - 
CLAUDIN-14 - NP_036262.1 - 
CLAUDIN-15 - NP_055158.1 - 
CLAUDIN-16 - NP_006571.1 ENSP00000264734 
CLAUDIN-17 - NP_036263.1 - 
CLAUDIN-18.1 - NP_057453.1 - 
CLAUDIN-18.2 - NP_001002026.1 - 
CLAUDIN-19 - NP_683763.2 - 
CLAUDIN-20 - NP_001001346.1 - 
CLAUDIN-22 - NP_001104789.1 - 
CLAUDIN-23 - NP_919260.2 - 
EMP-1 - NP_001414.1 ENSP00000410755 
EMP-2 - NP_001415.1 ENSP00000352540 
EMP-3 - NP_001416.1 ENSP00000270221 
PMP22 - NP_000295.1 ENSP00000409824 
LIM2/MP20 - NP_001155220.1 ENSP00000221973 
CLP24 - NP_078876.2 ENSP00000253934 
PERP - NP_071404.2 ENSP00000397157 
TMEM47 - NP_113630.1 ENSP00000275954 
CACNG1 - NP_000718.1 ENSP00000226021 
CACNG2 - NP_006069.1 ENSP00000300105 
CACNG3 - NP_006530.1 ENSP00000005284 
CACNG4 - NP_055220.1 ENSP00000262138 
CACNG5a - NP_665810.1 ENSG00000075429 
CACNG5b - NP_055219.1 - 
CACNG6 - NP_665813.1 ENSP00000252729 
CACNG7 - NP_114102.2 ENSP00000222212 
CACNG8 - NP_114101.4 ENSP00000270458 
GAPDH NM_002046.3 - - 
SOCS3 - NP_003946.3 - 
 
Table 9.2 Mus musculus DNA and protein sequences 
Name DNA Protein  
Tmem114 NM_029070.2 NP_083346.1 
Tmlp1 NM_001085535.1| NP_001079004.1 
Hprt NM_013556.2 - 
Socs3 - NP_031733.1 
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Table 9.3 Xenopus tropicalis DNA and protein sequences 
Name DNA Protein  
Tmem114 XM_002939438.1 XP_002939484.1 
Lim2 NM_001102779.1 - 
Gapdh NM_001004949.1 - 
 
Table 9.4 Danio rerio DNA and protein sequences 
Name DNA Protein  
Claudin-2 - NP_001004559.2 
Claudin-7 - NP_001002340.1 
Claudin-10 - NP_001007038.1 
Claudin-11 - NP_571847.2 
Claudin-15 - NP_956698.1 
Claudin-I - NP_571843.1 
Claudin-J - NP_571844.1 
Claudin-K - NP_001003464.1 
Cacng1 - NP_999849.1 
Cacng2 - NP_956935.1 
Cacng3-like - XP_693299.1 
Cacng5-like - XP_001337872.1 
Cacng6 - NP_001076560.1 
Cacng6-like - XP_001342833.1 
Cacng8-like - XP_001342922.2 
Socs3a - NP_956244.1 
Socs3b - NP_998469.1 
 
Table 9.5 TMEM114 orthologues DNA and Protein Sequences 
Name DNA Protein  
Homo sapiens NM_001146336.1 NP_001139808.1 
Macaca mulatta - NP_001181105.1 
Mus musculus NM_029070.2 NP_083346.1 
Rattus norvegicus - NP_001128110.1 
Bos taurus - NP_001178169.1 
Canis familiaris XM_547134.2 XP_547134.2 
Gallus gallus - XP_001235110.1 
Monodelphis domestica - XP_001367110.1 
Xenopus tropicalis XM_002939438.1 XP_002939484.1 
Danio rerio - XP_001922308.1 
 
Table 9.6 TMLP1 orthologues DNA and Protein Sequences 
Name DNA Protein  
Homo sapiens XM_941058.2 XP_946151.1 
Mus musculus NM_001085535.1 NP_001079004.1 
Rattus norvegicus - XP_001081744.1 
Bos taurus - XP_616745.3 
Canis familiaris XM_548670.1 XP_548670.1 
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9.3 Primer Information 
9.3.1 Sequencing Primers 
 
Table 9.7 Primers used to sequence coding regions of TMEM114 
Tm = Annealing temperature 
Primer Sequence 5’-3’ Tm Additional 
information 
Exon 1F GACGGGGGCAGGAGCAGAG 62.5 °C 5 % DMSO 
Exon 1R GAGGAGTGCGCGCCAAGC 62.5 °C 5 % DMSO 
Exon 2F CAGACGAGGGTGCTGCACAGA 62.5 °C 5 % DMSO 
Exon 2R CCCGGCTGTTTTGGGAAAGG 62.5 °C 5 % DMSO 
Exon 3F CGTAGGGGCAGTGACAGTGTGG 62.5 °C 5 % DMSO 
Exon 3R GGATCCCCCTCGTTTGCTGA 62.5 °C 5 % DMSO 
Exon 4F GCGAGGAGGAGGAGGGGAGT 62.5 °C 5 % DMSO 
Exon 4R CGATGGAGATCGGTCGGTGA 62.5 °C 5 % DMSO 
 
Table 9.8 Primers used to sequence plasmids 
Primer Sequence 5’-3’ Tm Additional 
information 
M13 F GTAAAACGACGGCCAG 45 °C - 
M13 R CAGGAAACAGCTATGAC 45 °C - 
T7 F TAATACGACTCACTATAGGG 50 °C - 
 
 
9.3.2 RT-PCR primers 
 
Table 9.9 Primers used to detect Homo sapiens cDNA expression. h = Homo sapiens. m 
= Mus musculus. xt = Xenopus tropicalis. cf = Canis familiaris 
Primer Sequence 5’-3’ Tm Additional 
information 
hTMEM114 exon 1F GCTCAGCTTTGTGCTCCTG 58.8 °C - 
hTMEM114 exon 2R GCTGACTGTCACGTTCTCCA 58.8 °C - 
hTMLP1 exon 1F GCCAGCGACTACTGGTACATC 55 °C - 
hTMLP1 exon 4R CTGAGAGCAGGAGGGTTCC 55 °C - 
hGAPDH F GAAGGTGAAGGTCGGAGTC 60 °C - 
hGAPDH R GAAGATGGTGATGGGATTTC 60 °C - 
mTmem114 exon 1F AGAGCCTCTGAGCTCCCACT 58.5 °C - 
mTmem114 exon 2R GCTGACCGTCACATTCTCCT 58.5 °C - 
mTmlp1 exon 1F CCAGCGACTACTGGTACATCC 55 °C - 
mTmlp1 exon 4R GAAGCTGATGTGCACGTTCT 55 °C - 
mHprt F GCTGGTGAAAAGGACCTCT 52.5 °C - 
mHprt R CACAGGACTAGAACACCTGC 52.5 °C - 
xtTmem114 5’UTR F TGGATTCCTCTTCTGTATCTGC 55.3 °C - 
xtTmem114 exon 2R CCAAGCCGAAAGGGATTTAT 55.3 °C - 
xtGapdh F GCAGTGTATGTGGTGGAATCT 45 °C - 
xtGapdh R AAGTTGTCATTGATGACCTTTGC 45 °C - 
cfTmem114 exon 3F CAGCCTGATCCTGATGGTTT 52 °C - 
cfTmem114 exon 4R GGTCCAGGAGGGCTTTCTC 52 °C - 
cfTmlp1 exon 1 F GGTGGCCAGCGACTACTGGT 53.5 °C - 
cfTmlp1 exon 4 R GGAACTGAAGAGGCCGCAGA 53.5 °C - 
cfGapdh F GAAGGTGAAGGTCGGAGTC 55 °C - 
cfGapdh R GAAGATGGTGATGGGATTTC 55 °C - 
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9.3.3 Primers used for cloning 
 
Table 9.10. Primers used for cloning. Restriction enzyme sites are coloured in blue. 
Termination codons are coloured in red. V5 tags are coloured in green. 
Insert Primer Sequence 5’-3’ Tm 
mTmem114 mTmem114 Xba I F 
GGCTATCTAGAACCATGCGGGTGCGCCTG
GGCGCTCTG 
60 °C 
 mTmem114 Eco RI R 
GGCTAGAATTCTCAGATGGCTTGGTCCTG
CCTCTGGCTCAG 
60 °C 
mTmem114_SPM 
mTmem114_SPM XbaI 
F 
GGCTATCTAGAACCATGACCGACTTCTGGT
ACATCATCG 
60 °C 
 mTmem114 Eco RI R 
GGCTAGAATTCTCAGATGGCTTGGTCCTG
CCTCTGGCTCAG 
60 °C 
mTmem114_SPM-
V5 
mTmem114_SPM XbaI 
F 
GGCTATCTAGAACCATGACCGACTTCTGGT
ACATCATCG 
60 °C 
 mTmem114 V5 R 
CCTCACGTAGAATCGAGACCGAGGAGAGG
GTTAGGGATAGGCTTACCGATGGCTTGGT
CCTGCCTCTGGCTCAG 
60 °C 
mTmlp1 mTmlp1 Xba I F 
GGCTATCTAGAACCATGCGGGTGCGCCTG
GGCGCTCTG 
64 °C 
 mTmlp1 Eco RI R 
GGCTAGAATTCTCAGAGGATCACAGAGTG
GGGCACTC 
64 °C 
mTmlp1-V5 mTmlp1 Xba I F 
GGCTATCTAGAACCATGCGGGTGCGCCTG
GGCGCTCTG 
64 °C 
 mTmlp1 V5 Eco RI R 
GGCTAGAATTCTCACGTAGAATCGAGACC
GAGGAGAGGGTTAGGGATAGGCTTACCGA
GGATCACAGAGTGGGGCACTC 
64 °C 
mTmlp1_SPM mTmlp1_SPM XbaI F 
GGCTATCTAGAACCATGTGGTACATCCTG
GAGGTGGCG 
64 °C 
 mTmlp1 Eco RI R 
GGCTAGAATTCTCAGAGGATCACAGAGTG
GGGCACTC 
64 °C 
mTmlp1_SPM-V5 mTmlp1_SPM XbaI F 
GGCTATCTAGAACCATGTGGTACATCCTG
GAGGTGGCG 
64 °C 
 mTmlp1 V5 Eco RI R 
GGCTAGAATTCTCACGTAGAATCGAGACC
GAGGAGAGGGTTAGGGATAGGCTTACCGA
GGATCACAGAGTGGGGCACTC 
64 °C 
xtTmem114-5‟UTR-
V5 
xtTmem114 5‟UTR F TGGATTCCTCTTCTGTATCTGC 60 °C 
 xtTmem114-V5clone_R 
CCCTCACGTAGAATCGAGACCGAGGAGAG
GGTTAGGGATAGGCTTACCTATAACCTGCT
CCCGTCTTCTT 
60 °C 
xtTmem114-EST xtTmem114_in situ F GGAATGCTTTTCCTGTTTGG 60 °C 
 xtTmem114_in situ R GCTTTCCGTTTTCAGAAGCA 60 °C 
xtLim2 xtLim2 F GGATGATGTACAGCTTTATGGGAGGAGG 60 °C 
 xtLim2 R GGTTAACGGGGTCCTGACCCTCG 60 °C 
 
Table 9.11 Site-directed mutagenesis primers 
Clone Primer Sequence 5’-3’ Tm 
mTmem114-V5 p.R2Q R2Q F TCTAGAACCATGCAGGTGCGCCTGGGC 68 °C 
 R2Q R GCCCAGGCGCACCTGCATGGTTCTAGA 68 °C  
mTmem114-V5 p.P52L P52L F GGGACCAGGGACTGGCCAACCGCAG 68 °C 
 P52L R CTGCGGTTGGCCAGTCCCTGGTCCC 68 °C 
mTmem114-V5 p.N54K N54K F GGGACCGGCCAAACGCAGCCAGCAAGAGCC 68 °C 
 N54K R GGCTCTTGCTGGCTGCGTTTGGCCGGTCCC 68 °C 
mTmem114-V5 p.N88K N88K F TTCTGGCAGGAGAAAGTGACGGTCAGCGAC 68 °C 
 N88K R GTCGCTGACCGTCACTTTCTCCTGCCAGAA 68 °C 
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Table 9.12 TMEM114 promoter amplification and sequencing primers 
Primer Use Primer name Primer sequence Tm 
Amplification Amplification_F CCACCTTCAGGTAGGCCCCAGTGTTTGTTGC 68 °C 
Amplification Amplification_R TCTGGATTTCCGCCCCAGCCCTTTTTCTTGGC 68 °C  
Sequencing Amplification_F CCACCTTCAGGTAGGCCCCAGTGTTTGTTGC 68 °C 
Sequencing WTPromSeqStep1F TGCTGATGCCCTTGATAATG 60 °C 
Sequencing WTPromSeqStep2F   CCTTACGAATGGATCACAGGA 60 °C 
Sequencing WTPromSeqStep3F ATGGTAATGACCGTGGTGGT 60 °C 
Sequencing WTPromSeqStep4F TGGTGGTGGTAATGGTTGG 60 °C 
Sequencing PromGap_R CATCACCCACGGACAACAC 60 °C 
Sequencing Gap259bp_F  GGCAATGGTGGTGATAGTGA 60 °C 
 
 
9.4 Constructs used in this study 
Table 9.13 Constructs used in this study 
Construct Name Template  Cloned by 
pcDNA3.1(-) mTmem114 pcDNA3.1(-) mTmem114-V5 GJ Maher 
pcDNA3.1(-) mTmem114-SPM pcDNA3.1(-) mTmem114 GJ Maher 
pcDNA3.1(-) mTmem114-V5 
RIKEN 4930511J11 cDNA IMAGE 
5357758 
Dr. J Urquhart 
pcDNA3.1(-) mTmem114-V5-SPM pcDNA3.1(-) mTmem114-V5 GJ Maher 
pcDNA3.1(-) mTmem114-V5 p.R2Q pcDNA3.1(-) mTmem114-V5 GJ Maher 
pcDNA3.1(-) mTmem114-V5 p.P52L pcDNA3.1(-) mTmem114-V5 GJ Maher 
pcDNA3.1(-) mTmem114-V5 p.A146V pcDNA3.1(-) mTmem114-V5 Dr. J Urquhart 
pcDNA3.1(-) mTmem114-V5 p.N54K pcDNA3.1(-) mTmem114-V5 GJ Maher 
pcDNA3.1(-) mTmem114-V5 p.N88K pcDNA3.1(-) mTmem114-V5 GJ Maher 
pcDNA3.1(-) mTmem114-V5 p.N54K N88K pcDNA3.1(-) mTmem114-V5 p.N88K GJ Maher 
pcDNA3.1(-) mTmlp1 Mus musculus testis cDNA GJ Maher 
pcDNA3.1(-) mTmlp1-SPM pcDNA3.1(-) mTmlp1 GJ Maher 
pcDNA3.1(-) mTmlp1-V5 pcDNA3.1(-) mTmlp1 GJ Maher 
pcDNA3.1(-) mTmlp1-V5-SPM pcDNA3.1(-) mTmlp1-V5-SPM GJ Maher 
pGEM T easy xtTmem114-5‟UTR-V5 X. tropicalis stage 45 eye cDNA GJ Maher 
pGEM T easy xtTmem114-EST X. tropicalis stage 45 eye cDNA GJ Maher 
pGEM T easy xtLim2 X. tropicalis stage 45 eye cDNA GJ Maher 
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9.5 Vector maps 
 
Figure 9.1 pcDNA3.1(-) vector map and sequence reference points. (Invitrogen catalogue 
number V795-20) 
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Figure 9.2 pGEM T easy vector map, sequence reference points and sequence of the 
promoter and multiple cloning site (Promega catalogue number A1360)  
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Figure 9.3. pEGFP-C1 vector map and sequence reference points (Clontech catalogue 
number 6084-1) 
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9.6 Sequence of the gap in the upstream sequence of TMEM114.  
Bold = forward primer. Italic = reverse primer. Colour represents sequence identified by that 
specific primer. Underlined = new sequence. Grey font = 5‟UTR. Black font = coding 
sequence. The highlighted sequence was submitted to Genbank (accession GQ267544.1) 
 
 
 
 
NW_001838342 
 
 
 
ccaccttcaggtaggccccagtgtttgttgctcccctctatgtgtccatgtgttcttatcatttagctccc
acttgtaagtgaaaacatgcaatatttggttttctgttccggtgttaatttgctaaggataatggcctcca
gctccatccgtgttcctgcaaaggacataatcttgttcttttttatggcagcatagtattccatggtatag
cctaccacattttctttatccaatctaccattgatgggcatttaggttgattctatatctttgctatcata
gttggactcaaatatttagggtgggtctgacttctcccactctggctccaagagtagacgggtgactgagg
cttggccaattagcacatctggtccctttgaatgatagagattgattcagagacgggcacatgaccaaaaa
caggccaatgagatttaattctggggatctggcactattgagagagagattatttctttttcttggagctg
ctaagctgtgaaactggctcctatgattgaacaaatgagagcctgcttgaaaaatgaagtcaagcaagagg
aaaacaactgagaggtggcaagaagaagaggaagagggaagagattgaatctcaaagacattgtaagggct
cctgggatcagcctcaactgaattttacctacatctctcaagtcgacggtgaggactattttaatgatggt
ggaagtaaagataacagtagtagtgtgatggaggtgacagcaaaattatcagtgatgatggttttggaaaa
gatctatcttcatcaagatagtggtggcggggtgatgaaacagaatggtctgcagaatcaagggagagtgt
attcttgctggtgatagctctgccagggtgctgatgcccttgataatgaagatgaggatgacagtgatgta
gattaaggtggtattgggaaggaagaataaagggaaaggataactctcaaccccagcctatcaccgagccc
taacaactctactccctcaacttttaaaaactctatccacttcactctctgctcgctgctgcccccaccct
agcccaagtcagcaggatcttgcttcttcttctacgatgtcctcctaagtggccttcttgttccctttctt
gtctctctatattctatattccacactacagcaagcatagtgagatttttttaatacgtaagttagaacat
tttacttttgtgctgaaaacggttcagtggtttggactaaaattgaactctttatcatggatctcaagagc
tgcatgacctgacaaattattataccctcaatctcatttccctctggttgctcttcccttactacattcta
gcctgatggcccttctttcgatttctctagaatggaccaaacccctctataagccattctctagacacgga
tacttttataaccttcatgtctcagcatcaatgtcacttcctcagagaagcccagtgagatctcccctctg
atactttctctcatagcaccctgtcgtaagcacgctttgatgattctcttccaacctgaccagcacttacc
aacttttggaccttgatacaatggtcccttacgaatggatcacaggagtgccaagattttgattcctcagc
cataaggtcagcattgaggggctttagtagctgtaactcctgaggattggtcatccccagtatctggaagc
ctcttctgttaatgagccatgcaaatataggtattttctctgtgtcccctactttgtaaaagtctgggaag
cctgaatcctatatttcttaagggcaggacttgtttttggattgttcatgcctatattcttaacatagact
atagcatcagacacatagaaggtaccggaagtatttcttgaaggagtaaaaggttttatggtggtgaagaa
gatggtggaattgataagagtgatggtgatgataaagaggagagtggtgctggtgctggtggtggtagtga
tgatgatggtgatggtcatggtggtggtgatggtaatgaccgtggtggtgatagtggtaatggtggtgatg
atggtggtgatgatgatggtggtgatagtggtaatggtggtgatgatggtggtgatgatgatggtgatggt
ggtgatgatggtggtggtaatggttggtggtgatggtggtggttggtggtgatggtggtggtgatgatgat
ggtgatgacgatggcaatgatggtggtagtaatgatggtggtggtggtgatggtggtgatggtggtgatgg
tggtggtggtggtgatggtggtgatggtggtgttgtctgtggtgatggtgatggtggtggtgatggtggtg
gtgatggtgatggtggtgatggtggtgttgtccatggtgatggtgatggtggtggttgtggtgatggtggt
ggtgatgatgatggtgatgacgatggcaatggtggtgatagcgatgatggtggtggtggtgatggtggtga
tggtggtggtggtgggtggtgatggtggtgaagatgatgtggtgatggtagtgatgatggcggtgttggtg
gtgatgatggtgatggtggtgatggtggtgttgtccgtgggtgatggtgatggtggtggtggtgatgatga
tgatggtgatggtggtggtgttggtgatgctgctgctggtgatgatggtggtgatgatgatgatggtgatg
gtagtgatgacggtgttgttgttggtgatgatgatgatggtgatggtggtgctgttggtgatgctgctgct
ggtgatggtggtgatgatgatggtgatggtagtgatgattgtgttgttgttggtggtgatgttgatgatgg
tgatggtggtggtggtgatgatggtggcaatgctggtggctatgataatgaagaaagactttgggggtaga
aatgatagattctgaggacctgaactacctcagtgctttagagaacttttatgaaaaattaatgtgccttt
tcacattctagtcagcccagactacactcgaaggtggattttggaggaagggtacttggagctggaggggc
tcttggagatgatttgcaaatcctggcgggactgtgaggcccgccacacccctccttctttctgccccagg
tggtcccaaggccgcctgcccttccacaccggcagcctccagcgctccagggctggggaccgcccccgtcc
atgctgcgtgcgcactccgagcttttcctcggcgaggaggagggctcagagggtcagctgcgccccggcca
gagcaggagctgcgggaagaccctggagagcagggctgggagtggggatctggcagtgtggggccaagaaa
aagggctggggcggaaatccagaGACAGAGGCAGAGAGGGGAGCATCTGGGATCGTGGGGAGGGTTCGTGG
AGAGTGAGGCAGGGGAATGGAGGGAGTAGGAGTCTGGGGAAAGTGAGGATTTTGAAGTGAGAGAGTCCGCT
TGGGCTGGGCGTGGAGGGCCGAGGGTGGAGTGGGGTTGAGGGACGAGGTGGGTTAAGGTGCTGGTGGGGAA
GGACTAGAGCTTCCAGGAGGGTCTGAAGGCGGAGGTGGAGGTCGGACAGCACAAGTGAGAGTGAGGGGGTC
TGTAGGTAGAGCTGGCATTGGAGGGGTGGGAACGTGGACGGCGGCTGAGCGGGGGGCGCGTGCAGGTCGGA
GCCGGCAGGTGAGGAGCCAGGGTCTAAGCTAGGGCCCGGGGTCCAAAGGAAAGGCTTTCAGATCTGAGCTC
CGCGGCTCTGGCGGCGGTGGAGCTGGGAGCCCGCGGTGGCCGGCTGGGGACGGGGGCAGGAGCAGAGGGGT
CGCGCCGCGGCCACTGGAACCCGCGGCTGCTGGTCCTGGGCTCGGCGATGCGGGTGCACCTGGGCGGGCTG  
                                                                                   M  R  V  H  L  G  G  L  
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9.7 Clinical phenotypes of patients screened for mutations in TMEM114 
Table 9.14. Full clinical phenotypes and DNA changes of patients screened for 
mutations in TMEM114. Patients are categorised according to clinical phenotype. 
 
Code Ocular phenotype Non-ocular  phenotype DNA change 
Protein 
change 
B7 bilateral anophthalmia  - - - 
B10 bilateral anophthalmia  - - - 
C7 bilateral anophthalmia 
(familial) 
 - 
-24C>T 
(homo);  
c.440 -7C>G 
(homo) - 
D9 bilateral anophthalmia 
 - 
'-24C>T 
(homo) - 
E7 bilateral anophthalmia 
 - 
-24C>T; c.440 
-7C>G - 
H9 bilateral anophthalmia   - - - 
B1 bilateral anophthalmia bilat sensory neural deafness, axial hypotonia 
and developmental delay.  - - 
D10 bilateral anophthalmia, optic 
nerve hypoplasia, atrophic 
chiasm 
 interhemispheric cyst, seizures, cup shaped 
ears, agenesis of corpus callosum 
-24C>T;  
c.440C>T p.A147V 
E1 bilateral anophthalmia  microcephaly, spastic dystonic quadriplegia, 
ASD, MR, laryngeal cleft, diaphragmatic 
eventration, 2-3 toe syndactyly, normal 
chromosomes - - 
E8 bilateral A saddle nose, dysmorphic ears and navel, 
micrognathia,  hypospadias, aortic coartation    - - 
F8 bilat A, ON agenesis 
 rhizomelia, contractures 
-24C>T; c.440 
-7C>G - 
G2 bilateral anophthalmia cleft palate, cutaneous syndactyly of left III-IV 
fingers and of bilateral II-III toes, microcephaly, 
severe mental delay. Brain MRI: hydrocephalus, 
vermian hypoplasia and corpus callosum 
hypogenesia. - - 
H3 bilateral anophthalmia right microtia, profound developmental delay 
and mental retardation, no speech, difficulty 
standing and walking, hypotonic, absent left 
kidney, MRI scan pending 
-24C>T; c.440 
-7C>G - 
          
A6 M, A 
 - 
-24C>T; 
c.13C>T;  
c.440 -7C>G p.L5L 
A10 anophthalmia (right) and 
severe microphthalmia (left) 
 - 
- 
- 
B6 anopthalmia, 
microphthalmia, arhinia  - 
- 
- 
C6 M, A  - - - 
F5 Anophthalmia Unilateral & 
Microphthalmia Unilateral 
 - -24C>T - 
G5 Micropthalmia and 
anopthalmia.  - -24C>T - 
H7 A and severe M,   - - - 
C10 Anophthalmia (left), 
microphthalmia (right), blind 
bilateral congenital choanal stenosis/atresia, 
facial hemimicrosomia - - 
D2 anophthalmia (right) and 
microphthalmia 
 
 
 
bilateral cleft lip and choanal atresia, 
micropenis, cryptorchidism, developmental 
delay, increased liver dimension,  unilateral 
(right) kidney ectopia with rotation defect, 
severe anomalies on X-ray - - 
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D6 L anophthalmia, R 
microphthalmia 
pituitary hypoplasia, hypoplastic optic chiasm, 
hypothalamic abnormality per AJB, hypoplastic 
CC, CLP. - - 
H1 left sided anophthalmia & 
right sided severe 
microphthalmia 
mental retardation, bilateral cleft lip & palate 
and a scoliosis, aplasia of septum pellucidum c.440 -7C>G - 
H2 Septo-optic dysplasia with 
anophthalmia 
OD/microphthalmia OS,  severe developmental delay c.440 -7C>G  - 
     
C11 A, M with C, optic disc 
hypoplasia  - -24C>T - 
D7 left A, right severe M with 
coloboma 
repetitive hand movements, rocking and 
echolalia. Normal chrs - - 
          
A4 Bilateral microphthalmia & 
congenital cataracts, 
secondary glaucoma, 
nystagmus and global 
developmental delay  - - - 
A9 bilateral microphthalmia and 
cataracts  - - - 
B8 bilat M and sclerocornea   - -24C>T - 
B9 bilateral microphthalmia and 
corneal opacities 
 - 
-24C>T; c.440 
-7C>G - 
C5 Microphthalmia & Cataracts 
Bilateral.  - - - 
D8 bilateral microphthalmia, 
cataracts  -     
F6 bilateral microphthalmia  - - - 
G7 bilat severe M, corneal 
opacification, iris 
abnormalities    - - - 
B3 Bilateral microphthalmia & 
schleroderma of cornea 
bilaterally 
 facial dysmorphism, microcephaly, short 
stature & developmental delay - - 
D1 bilat microphthalmia renal reflux, cryptorchidism, delayed speech 
and walking, PDA that resolved -24C>T - 
E6 bilateral microphthalmia and 
sclerocornea 
 L undescended testes, chordee with penile 
torsion, very severe microcephaly, complete 
agenesis of the corpus callosum 
-24C>T 
(homo); c.440 -
7C>G (homo) - 
E9 bilateral microphthalmia and 
cataract, iris hypoplasia, 
corneal haze, ectopia uvea infantile spasms - - 
F1  microphthalmia, aniridia, 
totally blind developmental delay, pervasive disorder? - - 
F9 Bilateral microphthalmia, left 
cornea transplant 
(unsuccessful), rudimentary 
lens & possible iris, right 
sclerocornea & glaucoma,  
senses light.   
Respiratory tract infection, cerebellar 
hypoplasia (vermis), streak gonads?, empty 
scrotum, small penis & corpus callosum 
agenesis - - 
G6 bilateral aniridia and 
microphthalmia 
limbal stem cell deficiency with early pannus, 
keratopathy, corneal oedema, cataract, uveal 
coloboma. c.440 -7C>G - 
G8 severe bilateral 
microphthalmia/anophthalmi
a diaphragmatic hernia 
-24C>T; c.440 
-7C>G - 
H4 Severe bilateral 
microphthalmia 
Severe undergrowth, unilateral cleft lip/palate 
repaired, hypoplastic midface, clipped ears, 
anterior encephalocele repaired, 
cryptorchidism, severe to profound mental 
retardation, no speech     
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H5 Bilateral 
anopthalmia/micropthalmia  congenital abnormalities - - 
H8 bilat M, sclerocornea Pierre Robin Syndrome - - 
          
A7 bilateral microphthalmia, 
colobomas, retinal 
dystrophy    c.134C>T p.P45L 
A11 bilat M and C    - - - 
B12 bilat M, C  - - - 
D5 Microphthalmia & Coloboma 
Bilateral.  -     
D11 bilat M, C, heterochromia, 
cataract  - - - 
E10 bilateral microphthalmia, 
coloboma, acentric pupils 
 - - - 
E11 bilat M and C    - - - 
G11 bilat M, C, heterochromia  - -24C>T - 
H12 bilat M and C and cataracts, 
abnormal anterior segment   
 - -24C>T (homo) - 
G3 Bilateral severe 
microphthalmia and iris, 
retinal and optic cup 
coloboma 
cryptorchidism, hypotonia, microcephaly, 
severe mental retardation - - 
G10 bilateral microphthalmia, 
retinal coloboma 
absent right kidney, cystic dyspastic left kidney, 
bilateral cryptorchidism, adducted left thumb, 
pseudoarthrosis of right clavicle 
-24C>T 
c.5G>A p.R2Q 
          
B11 bilat M, unilat C   - -24C>T - 
C9 congenital bilateral 
microphthalmia, 
translucency of cornea, 
coloboma on MRI  - - - 
C12 severe bilat M, left iris C, 
retinal defect  - - - 
C2 bilateral microphthalmia and 
cataracts, unilateral 
coloboma 
microcephaly, seizures, self-aggressive and 
autistic behaviour, severe mental retardation - - 
          
F10 unilateral (left) 
microphthalmia with 
cataract,  - - - 
A2 left microphthalmia v high palate, joint laxity, scoliosis, left 
accessory nipple, learning problems, 
chr15q12.2 del 
-24C>T; c.440 
-7C>G - 
B4 Unilateral severe 
microphthalmia 
severe short stature, hypospadias, 2/3 
sundactyly and mild developmental delay   
-24C>T; c.440 
-7C>G - 
          
F11 left M, right C, abnormal 
retina  - 
 -24C>T; c.440 
-7C>G  - 
C3 Microphthalmia left and 
coloboma right,  
developmental delay, some dysmorphic 
features including a single palmar crease in 
right hand and umbilical hernia - - 
D3 unilateral microphthalmia 
(left), retinal coloboma 
bilateral sensorineural deafness, developmental 
delay, ankyloglossia, dysplastic ear, micropenis -24C>T - 
H6 left microphthalmia,  right 
coloboma 
ambiguous genetalia and cleft right hand, 
complex phenotype - - 
          
E5 Optic Fissure Closure 
Defect Bilat.  Possible 
Retinal Degeneration   - - 
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A1 bilateral coloboma/mild 
aniridia 
epilepsy, pachygyria, hypotonia, developmental 
delay - - 
A3 bilateral iris and 
choroiretinal coloboma 
developmental delay, dilated renal pelvis, 
laryngomalacia, undescended testis.  - - 
          
D12 unilat M, bilat C and 
cataracts   - - 
E12 unilat M, bilat C and 
cataracts   - - 
F12 unilat M, bilat C, iris 
pupillary membrane 
remnant, cataract   - - 
A12 left M, bilat C, 
heterochromia   - - 
B2 unilateral (R)  
microphthalmia, bilateral 
coloboma 
  
-24C>T 
(homo);  
c.440 -7C>G 
(homo) - 
          
F3 Right iris coloboma macrocephaly, learning difficulties.   - - 
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